Clinical trial NCT03268005
Conditions: Diabetes Diabetes Mellitus, Type 2
Sponsor: Novo Nordisk A/S
Start date: 2017-09-19; Completion date: 2019-01-29
Enrollment: 1264 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
The study compares 2 medicines for type 2 diabetes: fast-acting insulin aspart (a new medicine) and NovoRapid®/NovoLog® (a medicine doctors can already prescribe). Fast-acting insulin aspart will be tested to see how well it works and if it is safe. Participants will get either fast-acting insulin aspart or NovoRapid®/ NovoLog® - which treatment you get is decided by chance. Both medicines will be taken together with insulin degludec. Participants will need to take 1 injection 4 times every day (all insulins will be provided in pens). The study will last for about 8 months (34 weeks).

Detailed description:

Arms: arm 1: None arm 2: None
Interventions: intervention 1: Faster-acting insulin aspart intervention 2: Insulin aspart intervention 3: Insulin degludec intervention 4: Metformin
Intervention descriptions: intervention 1: Faster aspart given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted. intervention 2: Insulin aspart given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted. intervention 3: Insulin degludec given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted. intervention 4: Only participants who took metformin before the study should take metformin tablets, same dose as before the study

Protocol documents:
Prot_000.pdf: 
Cover Page for Protocol 
Sponsor name: 
Novo Nordisk A/S 
NCT number 
NCT03268005 
Sponsor trial ID: 
NN1218-4113 
Official title of study: 
Efficacy and Safety of Fast-acting Insulin Aspart Compared to 
NovoRapid® both in Combination with Insulin Degludec with 
or without Metformin in Adults with Type 2 Diabetes  
(onset® 9) 
Document date: 
20 June 2019 


/LQN
/LQN
/LQN
/LQN
/LQN
/LQN
/LQN
/LVWRIFRQWHQWV
3URWRFROYHUVLRQ
3URWRFROYHUVLRQ
$SSHQGL[$ 9HUVLRQ
$SSHQGL[$ 9HUVLRQ
$WWDFKPHQW,DQG,,
3URWRFRODPHQGPHQW 
3URWRFRODPHQGPHQW 
&21),'(17,$/
'DWH
1RYR1RUGLVN
9HUVLRQ
6WDWXV
)DVWDFWLQJLQVXOLQDVSDUW
7ULDO,'11
&OLQLFDO7ULDO5HSRUW
$SSHQGL[
-XQH

)LQDO
3URWRFRODQGSURWRFRODPHQGPHQWV
CONFIDENTIAL
 
 
 
 
 
Redacted protocol 
Includes redaction of personal identifiable information only. 
 
 
 
. 
 
 


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
1 of 113
Protocol
Trial ID:NN1218-4113
Efficacy and Safety of Fast-acting Insulin Aspart Compared to 
NovoRapid® both in Combination with Insulin Degludec with or 
without Metformin in Adults with Type 2 Diabetes (onset® 9)
Trial phase: 3b
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
2 of 113
Table of Contents
Page
Table of Contents..............................................................................................................................................2
Table of Figures................................................................................................................................................5
Table of Tables..................................................................................................................................................5
List of abbreviations.........................................................................................................................................6
1
Summary....................................................................................................................................................8
2
Flow chart ................................................................................................................................................11
3
Background information and rationale for the trial............................................................................14
3.1
Background information..............................................................................................................14
3.1.1
Therapeutic Area........................................................................................................14
3.1.2
NovoRapid® (Insulin aspart) ......................................................................................15
3.1.3
Fast-acting insulin aspart ...........................................................................................15
3.1.4
Insulin degludec.........................................................................................................16
3.2
Rationale for the trial...................................................................................................................17
4
Objectives and endpoints........................................................................................................................18
4.1
Objectives ....................................................................................................................................18
4.2
Endpoints .....................................................................................................................................18
4.2.1
Primary endpoint........................................................................................................18
4.2.2
Secondary endpoints..................................................................................................18
4.2.2.1
Confirmatory secondary endpoints .....................................................18
4.2.2.2
Supportive secondary endpoints..........................................................19
5
Trial design ..............................................................................................................................................21
5.1
Type of trial .................................................................................................................................21
5.2
Rationale for trial design..............................................................................................................22
5.2.1
Rational for choice of non-inferiority margin............................................................22
5.3
Treatment of subjects...................................................................................................................22
5.4
Treatment after discontinuation of trial products.........................................................................23
5.5
Rationale for treatment ................................................................................................................23
6
Trial population.......................................................................................................................................25
6.1
Number of subjects......................................................................................................................25
6.2
Inclusion criteria ..........................................................................................................................25
6.3
Exclusion criteria.........................................................................................................................26
6.4
Run-in period exclusion criteria...................................................................................................27
6.5
Randomisation criterion...............................................................................................................28
6.6
Criteria for premature discontinuation of trial products ..............................................................28
6.7
Withdrawal from trial ..................................................................................................................28
6.8
Subject replacement.....................................................................................................................29
6.9
Rationale for trial population.......................................................................................................29
7
Milestones.................................................................................................................................................30
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
3 of 113
8
Methods and assessments .......................................................................................................................31
8.1
Visit procedures...........................................................................................................................31
8.1.1
Screening (Visit 1).....................................................................................................31
8.1.2
Run-in ........................................................................................................................32
8.1.3
Randomisation ...........................................................................................................33
8.1.4
Phone contacts ...........................................................................................................33
8.1.5
Fasting visits ..............................................................................................................33
8.1.6
Rescheduled visits......................................................................................................33
8.1.7
End of treatment.........................................................................................................33
8.1.8
Follow-up period........................................................................................................34
8.1.9
Premature discontinuation of trial products...............................................................34
8.1.10
Withdrawal from trial ................................................................................................36
8.1.10.1
Lost to follow-up.................................................................................37
8.1.11
Review of results .......................................................................................................37
8.2
Subject related information/assessments .....................................................................................37
8.2.1
Demography...............................................................................................................37
8.2.2
Diabetes history and diabetes complications .............................................................38
8.2.3
Hypoglycaemia unawareness.....................................................................................38
8.2.4
Concomitant illness and medical history...................................................................38
8.2.5
Concomitant medication............................................................................................39
8.2.6
Concomitant medication (diabetes) ...........................................................................39
8.2.7
Childbearing potential................................................................................................40
8.2.8
Tobacco use ...............................................................................................................40
8.3
Efficacy assessments....................................................................................................................40
8.3.1
Meal test.....................................................................................................................40
8.3.2
Self-measured plasma glucose...................................................................................44
8.3.3
Insulin dose................................................................................................................46
8.4
Safety assessments.......................................................................................................................46
8.4.1
Adverse events...........................................................................................................46
8.4.1.1
Medication error..................................................................................47
8.4.1.2
Adverse events requiring additional data collection ...........................47
8.4.2
Hypoglycaemic episodes ...........................................................................................48
8.4.3
Eye examination ........................................................................................................51
8.4.4
Electrocardiogram – 12 lead......................................................................................51
8.4.5
Body measurements...................................................................................................52
8.4.6
Physical examination.................................................................................................52
8.4.7
Vital signs ..................................................................................................................53
8.5
Laboratory assessments ...............................................................................................................53
8.5.1
Laboratory assessments for efficacy..........................................................................54
8.5.2
Laboratory assessments for safety .............................................................................55
8.6
Other assessments........................................................................................................................56
8.6.1
Dietary training in simple carbohydrate counting......................................................56
8.6.2
Training in the pen injector........................................................................................56
8.6.3
eDiary.........................................................................................................................56
8.7
Subject compliance......................................................................................................................57
9
Trial supplies ...........................................................................................................................................58
9.1
Trial products...............................................................................................................................58
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
4 of 113
9.2
Labelling......................................................................................................................................58
9.3
Storage .........................................................................................................................................59
9.4
Drug accountability and destruction............................................................................................59
9.5
Auxiliary supplies........................................................................................................................60
10 Interactive voice/web response system ..................................................................................................61
11 Randomisation procedure and breaking of blinded codes..................................................................62
11.1
Breaking of blinded codes ...........................................................................................................62
12 Adverse events, technical complaints and pregnancies .......................................................................63
12.1
Definitions ...................................................................................................................................63
12.1.1
Adverse event ............................................................................................................63
12.1.2
Serious adverse event.................................................................................................64
12.1.3
Non-serious adverse event.........................................................................................65
12.1.4
Medication errors.......................................................................................................65
12.1.5
Adverse events requiring additional data collection..................................................65
12.1.6
Technical complaints.................................................................................................66
12.2
Reporting of adverse events.........................................................................................................66
12.3
Follow-up of adverse events........................................................................................................68
12.4
Technical complaints and technical complaint samples ..............................................................69
12.4.1
Reporting of technical complaints .............................................................................69
12.4.2
Collection, storage and shipment of technical complaint samples ............................70
12.5
Pregnancies in female subjects ....................................................................................................71
12.6
Precautions and/or overdose ........................................................................................................72
12.7
Committees related to safety........................................................................................................73
12.7.1
Novo Nordisk safety committee ................................................................................73
13 Case report forms....................................................................................................................................74
13.1
Corrections to case report forms..................................................................................................74
13.2
Case report form flow..................................................................................................................75
14 Monitoring procedures ...........................................................................................................................75
15 Data management....................................................................................................................................76
16 Computerised systems.............................................................................................................................76
17 Statistical considerations ........................................................................................................................78
17.1
Sample size calculation................................................................................................................80
17.2
Definition of analysis sets............................................................................................................82
17.3
Primary endpoint..........................................................................................................................82
17.4
Secondary endpoints....................................................................................................................86
17.4.1
Confirmatory secondary endpoints............................................................................86
17.4.2
Supportive secondary endpoints ................................................................................88
17.4.2.1
Efficacy endpoints...............................................................................88
17.4.2.2
Safety endpoints..................................................................................92
18 Ethics........................................................................................................................................................98
18.1
Benefit-risk assessment of the trial..............................................................................................98
18.2
Informed consent .......................................................................................................................100
18.3
Data handling.............................................................................................................................101
18.4
Information to subjects during trial............................................................................................101
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
5 of 113
18.5
Premature termination of the trial and/or trial site.....................................................................101
19 Protocol compliance..............................................................................................................................102
19.1
Protocol deviations ....................................................................................................................102
19.2
Prevention of missing data.........................................................................................................102
20 Audits and inspections ..........................................................................................................................103
21 Critical documents ................................................................................................................................103
22 Responsibilities......................................................................................................................................104
23 Reports and publications......................................................................................................................106
23.1
Communication of results..........................................................................................................106
23.2
Investigator access to data and review of results.......................................................................107
24 Retention of clinical trial documentation............................................................................................108
24.1
Retention of clinical trial documentation...................................................................................108
25 Institutional Review Boards/Independent Ethics Committees and regulatory authorities............109
26 Indemnity statement .............................................................................................................................110
27 References..............................................................................................................................................111
Appendix A
Titration Guideline
Attachment I  Global list of key staff and relevant departments and suppliers 
Attachment II
Country list of key staff and relevant departments, if applicable for the individual country
Table of Figures
Page
Figure 5–1
Trial Design. ...........................................................................................................................21
Figure 12–1
Reporting of AEs....................................................................................................................67
Figure 17–1
Novo Nordisk classification of hypoglycaemia......................................................................94
Figure 17–2
ADA classification of hypoglycaemia....................................................................................95
Table of Tables
Page
Table 8–1
Meal test schedule...................................................................................................................42
Table 8–2
7-point SMPG profiles with additional 9-point SMPG profile...............................................45
Table 9–1
Trial products..........................................................................................................................58
Table 9–2
Storage conditions ..................................................................................................................59
Table 17–1
Specifications assumed for sample size calculations..............................................................81
Table 17–2
Sensitivity of sample size to power ........................................................................................81
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
6 of 113
List of abbreviations
ADA
American Diabetes Association
AE
adverse event
ALT
alanine aminotransferase
AST
aspartate aminotransferase
BG
Blood glucose
CRF
case report form
DUN
dispensing unit number
ECG
electrocardiogram
eCRF
electronic case report form
eDiary
electronic diary 
FAS
full analysis set
FDA
U.S. Food and Drug Administration
FPG
fasting plasma glucose
GCP
Good Clinical Practice
GLP-1
glucagon-like peptide-1
HbA1c
glycosylated haemoglobin
IB
Investigator’s Brochure
ICH
International Conference on 
Harmonisation of Technical 
Requirements for Registration of 
Pharmaceuticals for Human Use
IEC
independent ethics committee
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
7 of 113
IMP
investigational medicinal product
IRB
institutional review board
IWRS
interactive voice/web response 
system
LPLV
last patient last visit
NIMP
non-investigational medicinal 
product
OAD
oral antidiabetic drug
PG
plasma glucose
PPG
postprandial glucose
PP
per protocol
SAE
serious adverse event
SmPC
summary of product characteristics
SMPG
self-measured plasma glucose
SUSAR
suspected unexpected serious adverse 
reaction
T1DM
Type 1 diabetes mellitus
T2DM
Type 2 diabetes mellitus
TEAE
Treatment Emergent Adverse Event 
TMM
Trial Materials Manual
UTN
Universal Trial Number
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
8 of 113
1
Summary
Objective(s) and endpoint(s):
Primary objective
To confirm the effect in terms of glycaemic control of treatment with fast-acting insulin aspart 
compared to NovoRapid® both in combination with insulin degludec with or without metformin in 
adults with type 2 diabetes mellitus treated with a basal-bolus regimen, using a non-inferiority 
approach.
Secondary objectives
To confirm superiority of fast-acting insulin aspart compared to NovoRapid® both in combination 
with insulin degludec with or without metformin in adults with type 2 diabetes mellitus treated with 
a basal-bolus regimen in terms of:
!
Postprandial glucose regulation 
!
Overall glycaemic control 
!
Postprandial glucose excursions 
To compare the safety of fast-acting insulin aspart to NovoRapid® both in combination with insulin 
degludec with or without metformin in adults with type 2 diabetes mellitus treated with a basal-
bolus regimen.
Primary endpoint
Change from baseline in HbA1c 16 weeks after randomisation
Key secondary endpoints
Confirmatory secondary endpoints:
!
Change from baseline in 1-hour postprandial glucose increment 16 weeks after 
randomisation (meal test)
!
Change from baseline in 1,5-anhydroglucitol 16 weeks after randomisation
Trial design:
This is a phase 3b, 16-week, multicentre, multinational, 1:1 randomised, double-blind, active 
controlled, treat-to-target, parallel group trial with a 12-week run-in period comparing the effect and 
safety of fast-acting insulin aspart to NovoRapid® both in combination with insulin degludec with 
or without metformin in subjects with type 2 diabetes mellitus treated with a basal-bolus regimen. 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
9 of 113
The trial includes two blinded dosing arms - mealtime fast-acting insulin aspart and mealtime 
NovoRapid®.
Trial population:
A total of 1803 subjects with Type 2 diabetes mellitus are planned to be screened and 1072 are 
planned to be randomised.
Key inclusion criteria:
!
Male or female, age ≥ 18 years at the time of signing informed consent.
!
Diagnosed with type 2 diabetes mellitus≥ 10 years prior to screening (Visit 1).
!
Treated with a basal-bolus insulin regimen ≥ 1 year prior to the day of screening (Visit 1). A 
basal-bolus insulin regimen is defined as basal insulin once or twice daily and bolus insulin 
analogue taken with meals at least 3 times daily. Treatment with premixed insulin or soluble 
insulin combination is not considered a basal-bolus regimen.
!
Treated with or without oral antidiabetic drugs including extended release formulations. 
HbA1c 7.0-10.0% (both inclusive) as assessed by central laboratory at screening (Visit 1).
Key exclusion criteria:
!
Any of the following: myocardial infarction, stroke, hospitalization for unstable angina or 
transient ischaemic attack within the past 180 days prior to the day of screening (Visit 1). 
!
Subjects presently classified as being in New York Heart Association (NYHA) Class IV. 
!
Planned coronary, carotid or peripheral artery revascularisation known on the day of 
screening (Visit 1).
!
Treatment with injectable GLP-1 receptor agonists in a period of 90 days prior to screening 
(Visit 1). 
!
Anticipated initiation or change in concomitant medications (for more than 14 consecutive 
days) known to affect weight or glucose metabolism (e.g. treatment with orlistat, thyroid 
hormones, or corticosteroids).
Randomisation criterion:
!
HbA1c ≤ 9.0% measured by the central laboratory at Visit 13 (week -1).
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
10 of 113
Key Assessments:
!
HbA1c
!
Postprandial glucose increment (meal test)
!
1,5-anhydroglucitol 
!
Hypoglycaemic episodes
!
Adverse events
Trial product(s):
Investigational medicinal products:
!
Test products: 
o
Fast-acting insulin aspart, 100 U/mL solution for subcutaneous injection, 3 mL 
PDS290 pen injector (blinded) 
o
Insulin degludec, 100U/mL solution for subcutaneous injection, 3 mL PDS290 pen 
injector 
!
Reference therapy: 
o
Insulin aspart (NovoRapid®), 100 U/mL solution for subcutaneous injection, 3 mL 
PDS290 pen injector (blinded)
Other medicinal products: 
!
Rapid acting insulin analogues (NovoRapid® or marketed formulations of insulin lispro or 
insulin glulisine) during run-in period
!
Metformin, tablets for oral use
CONFIDENTIAL


Protocol
UTN: U1111-1180-0636
Date:
28 March 2017
Status:
Final
1RYR1RUGLVN
Trial ID: NN1218-4113
EudraCT no.: 2016-000878-38
Version:
2.0
Page:
11 of 113
2
Flow chart
NN1218-4113
Protocol section
Screening
12-week run-in period
Randomisation
16- week treatment period
Blinded trial product
End of treatment
Premature 
discontinuation
Follow-up 1
Follow-up 2
Visit (V)
Phone contact (P)
V1
V2
P3
P4
V5
P6
P7
P8
V9
P10
P11
P12
V13
V14
P15
V16
P17
V18
P19
P20
P21
V22
P23
P24
P25
V26
P27
P28
P29
V30
V30A
V31
P32
Time of visit (weeks)
-14
-12
-11
-10
-9
-8
-7
-6
-5
-4
-3
-2
-1
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
+7 
days
+30
days
Visit window (days)
+10
±3
±3
±3
±3
±3
±3
±3
0
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
+10
+5
SUBJECT RELATED INFO/ASSESSMENTS
Informed consent
18.2
X
In/exclusion criteria
6.2 6.3
X
X
Run-in period exclusion criteria
6.4
X
X
X
X
X
X
X
Randomisation criterion
6.5
X
Randomisation
8.1.3
X
Criteria for premature discontinuation of trial 
products
6.6
X
X
X
X
X
X
X
X
X
Demography 
8.2.1
X
Tobacco use
8.2.8
X
Diabetes history and diabetes complications
8.2.2, 
8.2.6
X
Hypoglycaemia unawareness 
8.2.3
X
Concomitant illness and medical history
8.2.4
X
Concomitant medication
8.2.5
8.2.6
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Child-bearing potential
8.2.7
X
EFFICACY
Meal test
8.3.1
X
X
X
4-point profile (SMPG)
8.3.2
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
7-9-7-point profile (SMPG)
8.3.2
X
X
X
X
1,5-anhydroglucitol
8.5.1
X
X
X
X
X
X
Fasting plasma glucose
8.5.1
X
X
X
X


Protocol
UTN: U1111-1180-0636
Date:
28 March 2017
Status:
Final
1RYR1RUGLVN
Trial ID: NN1218-4113
EudraCT no.: 2016-000878-38
Version:
2.0
Page:
12 of 113
NN1218-4113
Protocol section
Screening
12-week run-in period
Randomisation
16- week treatment period
Blinded trial product
End of treatment
Premature 
discontinuation
Follow-up 1
Follow-up 2
Visit (V)
Phone contact (P)
V1
V2
P3
P4
V5
P6
P7
P8
V9
P10
P11
P12
V13
V14
P15
V16
P17
V18
P19
P20
P21
V22
P23
P24
P25
V26
P27
P28
P29
V30
V30A
V31
P32
Time of visit (weeks)
-14
-12
-11
-10
-9
-8
-7
-6
-5
-4
-3
-2
-1
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
+7 
days
+30
days
Visit window (days)
+10
±3
±3
±3
±3
±3
±3
±3
0
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
+10
+5
HbA1c
8.5.1
X
X
X
X
X
X
X
X
X
X
Fasting C-peptide
8.5.1
X
Lipids
8.5.1
X
X
X
X
X
SAFETY
Adverse events
8.4.1, 
12
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Injection site reactions 
8.4.1.2
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Hypoglycaemic episodes
8.4.2
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Technical complaints
12.1.6
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Body weight
8.4.5
X
X
X
Height
8.4.5
X
Physical examination
8.4.6
X
X
X
X
Vital signs
8.4.7
X
X
X
X
Eye examination
8.4.3
X
X
X
X
ECG
8.4.4
X
X
X
X
Biochemistry
8.5.2
X
X
X
X
X
Haematology
8.5.2
X
X
X
X
X
Pregnancy test
8.5.2
X
X
X
X
TRIAL MATERIAL
Dispensing visit
9.4
X
X
X
X
X
X
X
X
X
New (prescribed) dose of trial insulin
8.3.3
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Dosing (Start/stop date of trial insulin)
8.3.3
X
X
X
X
X
Insulin dose of basal and bolus insulin each day
8.3.3
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Drug accountability 
9.4
X
X
X
X
X
X
X
X
X
X
X


Protocol
UTN: U1111-1180-0636
Date:
28 March 2017
Status:
Final
1RYR1RUGLVN
Trial ID: NN1218-4113
EudraCT no.: 2016-000878-38
Version:
2.0
Page:
13 of 113
NN1218-4113
Protocol section
Screening
12-week run-in period
Randomisation
16- week treatment period
Blinded trial product
End of treatment
Premature 
discontinuation
Follow-up 1
Follow-up 2
Visit (V)
Phone contact (P)
V1
V2
P3
P4
V5
P6
P7
P8
V9
P10
P11
P12
V13
V14
P15
V16
P17
V18
P19
P20
P21
V22
P23
P24
P25
V26
P27
P28
P29
V30
V30A
V31
P32
Time of visit (weeks)
-14
-12
-11
-10
-9
-8
-7
-6
-5
-4
-3
-2
-1
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
+7 
days
+30
days
Visit window (days)
+10
±3
±3
±3
±3
±3
±3
±3
0
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
+10
+5
IWRS call
10
X
X
X
X
X
X
X
X
X
X
X
X
REMINDERS
Handout ID card
8.1.1
X
Confirmation of unchanged metformin
8.2.5
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Attend visit fasting
8.1.5
X
X
X
X
Training in carbohydrate counting
8.6.1
X
X
X
X
Handout direction for use
9.2
X
Training in trial product and pen handling
8.6.2
X
X
X
X
X
X
Handout pen differentiation guide
9.2
X
Training in pen differentiation
8.6.2
X
X
X
Handout and instruct in eDiary
8.6.3
X
Handout and instruct in BG meter use
8.3.2
X
Handout and instruct in subject mealtime insulin 
dose adjustment guide
8.3.3
X
eDiary collection
8.6.3
X
End of treatment
8.1.7
X
X
End of trial
X


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
14 of 113
3
Background information and rationale for the trial
The trial will be conducted in compliance with this protocol, ICH GCP1 and applicable regulatory 
requirements, and in accordance with the Declaration of Helsinki.2
In this document, the term investigator refers to the individual responsible for the overall conduct of 
the clinical trial at a trial site.
3.1
Background information
Improvement in long-term glucose control, as obtained with intensified insulin therapy, may reduce 
the incidence of complications and delay the progression of existing complications in people with 
Type 1 Diabetes Mellitus (T1DM) and Type 2 Diabetes Mellitus (T2DM).3, 4 Postprandial 
hyperglycaemia contributes significantly to the glycosylated haemoglobin (HbA1c) level and its 
control is thus essential for achieving the HbA1c target level.5 Postprandial hyperglycaemia is 
associated with increased risk of micro- and macro-vascular complications.6 Lowering of 
postprandial hyperglycaemia may reduce the progression of atherosclerosis and cardiovascular 
events in patients with T2DM.7
Basal-bolus insulin therapy aims at mimicking the physiological insulin response in the healthy 
state to the largest possible extent. For that purpose, rapid-acting insulin analogues were developed 
to more effectively control the postprandial glucose (PPG) excursions than subcutaneously injected 
human regular insulin, primarily through offering a faster onset and shorter duration of action.8
However, unmet needs exist within prandial insulin therapy for people with diabetes. The current 
insulin analogues are not able to match the speed of the normal physiological postmeal insulin 
secretion, leading to suboptimal control of blood glucose (BG), and exogenous insulin with a faster 
glucose lowering effect is needed for tighter PPG control. In addition, a faster glucose lowering 
effect is also likely to offer greater flexibility in the time of dosing around meals thus increasing 
convenience for the patients and may allow the patients to better match the insulin taken to the 
meal.9
For an assessment of benefits and risks of the trial, see Section 18.1
3.1.1
Therapeutic Area
Due to the progressive nature of T2DM, many patients are likely to be candidates for intensified 
insulin therapy. Prandial insulin supplementation is recommended by European Association for the 
Study of Diabetes (EASD)/American Diabetes Association (ADA) guidelines10 for treatment 
intensification in patients with T2DM who do not reach HbA1c target below 7.0% on oral 
antidiabetic drugs (OADs) and basal insulin alone. The recommendation is a stepwise addition of 
bolus insulin when significant PPG excursions occur. A trial investigating step-wise addition of 
bolus insulin (basal-plus regimen) showed that around 75% of patients enrolled in the trial needed 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
15 of 113
three boluses after 36 weeks of treatment.11 Results from the PREFER trial indicated that one-third 
of the total prandial insulin dose is delivered with each meal in the majority of patients achieving 
HbA1c ≤7.0%.12 When used as part of a basal-bolus regimen in patients with T2DM who had 
previously received other insulin and/or OAD regimens, insulin aspart in combination with insulin 
degludec was a safe, well tolerated and effective treatment associated with clinically relevant 
reductions in hyperglycaemia.13
3.1.2
NovoRapid® (Insulin aspart)
Insulin aspart is currently marketed worldwide as NovoRapid® (in US it is NovoLog®) and is a 
rapid-acting insulin analogue indicated for the treatment of diabetes. In the remainder of this 
protocol the name NovoRapid® will be applied for the marketed formulation of insulin aspart.
Insulin aspart is homologous to human insulin, with the exception of the substitution of proline with 
aspartic acid at position B28. The rapid action of insulin aspart is related to a weakened tendency of 
the insulin molecules to self-associate due to this modification and thereby is related to faster 
absorption as compared with regular human insulin. Compared with human insulin, NovoRapid®
has a faster onset and a shorter duration of action, resulting in superior postmeal glucose control by 
means of lowering total glucose excursion following a meal, both in subjects with T1DM3, 14, 15 and 
in subjects with T2DM.16-18 This also allows NovoRapid® to be injected immediately before a meal, 
in contrast to regular human insulin which should be injected 30 minutes prior to the meal.
For further details, please refer to the current version of the NovoRapid® EU Summary of Product 
Characteristics19(SmPC) and the U.S. NovoLog® Label Information20.
3.1.3
Fast-acting insulin aspart
Fast-acting insulin aspart (faster aspart) (markedet as Fiasp®) is insulin aspart in a new formulation. 
Faster aspart is being developed with the objective of achieving an increased early absorption of 
insulin aspart compared to NovoRapid® thereby providing a faster insulin action. Faster aspart aims 
at approaching the physiological prandial insulin secretion pattern better than currently available 
treatment and thereby more effectively controlling the PPG excursions and achieving a better PPG
control and increased flexibility in the time of dosing around meals compared with NovoRapid®. 
Results from clinical pharmacology trials in adults comparing pharmacokinetic and 
pharmacodynamic properties of faster aspart and NovoRapid® have shown that faster aspart resulted 
in an earlier onset of appearance and a greater early exposure to insulin aspart than NovoRapid® in 
subjects with T1DM, with the largest difference found within the first 15 minutes after injection. 
Faster aspart also resulted in a greater early glucose-lowering effect than NovoRapid®, but no 
statistically significant difference between faster aspart and NovoRapid® in total glucose-lowering 
effect.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
16 of 113
In a therapeutic confirmatory basal-bolus trial in adult subjects with T1DM, faster aspart taken with 
the meal in combination with Levemir® effectively improved glycaemic control and the reduction in 
HbA1c was statistically significantly larger than with NovoRapid®. Mealtime faster aspart provided 
superior PPG control compared to NovoRapid® based on 2-hour PPG increment during a meal test. 
A statistically significant difference was also demonstrated for 1-hour PPG increment (meal test) in 
favour of mealtime faster aspart. No statistically significant difference was seen in overall rate of 
severe or BG confirmed hypoglycaemic episodes between mealtime faster aspart and NovoRapid®. 
The rate during the first one hour after start of a meal, constituting a smaller fraction of all severe or 
BG confirmed hypoglycaemic episodes, was statistically significantly higher for faster aspart 
compared to NovoRapid®. The overall safety profile for faster aspart and NovoRapid® was similar 
and as expected for insulin aspart.
In a therapeutic confirmatory basal-bolus trial in adult subjects with T2DM, adding and titrating 
mealtime faster aspart in combination with insulin glargine also effectively improved glycaemic 
control and non-inferiority to NovoRapid® regarding HbA1c change from baseline was confirmed. A 
statistically significant benefit in 2-hour PPG increment (meal test) could not be confirmed for 
faster aspart compared to NovoRapid®. A statistically significant difference was demonstrated for 
1-hour PPG increment (meal test) in favour of faster aspart compared to NovoRapid®. No 
statistically significant difference was seen in overall rate of severe or BG confirmed 
hypoglycaemic episodes between faster aspart and NovoRapid®. The rate during the first two hours 
after start of a meal, constituting a small fraction of all severe or BG confirmed hypoglycaemic 
episodes, was statistically significantly higher for faster aspart compared to NovoRapid®. The 
overall safety profile for faster aspart and NovoRapid® was similar and as expected for insulin 
aspart.
The safety profile of faster aspart is expected to be similar to that of NovoRapid®. The insulin aspart 
molecule has a well-known safety profile based on more than 15 years of clinical experience. 
Compared to NovoRapid® faster aspart contains excipients which results in a faster initial 
absorption of insulin aspart following subcutaneous injection. The added excipients are included in 
the U.S. Food and Drug Administration’s (FDA) list for approved drug products for injections, and 
no toxicological concerns have been predicted from subcutaneous use in humans at the proposed 
concentrations. For further details, please refer to the current version of the Fiasp® SmPC21. If not 
approved in the country of interest detailed information for faster aspart is available in the current 
edition of the Investigator’s Brochure (IB)22 and any updates hereof.
At the time of this protocol issuance, faster aspart is approved in EU and Canada among others.
3.1.4
Insulin degludec
Insulin degludec (marketed as Tresiba®) is a basal insulin with an ultra-long duration of action for 
once-daily subcutaneous administration at any time of the day, preferably at the same time every 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
17 of 113
day. After subcutaneous injection, soluble and stable multi-hexamers are formed creating a depot of 
insulin in the subcutaneous tissue. Insulin degludec monomers gradually separate from the multi-
hexamers thus resulting in a slow and continuous delivery of insulin degludec into the circulation, 
leading to the observed ultra-long pharmacokinetic and pharmacodynamic profiles and thereby a 
flat and stable glucose-lowering effect. The duration of action of insulin degludec is beyond 42 
hours within the therapeutic dose range.
For further details please refer to the current version of the Tresiba® SmPC23. If not approved in the 
country of interest detailed information for insulin degludec is available in the current edition and 
any updates of the IB24.
At the time of this protocol issuance, insulin degludec is approved in more than 70 countries 
including US, EU and Japan.
3.2
Rationale for the trial
The purpose of this trial is to confirm the effect and compare safety of faster aspart compared to 
NovoRapid® both in combination with insulin degludec with or without metformin in subjects with 
T2DM treated with a basal-bolus regimen. This trial will provide new information in subjects with 
T2DM already treated with a basal-bolus regimen as this was not studied in the phase 3a
programme.
In the European Medicines Agency (EMA) and FDA note for guidance on clinical investigation of 
medicinal products for the treatment of diabetes, HbA1c is considered the most widely accepted 
measure of overall, long-term glucose control. Consequently, HbA1c will be included as the primary 
endpoint.25, 26
The trial is intended to confirm that administration of faster aspart gives overall glycaemic control 
non-inferior to NovoRapid® and to confirm that faster aspart, with its faster onset of action, is
capable of demonstrating superior control of postprandial glucose regulation and excursions as well 
as a greater reduction in HbA1c in subjects with T2DM.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
18 of 113
4
Objectives and endpoints
4.1
Objectives
Primary objective
To confirm the effect in terms of glycaemic control of treatment with faster aspart compared to 
NovoRapid® both in combination with insulin degludec with or without metformin in adults with 
T2DM treated with a basal-bolus regimen, using a non-inferiority approach.
Secondary objectives
To confirm superiority of faster aspart compared to NovoRapid® both in combination with insulin 
degludec with or without metformin in adults with T2DM treated with a basal-bolus regimen in 
terms of:
!
Postprandial glucose regulation
!
Overall glycaemic control 
!
Postprandial glucose excursions 
To compare the safety of faster aspart to NovoRapid® both in combination with insulin degludec 
with or without metformin in adults with T2DM treated with a basal-bolus regimen.
4.2
Endpoints
Baseline is defined as randomisation (Visit 14) 
4.2.1
Primary endpoint
Change from baseline in HbA1c 16 weeks after randomisation
4.2.2
Secondary endpoints
4.2.2.1
Confirmatory secondary endpoints
!
Change from baseline in 1-hour PPG increment 16 weeks after randomisation (meal test)
!
Change from baseline in 1,5-anhydroglucitol 16 weeks after randomisation
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
19 of 113
4.2.2.2
Supportive secondary endpoints
Supportive secondary efficacy endpoints
!
Change from baseline in fasting plasma glucose (FPG) 16 weeks after randomisation
!
If a subject achieves HbA1c targets 16 weeks after randomisation:
o
HbA1c < 7.0% 
o
HbA1c < 7.0% without severe hypoglycaemia
!
Change from baseline in 30- minutes, 1- hour,  2- hour, 3- hour and 4- hour PPG and 30-
minutes, 2- hour, 3- hour and 4- hour PPG increment 16 weeks after randomisation (meal 
test)
!
Change from baseline in endpoints derived from the 7-9-7-point self-measured plasma 
glucose (SMPG) profile 16 weeks after randomisation:
o
Mean of the 7-9-7-point profile
o
Postprandial glucose and PPG increment (mean, breakfast, lunch, main evening meal)
o
Fluctuation in 7-9-7-point profile
o
Change in the nocturnal SMPG measurements
!
If a subject achieves PPG target (overall mean of daily PPG measurements in 7-9-7-point 
SMPG profile) 16 weeks after randomisation:
o
Overall PPG (1 hour) ≤7.8 mmol/L [140 mg/dL]
o
Overall PPG (1 hour) ≤7.8 mmol/L [140 mg/dL] without severe hypoglycaemia
!
Insulin dose (Units/day and Units/kg/day; total basal, total bolus and individual meal insulin 
dose) 16 weeks after randomisation
!
Change from baseline in lipids-lipoproteins profile 16 weeks after randomisation (total 
cholesterol, high density lipoproteins (HDL) cholesterol, low density lipoproteins (LDL) 
cholesterol)
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
20 of 113
Supportive secondary safety endpoints
!
Number of treatment emergent adverse events (AEs) during 16 weeks after randomisation
!
Number of treatment emergent injection site reactions during 16 weeks after randomisation
!
Number of treatment emergent hypoglycaemic episodes classified both according to the
ADA definition and Novo Nordisk definition during 16 weeks after randomisation
o
Overall
o
Daytime hypoglycaemic episodes
o
Nocturnal hypoglycaemic episodes (00:01-05:59 – inclusive)
o
Hypoglycaemic episodes from start of meal until 1, 2, 4 hours and from 2 hours 
(exclusive) to 4 hours (inclusive) after start of meal
!
Change from baseline in clinical evaluations 16 weeks after randomisation:
o
Physical examination
o
Vital signs (diastolic blood pressure, systolic blood pressure and pulse)
o
Electrocardiogram 
o
Fundoscopy/fundus photography
!
Change from baseline in central laboratory assessments 16 weeks after randomisation:
o
Haematology (erythrocytes, haematocrit, haemoglobin, leucocytes, thrombocytes)
o
Biochemistry (alanine aminotransferase (ALT), aspartate aminotransferase (AST), 
albumin, alkaline phosphatase, creatinine, potassium, sodium, total bilirubin)
!
Change from baseline in body weight and body mass index 16 weeks after randomisation
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
21 of 113
5
Trial design
5.1
Type of trial
This is a phase 3b, 16-week, multicentre, multinational, 1:1 randomised, double-blind, active 
controlled, treat-to-target, parallel group trial with a 12-week run-in period comparing the effect and 
safety of faster aspart to NovoRapid® both in combination with insulin degludec with or without 
metformin in subjects with T2DM treated with a basal-bolus regimen. 
Figure 5–1
Trial Design.
The trial design is summarised in Figure 5–1. The total duration of the trial is approximately 34 
weeks divided into the following periods:
!
An approximately 2-week screening period
!
A 12-week run-in period primarily for optimisation of the basal insulin and subject training
!
A 16-week treatment period
!
A 30-day follow-up period: FU1; 7 days after end of treatment and FU2; 30 days after end 
of treatment 
The trial includes a screening period followed by weekly visits/phone contacts during the trial. At 
Visit 2, all eligible subjects will be enrolled in a 12-week run-in period. After the run-in period, 
subjects eligible for randomisation (HbA1c ≤ 9.0% measured at Visit 13) will be randomised (1:1) to 
receive double blinded treatment with either faster aspart or NovoRapid® both in combination with 
once daily insulin degludec with or without metformin.  
   -14    -12 weeks        
                    
0
                 
                                        
  16 weeks +7d+30d   
Screening
Randomisation
Faster aspart + insulin degludec ± metformin
NovoRapid® + insulin degludec ± metformin 
End of 
treatment
Basal titration
Bolus titration
Bolus insulin analogue + insulin 
degludec ± metformin
FU1   FU2
12-week run-in period
16-week treatment 
period
HbA1c ≤9.0 % 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
22 of 113
All subjects will have a standardised meal test at baseline (Visit 14 before randomisation) and at 
end of treatment (Visit 30). The meal test will be described in more details in section 8.3.1.
After the 16-week treatment period, each subject will have a 30-day safety follow-up period.
5.2
Rationale for trial design
The 12-week run-in period has been included to ensure the subjects are being trained in the trial 
procedures and that the basal insulin titration is optimised. A 16-week treatment period is needed to 
obtain valid and adequate efficacy and safety data. 
The rational for the simple carbohydrate counting (carbohydrate awareness) is to ensure that 
subjects are able to better control the carbohydrate amount of their meals aiming at a similar 
carbohydrate intake between days as a supplement to the algorithm based titration.
The rationale for the meal test is to evaluate PPG regulation after a standardised meal when 
injecting faster aspart compared to NovoRapid®.
The treat-to-target approach, and thereby the very high frequency of contacts, has been chosen in 
order to ensure optimal titration of faster aspart and NovoRapid®.
The 7-day follow-up visit and 30-day follow up contact are introduced in order to collect 
information on AEs occurring in the follow-up period.
5.2.1
Rational for choice of non-inferiority margin 
In a recently finalised faster aspart trial (NN1218-4049, data on file) with a bolus insulin naïve 
T2DM adult population comparing a basal insulin treatment in addition to metformin to a full basal-
bolus insulin treatment in addition to metformin the estimated treatment effect in change from 
baseline HbA1c was - 0.94% [-1.17; -0.72]. In this trial the addition of 3 times daily faster aspart led 
to a reduction in HbA1c of 1.16% after 18 weeks of treatment. In a similar phase 4 trial27
investigating the stepwise addition of NovoRapid® to a full basal-bolus regimen in bolus naïve 
T2DM adults the observed reduction in HbA1c after 21 weeks of treatment was 1.15% (data ANA-
3786, data on file) with 3 times daily NovoRapid® added to basal insulin. This gives some 
indication that the effect of NovoRapid® versus placebo would be close to the 0.94% observed in 
trial NN1218-4049. Thus using a non-inferiority margin of 0.4%, one of the suggested margins in 
the FDA guidance26, an improvement of approximately 0.54% would have been preserved using the 
0.4% non-inferiority margin.
5.3
Treatment of subjects
At Visit 2, all eligible subjects will be enrolled in a run-in period where all subjects will be 
transferred from their pre-trial basal insulin treatment to insulin degludec once daily. They must 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
23 of 113
continue their pre-trial bolus insulin analogue with or without metformin. All OADs, except for 
metformin must be stopped at Visit 2. For subjects treated with metformin prior to the trial, they 
should continue with their pre-trial dose of metformin. The dose and dosing frequency of metformin 
should not be changed at any time during the trial, unless due to safety concerns. Initiation of any 
other diabetes treatmentis not allowed during the screening, run-in or treatment period and must be 
reported (see section 8.2.6).This includes metformin for subjects not treated with metformin prior 
to the trial. During the run-in period, the investigator will focus on optimising the basal insulin 
treatment using a treat-to-target approach following the titration guideline (Appendix A). The bolus 
insulin will not be titrated during the run-in period unless the investigator finds it necessary to 
adjust the bolus insulin for safety reasons. All subjects will receive dietary training regarding simple 
carbohydrate counting (carbohydrate awareness) in the run-in period.
All subjects should consume 3 main meals (breakfast, lunch and dinner) daily throughout the trial.
In the treatment period, eligiblesubjects must discontinue their pre-trial bolus insulin analogue and 
will receive double blinded treatment with either fasteraspart or NovoRapid®both in combination 
with once daily insulin degludec with or without metformin. The investigator should focus on 
optimising the bolus insulintreatment following thebolus dosing algorithm as described in the 
titration guideline (Appendix A). Surveillance of insulin titration will be performed by Novo 
Nordisk.
The maximum duration of treatment will be 28weeks. No maximum dose is specified. Doses are 
adjusted according to SMPGvalues (Appendix A).
Use of flash glucose monitoring or a real time continuous glucose monitoring system is not allowed 
throughout the trial.
5.4
Treatment after discontinuation of trial products
When discontinuing trial products, the subject should be switched to a suitable marketed product at 
the discretion of the investigator. Doses of subsequent antidiabetic treatment should be carefully 
titrated based on BG measurements, considering the stable effect and long half-life of insulin 
degludec.
5.5
Rationale for treatment
Based on the currently available pharmacokinetic data on faster aspart, it is anticipated that 
treatment with faster aspart as a mealtime insulin will enable insulin therapy to more closely 
approach a physiologic insulin secretory pattern. Consequently, the PPG excursions may be more 
effectively controlled. For further details, please refer to the current version of the faster aspart 
SmPC21 or IB.22
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
24 of 113
NovoRapid® will be used as a comparator to faster aspart in order to compare the effect and safety 
of faster aspart to the currently marketed insulin aspart formulation. As this is a double-blind trial, 
NovoRapid® and faster aspart will be titrated following the same recommendations.
Insulin degludec has been chosen as the basal insulin because it is a once-daily basal insulin and as 
effect and safety has been confirmed in adult subjects. The flat and stable glucose-lowering effect of 
insulin degludec makes it optimal when assessing the properties of bolus insulin (faster aspart 
compared to NovoRapid®).
Combination of insulin treatment with metformin is associated with better glycaemic control, fewer 
hypoglycaemic events, and less weight gain than treatment with insulin alone, therefore metformin 
should be continued when type 2 patients are on insulin therapy.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
25 of 113
6
Trial population
6.1
Number of subjects 
Number of subjects planned to be screened: 1803
Number of subjects planned to be included in the run-in period: 1262
Number of subjects planned to be randomised: 1072
A screening failure rate of approximately 30% and a run-in failure rate of approximately 15% are 
anticipated for this trial.
6.2
Inclusion criteria
For an eligible subject, all inclusion criteria must be answered “yes”. 
1. Informed consent obtained before any trial-related activities. Trial-related activities are any 
procedures that are carried out as part of the trial, including activities to determine suitability 
for the trial. 
2. Male or female, age ≥ 18 years at the time of signing informed consent.
3. Diagnosed with type 2 diabetes mellitus ≥ 10 years prior to screening (Visit 1).
4. Treated with a basal-bolus insulin regimen ≥ 1 year prior to the day of screening (Visit 1). A 
basal-bolus insulin regimen is defined as basal insulin once or twice daily and bolus insulin 
analogue taken with meals at least 3 times daily. Treatment with premixed insulin or soluble 
insulin combination is not considered a basal-bolus regimen.
5. Treated with or without oral antidiabetic drugs including extended release formulations. 
6. HbA1c 7.0-10.0% (both inclusive) as assessed by central laboratory at screening (Visit 1).
7. Able and willing to adhere to the protocol including performance of SMPG profiles and 
meal test.
8. Able and willing to consume 3 main meals (breakfast, lunch and dinner) daily throughout 
the trial.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
26 of 113
6.3
Exclusion criteria
For an eligible subject, all exclusion criteria must be answered “no”. 
1. Known or suspected hypersensitivity to trial product(s) or related products.
2. Previous participation in this trial. Participation is defined as signed informed consent. 
3. Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing 
potential and not using an adequate contraceptive method (adequate contraceptive measure 
as required by local regulation or practice).
For Bulgaria, Czech Republic, Germany, Greece, Italy, Poland, Romania and Spain: The 
following contraceptive measures are considered adequate: 
o
combined (estrogen and progestogen containing) hormonal contraception associated 
with inhibition of ovulation (oral, transdermal or intravaginal)
o
progestogen-only hormonal contraception associated with inhibition of ovulation
(oral, injectable or implantable)
o
intrauterine device
o
intrauterine hormone-releasing system
o
sexual abstinence
o
vasectomised partner
o
double barrier method (a combination of male condom with either cap, diaphragm or 
sponge with spermicide)
4. Participation in any clinical trial of an approved or non-approved investigational medicinal 
product within 30 days before screening (Visit 1). Clinical trials do not include non-
interventional studies.
5. Any disorder, except for conditions associated with type 2 diabetes mellitus, which in the 
investigator’s opinion might jeopardise subject’s safety or compliance with the protocol.
6. Any of the following: myocardial infarction, stroke, hospitalization for unstable angina or 
transient ischaemic attack within the past 180 days prior to the day of screening (Visit 1). 
7. Subjects presently classified as being in New York Heart Association (NYHA) Class IV. 
8. Planned coronary, carotid or peripheral artery revascularisation known on the day of 
screening (Visit 1).
9. Inadequately treated blood pressure defined as Grade 3 hypertension or higher (Systolic 
≥180 mmHg or diastolic ≥110 mmHg) at screening (Visit 1).
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
27 of 113
10. Treatment with injectable GLP-1 receptor agonists in a period of 90 days prior to screening 
(Visit 1). 
11. Anticipated initiation or change in concomitant medications (for more than 14 consecutive 
days) known to affect weight or glucose metabolism (e.g. treatment with orlistat, thyroid 
hormones, or corticosteroids).
12. Proliferative retinopathy or maculopathy requiring acute treatment. Verified by fundus 
photography or pharmacologically dilated fundoscopy performed within the past 90 days 
prior to Visit 2.
13. Presence or history of malignant neoplasms within the past 5 years prior to the day of 
screening (Visit 1). Basal and squamous cell skin cancer and any carcinoma in-situ is 
allowed. 
14. For subjects treated with metformin: Any contraindications or restrictions to use of 
metformin (according to local labelling) at investigator’s discretion.
6.4
Run-in period exclusion criteria
The subject must be withdrawn from the trial during the run-in period if the following applies after 
screening (Visit 1), and before or at randomisation (Visit 14): 
1. Included in the trial in violation of the inclusion and/or exclusion criteria.
2. Pregnancy
3. Intention of becoming pregnant
4. Simultaneous participation in another clinical trial of an approved or non-approved 
investigational medicinal product.
5. Any of the following: myocardial infarction, stroke, hospitalization for unstable angina or 
transient ischaemic attack.
6. Planned coronary, carotid or peripheral artery revascularisation.
7. Any disorder which in the investigator’s opinion might jeopardise subject’s safety.
8. Inability or lack of willingness to adhere to the protocol, based on the investigator’s 
judgement.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
28 of 113
6.5
Randomisation criterion
To be randomised, the randomisation criterion must be answered “yes”.
1. HbA1c ≤ 9.0% measured by the central laboratory at Visit 13 (week -1).
6.6
Criteria for premature discontinuation of trial products
Efforts must be made so that subjects attend and complete all scheduled visit procedures. Subjects 
should stay in the trial irrespective of lack of adherence to randomised treatment, lack of adherence 
to visit schedule or missing assessments. Only subjects who decline any further contact with the site 
in relation to the trial will be considered as withdrawn from the trial (see Section 6.7).
The subject may be prematurely discontinued from trial products at the discretion of the investigator 
due to a safety concern.
The subject must be prematurely discontinued from trial products if the following applies after 
randomisation:
1. Included in the trial in violation of the inclusion and/or exclusion criteria and/or randomised 
in violation of the randomisation criterion.
2. Pregnancy 
3. Intention of becoming pregnant
4. Simultaneous participation in another clinical trial of an approved or non-approved 
investigational medicinal product.
See Section 8.1.9 for procedures to be performed for subjects discontinuing trial products
prematurely.
6.7
Withdrawal from trial
The subject may withdraw consent at will at any time.
A subject is considered withdrawn from trial if the following applies before Visit 30:
!
Subject is lost to follow up (see Section 8.1.10))
!
Subject withdraws consent 
!
Death
Subjects withdrawing from trial before randomisation are considered screening or run-in failures.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
29 of 113
If the subject considers withdrawing consent the investigator must underline to the subject the 
importance of continuing in the trial despite trial product discontinuation. If the subject agrees to 
discontinue trial products but to stay in the trial, procedures described in section 8.1.9 must be 
followed. 
See Section 8.1.10 for procedures to be performed for subjects withdrawing consent after 
randomisation. 
6.8
Subject replacement
Subjects who discontinue trial products prematurely or withdraw from trial will not be replaced.
6.9
Rationale for trial population 
The trial population consists of adult subjects with T2DM who have been treated with a basal-bolus 
insulin regimen for at least 365 days, but are not optimally controlled as demonstrated by an HbA1c
≥ 7.0%, and may benefit from intensified insulin titration using a treat-to-target approach. The 
subjects need to have had T2DM for at least 10 years to ensure more progressed disease requiring a 
full basal bolus insulin supplementation. The subjects need to be on a basal-bolus insulin regimen 
for at least 365 days in order to ensure that they have been adequately educated and are familiar 
with using the intensive regimen required in this trial. This will also help to avoid including newly 
diagnosed patients that could enter in the metabolic remission period.
Subjects with an HbA1c > 10% are not included in this trial. This is because the trial protocol 
requires strict adherence and good subject compliance and a likely cause of elevated HbA1c > 10% 
in a diabetic subject is poor compliance with treatment regimens or an atypical course of the 
disease. The upper HbA1c limit is also expected to select a population that can achieve adequate 
basal insulin coverage in the 12-week run-in basal insulin titration period. Subjects in good 
glycaemic control defined as HbA1c <7.0 % may not benefit from this trial and hence the lower cut-
off value has been chosen. Subjects with an HbA1c > 9% are not eligible to be randomised into the 
treatment period of the trial. This is because the trial protocol requires strict adherence and good 
subject compliance, a likely cause of HbA1c > 9% after 12-week basal insulin titration period is poor 
compliance with treatment regimens or an atypical course of the disease.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
30 of 113
7
Milestones
Planned duration of recruitment period: 36 weeks
End of trial is defined as last patient last visit (LPLV).
Recruitment:
The screening and randomisation rate will be followed closely via the interactive voice/web 
response system (IWRS) in order to estimate when to stop screening. All investigators will be 
notified immediately when the recruitment period ends, after which no further subjects may be 
screened and the IWRS will be closed for further screening. All subjects screened during the 
recruitment period and found eligible for randomisation can be randomised within the timelines 
specified in the flow chart (see Section 2).
Trial registration:
Information of the trial will be disclosed at clinicaltrials.gov and novonordisk-trials.com. According 
to the Novo Nordisk Code of Conduct for Clinical Trial Disclosure28, it will also be disclosed 
according to other applicable requirements such as those of the International Committee of Medical 
Journal Editors (ICMJE)29, the FDA Amendment Act (FDAAA)30, European Commission 
Requirements31, 32 and other relevant recommendations or regulations. If a subject requests to be 
included in the trial via the Novo Nordisk e-mail contact at these web sites, Novo Nordisk may 
disclose the investigator’s contact details to the subject. As a result of increasing requirements for 
transparency, some countries require public disclosure of investigator names and their affiliations.
Primary Completion Date is the last assessment of the primary endpoint, and is for this protocol last 
subject first visit + 30 weeks corresponding to Visit 30. If the last subject is withdrawn/dropout 
early the Primary Completion Date is the date when the last subject would have completed Visit 30. 
The Primary Completion Date determines the deadline for results disclosure at clinicaltrials.gov
according to FDAAA.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
31 of 113
8
Methods and assessments
8.1
Visit procedures
The following sections describe the assessments and procedures. These are also included in the flow 
chart (see Section 2).
8.1.1
Screening (Visit 1)
Informed consent must be obtained before any trial related activity, see Section 18.2.
All subjects must be provided with a copy of their own signed and dated informed consent form.
Subjects will continue on their current diabetes treatment until start of run-in period (Visit 2) and 
they will not be supplied with any trial products until then.
The investigator must keep a subject screening log, a subject identification code list and a subject 
enrolment log. Only subjects who have signed the informed consent form should be included on the 
logs. The subject screening log and subject enrolment log may be combined in one log.
At screening, subjects will be provided with a card stating that they are participating in a trial and 
giving contact address(es) and telephone number(s) of relevant trial site staff. Subjects should be 
instructed to return the card to the investigator at the last trial visit or to destroy the card after the 
last visit.
Each subject will be assigned a unique 6-digit subject number which will remain the same 
throughout the trial. A screening session must be performed in the IWRS.
Screening failures
For screening failures the screening failure form in the electronic case report form (eCRF) must be 
completed with the reason for not continuing in the trial. Serious AEs (SAEs) from screening 
failures must be transcribed by the investigator into the eCRF. Follow-up on SAEs must be carried 
out according to Section 12.
A screening failure session must be made in the IWRS. When data has been monitored and queries 
have been resolved the case book must be signed.
Re-screening is NOT allowed if the subject has failed one of the inclusion, exclusion or 
randomisation criteria, this includes re-sampling if the subject has failed one of the inclusion,
exclusion or randomisation criteria related to laboratory parameters.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
32 of 113
8.1.2
Run-in
If the subject is found eligible to continue in the trial the subject will enter a run-in period. Visit 2 
can take place as soon as the subject has been found eligible and must take place no later than 17 
days after screening. 
In- or exclusion criteria must not be ticked “Yes” or “No” in the eCRF before source data is 
available. In case source data is not available “Result pending” must be chosen. This is particularly 
relevant for lab samples and in some cases the ECG (electrocardiogram) and eye examination 
result. The results of all the screening assessments must be available (including central laboratory 
results) and must have been reviewed by the investigator before the subject can enter the run-in 
period.
At start of the run-in period (Visit 2), the subject will receive the basal insulin trial product (Insulin 
degludec). The subjects must be trained in how to handle the insulin pen injectors (see section 
8.6.2). Training may be repeated during the trial if necessary. First date of trial product (basal 
insulin) must be recorded in the eCRF.
A run-in dispensing session must be performed in the IWRS. A drug accountability session 
confirming dispensing of allocated trial product should also be performed when dispensing trial 
product.
The BG meter and electronic diary (eDiary) should be provided to the subjects at Visit 2. Subjects 
must be trained in the BG meter and eDiary and complete a practise eDiary training, before the 
eDiary can be used.
Run-in failures
If the subject is not eligible to be randomised (i.e. has met one of the run-in period exclusion 
criteria, has not met the randomisation criterion or withdraw from trial before randomisation) then 
the subject will be considered a run-in failure. Consequently, a run-in failure session must be made 
in the IWRS system and a run-in failure form must be completed in the eCRF together with the 
reason for not continuing in the trial. The last date of trial product must be captured in the eCRF. 
No follow-up visit should take place and no additional assessments are needed.
The eDiary must be returned to the site. 
For Argentina, Russia, Serbia and Ukraine: The BG meter should also be collected by the 
investigator.
SAEs and non-serious AEs from run-in failures must be recorded by the investigator in the eCRF. 
Follow-up of AEs must be carried out according to section 12.3.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
33 of 113
When data has been monitored and queries have been resolved the case book must be signed in the 
eCRF.
8.1.3
Randomisation 
If the subject meets the randomisation criterion as measured at Visit 13, then the subject will at 
Visit 14 be randomised into one of the two treatment arms using an IWRS randomisation session. A 
drug accountability session confirming dispensing of allocated trial products should also be 
performed when dispensing trial products.
First date of the randomised trial product (bolus insulin) must be recorded in the eCRF.
The subject must attend randomisation visit fasting. For definition of fasting, please see section 
8.1.5.
Investigator must hand out the subject mealtime insulin dose adjustment guide and instruct subjects
how to self-titrate (section 8.3.3 and Appendix A).
8.1.4
Phone contacts
Before any phone contact, both the investigator and subject should agree on the timing and direction 
of the call. The investigator remains responsible for ensuring that the phone contacts occur even if it 
is agreed that the subject should call the site. A phone contact may be converted to a site visit if 
needed.
8.1.5
Fasting visits
The subjects must attend the visits specified in the flowchart (section 2) in a fasting condition. 
Fasting is defined as at least eight hours without drink or food intake prior to the visit except for 
water.
Insulin dosing (including basal insulin) and medication which should be taken with or after a meal 
should be withheld until blood sampling has been performed. If a subject attends the visit non-
fasting, then the subject’s blood samples, meal test and body weight measurement must be re-
scheduled within the visit window and at Visit 14 before randomisation to trial product.
8.1.6
Rescheduled visits
The date of the rescheduled assessment in the eCRF should reflect the actual date of the rescheduled 
assessment (i.e. the actual visit date will differ from the assessment date under the same visit).
8.1.7
End of treatment
At end of treatment trial products must be discontinued and a completion IWRS session must be 
performed. Last date on the basal and bolus trial insulin must be recorded in eCRF.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
34 of 113
The subject must be switched to a suitable marketed product at the discretion of the investigator and 
this product must be recorded on the concomitant medication (diabetes) form in eCRF, as described 
in section 8.2.6.
8.1.8
Follow-up period
The follow-up visit 1 (FU1) is a site visit and must take place 7-17 days after the end of treatment 
visit. Follow-up contact 2 (FU2) is a phone contact and must take place 30-35 days after the end of 
treatment visit.
Follow-up visit 1
The following data will be collected:
!
AEs 
!
Concomitant medication
!
Current diabetes medication
!
Hypoglycaemic episodes
!
Additional information on injection site reactions
Follow-up contact 2
The following data will be collected:
!
AEs
!
Concomitant medication
!
Current diabetes medication
!
Hypoglycaemic episodes
8.1.9
Premature discontinuation of trial products
If a subject prematurely discontinues trial products after randomisation (Visit 14), the investigator 
must undertake procedures similar to those for Visit 30 as soon as possible, also called Visit 30A 
(see flowchart section 2). 
Premature discontinuation of trial products must be registered in the eDiary webportal. This must be 
performed at least 4 days prior to Visit 30A to ensure scheduling of the 7-9-7-point SMPG profile 
on the three days prior to Visit 30A. Subjects should perform this 7-9-7 point SMPG profile before 
discontinuing trial products.
At Visit 30A subjects must undergo the meal test before discontinuing trial products. The meal test 
should be performed with bolus trial insulin. If it is not feasible due to safety reasons including 
pregnancy as judged by the investigator the meal test should be performed with the marketed bolus 
product the subject is switched to. 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
35 of 113
The primary reason for premature discontinuation of trial products must be specified in the eCRF, 
and final drug accountability must be performed. A treatment discontinuation session must be made 
in the IWRS after the final meal test.
The subject should be switched to a suitable marketed product at the discretion of the investigator. 
The medication should be recorded on the concomitant medication (diabetes) form in the eCRF, as 
described in section 8.2.6 at each contact after trial product discontinuation.
The subject should also complete the follow-up visits (FU1 and FU2) 7 days and 30 days after 
discontinuation of trial product. Visit 31 (FU1) can be converted into a phone contact as the eDiary 
will not be collected at this visit for the subjects that discontinue trial products prematurely.
In addition, subjects prematurely discontinued from trial products should continue with the per 
protocol planned visits at 4 (Visit 18), 8 (Visit 22), 12 (Visit 26), 16 (Visit 30) weeks after 
randomisation depending on when the subject discontinues trial products. The meal test at Visit 30
should be done with the subjects’ currently prescribed insulin treatment with the same bolus insulin 
dose as at baseline. 
The following assessments are not applicable for subjects that prematurely discontinue trial 
products: 4 point profiles, daily doses of trial insulin, time of injection, dose recommendation, 
reason for deviation and collection of technical complaints.
In the following situations, only one visit should take place:
!
If Visit 30A is within 2 weeks of one of the per protocol planned visits, only Visit 30A 
should be performed
!
If any per protocol planned visit and the windows of a follow-up visit are overlapping 
according to visit schedule, only the per protocol planned visit should be performed
It should be documented in the medical records if subject refuses to attend a visit from Visit 30A 
and onwards.
The eDiary must be returned to the site at the last site visit (Visit 30). 
A subject that permanently discontinues trial product before the End of Treatment visit (V30), will 
be considered to be a treatment non-completer. 
For Argentina, Russia, Serbia and Ukraine: The BG meter should be collected by the investigator at
the last scheduled site visit (Visit 30).
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
36 of 113
eDiary records after premature discontinuation of trial products:
Date, actual clock time and value of the SMPG measurements performed as part of the 7-9-7-point 
profiles on the three consecutive days prior Visit 30A, Visit 22 and Visit 30 will be transferred to 
the eDiary, where each measurement should be assigned to the corresponding time point.
For hypoglycaemic episodes only a reduced amount of information should be recorded from one 
day after Visit 30A and to Visit 30 (see section 8.4.2):
8.1.10
Withdrawal from trial
If a subject withdraws consent, the investigator must aim to undertake procedures similar to those 
for Visit 30 including the meal test, as soon as possible, also called Visit 30A. The investigator must 
encourage the subjects to undergo the meal test at Visit 30A. The meal test must be performed with 
bolus trial insulin according to randomisation. If it is not feasible due to safety reasons including 
pregnancy as judged by the investigator the meal test should be performed with the marketed bolus 
product the subject is switched to.
If the subject agrees, the investigator must aim to perform the follow up visits (FU1 and FU2) 7 and 
30 days after discontinuation of trial product.
In case a premature discontinuation of trial product subject chooses to withdraw consent from trial 
after completing Visit 30A, FU1 and FU2, the investigator must encourage the subjects to undergo 
procedures of Visit 30, as soon as possible, whereas FU1 and FU2 are not to be completed again.
The end of treatment and end of trial form in the eCRF must be completed, and final drug 
accountability must be performed even if the subject is not able to come to the trial site. A treatment 
discontinuation session must be made in the IWRS. The case book must be signed.
Although a subject is not obliged to give his/her reason(s) for withdrawing consent, the investigator 
must make a reasonable effort to ascertain the reason(s), while fully respecting the subject’s rights. 
Where the reasons are obtained, the primary reason for withdrawing consent must be specified in 
the eCRF.
A subject that is withdrawn from trial before the End of Treatment Visit (V30), will be considered 
to be a treatment non-completer and a trial non-completer. 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
37 of 113
8.1.10.1
Lost to follow-up
The following actions must be taken in relation to a subject who fails to attend the site for a 
required visit:
!
The site must attempt to contact the subject and reschedule the missed visit as soon as 
possible
!
The site must re-train the subject in the importance of maintaining the scheduled visits 
In cases in which the subject is deemed lost to follow-up the investigator must make every effort to 
regain contact with the subject (e.g. telephone calls to friends or family members, e-mails or 
certified letter to the subject as applicable). These contact attempts must be documented in the 
subject’s medical records. Should the subject continue to be unreachable, only then will he/she be 
considered to have withdrawn from the trial with the primary reason being “lost to follow-up”.
8.1.11
Review of results
Review of ECG results, eye examination report, laboratory reports, data entered in the eDiaries etc. 
must be documented either on the documents, printouts, in the eDiary webportal or in the subject’s 
medical record.
If clarification of entries or discrepancies in the eDiary is needed, the subject must be questioned 
and a conclusion made in the subject’s medical record. Care must be taken not to bias the subject.
Any discrepancies or missing data points available elsewhere related to a 7-9-7 point profile or 
hypoglycaemic episodes must be corrected or added.
8.2
Subject related information/assessments 
8.2.1
Demography
Demography will be recorded at screening and consists of:
!
Date of birth (according to local regulation)
!
Sex
!
Ethnicity (according to local regulation)
!
Race (according to local regulation)
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
38 of 113
8.2.2
Diabetes history and diabetes complications 
Diabetes history and diabetes complications will be recorded at screening and consists of:
!
Date of diagnosis of T2DM 
!
!
Information regarding diabetes complications including date of onset
–
Diabetic retinopathy
–
Diabetic neuropathy
–
Diabetic nephropathy
–
Macroangiopathy (including peripheral vascular disease)
8.2.3
Hypoglycaemia unawareness 
Information on hypoglycaemia unawareness will be recorded at screening according to Clarke’s 
questionnaire, question 8.33
The investigator must ask the subject in the following way: “To what extent can you tell by your 
symptoms that your blood glucose is low?” The subject can answer never, rarely, sometimes, often 
or always.
Subjects answering ‘never, rarely or sometimes’ are considered as having impaired awareness of 
hypoglycaemia.
8.2.4
Concomitant illness and medical history
–
A concomitant illness is any illness that is present at the start of the trial (i.e. at the first 
visit (Visit 1)) or found as a result of a screening procedure or other trial procedures 
performed before exposure to trial product. 
T2DM and diabetes complications should be reported separately in the Diabetes History/Diabetes 
Complications Form in the eCRF.
Medical history is a medical event that the subject has experienced in the past. Only relevant 
medical history, as judged relevant by the investigator, should be reported. 
The information collected for concomitant illness and medical history should include diagnosis, 
date of onset and date of resolution or continuation, as applicable.
Any change to a concomitant illness should be recorded during the trial. A clinically significant 
worsening of a concomitant illness must be reported as an AE.
It must be possible to verify the subject’s medical history in source documents such as subject’s 
medical record. If a subject is not from the investigators own practice; the investigator must make 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
39 of 113
reasonable effort to obtain a copy of subject’s medical record from relevant party e.g. primary 
physician. The investigator must document any attempt to obtain external medical information by 
noting the date(s) when information was requested and who has been contacted.
8.2.5
Concomitant medication
A concomitant medication is any medication, other than the trial product(s), which is taken during 
the trial, including the screening, run-in, treatment and follow-up periods.
Details of any concomitant medication must be recorded at Visit 1. Changes in concomitant 
medication must be recorded at each visit as they occur. 
The information collected for each concomitant medication includes trade name or generic name, 
indication, start date and stop date or continuation. 
If a change is due to an AE, then this must be reported according to Section 12. If the change 
influences the subject’s eligibility to continue in the trial, the monitor must be informed.
8.2.6
Concomitant medication (diabetes)
Any diabetes medication other than the trial product(s) which is taken during the trial, including the 
screening, run-in, treatment and follow-up periods must be recorded in a separate concomitant 
medication (diabetes) form in the eCRF including the trade name or generic name, total daily dose, 
frequency, start date and stop date or continuation. For subjects treated with metformin it is the start 
date and dose of last stable metformin dose which should be reported.
At the run-in visit (Visit 2) basal insulin and all OADs except for metformin must be discontinued 
and a stop date recorded. For subjects treated with metformin, investigator should at each weekly 
contact (visit or phone contact), confirm with the subject that dose and frequency of metformin has 
been unchanged. This should be documented in the medical records. 
At the randomisation visit (Visit 14) pre-trial bolus insulin must be discontinued and a stop date 
recorded.
It is important to ensure subjects adhere to treatment. Therefore, during the treatment period the 
investigator must also at each weekly contact (visit or phone contact), evaluate if the subject has 
taken any ancillary treatment since last contact. Ancillary treatment is defined as any diabetes 
medication - other than randomised treatment (trial products in the basal-bolus regimen with or 
without metformin) initiated in case of unsatisfactory glycaemic control. It should be registered as 
such on the concomitant medication (diabetes) form in the eCRF. For subjects not treated with 
metformin prior to the randomisation, initiation of long term use of metformin is considered as 
ancillary treatment. A medication error (Section 8.4.1.1) is as such not considered as ancillary 
treatment.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
40 of 113
8.2.7
Childbearing potential
It must be recorded in the eCRF whether female subjects are of childbearing potential. Reason for 
not being of childbearing potential must be documented in the medical records. 
Pregnancy testing must be performed on female subjects of childbearing potential as described in 
Section 8.5.2. Female subjects of childbearing potential must be instructed to use adequate 
contraceptive methods throughout the trial and until 1 week after end of treatment.
Female of non-childbearing potential is defined as:
!
Female who has undergone a hysterectomy, bilateral oophorectomy or bilateral tubal 
ligation 
!
Postmenopausal defined as no menses for 12 months without an alternative medical cause
!
Other medical reasons preventing childbearing potential 
8.2.8
Tobacco use
Details of tobacco use must be recorded at Visit 1. Smoking is defined as smoking at least one 
cigarette or equivalent daily. 
Smoking status:
!
Never smoked
!
Previous smoker
!
Current smoker
8.3
Efficacy assessments
8.3.1
Meal test
The subject will undergo a standardised liquid meal test at two visits (see flowchart section 2) and 
will have their 30 minute and 1, 2, 3 and 4 hour PPG measured. The total duration of the meal test is 
expected to be up to 6 hours including preparations. During that time 6 blood samples will be 
drawn, as specified in the Table 8–1. 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
41 of 113
Before initiation of the meal test 
The subject should be instructed to: 
!
Follow normal routine regarding eating and exercise habits on the day prior to the meal test
!
Refrain from intake of alcohol and use of medications that affect motility (i.e. prokinetics, 
anticholinergics, tricyclic antidepressants) on the day prior to the meal test, unless the 
subject was on this medication at trial entry and does not change the product or product dose
!
Remember to bring their current/trial bolus and basal insulin, eDiary and BG meter to the 
meal test visits
!
Attend the meal test visits in a fasting condition. For definition of fasting, please refer to 
section 8.1.5. If subjects are normally dosing basal insulin in the morning, it is important 
they wait until after completion of the meal test
!
Achieve an SMPG value within a range of 4.0-8.8 mmol/L [71-160 mg/dL] before 
beginning the meal test. The SMPG value should be verified at the site before starting the 
meal test.
The meal test should be re-scheduled within the visit window and at Visit 14 before randomisation 
to trial product in case:
!
any hypoglycaemic episode occurs from midnight before the meal test 
!
the subject is not fasting or 
!
the SMPG value is outside the range.
At Visit 14 (randomisation visit) the investigator must evaluate if the subject is eligible to continue 
in the trial before the meal test is performed. Only subjects eligible for randomisation should have 
the Visit 14 meal test performed.
Bolus insulin dose and meal test carbohydrate calculation
The standardised liquid meal will be provided by Novo Nordisk. The volume of the liquid meal
should be measured out by the investigator to be the equivalent to 78 grams of digestible 
carbohydrates. 
At the baseline meal test, the bolus insulin dose should be calculated by the investigator by dividing 
the carbohydrate content of the standardised meal by a calculated insulin:carbohydrate ratio. The 
insulin:carbohydrate ratio in this trial is calculated by dividing 500 by the total daily dose (taken 
from the day before) of both basal and bolus insulin. The calculated dose should be rounded to the 
nearest whole unit. 
Same bolus insulin dose will be used for the meal test at end of treatment. The insulin should be 
administered subcutaneously in the abdomen in accordance with Table 8–1.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
42 of 113
Initiation of meal test
The subject’s body weight must be measured before start and a blood sample must be drawn two 
minutes before intake of the standardised meal. 
For the meal test at Visit 14 the subject must receive the bolus insulin that was also used in the run-
in period. 
For the meal test at Visit 30 the subject should receive the bolus trial insulin they were randomised 
to and have used throughout the treatment period. If subject has been prematurely discontinued they 
should perform a meal test both at Visit 30A and again at Visit 30; the meal test at Visit 30 should 
be performed with the marketed bolus product the subject was switched to. 
The start of consumption of the liquid meal is defined as time point 0. The subject must consume
the liquid meal as quickly as possible and within 12 minutes. The investigator should confirm that 
the subject consumed the required volume of the standardised liquid meal in the eCRF.
Table 8–1
Meal test schedule
Time point 
(minutes)
Blood 
sample 
SMPG 
values 
Standardised meal
Bolus insulin injection
Before start 
of meal test
X (within target 
range 4.0-8.8 
mmol/L [71-160 
mg/dL])
-2
X
0
X (as appropriate 
to ensure 
subject’s safety)
X
X
Insulin injection at the start of the meal
30
X
60
X
120
X
180
X
240
X
End of meal 
test
X (for subject’s 
safety)
Conduct of meal test
The subject should stay in the clinic to have the blood samples drawn after 30 minutes, 1, 2, 3 and 4 
hours from the start of the standardised meal, as detailed in Table 8–1. The samples will be 
analysed by the central laboratory.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
43 of 113
During the meal test the subject should be resting in a chair. No smoking or intake of food and 
liquids will be allowed during the meal test, except for water consumption which is allowed two 
hours after intake of the standardised meal.
If SMPG values ≤3.9 mmol/L [70 mg/dL] are measured, then the hypoglycaemia should be treated 
with glucose rescue treatment according to local practice and the meal test should continue 
according to the investigator’s discretion. The hypoglycaemic episode must be reported. Please see 
section 8.4.2. 
After the end of the meal test, the investigator should make sure that the subject is safe to leave the 
site by performing an additional SMPG measurement.
Only after the meal test at Visit 14 is completed, the subject will be allowed to start treatment with 
randomised trial product. 
Data collection
The following must be recorded in relation to the meal test: 
!
Fasting status
!
SMPG value measured before the meal test and within allowed ranges and the time of the 
measurement
!
Actual clock start and end time of standardised meal
!
Volume of meal consumed
!
Confirmation that the subject consumed the required volume of the standardised meal
!
Batch number of the standardised meal consumed
!
Actual clock time and dose of bolus insulin 
!
Actual clock time of blood samples
!
Hypoglycaemic episodes, if relevant
o
SMPG value, time of intervention and amount of glucose rescue treatment and 
hypoglycaemic episode form
Laboratory results from meal test data will be loaded directly into the trial database by the central 
laboratory. The meal test results will not be provided to the investigator until after LPLV in order to 
keep the blinding of the subject and investigator.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
44 of 113
8.3.2
Self-measured plasma glucose
At Visit 2, subjects will be provided with a BG meter including ancillaries as well as instructions 
for use, if needed. The subjects will be instructed in how to use the device.
The BG meters use test strips calibrated to plasma values. Therefore, all measurements performed 
with capillary blood are automatically calibrated to plasma equivalent glucose values, which will be 
shown on the display. 
Only the BG meter provided by Novo Nordisk should be used for the measurements required in the 
protocol. 
For Argentina, Russia, Serbia and Ukraine: The BG meter should be collected by the investigator at 
the last scheduled site visit FU1 (Visit 31).
Subjects must be instructed in how to transfer the results of the SMPG values daily into the 
eDiaries.
4-point self-measured plasma glucose profile 
The 4-point SMPG profile will be recorded for insulin titration purposes. Subjects will be instructed 
to perform 4-point profiles every day from Visit 2 to Visit 30 for titration purposes. The 
measurements should be performed at the following time points:
!
Before breakfast
!
Before lunch
!
Before main evening meal (dinner)
!
At bedtime
For SMPG measurements actual clock time, date and value should be transferred to the eDiary, 
where each measurement should be assigned to the corresponding time point.
SMPG values measured before breakfast, lunch, main evening meal, and at bedtime should be 
performed before any injection of bolus insulin and just before the start of the meal (breakfast, 
lunch or main evening meal). SMPG values measured before breakfast should be performed in a 
fasting condition. The 4-point profile is part of the 7- or 9-point profiles which are measured prior 
to selected site visits.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
45 of 113
7-9-7 point self-measured plasma glucose profile
The 7- and 9-point SMPG profiles will be used for titration purposes and evaluation of the effect of 
the trial. The subject will be instructed to perform a 7-9-7 point profile on the 3 consecutive days 
just before selected visits as outlined in the flowchart in section 2. See Table 8–2 (7-point profiles 
indicated as X and the 9-point profile indicated as √). 
Table 8–2
7-point SMPG profiles with additional 9-point SMPG profile
Time point
Day -3
7-point 
profile
Day -2
9-point 
profile
Day -1
7-point 
profile
Before breakfast
X
∀
∀ #X)a
60 minutes after the start of 
breakfast
X
∀ 
X
Before lunch
X
∀ 
X
60 minutes after the start of 
lunch
X
∀ 
X
Before main evening meal
X
∀ 
X
60 minutes after the start of 
main evening meal
X
∀ 
X
At bedtime
X
∀ 
X
At 4 am
∀ 
aThe last SMPG in the 9-point profile and the first SMPG of the 7-point profile on day-1 are overlapping.
For SMPG measurements actual clock time, date and value should be transferred to the eDiary, 
where each measurement should be assigned to the corresponding time point.
SMPG values measured before breakfast, lunch and main evening meal, and at bedtime should be 
performed before any insulin injection and just before the start of the meal (breakfast, lunch or main 
evening meal). SMPG values measured before breakfast should be performed in a fasting condition.
The measurements will be used to evaluate the glucose profile.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
46 of 113
8.3.3
Insulin dose
The subject should be instructed to report the following concerning dosing of trial products in the 
eDiary:
!
Date, actual clock time and dose of basal and bolus insulin on a daily basis from Visit 2 to 
Visit 30.
!
Date, actual clock time, and dose for other (extra) bolus insulin administration as well as 
time and type of previous main meal and reason for the extra bolus from Visit 2 to Visit 30.
Dosing and dose adjustment (new dose)
The recommended insulin doses will be calculated in the eDiary webportal based on 
recommendations from the Insulin Titration Guideline (see Appendix A). At each visit/phone 
contact the investigator will titrate the subjects by making prescribed dose adjustments based on the 
recommendation from the eDiary webportal if applicable and provide the new prescribed dose to 
the subject. 
Investigator must hand out the subject mealtime insulin dose adjustment guide at Visit 14 and 
should instruct subjects to perform self-titration of bolus (mealtime) trial insulin between the 
scheduled visits/phone contacts from Visit 14 to Visit 30. 
The investigator should record the following in the eDiary webportal:
!
Prescribed doses of trial products
!
Reason for deviating in dose adjustments from the titration guideline, if applicable
The subject should report the following in the eDiary: 
!
Dose adjustment of bolus trial insulin 
8.4
Safety assessments  
In case of an abnormal and clinically significant finding, the investigator must record the finding on 
the concomitant illness form if it is present at screening. Any new finding fulfilling the definition 
stated in section 12 during the trial and any clinically significant worsening from baseline must be 
reported as an AE.
8.4.1
Adverse events
Adverse events (AEs) must be reported at each visit in accordance with the procedures outlined in 
Section 12.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
47 of 113
8.4.1.1
Medication error
If a medication error is observed during the trial, the following information is required and a 
specific event form must be completed in the eCRF in addition to the AE form:
!
Trial product(s) involved
!
Classification of medication error
!
Whether the subject experienced any hypoglycaemic episode and/or AEs as a result of the 
medication error
!
Suspected primary reason for the medication error
For definition of medication errors, see Section 12.1.4.
8.4.1.2
Adverse events requiring additional data collection
For some AEs additional data collection is required and specific event forms must be completed in 
the eCRF in addition to the AE form. 
In case any of these events fulfil the criteria for a SAE, please report accordingly, see Section 12.
Injection site reaction
If an event of injection site reaction is observed the following additional information must be 
obtained if available on the injection site reaction form:
!
Type of reaction – local or generalised
!
Symptoms associated with the event
!
Treatment given for the event
!
Association with the trial product(s)
!
Relevant risk factors associated with the event
The investigator has to evaluate whether further actions are needed (e.g. extra visits, supervised 
injection, premature discontinuation of trial products, dermatologist consultation).
If any injection site reactions occur after Visit 31 they should still be recorded as AEs, but the 
additional data collection on the specific event form in the eCRF is not required.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
48 of 113
8.4.2
Hypoglycaemic episodes
Plasma glucose should always be measured and recorded when a hypoglycaemic episode is 
suspected. 
All plasma glucose (PG) values:
!
≤ 3.9 mmol/L (70 mg/dL) or 
!
> 3.9 mmol/L (70 mg/dL) occurring in conjunction with hypoglycaemic symptoms 
should be reported in the eDiary by the subject from Visit 2 to Visit 31 (FU1) and in the eCRF by 
the investigator from FU1 to FU2 according to the instructions below . However, only a reduced 
amount of information will be collected for hypoglycaemic episode as marked with an asterisk* in 
this section in the following periods:
!
During the run-in period from Visit 2 to Visit 14 
!
One day after Visit 30 to FU2
!
For subjects discontinuing trial products prematurely: One day after Visit 30A to Visit 30 
In case a subject is not able to fill in the eDiary e.g. in case of a fatal event, then investigator will be 
allowed to report the hypoglycaemic episode in the eCRF. 
Upon onset of a hypoglycaemic episode the subject is recommended to measure PG every 15 
minutes until the SMPG value is >3.9 mmol/L (70 mg/dL) and/or symptoms have been resolved in 
accordance to current guidelines.34
A SMPG value ≤3.9 mmol/L (70 mg/dL) or hypoglycaemic symptoms must trigger a 
hypoglycaemic episode form to be completed by the subject. Repeated SMPG measurements and/or 
symptoms, occurring within a period of 60 minutes after onset on a hypoglycaemic episode, will by 
default be considered as one hypoglycaemic episode until a succeeding SMPG value is >3.9 
mmol/L (70 mg/dL) and/or symptoms have been resolved and should be reported on one 
hypoglycaemic episode form. SMPG measurements ≤3.9 mmol/L (70 mg/dL) or hypoglycaemic 
symptoms after the 60 minutes period shall trigger the reporting of a new hypoglycaemia episode 
and prompt the subject to fill out a new hypoglycaemic episode form until a succeeding 
measurement is >3.9 mmol/L (70 mg/dL) and/or symptoms have been resolved.
In case of several low SMPG values within the 60 minutes interval, the lowest value is the one that 
will be reported as the SMPG value for the hypoglycaemic episode but the start time of the episode 
will remain as the time for the first SMPG value and/or symptom.
The eDiary will automatically link multiple values within 60 minutes to the same hypoglycaemic 
episode following above principles.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
49 of 113
The record should include the following information:
!
Start date and time of the hypoglycaemic episode*
!
The PG level before treating the episode (if available) and any follow up measurements.*
The lowest value measured during the hypoglycaemic episode will be reported as the PG value 
for the episode, the remaining values will be kept as source data in the eDiary.
!
Whether the episode was symptomatic (Yes/No)*
A hypoglycaemic episode starting without symptoms should be updated to symptomatic if the 
subject experiences symptoms later during the episode. The subject is therefore to be questioned 
whether there are changes to symptoms for each low SMPG value within the 60 minutes period 
or until the subject has confirmed that the hypoglycaemic episode is symptomatic.
!
Whether the subject was able to treat him/herself*
If the severity of a hypoglycaemic episode aggravates, only one hypoglycaemic episode should 
be reported reflecting the most severe degree of hypoglycaemia. The subject is therefore to be 
questioned whether he/she is able to self-treat for each low SMPG value within the 60 minutes 
period or until the subject respond that he/she is not able to self-treat.
!
Date, time and dose of last bolus insulin administration prior to the episode 
!
Date, time and dose of last basal administration prior to the episode 
!
Date and time of last main meal (not including snacks) prior to the episode
!
Whether the episode occurred in relation to physical activity
!
Change in any concomitant illness
!
Any sign of fever and/or other acute disease 
!
Whether the subject was asleep when the episode occurred
–
If yes, whether the symptoms of the episode woke up the subject
The answer to the question: "Was the subject able to treat him/herself?" must be answered "No" for 
an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or 
take other corrective actions. Plasma glucose concentrations may not be available during an event, 
but neurological recovery following the return of PG to normal is considered sufficient evidence 
that the event was induced by a low PG concentration.34
Oral carbohydrates must not be given if the subject is unconscious.
If the question "Was the subject able to treat him/herself?" is answered "No", the following 
information should be recorded by the subject:
!
Who assisted in the treatment of the hypoglycaemic episode (i.e. medical person or non-
medical person)?
!
Where the treatment was administered (in clinic/emergency room/hospital or other. If the 
subject was treated in clinic/emergency room/hospital, whether they were transported in an 
ambulance or not)
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
50 of 113
!
Type of treatment provided by another person (i.e. oral carbohydrates, glucagon, IV glucose 
or other)
!
Were symptoms alleviated after administration of treatment?*
!
Factors contributing to the episode (i.e. physical activity, missed meal, diet change, 
medication error (i.e. overdose, mix-up between products, incorrect use of device), 
miscalculation of dose of antidiabetic medication, other factors not listed or unknown)
!
Did the subject experience seizure?*
!
Was the subject unconscious/comatose?*
!
Did the subject experience any of the following symptoms35 (layman term used in the
eDiary is specified in brackets if different from the protocol term)? 
–
Autonomic: sweating, trembling, hunger or palpitations (rapid or irregular heart beat)
–
Neuroglycopenic: confusion, drowsiness, speech difficulty, visual disturbances, odd 
behaviour, impaired balance or incoordination (reduced ability to coordinate movement)
–
General malaise: headache or malaise (feeling discomfort/unease)
!
Other symptoms 
The investigator must review the eDiary data for correct reporting of SMPGs and hypoglycaemic 
episodes. In case of incomplete or incorrect data in the eDiary, the subject must be questioned 
whether there have been any severe hypoglycaemic episodes since the last visit, i.e. any 
hypoglycaemic episodes where the subject was not able to self-treat. Any severe hypoglycaemic 
episodes must be reported. 
Low SMPG values for non-severe hypoglycaemic episodes not having a hypoglycaemic episode 
form completed within 7 days since the SMPG measurement should be reported on a 
hypoglycaemic episode form with as much information as possible. Novo Nordisk will not query 
for additional data except for the start date, SMPG value and whether the subject was able to self-
treat due to decreased validity of such data.36, 37
The subject must be re-trained in how to report hypoglycaemic episodes if the investigator identifies 
unreported hypoglycaemic episodes.
If the hypoglycaemic episode fulfils the criteria for an SAE then an AE form and a safety 
information form (SIF) must also be filled in the eCRF, see Section 12. One AE-form and SIF can 
cover several hypoglycaemic episode forms if the subject has not recovered between the episodes.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
51 of 113
8.4.3
Eye examination
Fundus photography/pharmacologically dilated fundoscopy must be performed by the investigator, 
a local ophthalmologist, or an optometrist according to local practice. The result of the fundus 
photography/pharmacologically dilated fundoscopy must be interpreted locally by the investigator. 
To document this, the investigator must sign and date the result page or write the interpretation in 
the subject’s medical records. 
The evaluation must follow the categories:
!
Normal
!
Abnormal
–
Was the result clinically significant? (Yes/No)
Abnormal and clinically significant findings must be recorded as described in Section 8.4.
If a fundus photography/pharmacologically dilated fundoscopy has been performed within 90 days 
before Visit 2 and if the results are available at Visit 2, then the procedure does not need to be 
repeated. If performed before the subject consents to participate in the trial, it must also be stated in 
the subject’s medical records that this procedure was not performed in relation to the trial.
The eye examination must be performed prior to administration of bolus trial insulin at Visit 14 (the 
results do not need to be available for randomisation). An eye examination performed within 14 
days prior to randomisation is acceptable.
Eye examination obtained within 21 days prior to Visit 30 is acceptable if the result is available at 
the visit.
For subjects prematurely discontinued trial products: eye examination performed 21 days in 
advance of Visit 30A are acceptable if the results are available at the scheduled visits. However eye 
examination performed at Visit 14 cannot be accepted for the Visit 30A.
8.4.4
Electrocardiogram – 12 lead
An electrocardiogram (ECG)-12 lead must be performed locally. The ECG must be interpreted by 
the investigator, and documented by investigator signature and date on the ECG print-out or write 
the interpretation of the ECG in the subject’s medical records.
The evaluation must follow the categories:
!
Normal
!
Abnormal
–
Was the result clinically significant? (Yes/No)
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
52 of 113
Abnormal and clinically significant findings must be recorded as described in Section 8.4
If an ECG-12 lead has already been performed within 21 days before screening (Visit 1), and if the 
results are available at the screening visit, the procedure does not need to be repeated. If performed 
before the subject consents to participate in the trial it must also be stated in the subject’s medical 
records that this procedure was not performed in relation to the trial.
ECGs performed 21 days in advance of Visit 14 and Visit 30 are acceptable if the results are 
available at the scheduled visits.
For subjects prematurely discontinued trial products: ECGs performed 21 days in advance of Visit 
30A are acceptable if the results are available at the scheduled visits. However ECGs performed at 
Visit 14 cannot be accepted for the Visit 30A.
8.4.5
Body measurements
Height (without shoes) will be measured at site in centimetres (cm) or inches (in) and recorded to 
one decimal place in the eCRF.
Body weight should be measured in kilograms (kg) or pounds (lb) without overcoat and shoes, and 
wearing only light clothing. Body weight must be measured prior to the start of the meal test at 
Visit 14 and Visit 30.
Body weight will be recorded to one decimal place. The body weight should be assessed on the 
same weighing scale equipment throughout the trial, if possible. 
BMI will automatically be calculated by the eCRF.
8.4.6
Physical examination
Physical examination will include examination of:
!
the respiratory system
!
the cardiovascular system
!
the central and peripheral nervous system
!
the gastrointestinal system, including the mouth
!
the musculoskeletal system
!
the skin
!
the head, ears, eyes, nose, throat and neck
The results must be transcribed to the eCRF as:
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
53 of 113
!
Normal
!
Abnormal
–
Was the result clinically significant? (Yes/No)
Abnormal and clinically significant findings must be recorded as described in Section 8.4
8.4.7
Vital signs
Diastolic blood pressure, systolic blood pressure and pulse should be assessed while the subject is in 
a sitting position after five minutes of rest. If the subject is using antihypertensive medication to 
control the blood pressure, then the medication should be taken as usual prior to assessing vital 
signs. 
At screening (Visit 1) blood pressure needs to be measured three times and all values should be 
recorded in the eCRF. The mean value will be calculated by the eCRF, and must be used to assess 
the relevant exclusion criterion; please see section 6.3.
Abnormal and clinically significant findings must be recorded as described in Section 8.4
8.5
Laboratory assessments
Except for urine pregnancy testing, which will be performed locally, all laboratory analyses will be 
performed by a central laboratory contracted by Novo Nordisk. The central laboratory will provide 
all laboratory supplies for the sampling and transportation of all blood and urine samples taken 
during the trial.
A detailed description of the procedures for obtaining the samples, handling, storage, and shipment 
of the samples are specified in a trial-specific laboratory manual provided to the sites by the central 
laboratory. Information regarding laboratory materials such as tubes and labels are also described. 
Laboratory samples can be drawn on another day than on the day of the actual visit, as long as it is 
within the visit window, as stated in the flowchart in section 2. 
If laboratory samples need to be retaken due to missing result(s) (e.g. haemolysed, sample leaked 
during transit, sample not being conclusive, lost in transit, etc.), the subject should be called in for 
resampling. Please see the laboratory manual for further guidance.
Samples will be coded in order to keep subject’s identity anonymous. 
The laboratory provides results to the trial sites in the units preferred by the trial sites while the 
results that are transferred to the trial database will always be in SI units.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
54 of 113
The laboratory equipment may provide analyses not requested in the protocol but produced 
automatically in connection with the requested analyses according to specifications in the laboratory 
standard operating procedures. Such data will not be transferred to the trial database, but abnormal 
values will be reported to the investigator. The investigator must review all laboratory results for 
concomitant illnesses and AEs and report these according to Section 8.2.4 and Section 12. Review 
of laboratory reports must be documented either on the documents and/or in the subject's medical 
record.
Only laboratory samples specified in the protocol must be sent to the central laboratory for analysis; 
if additional laboratory sampling is needed, e.g. to follow up on AEs, this must be done at a local 
laboratory.
Laboratory samples will be destroyed on an ongoing basis and no later than at finalisation of the 
clinical trial report.
8.5.1
Laboratory assessments for efficacy
Glucose metabolism 
Plasma glucose will be measured during the meal test. See section 8.3.1.
FPG is measured in order to evaluate metabolic control. The subject must attend these visits fasting. 
For definition of fasting, see Section 8.1.5.
A FPG result ≤3.9 mmol/L (70 mg/dL) should not be reported as a hypoglycaemic episode but as a 
clinical laboratory AE (CLAE) at the discretion of the investigator (see Section 12.1.1). 
The level of 1,5-anhydroglucitol (GlycoMark) is measured in order to evaluate post prandial 
glucose excursions. 
Blood samples will be drawn to determine the HbA1c level in order to evaluate metabolic control. 
Fasting C-peptide is measured at randomisation in order to reflect endogenous insulin secretion.
Lipids
Blood samples for lipids will be analysed to determine:
!
Total cholesterol
!
High density lipoprotein (HDL) cholesterol
!
Low density lipoprotein (LDL) cholesterol
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
55 of 113
8.5.2
Laboratory assessments for safety
Biochemistry
Blood samples for biochemistry will be analysed to determine:
!
ALT
!
AST
!
albumin
!
alkaline phosphatase
!
creatinine
!
potassium
!
sodium
!
total bilirubin
!
total protein
!
eGFR(estimated glomerular filtration rate) at screening
eGFR will be calculated by the central laboratory based on the creatinine value using the CKD-EPI 
equation in order to access exclusion criteria 15 according to local label.33
Haematology
Blood samples for haematology will be analysed to determine:
!
erythrocytes
!
haematocrit
!
haemoglobin
!
leucocytes
!
thrombocytes 
Pregnancy testing
For females of childbearing potential (see section 8.2.7), a blood human Chorion Gonadotropin 
(hCG) pregnancy test will be performed at the visits indicated in the flowchart in section 2. In 
addition, urine pregnancy tests will be performed locally during the trial if pregnancy is suspected
or if required by local law. A positive urine test should be followed by a confirmatory serum-hCG 
(central laboratory).
The central laboratory will provide the pregnancy kits for urine testing performed locally at the site.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
56 of 113
8.6
Other assessments
8.6.1
Dietary training in simple carbohydrate counting
During the run-in period all subjects should have dietary training regarding simple carbohydrate 
counting (e.g. sessions with a diabetes educator, dietician or qualified site staff) to improve 
subject’s carbohydrate awareness and understanding of their eating habits effect on their diabetes. It 
is the investigator’s responsibility to ensure that the subject is adequately trained and has a 
satisfactory knowledge in:
!
Recognition of carbohydrates in commonly eaten foods 
!
Ability to count the carbohydrate content in typical portions of simple foods
!
Ability to interpret a nutrition label for carbohydrate content 
!
Glycaemic targets 
!
Preventing and treating hypoglycaemia using carbohydrate foods
!
Ability to sum the carbohydrate content of a meal 34
A 3x24-hour meal record should be filled in by the subject prior to the visits indicated in the 
flowchart (Section 2) in order to evaluate the subject’s ability to count the carbohydrate content of 
the meal. The meal records will not be collected by the sponsor.
8.6.2
Training in the pen injector
The subjects must be trained in how to handle the pen injector when handed out the first time. 
Training must be repeated according to flowchart (Section 2) in order to ensure correct use of the 
pen injector. The following should be emphasised:
!
Always use a new needle for each injection as this will prevent contamination and blocked 
needles
!
Remember to prime the pen to ensure product flow 
!
The needle should be kept in the skin while counting slowly to 6 after the dose counter has 
returned to zero after injection. If the needle is removed too early then the full dose may not 
have been delivered.
!
Always check that the correct insulin pen is used (bolus or basal) e.g. by colour coding and 
label. Use the pen differentiation guide as a reference.
!
In-use time and storage conditions of pen-injectors (Section 9.3).
8.6.3
eDiary
At the run-in visit (Visit 2) the subjects will be provided with an eDiary device. The investigator 
must carefully instruct the subject in how to use the eDiary. All data entered in the eDiary is 
considered source data, as described in sections 8.3.2, 8.3.3 and 8.4.2.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
57 of 113
The investigator should record the following administrative information in the eDiary/webportal:
!
Subject ID
!
7-9-7-point profile scheduling and confirmation
!
Visit confirmation 
!
Hypoglycaemic episode confirmation
!
Premature discontinuation of trial products, if applicable
All data entered by the subject in the eDiary will be transferred electronically to the ePRO database. 
Investigator must review data for the subjects belonging to the site through the eDiary webportal. 
The review of hypoglycaemic episode must be documented in the webportal or in the subject’s 
medical record, while review of remaining data must be documented in the subject’s medical 
record. The review of data must be performed before or during each visit/phone contact.
Selected titration data (e.g. certain SMPGs and dose data) will only be used during the trial for 
central titration surveillance, to ensure compliance with the titration guideline (Appendix A), and 
will not be reported in the CTR. All data will be stored by Novo Nordisk (Section 24).
The eDiary should be collected by the investigator at FU1 (Visit 31).The subject should be provided 
with a paper diary for collecting hypoglycaemic episodes in the remaining follow up period. The 
paper diary will not be returned to site by the subject since FU2 is a phone contact. Consequently, 
source data for FU2 (Phone Contact 32) is the notes written in subject’s medical record.
8.7
Subject compliance
Throughout the trial, the investigator will remind the subjects to follow the trial procedures and 
requirements to ensure subject compliance. In addition, subject compliance will be assessed by 
monitoring of drug accountability at specified visits, please refer to the flow chart (Section 2). The 
unused amount of investigational medicinal product (IMP) will be assessed against the dispensed 
amount and, in case of discrepancies, the subject must be asked to clarify.
If a subject is found to be non-compliant, the investigator will remind the subject of the importance 
of following the instructions given including taking the trial products as prescribed.
The investigator will at each weekly contact (visit or phone contact) assess the subject’s compliance 
by evaluating the glycaemic control, adherence to treatment and the visit schedule and completion 
of the subject’s eDiary including the SMPG profiles, dose and hypoglycaemia reporting.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
58 of 113
9
Trial supplies
Trial supplies comprise trial products and auxiliary supplies. Additional details regarding trial 
supplies can be found in the Trial Materials Manual (TMM).
Trial products must not be dispensed to any person not included in the trial.
Trial product must not be used, if it does not appear clear and colourless.
9.1
Trial products
The following trial products will be provided by Novo Nordisk A/S, Denmark:
Table 9–1
Trial products
Trial product
Strength
Dosage form
Route of 
administration
Container/
delivery device
Faster aspart, 
(IMP), test product
100 U/ml 
Solution for 
injection
Subcutaneously
3 ml prefilled 
pen
Insulin aspart 
(NovoRapid®)
(IMP), reference therapy
Insulin degludec
(IMP), test product
100 U/ml
Solution for 
injection
Subcutaneously
3 ml prefilled 
pen
The following non-investigational medicinal products (NIMP) will not be provided by Novo 
Nordisk. However, they will be reimbursed if required according to local regulations.
!
Rapid acting insulin analogues (NovoRapid® or marketed formulations of insulin lispro or 
insulin glulisine) in the run-in period
!
Metformin, tablets for oral use
The comparator and active drug are visually identical.
9.2
Labelling
The trial products will be labelled in accordance with Annex 1338, local regulations and trial 
requirements.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
59 of 113
Each trial site will be supplied with sufficient trial products for the trial on an on-going basis 
controlled by the IWRS. Trial product will be distributed to the trial sites according to enrolment 
and randomisation.
The investigator must document that direction for use is given to the subject orally and in writing at 
the first dispensing visit (Visit 2). Additionally, the pen differentiation guide must be provided to 
subjects at randomisation (Visit 14). Direction for use and pen differentiation guide can be provided 
as needed at the following dispensing visits.
9.3
Storage 
Table 9–2
Storage conditions
Trial product
Storage conditions
(not-in-use)
In-use conditions
In-use timea
Faster aspart
Store in refrigerator
(2°C – 8°C)
Do not freeze
Protect from light
Store below 30°C
Do not refrigerate
Do not freeze
Protect from light
Use within 4 
weeks
Insulin aspart
(NovoRapid®)
Insulin degludec 
Store in refrigerator
(2°C – 8°C)
Do not freeze
Protect from light
Do not store above 30°C
Protect from light
Can be stored in refrigerator 
(2°C – 8°C)
Do not freeze
Use within 8
weeks
a In-use time starts when first dose is taken
The investigator must ensure that trial product is kept under proper storage conditions and record 
and evaluate the temperature. The investigator must inform Novo Nordisk immediately if any trial 
product has been stored outside specified conditions (e.g. outside temperature range). Additional 
details regarding handling of temperature deviations can be found in the TMM.
Trial product that has been stored improperly must not be dispensed to any subject before it has 
been evaluated and approved for further use by Novo Nordisk. The investigator must take 
appropriate action to ensure correct storage.
9.4
Drug accountability and destruction
Drug accountability of all trial products received at site is the responsibility of the investigator.
Returned trial product (used/partly used and/or unused), expired or damaged trial product can be 
stored at room temperature and must be stored separately from non-allocated trial product.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
60 of 113
Non-allocated trial products (expired, damaged and available) must be accounted as unused at the 
latest at closure of the trial site.
Subjects are instructed to return all used, partly used and unused trial product at each dispensing 
visit after Visit 2. Please refer to the flowchart (section 2) for timing of the dispensing visits.
Destruction of trial products can be performed on an on-going basis and will be done according to 
local procedures after accountability is finalised and reconciled by the monitor in the IWRS. 
Destruction of products must be documented in the IWRS.
9.5
Auxiliary supplies
The following will be provided by Novo Nordisk:
!
Direction for use for the prefilled pens
!
Novo Nordisk needles
!
Standardised liquid meal (for the meal test)
!
MyGlucoHealth Wireless Meter (CE approved) and strips, lancets and control solution for 
BG meters
!
eDiary
Only needles provided by Novo Nordisk must be used for administration of trial product.
The BG meter has not been approved in Argentina, Russia, Serbia and Ukraine and will be labelled 
for investigational use only. The BG meter has been selected in order to have automatic transfer of 
SMPG data to the eDiary and thereby increase the accuracy of SMPG values. It is expected that the 
better accuracy in SMPG data will facilitate an improvement in the insulin titration efforts during 
the trial. 
Please refer to the TMM for further auxiliary details.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
61 of 113
10
Interactive voice/web response system
A trial-specific IWRS will be set up which can be accessed at any time via the internet or telephone. 
Access to the IWRS must be restricted to and controlled by authorised persons. 
IWRS is used for:
!
Medication arrival
!
Screening
!
Screening failure
!
Run-in dispensing
!
Run-in failure
!
Randomisation
!
Dispensing
!
Dispensing Verification (when barcode scanner is used)
!
Treatment discontinuation 
!
Completion
!
Code break
!
Drug accountability
!
Data change
IWRS user manuals will be provided to each trial site.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
62 of 113
11 Randomisation procedure and breaking of blinded codes
At randomisation (Visit 14) the subject will be randomised to either faster aspart or NovoRapid®, 
both in combination with once daily insulin degludec with or without metformin.
The randomisation will be carried out in a 1:1 manner to the 2 different treatment possibilities 
described below using the IWRS:
!
Faster aspart and insulin degludec with or without metformin
!
NovoRapid® and insulin degludec with or without metformin
The investigator, subject and sponsor will be blinded to the bolus treatment.
11.1
Breakingof blinded codes
The IWRSwill notify Novo Nordisk (monitor and the Global Safety department) immediately after 
the code is broken.
The code for a particular subject may be broken in a medical emergency if knowing the actual 
treatment would influence the treatment of the subject. Whenever a code is broken the person 
breaking the code must print the Code Break Confirmation Notification generated by the IWRS, 
record the reason, and sign and date the document.
When the code is broken, the treatment allocationwill be accessible to the investigator and the 
Novo Nordisk Global Safety department.If IWRS is not accessible at the time of code break the 
IWRS helpdesk should be contacted. Contact details are listed in Attachment I.
If the code has been brokenby investigator, the subject must discontinue treatment with trial 
product and a treatment discontinuation session must be completed in IWRS.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
63 of 113
12 Adverse events, technical complaints and pregnancies
12.1
Definitions
12.1.1
Adverse event 
An adverse event (AE) is any untoward medical occurrence in a subject administered a medicinal 
product, and which does not necessarily have a causal relationship with this treatment. 
An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory 
finding), symptom or disease temporally associated with the use of a product, whether or not 
considered related to the product. 
An AE includes:
!
A clinically significant worsening of a concomitant illness.
!
A clinical laboratory AE (CLAE): a clinical laboratory abnormality which is clinically 
significant, i.e. an abnormality that suggests a disease and/or organ toxicity and is of a 
severity that requires active management. Active management includes active treatment or 
further investigations, for example change of medicine dose or more frequent follow-up due 
to the abnormality.
The following should not be reported as AEs:
!
Pre-existing conditions, including those found as a result of screening or other trial 
procedures performed before exposure to trial product (pre-existing conditions should be 
reported as medical history or concomitant illness).
!
Pre-planned procedures unless the condition for which the procedure was planned has 
worsened from the first trial related activity after the subject has signed the informed 
consent.
!
Non-serious hypoglycaemia is an AE, but is reported on a hypoglycaemic episode form 
instead of on an AE form, see Section 8.4.2.
The following three definitions are used when assessing an AE:
!
Severity 
–
Mild – no or transient symptoms, no interference with the subject’s daily activities.
–
Moderate – marked symptoms, moderate interference with the subject’s daily activities.
–
Severe – considerable interference with the subject’s daily activities; unacceptable.
!
Causality 
Relationship between an AE and the relevant trial product(s): 
–
Probable - Good reason and sufficient documentation to assume a causal relationship.
–
Possible - A causal relationship is conceivable and cannot be dismissed.
–
Unlikely - The event is most likely related to aetiology other than the trial product.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
64 of 113
•
Final outcome
–
Recovered/resolved - The subject has fully recovered, or by medical or surgical treatment 
the condition has returned to the level observed at the first trial-related activity after the 
subject signed the informed consent.
–
Recovering/resolving - The condition is improving and the subject is expected to recover 
from the event. This term is only applicable if the subject has completed the trial or has died 
from another AE.
–
Recovered/resolved with sequelae - The subject has recovered from the condition, but 
with lasting effect due to a disease, injury, treatment or procedure. If a sequela meets an 
SAE criterion, the AE must be reported as an SAE.
–
Not recovered/not resolved - The condition of the subject has not improved and the 
symptoms are unchanged, or the outcome is not known.
–
Fatal - This term is only applicable if the subject died from a condition related to the 
reported AE. Outcomes of other reported AEs in a subject before he/she died should be 
assessed as “recovered/resolved”, “recovering/resolving”, “recovered/resolved with 
sequelae” or “not recovered/not resolved”. An AE with fatal outcome must be reported as 
an SAE.
–
Unknown - This term is only applicable if the subject is lost to follow-up.
12.1.2
Serious adverse event
A serious adverse event (SAE) is an experience that at any dose results in any of the following:
!
Death.
!
A life-threateninga experience.
!
In-patient hospitalisationb or prolongation of existing hospitalisation.
!
A persistent or significant disability or incapacityc.
!
A congenital anomaly or birth defect.
!
Important medical events that may not result in death, be life threateninga or require 
hospitalisationb may be considered an SAE when - based on appropriate medical judgement 
- they may jeopardise the subject and may require medical or surgical intervention to 
prevent one of the outcomes listed in the definition of SAEd. 
a. The term “life threatening” in the definition of SAE refers to an event in which the subject was at 
risk of death at the time of the event. It does not refer to an event which hypothetically might have 
caused death if it was more severe.
b. The term “hospitalisation” is used when a subject: 
–
Is admitted to a hospital or in-patient, irrespective of the duration of physical stay, or 
–
Stays at the hospital for treatment or observation for more than 24 hours.
Medical judgement must always be exercised, and when in doubt, the hospital contact should be 
regarded as a hospitalisation. Hospitalisations for administrative, trial related and social purposes do 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
65 of 113
not constitute AEs and should therefore not be reported as AEs or SAEs. Hospital admissions for 
surgical procedures, planned before trial inclusion, are not considered AEs or SAEs.
c. A substantial disruption of a subject’s ability to conduct normal life functions (e.g. following the 
event or clinical investigation the subject has significant, persistent or permanent change, 
impairment, damage or disruption in his/her body function or structure, physical activity and/or 
quality of life).
d. For example intensive treatment in an emergency room or at home of allergic bronchospasm, 
blood dyscrasia or convulsions that do not result in hospitalisation, or development of drug 
dependency or drug abuse.
The following AEs must always be reported as an SAE using the important medical event criterion 
if no other seriousness criteria are applicable:
!
suspicion of transmission of infectious agents via the trial product 
!
risk of liver injury defined as ALT or AST >3 x UNL and total bilirubin >2 x UNL, where 
no alternative aetiology exists (Hy's law).
12.1.3
Non-serious adverse event
A non-serious AE is any AE which does not fulfil the definition of an SAE.
12.1.4
Medication errors
A medication error concerning trial products is defined as:
!
Administration of wrong drug. 
Note: Use of wrong dispensing unit number (DUN) is not considered a medication error unless 
it results in administration of wrong drug.
!
Wrong route of administration, such as intramuscular instead of subcutaneous.
!
Administration of an overdose with the intention to cause harm (e.g. suicide attempt), 
misuse or abuse of trial product.
!
Accidental administration of a lower or higher dose than intended. The administered dose 
must deviate from the intended dose to an extent where clinical consequences for the trial 
subject were likely to happen as judged by the investigator, although they did not 
necessarily occur.
Medication errors must be reported on an AE form and a specific event form, see Section 8.4.1.1.
12.1.5
Adverse events requiring additional data collection
AEs requiring additional data collection are AEs where the additional data will benefit the 
evaluation of the safety of the trial product.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
66 of 113
In this trial the following AEs require the completion of specific event forms in the eCRF
!
Injection site reaction
For details, see Section 8.4.1.2.
12.1.6
Technical complaints
A technical complaint is any written, electronic, or oral communication that alleges product 
(medicine or device) defects. The technical complaint may be associated with an AE, but does not 
concern the AE itself.
Examples of technical complaints:
!
The physical or chemical appearance of trial products (e.g. discoloration, particles or 
contamination)
!
All packaging material including labelling
!
Problems related to devices (e.g. to the injection mechanism, dose setting mechanism, push 
button or interface between the pen and the needle)  
12.2
Reporting of adverse events
All events meeting the definition of an AE must be collected and reported. This includes events 
from the first trial-related activity after the subject has signed the informed consent until the end of 
the post-treatment follow-up period (FU2). For subjects discontinuing trial products prematurely 
this also includes events after the post-treatment follow-up period until the last contact (Visit 30). 
The events must be recorded in the applicable eCRF forms in a timely manner, see timelines below 
and Figure 12–1. 
During each contact with the trial site staff, the subject must be asked about AEs and technical 
complaints, for example by asking: “Have you experienced any problems since the last contact?”
All AEs, either observed by the investigator or subject, must be reported by the investigator and 
evaluated.
All AEs must be recorded by the investigator on an AE form. The investigator should report the 
diagnosis, if available. If no diagnosis is available, the investigator should record each sign and 
symptom as individual AEs using separate AE forms.
For SAEs, a safety information form must be completed in addition to the AE form. If several 
symptoms or diagnoses occur as part of the same clinical picture, one safety information form can 
be used to describe all the SAEs. 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
67 of 113
For all non-serious AEs, the applicable forms should be signed when the event is resolved or at the 
end of the trial at the latest.
Timelines for initial reporting of AEs:
The investigator must complete the following forms in the eCRF within the specified timelines:
!
SAEs: The AE form within 24 hours and the safety information form within 5 calendar
days of the investigator’s first knowledge of the SAE. Both forms must be signed within 7 
calendar days from the date the information was entered in the eCRF. 
For SAEs requiring reporting on a specific event form: In addition to the above the 
specific event form within 14 calendar days from the investigator’s first knowledge of the 
AE.
If the eCRF is unavailable, the concerned AE information must be reported on a paper AE form and 
sent to Novo Nordisk by fax, e-mail or courier within the same timelines as stated above. When the 
eCRF becomes available again, the investigator must enter the information on the form into the 
eCRF.
Contact details (fax, telephone, e-mail and address) are provided in the investigator trial master file. 
AE identified
Does the AE require 
a specific event 
form?
AE form < 24 hours
SIF < 5 calendar days
Specific event form 
For SAEs: 
< 14 calendar days
Is the Adverse Event 
serious or non-
serious?
AE form
Non-serious
Serious
No
Yes
Queries and follow-up 
requests to be resolved 
< 14 calendar days
Timelines are for the completion of forms from the time of investigator’s awareness.
AEs requiring specific event forms are descibed in Section 12.1.4 and 12.1.5.
No additional action
AE: Adverse Event   SIF: Safety Information form
Figure 12–1
Reporting of AEs 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
68 of 113
Novo Nordisk assessment of AE expectedness: 
Novo Nordisk assessment of expectedness is performed according to the following reference 
documents:
!
Faster aspart IB22 current version and any updates thereto.
!
Insulin degludec Company Core Data Sheet current version and any updates thereto.
!
NovoRapid®, Company Core Data Sheet current version and any updates thereto.
Reporting of trial product-related SUSARs by Novo Nordisk:
Novo Nordisk will notify the investigator of trial product-related suspected unexpected serious 
adverse reactions (SUSARs) in accordance with local requirements and ICH GCP.1 In addition, the 
investigator will be informed of any trial-related SAEs that may warrant a change in any trial 
procedure.
In accordance with regulatory requirements, Novo Nordisk will inform the regulatory authorities, 
including EMA, of trial product-related SUSARs. In addition, Novo Nordisk will inform the 
IRBs/IECs of trial product-related SUSARs in accordance with local requirement and ICH GCP1, 
unless locally this is an obligation of the investigator.
Novo Nordisk and non-Novo Nordisk products used as concomitant medication or non-
investigational medicinal product:
If an AE is considered to have a causal relationship with a non-Novo Nordisk and Novo Nordisk 
marketed product used as NIMP (NovoRapid® in run-in period) and metformin or concomitant 
medication in the trial, it is important that the suspected relationship is reported to Novo Nordisk, 
e.g. in the alternative aetiology section on the safety information form. Novo Nordisk may need to 
report this AE to relevant regulatory authorities.
12.3
Follow-up of adverse events
The investigator must record follow-up information by updating the forms in the eCRF. 
Follow-up information must be reported to Novo Nordisk according to the following:
!
SAEs: All SAEs must be followed until the outcome of the event is “recovered/resolved”, 
“recovered/resolved with sequelae” or “fatal”, and until all queries have been resolved. 
Cases of chronic conditions, cancer or AEs ongoing at time of death (where death is due to 
another AE) may be closed with the outcome “recovering/resolving” or “not recovered/not 
resolved”. Cases can be closed with the outcome of “recovering/resolving” when the subject 
has completed the follow-up period and is expected by the investigator to recover.
The SAE follow-up information should only include new (e.g. corrections or additional) 
information and must be reported within 24 hours of the investigator’s first knowledge of the 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
69 of 113
information. This is also the case for previously non-serious AEs which subsequently become 
SAEs. 
!
Non-serious AEs: Non-serious AEs must be followed until the outcome of the event is 
“recovering/resolving”, “recovered/resolved” or “recovered/resolved with sequelae” or until 
the end of the follow-up period stated in the protocol, whichever comes first, and until all 
queries related to these AEs have been resolved. Cases of chronic conditions, cancer or AEs 
ongoing at time of death (where death is due to another AE) may be closed with the 
outcome “recovering/resolving” or “not recovered/not resolved”. Cases can be closed with 
the outcome of “recovering/resolving” when the subject has completed the follow-up period 
and is expected by the investigator to recover.
The investigator must ensure that the recording of the worst case severity and seriousness of an 
event is kept throughout the trial. A worsening of an unresolved AE must be reported as follow up 
with re-assessment of severity and/or seriousness of the event.
Queries or follow-up requests from Novo Nordisk must be responded to within 14 calendar days
from the date of receipt of the request, unless otherwise specified in the follow-up request.
SAEs after end of trial: If the investigator becomes aware of an SAE with a suspected causal 
relationship to the IMP occurring to a subject after the subject has ended the trial, the investigator 
should report this SAE within the same timelines as for SAEs during the trial. 
12.4
Technical complaints and technical complaint samples
12.4.1
Reporting of technical complaints
For Novo Nordisk Products
All technical complaints on any of the following products:
!
Faster aspart, 100 U/mL solution for subcutaneous injection, 3 mL PDS290 pen injector 
(blinded)
!
NovoRapid®, 100 U/mL solution for subcutaneous injection, 3 mL PDS290 pen injector 
(blinded)
!
Insulin degludec, 100U/mL solution for subcutaneous injection, 3 mL PDS290 pen injector 
(open)
!
Novo Nordisk Needles
which occur from the time of first usage of the product until the time of the last usage of the 
product, must be collected and reported to Customer Complaint Center, Novo Nordisk.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
70 of 113
Contact details (fax, e-mail and address) are provided in Attachment I to the protocol.
The investigator must assess whether the technical complaint is related to any AEsand/or SAEs.
Technical complaints must be reported on a separate technical complaint form:
!
One technical complaint form must be completed for each affected DUN
!
If DUN is not available, a technical complaint form for each batch, code or lot number must
be completed
The investigator must complete the technical complaint form in the eCRF within the following 
timelines of the trial site obtaining knowledge of the technical complaint:
!
Technical complaint assessed as related to an SAE within 24 hours
!
All other technical complaints within 5 calendar days
If the eCRF is unavailable or when reporting a technical complaint that is not subject related, the 
information must be provided on a paper form by fax, e-mail or courier to Customer Complaint 
Center, Novo Nordisk, within the same timelines as stated above. When the eCRF becomes 
available again, the investigator must enter the information on the technical complaint form in the 
eCRF.
Only technical complaints related to AEs will be reported in the clinical trial report.
For BG meters, strips, lancets and control solution 
All Technical Complaints on BG meter, strips, lancets and control solution should be reported
directly to the supplier using the supplier reporting form within the following timelines: 
!
Technical complaint assessed as related or potential related to an SAE within 24 hours
!
All other technical complaints within 5 calendar days
Contact details (e-mailand address) are provided in Attachment I to the protocol. 
12.4.2
Collection, storage and shipment of technical complaint samples
For Novo Nordisk Products
The investigator must collect the technical complaint sample and notify the monitor within 5 
calendar days of obtaining the sample at trial site. The monitor must coordinate the shipment to 
Customer Complaint Center, Novo Nordisk (the address is provided in Attachment I) and ensure 
that the sample is sent as soon as possible. A copyof the technical complaint form must be included 
in the shipment of the sample. If several samples are returned in one shipment, the individual 
sample and the corresponding technical complaint form must be clearly separated.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
71 of 113
The investigator must ensure that the technical complaint sample contains the batch, code or lot 
number and, if available, the DUN. All parts of the DUN should be returned.
If the technical complaint sample is unobtainable, the investigator must specify on the technical 
complaint form why it is unobtainable. 
Storage of the technical complaint sample must be done in accordance with the conditions 
prescribed for the product.
For BG metersstrips, lancets and control solution 
The investigator must collect the technical complaint sample and send it to the supplierusing the 
contact details provided in Attachment I.
12.5
Pregnancies in female subjects 
Female subjects must be instructed to notify the investigator immediately if they become pregnant 
during the trial. The investigator must report any pregnancy in subjects who have received trial 
product(s).
The investigator must follow the pregnancy until the pregnancy outcome and the newborn infant is 
one month of age.
The investigator must report information about the pregnancy, pregnancy outcome, and health of 
the newborn infant(s), as well as AEs in connection with the pregnancy, and AEs in the foetus and 
newborn infant.
The following must be collected and reported by the investigator to Novo Nordisk electronically 
(e.g. in PDF format), or by fax or courier:
1. Reporting of pregnancy information
Information about the pregnancy and pregnancy outcome/health of the newborn infant(s) has to
be reported on Maternal Form 1A and 1B, respectively.
When the pregnancy outcome is abnormal (i.e. congenital anomalies, foetal death including 
spontaneous abortion and/or any anomalies of the foetus observed at gross examination or 
during autopsy), and/or when a congenital anomaly is diagnosed within the first month, further 
information has to be reported for the female subject on Maternal Form 2. In addition, 
information from the male partner has to be reported on the Paternal Form, after an informed 
consent has been obtained from the male partner.
Initial reporting and follow-up information must be reported within 14 calendar days of the 
investigator’s first knowledge of initial or follow-up information.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
72 of 113
2. Reporting of AE information
The investigator has to report AEs in connection with the pregnancy as well as in the foetus and 
newborn infant(s). The SAEs that must be reported include abnormal outcome, such as foetal 
death (including spontaneous abortion), and congenital anomalies (including those observed at 
gross examination or during autopsy of the foetus), as well as other pregnancy complications 
fulfilling the criteria of an SAE.
Forms and timelines for reporting AEs:
Non-serious AEs: 
!
AE forma within 14 calendar days of the investigator’s first knowledge of the initial or 
follow-up information to the non-serious AE.
SAEs: 
!
AE forma within 24 hours of the investigator’s first knowledge of the SAE.
!
Safety information form within 5 calendar days of the investigator’s first knowledge of the 
SAE.
!
SAE follow-up information to the AE form and/or safety information form within 24 
hours of the investigator’s first knowledge of the follow-up information.
a 
It must be clearly stated in the AE diagnosis field on the AE form if the event occurred in 
the subject, foetus or newborn infant. If the AE occurred in the foetus or newborn infant, the AE 
can only be reported on paper AE and safety information form.
Any queries or follow-up requests from Novo Nordisk to non-serious AEs, SAEs and pregnancy 
forms must be responded to by the investigator within 14 calendar days from the date of receipt of 
the request, unless otherwise specified in the follow-up request.
12.6
Precautions and/or overdose
During treatment with insulin, there is a risk of hypoglycaemia (see section 8.4.2). Symptoms of 
hypoglycaemia usually occur suddenly and may include cold sweat, nervousness or tremor, anxious 
feelings, unusual tiredness, confusion, difficulty in concentration, excessive hunger, temporary 
vision changes, headache, nausea, and palpitation. Prolonged or severe hypoglycaemia can lead to a 
loss of self-control, spasms, and/or unconsciousness and, in extreme cases, death.
Asymptomatic hypoglycaemia and symptoms of hypoglycaemia should be treated with 
carbohydrates. Mild to moderate symptoms can be treated by ingestion of carbohydrate (for 
example, juice). Severe hypoglycaemia resulting in the loss of consciousness should be treated with 
parenteral glucose, glucagon or dextrose.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
73 of 113
For further details, please refer to the current version of faster aspart IB22, Insulin degludec IB24 and 
for NovoRapid®, please refer to the current versions of the SmPC19 or U.S. Novolog® Label 
Information.20
12.7
Committees related to safety
12.7.1
Novo Nordisk safety committee
Novo Nordisk will constitute an internal faster aspart safety committee to perform ongoing safety 
surveillance. The faster aspart safety committee may recommend unblinding of any data for further 
analysis, and in this case an independent ad hoc group will be established in order to maintain the
blinding of the trial personnel.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
74 of 113
13 Case report forms 
Novo Nordisk will provide a system for the eCRF. This system and support services to the system 
will be provided by an external supplier.
Ensure that all relevant questions are answered, and that no empty data field exists. If a test or an 
assessment has not been done and will not be available, or if the question is irrelevant (e.g. is not 
applicable), indicate this according to the data entry instructions.
The following will be provided as paper case report forms (CRFs):
!
Pregnancy forms
The following will be provided as paper CRFs to be used when access to the eCRF is revoked or if 
the eCRF is unavailable:
!
AE forms 
!
Safety information forms
!
Technical complaint forms (also to be used to report complaints that are not subject related 
(e.g. discovered at trial site before allocation)
On the paper CRF forms print legibly, using a ballpoint pen. Ensure that all questions are answered, 
and that no empty data blocks exist. Ensure that no information is recorded outside the data blocks. 
If a test/assessment has not been done and will not be available, indicate this by writing “ND” (not 
done) in the appropriate answer field in the CRF. If the question is irrelevant (e.g. is not applicable) 
indicate this by writing “NA” (not applicable) in the appropriate answer field. Further guidance can 
be obtained from the instructions in the CRF.
The investigator must ensure that all information is consistent with the source documentation. By 
electronically signing the case book in the eCRF, the investigator confirms that the information in 
the eCRF and related forms is complete and correct.
13.1
Corrections to case report forms 
Corrections to the eCRF data may be made by the investigator or the investigator’s delegated staff. 
An audit trail will be maintained in the eCRF application containing as a minimum: the old and the 
new data, identification of the person entering the data, date and time of the entry and reason for the 
correction.
If corrections are made by the investigator’s delegated staff after the date the investigator has signed 
the case book, the case book must be signed and dated again by the investigator.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
75 of 113
13.2
Case report form flow 
The investigator must ensure that data is recorded in the eCRF as soon as possible, preferably
within 5 days after the visit. Once data has been entered, it will be available to Novo Nordisk for 
data verification and validation purposes.
Site specific eCRF data (in an electronic readable format) will be provided to the trial site before 
access to the eCRF is revoked. This data must be retained at the trial site.
14 Monitoring procedures
Monitoring will be conducted using a risk based approach including risk assessment, monitoring 
plans, centralised monitoring and visits to trial sites. During the course of the trial, the monitor will 
visit the trial site to ensure that the protocol is adhered to, that all issues have been recorded, to 
perform source data verification and to monitor drug accountability. The first monitoring visit will 
be performed as soon as possible after first patient first visit at the trial site and no later than 4 
weeks after. The monitoring visit intervals will depend on the outcome of the centralised
monitoring of the eCRFs (remote assessment of data by Novo Nordisk), the trial site's recruitment 
rate and the compliance of the trial site to the protocol and GCP, but will not exceed 12 weeks until 
LPLV at the trial site.
The monitor must be given direct access to all source documents (original documents, data and 
records). Direct access includes permission to examine, analyse, verify and reproduce any record(s) 
and report(s) that are important to the evaluation of the trial. If the electronic medical record does 
not have a visible audit trail, the investigator must provide the monitor with signed and dated 
printouts. In addition the relevant trial site staff should be available for discussions at monitoring 
visits and between monitoring visits (e.g. by telephone).
All data must be verifiable in source documentation other than the eCRF. Data entered by the 
subject in the eDiary device will be recorded directly in the device. All data entered in the eDiary 
device will be automatically transferred to a database, where it is kept as a certified copy of the 
source data. Data entered in the device will upon confirmation of a successful back-up be deleted 
from the device. Hence the certified copy in the database is regarded as source data. For data 
entered by the investigator through the webportal the source documentation can be the medical 
records but if entered directly into the webportal, the database is regarded as source data.
For all data recorded the source document must be defined in a source document agreement at each 
trial site. There must only be one source defined at any time for any data element.
Source data generated by the trial site can be corrected by another person than the person entering 
the source data if accepted by local regulations; any correction must be explained, signed and dated 
by the person making the correction.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
76 of 113
The monitor will ensure that the eCRFs are completed and that paper CRFs are collected.
The following data will be source data verified for screening failures: 
!
Date for obtaining informed consent. 
!
Screen failure date and reason
!
Date of visit
!
Demography (date of birth, sex and race (according to local regulation))
!
Eligibility criteria
!
SAE
Monitors will review the subject’s medical records and other source data to ensure consistency 
and/or identify omissions compared to the eCRF. If discrepancies are found, the investigator must 
be questioned about these.
15 Data management
Data management is the responsibility of Novo Nordisk. Data management may be delegated under 
an agreement of transfer of responsibilities to a contract research organisation (CRO).
Appropriate measures, including encryption of data files containing person identifiable data, will be 
used to ensure confidentiality of subject data, when they are transmitted over open networks.
Data from central laboratories will be transferred electronically. In cases where data is transferred 
via non-secure electronic networks, data will be encrypted during transfer.
The subject and any biological material obtained from the subject will be identified by subject 
number and trial ID. Appropriate measures such as encryption or leaving out certain identifiers will 
be enforced to protect the identity of subjects in all presentations and publications as required by 
local, regional and national requirements.
16 Computerised systems
Novo Nordisk will capture and process clinical data using computerised systems that are described 
in Novo Nordisk Standard Operating Procedures and IT architecture documentation. The use and 
control of these systems are documented.
Investigators working on the trial may use their own electronic systems to capture source data.
The eDiary software and hardware implementation are compliant with the requirements of FDA 21 
CFR Part 11 and ICH E6 (EU directive for personal data protection). After trial finalisation, each 
site will be supplied with long-life DVDs. These DVDs will contain site-specific subject records 
including the subject’s eDiary data and audit trail as well as any data additions and corrections 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
77 of 113
made on each form. The eDiary vendor will furthermore retain and securely store copies of all 
archived documents and data for 50 years or as required by local data retention laws for trial data. 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
78 of 113
17 Statistical considerations
If necessary, a statistical analysis plan may be written in addition to the protocol, including a more 
technical and detailed elaboration of the statistical analyses. The statistical analysis plan will be 
finalised before database lock.
General considerations
In general, for endpoints evaluated as a change from baseline and/or where a baseline adjustment is 
made, baseline is defined as information collected at randomisation (Visit 14). In case a 
measurement is not available at randomisation, the most recent measurement prior to randomisation 
will be used as baseline. 
Two observation periods are defined, “in-trial” and “on-treatment”, and it will be specified which 
period each analysis will use.
!
In-trial: The observation period from date of randomisation and until last trial-related 
subject-site contact. The in-trial observation period includes data collected after treatment 
discontinuation.
!
On-treatment: The observation period from date of first dose of randomised 
NovoRapid®/faster aspart and to 7 days after the first occurrence of:
o
The day of last dose of randomised NovoRapid®/faster aspart
o
The day before initiation of ancillary treatment
All efficacy endpoints will be summarised and analysed using the full analysis set (FAS), unless 
otherwise stated. Safety endpoints will be summarised using the safety analysis set and analysed 
using the FAS. The FAS is defined in section 17.2.
Presentation of results from a statistical analysis will include the estimated mean treatment effects 
(LSMeans) for change from baseline, if applicable. Estimated mean treatment differences (or ratios) 
will be presented together with two-sided 95% confidence interval (CI) for all endpoints analysed 
statistically. 
Data collected before randomisation (Visit 14) will only be summarised descriptively.
The primary objective of the trial is to confirm the effect of treatment with faster aspart compared to 
NovoRapid®, both in combination with insulin degludec with or without metformin in adults with 
T2DM in terms of glycaemic control, using a non-inferiority approach. 
More specifically the upper limit of the 95% confidence interval for the difference between faster
aspart and NovoRapid® should be compared to a non-inferiority margin of 0.4%. If it is below or 
equal to 0.4% non-inferiority will be considered established and effect demonstrated. 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
79 of 113
The trial also aims to confirm superiority of treatment with faster aspart for a number of secondary 
confirmatory endpoints. The family-wise type I error rate will be controlled in the strong sense 
using a hierarchical (fixed sequence) testing procedure. This is based on a priority ordering of the 
null-hypotheses, and testing them in this order using the two-sided 95% confidence interval 
approach until an insignificant result appears. The effect is that rejection of a null hypothesis only 
will be considered for analyses where all previous null-hypotheses have been rejected in favour of 
faster aspart. 
The steps in the hierarchical testing procedure are as follows:
Step 1 (Primary analysis):  HbA1c non-inferiority of faster aspart versus NovoRapid®
Step 2: 1-hour PPG increment (meal test) superiority of faster aspart versus NovoRapid®
Step 3: HbA1c superiority of faster aspart versus NovoRapid®
Step 4: 1,5-anhydroglucitol superiority of faster aspart versus NovoRapid®
Estimands
Primary estimand
The primary estimand is defined as the treatment difference between subjects randomised to faster
aspart and NovoRapid® both in combination with insulin degludec with or without metformin, in 
adults with T2DM not optimally controlled with a basal-bolus regimen assessed by change from 
baseline in HbA1c 16 weeks after randomisation for all randomised subjects regardless of treatment 
discontinuation or use of ancillary treatment.  
The primary estimand assesses the expected benefit a future population with T2DM can achieve if 
prescribed to faster aspart as compared to NovoRapid®. By not putting any restrictions on the 
treatment adherence, this estimand aims at a difference as close as possible to the one that can be 
expected in real-world clinical practice, provided that the treatment adherence and use of ancillary 
treatment reflects clinical practice. Thereby the primary estimand provides a treatment difference 
for clinicians concerning the glycaemic effect of faster aspart compared to NovoRapid® in the day 
to day life in subjects with T2DM in an adult population.
Secondary estimand
A secondary estimand is defined as the treatment difference in change from baseline in HbA1c 16 
weeks after randomisation between treatment with faster aspart and treatment with NovoRapid®
both in combination with insulin degludec with or without metformin in adult subjects with T2DM
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
80 of 113
not optimally controlled with a basal-bolus regimen if all subjects had adhered to randomised 
treatment and did not receive ancillary treatment.  
The condition ‘adhered to randomised treatment and did not receive ancillary treatment’ should be 
interpreted as the exclusion of information collected after initiation of antidiabetic treatment that 
can mask or exaggerate the effect of the initially randomised treatment. Only data collected prior to 
discontinuation of trial product or initiation of ancillary treatment is used to draw inference. This 
avoids confounding effects of ancillary treatment.
The two estimands will be repeated for the confirmatory endpoints
!
Change from baseline in 1-hour PPG increment (meal test) 16 weeks after randomisation
!
Change from baseline in 1,5-anhydroglucitol 16 weeks after randomisation
17.1
Sample size calculation
The sample size is determined to ensure a sufficient power for step 1 and step 2 in the hierarchical 
testing procedure for the primary estimand presented in section 17. The power for step 3 and 4 in 
the hierarchical testing procedure will also be presented. The sample size is determined using a non-
inferiority limit of 0.4% in step 1, which was chosen as described in section 5.2.1. The statistical 
evaluation will be done as described in section 17.3.
In previous confirmatory trials where faster aspart has been investigated, the completion rates have 
been high. Therefore it will be expected that treatment discontinuation might be as low as 10% 
where trial discontinuation constitutes half of these and with similar withdrawal reasons in the 
treatment arms.
Power for the non-inferiority step (Step 1) is based on a t-statistic under the assumption of a one-
sided test of size 2.5% for the FAS. A mean treatment difference of -0.1% for the comparison 
between faster aspart and NovoRapid® in favour of faster aspart is expected. As trials in this 
population where data from treatment withdrawn subjects is retrieved is limited, a conservative 
estimate of the standard deviation (SD) in change from baseline in HbA1c of 0.8% was chosen. The 
power for superiority in step 3 will be calculated using the same assumptions as for step 1 but 
without the non-inferiority margin. 
For determination of power in step 2 in the hierarchical testing, where change from baseline in 1-
hour PPG increment 16 weeks after randomisation is compared between faster aspart and 
NovoRapid® a t-statistic with a two-sided test of size 5% is used, where the treatment difference is 
expected to be at least 0.6 mmol/L [11 mg/dL]. The SD=3.5 mmol/L [63 mg/dL] in change from 
baseline in 1-hour PPG increments 16 weeks after randomisation based on laboratory analysed PG 
in a standardised meal test will be considered reasonable based on trials NN1218-3852 and 
NN1218-3853.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
81 of 113
The power in step 4, where superiority of faster aspart over NovoRapid® in change from baseline in 
1,5-anhydroglucitol 16 weeks after randomisation is tested a t-statistic with a two-sided test of size 
5% is used. The mean treatment difference is expected to be at least 0.2 μg/mL and an SD of 
3.5μg/mL will be used based on trials NN1218-3852 and NN1218-3853.
The power calculations are done using proc power in SAS 9.4. Please refer to Table 17–1 for 
assumptions for the sample size calculation.
Table 17–1
Specifications assumed for sample size calculations
Statistical 
test
Significance 
level
Analysis 
population
Non-inferiority 
margin
SD
Mean 
difference
Randomisation 
scheme
Step 1 2-group t-test
One-sided 2.5 % FAS
0.4 % (absolute)
0.8 %
-0.1 %
1:1
Step 2 2-group t-test
Two-sided 5.0% FAS
NA
3.5 mmol/L
0.6 mmol/L
1:1
Step 3 2-group t-test
Two-sided 5.0% FAS
NA
0.8 %
-0.1 %
1:1
Step 4 2-group t-test
Two-sided 5.0% FAS
NA
3.5 μg/mL
0.2 μg/mL
1:1
In Table 17–2 the sensitivity of the sample size to the power shown for three different sizes of FAS. 
Three different choices of the mean difference are used to calculate the power in step 2.
Table 17–2
Sensitivity of sample size to power
N 
total
N 
per 
arm
Step 
1
Step 2
Step 
3
Step 4
FAS FAS Mean 
diff
(%)
SD
(%)
Power 
(%)
Mean 
diff
(mmol/L)
SD
(mmol/L)
Power 
(%)
Mean 
diff
(%)
SD
(%)
Power 
(%)
Mean
diff
(μg/mL)
SD
(μg/mL)
Power 
(%)
-0.1
0.8
>99.9
0.5
3.5
58.1
-0.1
0.8
47.4
0.2
3.5
13.9
920
460
-0.1
0.8
>99.9
0.6
3.5
73.8
-0.1
0.8
47.4
0.2
3.5
13.9
-0.1
0.8
>99.9
0.7
3.5
85.8
-0.1
0.8
47.4
0.2
3.5
13.9
-0.1
0.8
>99.9
0.5
3.5
64.7
-0.1
0.8
53.4
0.2
3.5
15.5
1072
536
-0.1
0.8
>99.9
0.6
3.5
80.1
-0.1
0.8
53.4
0.2
3.5
15.5
-0.1
0.8
>99.9
0.7
3.5
90.5
-0.1
0.8
53.4
0.2
3.5
15.5
-0.1
0.8
>99.9
0.5
3.5
70.4
-0.1
0.8
58.9
0.2
3.5
17.0
1224
612
-0.1
0.8
>99.9
0.6
3.5
85.0
-0.1
0.8
58.9
0.2
3.5
17.0
-0.1
0.8
>99.9
0.7
3.5
93.8
-0.1
0.8
58.9
0.2
3.5
17.0
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
82 of 113
In conclusion, 1072 subjects in the FAS (536 subjects per group) will ensure a marginal power of 
>99.9% to show non-inferiority in step 1, given that the actual treatment difference is -0.1%, and a 
marginal power of 80.1% to show superiority in step 2, given that the actual treatment difference is 
0.6 mmol/L.
Assuming a screening failure rate of 30% and run-in failure rate of 15%, 1803 subjects should be 
screened for inclusion in the trial.
17.2
Definition of analysis sets
The following analysis sets are defined in accordance with the ICH-E9 guidance 39.
!
Full Analysis Set (FAS) includes all randomised subjects. In exceptional cases, randomised 
subjects may be excluded from the FAS. In such cases, the reason for exclusion will be 
justified and documented. Subjects in the FAS will contribute to the evaluation “as 
randomised”
!
Per Protocol (PP) Analysis Set includes all subjects in the FAS, excluding subjects who:
o
Have violated any inclusion criteria
o
Have fulfilled any exclusion criteria
Subjects in the PP analysis set will contribute to the evaluation “as treated” 
!
Safety Analysis Set includes all subjects receiving at least one dose of randomised 
treatment. Subjects in the safety analysis set will contribute to the evaluation “as treated”. 
Randomised subjects who are lost to follow-up, and where no exposure information of the trial 
product or its comparator is available after randomisation, will be handled as unexposed.
Before data are released for statistical review, a blinded review of all data will take place to identify 
serious non-adherence to the protocol that may potentially affect the results. Furthermore, extreme 
values and outliers will be identified by the statistician during programming and data review,
according to ICH-E9.39 This will be performed by using a fake randomisation.
The subjects or observations to be excluded, and the reasons for their exclusion must be 
documented and signed by those responsible before database lock. The subjects and observations 
excluded from analysis sets, and the reason for this, will be described in the clinical trial report.
17.3
Primary endpoint
The primary endpoint is change from baseline in HbA1c 16 weeks after randomisation. 
Primary analysis:
1) The primary estimand will be addressed by the below primary analysis on all subjects 
included in the FAS and using the in-trial observation period. Note that if subjects withdraw 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
83 of 113
consent to contribute additional information or are completely lost to follow-up, missing data 
will occur. The primary analysis will be implemented as a statistical model using multiple 
imputations where the subjects without any available HbA1c measurements at scheduled 
visits will have their HbA1c value imputed from the available information from the treatment 
group the subject has been randomised to. Note that this resembles in essence a mixed model 
of repeated measurements analysis. Subjects without any post-randomisation measurements 
contribute to the analysis, as the missing values will be imputed. The analysis will be 
implemented as follows: 
!
In the first step, intermittent missing values are imputed using a Markov Chain 
Monte Carlo method, in order to obtain a monotone missing data pattern. This 
imputation is done for each group separately and 100 copies of the dataset will be 
generated. 
!
In the second step, for each of the 100 copies of the dataset, an analysis of variance 
model with region and metformin use at baseline (Yes/No) as factors and baseline 
HbA1c as covariate is fitted to the change in HbA1c from baseline to week 4 for each 
treatment group separately. The estimated parameters, and their variances, from 
these models are used to impute missing values at week 4 for subjects in each 
treatment group, based on region, metformin use at baseline (Yes/No) and baseline 
HbA1c.
!
In the third step, for each of the 100 copies of the dataset, missing values at week 8 
are imputed in the same way as for week 4. The imputations are based on an analysis 
of variance model with region and metformin use at baseline (Yes/No) as factors and 
baseline HbA1c and change from baseline in HbA1c at week 4 as covariates.
!
This stepwise procedure is then repeated sequentially for week 12 and 16.
!
For each of the complete data sets, the change from baseline to week 16 is analysed 
using an analysis of variance model with treatment, region and metformin use at 
baseline (Yes/No) as factors, and baseline HbA1c as a covariate. 
!
The estimates and standard deviations for the 100 data sets are pooled to one 
estimate and associated standard deviation using Rubin’s formula:
m =
1
100 
 m   


CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
84 of 113
SD =  1
100 
 SD



+ 1 + 1
100 
1
100 −1 
(m −m)


where mi and SDi are the estimated means and standard deviations for the 100 copies 
of the dataset, and mMI and SDMI are the pooled estimates.
!
From mMI  and  SDMI, the 95% confidence interval for the treatment differences is 
calculated. 
Non-inferiority of faster aspart will be considered confirmed if the upper boundary of the two-sided 
95% confidence interval is below or equal to 0.4% or equivalent if the p-value for the one-sided test 
of
H0: D > 0.4%    against   HA: D ≤ 0.4%
is less than or equal to 2.5%, where D is the mean treatment difference (faster aspart minus 
NovoRapid®).
Note that as the anticipated number of subjects discontinuing treatment, but not trial is low, multiple 
imputations based on such subjects is not expected to be suitable.
Provided that the hierarchical testing allows, the evaluation of superiority will be based on the same 
statistical model, as the primary analysis 1). The associated sensitivity analysis that follows will 
investigate the robustness of non-inferiority and superiority (analysis 3b and 3c) as well.
Sensitivity analysis for the primary analysis addressing the primary estimand
All sensitivity analyses for the primary analysis addressing the primary estimand will use the in-trial 
observation period.
2) First the primary analysis in 1) will be repeated, but excluding all factors except from 
treatment in the model. This analysis will explore the influence of the different factors.
3) The primary analysis approach chosen for this trial relies on the assumption that missing data 
is missing at random (MAR). This assumption implies that the HbA1c for subjects leaving the 
trial, after their withdrawal, develops in a similar way as the HbA1c for similar subjects that 
remain in the trial (not necessarily on treatment) and had similar development of HbA1c 
before withdrawal. The MAR assumption may be questionable for subjects withdrawing at 
own will. Therefore the statistical models using multiple imputation will be repeated with the 
following alteration:
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
85 of 113
a) Imputations will be done from the treatment arm that the subject was randomised to and 
a value of 0.4% (non-inferiority margin) is added to the change from baseline in HbA1c
at week 16 for subjects randomised to faster aspart who withdrew from the trial.40
b) Imputations will be done from the comparator arm (NovoRapid®). This will serve as a 
supplementary sensitivity analysis for the superiority analysis. It does not rely on the 
MAR assumption, but assumes that all subjects who withdraw from the trial in the faster
aspart arm shift to NovoRapid®. The imputation will be done conditional on observed 
information for subjects that withdraw from the faster aspart arm such that the treatment 
effect diminishes gradually after trial discontinuation (copy reference/conditional 
imputation). The analysis will use data from the in-trial observation period.
c) Imputation will be done from the comparator arm (NovoRapid®). This will serve as a 
supplementary sensitivity analysis for the superiority analysis. It does not rely on the 
MAR assumption, but it is assumed that all subjects who withdraw from the trial in the 
faster aspart arm respond at week 16 as if they have been treated with NovoRapid® for 
the entire trial. That is, all collected post-randomisation data for subjects who withdraw 
from the trial in the faster aspart arm will be set to missing. The analysis will use data 
from the in-trial observation period.
Analyses addressing the secondary estimand
All analyses addressing the secondary estimand will use the on-treatment observation period.
4) The secondary estimand will be analysed using the same statistical model using multiple 
imputations as the primary analysis in 1) except using the on-treatment observation period. 
5) A tipping point analysis based on a statistical model using multiple imputation model similar 
to 1), using the on-treatment observation period, will be made. In this analysis observations 
for subjects that discontinue randomised treatment are imputed based on the treatment arm 
they were randomised to and subjects discontinuing treatment in the faster aspart group are 
given a penalty. This is done to investigate the robustness of the conclusion in the primary 
analysis with respect to the MAR assumption and mimics a scenario where the HbA1c of the 
subjects discontinuing treatment in the faster aspart groups evolve less favourably than 
predicted. As a first step imputations will be done without penalty assuming MAR in the 
treatment group. Second, the imputed values for week 16 in the faster aspart group will be 
added a penalty. This is done repeatedly, gradually increasing the penalty until the 
conclusion from the non-inferiority analysis no longer holds. This will serve as a sensitivity 
analysis for the non-inferiority analysis and the specific value of the penalty that changes the 
conclusion will be used to evaluate the robustness of the conclusion of the non-inferiority 
analysis.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
86 of 113
6) A tipping point analysis based on a statistical model using multiple imputation, similar to 5) 
but with the modification that subjects discontinuing treatment due to non-eligibility 
(Subjects discontinuing randomised treatment prematurely due to criteria 1, 2, 3, and 4, 
which are defined in section 6.6) in the faster aspart group will not have a penalty added. 
These analyses are motivated by the fact that data from subjects prematurely discontinuing 
randomised treatment due to non-eligibility can reasonably be assumed to be missing 
completely at random. 
7) The same statistical model using multiple imputations as the analysis in 4), but using the PP 
analysis set and analysed using the on-treatment observation period. This analysis will 
investigate the situation that subjects might have deviated from the inclusion and exclusion 
criteria and will serve as sensitivity analysis for the non-inferiority analysis.
17.4
Secondary endpoints
17.4.1
Confirmatory secondary endpoints 
If the effect of treatment with faster aspart can be confirmed in the primary analysis, the trial also 
aims to confirm effect of treatment with faster aspart for a number of secondary confirmatory 
endpoints using a hierarchical (fixed sequence) testing procedure as described in section 17
(General consideration). This is based on a priority ordering of the null-hypotheses, and testing 
them in this order using the two-sided 95% confidence interval approach until an insignificant result 
appears. The effect is that rejection of the null hypothesis only, will be confirmed for endpoints 
where all previous null-hypotheses have been rejected in favour of faster aspart.
The confirmatory secondary endpoints are:
!
Change from baseline in 1-hour PPG increment 16 weeks after randomisation (meal test)
!
Change from baseline in 1,5-anhydroglucitol 16 weeks after randomisation
The steps in the hierarchical testing procedure are as follows:
Step 1 (Primary analysis):  HbA1c non-inferiority of faster aspart versus NovoRapid®
Step 2: 1-hour PPG increment (meal test) superiority of faster aspart versus NovoRapid®
Step 3: HbA1c superiority of faster aspart versus NovoRapid®
Step 4: 1,5-anhydroglucitol superiority of faster aspart versus NovoRapid®
The primary estimand for the primary endpoint will be repeated for the confirmatory secondary 
endpoints, change from baseline in 1-hour PPG increment (meal test) and change from baseline in 
1,5-anhydroglucitol 16 weeks after randomisation. The analyses related to these estimands are 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
87 of 113
defined below and will be used for the decisions to continue or not, throughout the hierarchical 
testing procedure. These analyses will be based on the FAS and use the in-trial observation period.
As sensitivity analysis the secondary analysis 4) will also be repeated for the confirmatory 
secondary endpoints. The analyses will be based on the FAS and using the on-treatment observation 
period.
Change from baseline in 1-hour PPG increment 16 weeks after randomisation (meal test) 
(step 2)
As the second step of the hierarchical testing procedure changes from baseline in 1-hour PPG 
increment (meal test) 16 weeks after randomisation will be tested for superiority of faster aspart 
compared to NovoRapid®.
The 1-hour PPG increment will be analysed based on the laboratory measured values in the meal 
test.
The 1-hour PPG increment endpoint will be analysed using the FAS and the in-trial observation 
period based on a multiple imputation technique where the change from baseline in 1-hour PPG 
increment at week 16 for subjects withdrawn from trial are imputed based on data from trial 
completers in the NovoRapid® arm. Multiple copies (100 copies) of the full dataset will be 
generated by imputing missing values based on estimated parameters as follows: 
!
An analysis of variance model with region and metformin use at baseline (Yes/No) as 
factors and baseline 1-hour PPG increment as covariate is fitted to the change from baseline 
in 1-hour PPG increment at week 16 for the NovoRapid® group only. The estimated 
parameters, and the variance, from this model are used to impute missing values using 
stochastic simulation at week 16 for subjects in both treatment groups in order to generate 
100 complete datasets.
!
For each of the complete data sets, the change from baseline to week 16 is analysed using an 
analysis of variance model with treatment, region and metformin use at baseline (Yes/No) as 
factors, and baseline 1-hour PPG increment as covariate.
!
The estimates and standard deviations for the 100 data sets are pooled to one estimate and 
associated standard deviation using Rubins formula. From this, the pooled estimates and 
95% confidence interval for the treatment difference is calculated.
The superiority will be assessed by comparing the upper limit of the 95% CI to 0. If the upper 95% 
CI is below 0 then superiority will be confirmed.
Change from baseline in HbA1c 16 weeks after randomisation (step 3)
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
88 of 113
Step 3 in the hierarchical testing procedure is to confirm superiority of change from baseline HbA1c
16 weeks after randomisation of the effect of treatment with faster aspart compared to NovoRapid®. 
Superiority will be based on the same 95% CI that was used for addressing the primary analysis. 
Superiority will be confirmed if the upper boundary of the two-sided 95% confidence interval of the 
mean treatment difference (faster aspart minus NovoRapid®) is below 0%.
Change from baseline in 1,5-anhydroglucitol 16 weeks after randomisation (step 4)
Step 4 in the hierarchical testing procedure is to confirm superiority of change from baseline 1,5-
anhydroglucitol 16 weeks after randomisation of the effect of treatment with faster aspart compared 
to NovoRapid®. The endpoint will be analysed based on all planned post baseline measurements 
until or at 16 weeks after randomisation using a model similar to the primary analysis 1), but with 
baseline 1,5-anhydroglucitol as covariate. Superiority will be confirmed if the upper boundary of 
the two-sided 95% confidence interval of the mean treatment difference (faster aspart minus 
NovoRapid®) is below 0.
17.4.2
Supportive secondary endpoints
17.4.2.1
Efficacy endpoints
All endpoints except insulin dose in this section will be assessed using the FAS and the in-trial 
observation period and repeated using the on-treatment observation period. Insulin dose will be 
presented using the safety analysis set and will therefore only use the on-treatment observation 
period.
Change from baseline in FPG 16 weeks after randomisation
Change from baseline in FPG 16 weeks after randomisation will be analysed based on all planned 
post baseline measurements until or at 16 weeks after randomisation using a model similar to 1) 
except with baseline FPG as covariate.
If a subject achieves HbA1c target 16 weeks after randomisation
HbA1c < 7.0%
A dichotomous (responder/non-responder) endpoint will be defined based on whether a Subject has 
met the HbA1c target (HbA1c <7.0%) 16 weeks after randomisation.  
This responder endpoint will be analysed based on a logistic regression model using treatment,
region and metformin use at baseline (Yes/No) as factors, and baseline HbA1c as covariate. In 
analysis of the in-trial observation period subjects without an HbA1c measurement at week 16 will 
be treated as non-responders. In the analysis using the on-treatment observation period both subjects
who discontinue randomised treatment or withdraw from trial is included as non-responders.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
89 of 113
HbA1c < 7.0% without severe hypoglycaemia
A dichotomous (responder/non-responder) endpoint will be defined based on whether a Subject has 
met the HbA1c target (HbA1c <7.0%) 16 weeks after randomisation without treatment emergent 
severe hypoglycaemic episodes.
This responder endpoint will be analysed based on a logistic regression model using treatment,
region and metformin use at baseline (Yes/No) as factors and baseline HbA1c as covariate. In the 
analysis of the in-trial observation period subjects without an HbA1c measurement at week 16 will 
be treated as non-responders. In the analysis using the on-treatment observation period both subjects
who discontinue randomised treatment or withdraw from trial will be included as non-responders.
Change from baseline in 30- minutes, 1- hour, 2- hour, 3- hour and 4- hour PPG and 30-
minutes, 2- hour, 3- hour and 4- hour PPG increment 16 weeks after randomisation (meal 
test)
Laboratory measured PG from the meal test will be analysed for 30 minutes, 1-hour, 2-hours, 3-
hours and 4-hours PPG separately. The corresponding PPG increments will be derived separately 
using each PPG measurement minus the pre-prandial PG measurement.
Change from baseline in PPG and PPG increment 16 weeks after randomisation will be analysed 
separately using a model similar to the model used in hierarchical testing procedure step 2 for 1-
hour PPG increment 16 weeks after randomisation (meal test) except with the corresponding 
baseline value as covariate.
Change from baseline in endpoints derived from the 7-9-7-point SMPG profile 16 weeks after 
randomisation
In general, analyses will be based on the entire 7-9-7-point SMPG profile except for the analyses of 
nocturnal endpoints where information in the 9-point SMPG profile will be utilised. 
PPG and PPG increments based on the 7-9-7-point SMPG profiles will be derived separately for PG 
measurements made 1 hour after the meal. In the following section this distinction will be 
considered implicit and without further explanation.
Pre-prandial PG and PPG will be recorded by the subjects as part of the 7-9-7-point SMPG profile 
prior to three defined visits. Individual mean mealtime PPG (post-breakfast, post-lunch, post-main 
evening meal) will be derived from the three profiles. Overall mean PPG will be derived from the 
individual derived mealtime PPG values.
PPG increment for each meal (breakfast, lunch, main evening meal) will be derived from the 7-9-7-
point SMPG profile as the difference between PPG values and the PG value before meal in each 
separate profile. The mean of the derived increments will then be calculated separately for each 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
90 of 113
meal. Mean 1 hour PPG increments over all meals will be derived as the mean of all corresponding 
mean meal increments. 
!
Change from baseline in mean of the 7-9-7-point SMPG profile
The mean of the 7-9-7-point SMPG profile is defined as the area under the curve profile 
divided by the measurement time, and is calculated using the linear trapezoidal technique.
Change from baseline in the mean of the 7-9-7-point SMPG profile 16 weeks after 
randomisation will be analysed based on all planned post baseline measurements until or at 
16 weeks after randomisation using a model similar to 1) except with the corresponding 
baseline value as covariate.
!
Change from baseline in PPG and PPG increment (mean, breakfast, lunch and main evening 
meal)
Change from baseline in PPG and PPG increment endpoints 16 weeks after randomisation 
for mean over all three meals and the individual meals will be analysed separately based on 
all planned post baseline measurements until or at 16 weeks after randomisation using a 
model similar to 1) except with the corresponding baseline value as covariate.
!
Change from baseline in fluctuation in 7-9-7-point SMPG profile
The fluctuation in the 7-9-7-point SMPG profile is defined as:
1
  |() −
|
 

!
where T, PG(t) and 
 denotes the length of the profile, the PG value at time t and the mean 
of the profile, respectively. It will be calculated using the linear trapezoidal technique.
Fluctuation in the 7-9-7-point SMPG profile will be logarithmically transformed and 
analysed based on all planned post baseline measurements until or at 16 weeks after 
randomisation using a model similar to 1) except with the corresponding log-transformed 
baseline value as covariate. Estimated treatment means and the estimated treatment 
differences with corresponding 95% CI will be back-transformed to the original scale, 
resulting in estimated geometric means, a treatment ration and a 95% CI for the treatment 
ratio.
!
Change from baseline in nocturnal SMPG measurements
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
91 of 113
Change from baseline in nocturnal SMPG measurements will be assessed by considering the 
difference between PG values available at bedtime, at 4 AM and the before breakfast value 
the following day: (4 AM PG value minus at bedtime PG value), (before breakfast PG value 
minus at bedtime PG value) and (before breakfast PG value minus 4 AM PG value).
Change from baseline in nocturnal SMPG measurements 16 weeks after randomisation will 
be analysed based on all planned post baseline measurements until or at 16 weeks after 
randomisation using a model similar to 1) except with the corresponding baseline values as 
covariate.
If a subject achieves PPG target (based on overall mean of daily PPG measurements in 7-9-7-
point SMPG profile) 16 weeks after randomisation:
Overall PPG (1 hour) ∃7.8 mmol/L [140 mg/dL]
A dichotomous (responder / non-responder) endpoint will be defined based on whether a Subject 
has reached an overall mean 1 hour PPG ∃7.8 mmol/L [140 mg/dL] 16 weeks after randomisation, 
where PPG is derived from the 7-9-7-point SMPG profile. 
This responder endpoint will be analysed based on a logistic regression model using treatment, 
region and metformin use at baseline (Yes/No) as factors, and baseline overall 1-hour mean PPG as 
covariate. In analysis of the in-trial observation period subjects without an overall mean 1 hour PPG 
at week 16 will be treated as non-responder. In the on- treatment observation period analysis both 
subjects who discontinue randomised treatment or withdraw from trial will be included as non-
responders.
Overall PPG (1-hour ) ∃7.8 mmol/L [140 mg/dL] without severe hypoglycaemia
A dichotomous (responder / non-responder) endpoint will be defined based on whether a Subject 
has reached an overall 1-hour PPG ∃7.8 mmol/L [140 mg/dL] 16 weeks after randomisation without 
any treatment emergent severe hypoglycaemic episodes. 
This responder endpoint will be analysed based on a logistic regression model using treatment,
region and metformin use at baseline (Yes/No) as factors, and baseline mean 1-hour PPG as 
covariate. In analysis of the in-trial observation period subjects without an overall mean 1 hour PPG 
at week 16 will be treated as non-responders. In the on- treatment observation period analysis both 
subjects who discontinue randomised treatment or withdraw from trial will be included as non-
responders. 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
92 of 113
Insulin dose (Units/day and Units/kg/day; total basal, total bolus, total daily insulin dose and 
individual meal insulin dose) 16 weeks after randomisation
The insulin doses will be summarised descriptively by treatment week according to regimen, both 
by meal type and as total daily dose in units and units/kg (total daily and separately for each 
mealtime dose). Insulin doses will be summarised using the on-treatment observation period and 
using the safety analysis set.
Change from baseline in lipids-lipoproteins profile 16 weeks after randomisation
Change from baseline in lipid endpoints (total cholesterol, HDL cholesterol, LDL cholesterol) will 
be logarithmically transformed and analysed separately based on all planned post baseline 
measurements until or at 16 weeks after randomisation using a model similar to 1) except with the 
corresponding log-transformed baseline as covariate. Estimated treatment means and the estimated 
treatment difference with corresponding 95% CI will be back-transformed to the original scale, 
resulting in estimated geometric means, a treatment ratio and a 95% CI for the treatment ratio.
17.4.2.2
Safety endpoints
In terms of AEs, as a minimum, SAEs will be tabulated separately using the in-trial observation 
period.
All events in the in-trial observation period will be listed with information about whether it 
appeared in the on-treatment observation period or not.
Number of treatment emergent adverse events
Adverse events (AEs) will be coded using the Medical Dictionary for Regulatory Activities 
(MedDRA). AEs will be presented based on system organ class and preferred terms.
A Treatment Emergent Adverse Event (TEAE) is defined as an event that has an onset date on or 
after the first day of exposure to randomised treatment, and no later than seven days after the last 
day of exposure to randomised treatment.
TEAEs are summarised descriptively, whereas AEs not defined as treatment emergent are presented 
in listings, including AEs reported in the 30-day follow-up period. The summaries of TEAEs are 
made displaying the number of subjects with at least one event, the percentage of subjects with at 
least one event, the number of events and the event rate per 100 patient years of exposure. These 
summaries are done by seriousness, severity, relation to insulin treatment, relation to technical 
complaint, premature treatment discontinuation due to AEs, AEs leading to withdrawal from trial
and outcome.
Furthermore, summary tables based on system organ class and preferred terms are made for:
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
93 of 113
!
All TEAEs
!
Serious TEAEs
!
Possibly and probably related TEAEs
!
Severe TEAEs
!
TEAEs with preferred term that are experienced by at least 5% of the subjects in any 
treatment arm or by at least 5% of all subjects
For AEs where additional information is recorded, this will be listed.
AEs occurring during the run-in period are considered non-treatment emergent and will be 
summarised separately.
Number of treatment emergent injection site reactions
Treatment emergent injection site reactions occurring during the trial will be summarised and listed.
Classification of Hypoglycaemia
Treatment emergent: hypoglycaemic episodes will be defined as treatment emergent if the onset of 
the episode occurs on or after the first day of exposure to randomised treatment, and no later than 
one day after the last day of exposure to randomised treatment.
Nocturnal hypoglycaemic episodes: episodes occurring between 00:01 and 05.59 both inclusive.   
Hypoglycaemic episodes are classified according to the Novo Nordisk classification of 
hypoglycaemia (see Figure 17–1) and the ADA classification of hypoglycaemia (see Figure 17–2).
Novo Nordisk classification of hypoglycaemia
In normal physiology, symptoms of hypoglycaemia occur below a PG level of 3.1 mmol/L (56 
mg/dL).41 Therefore, Novo Nordisk has included hypoglycaemia with PG levels below this cut-off 
point in the definition of BG confirmed hypoglycaemia.
Novo Nordisk uses the following classification (see Figure 17–1) in addition to the ADA 
classification: 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
94 of 113
!
Severe hypoglycaemia according to the ADA classification.34
!
Severe or BG confirmed hypoglycaemia: An episode that is severe according to the ADA 
classification34 or BG confirmed by a PG value <3.1 mmol/L (56 mg/dL) with or without 
symptoms consistent with hypoglycaemia. 
Hypoglycaemic
episode
PG ≤ 3.9 mmol/L 
(70 mg/dL) 
or 
Alleviation of 
symptoms 
or
Seizure, coma or 
fatal 
SMPG
measurement
PG < 3.1 mmol/L
(56 mg/dL)
with symptoms
PG < 3.1 mmol/L
(56 mg/dL)
without
symptoms
Symptomatic BG 
confirmed 
hypoglycaemia
Asymptomatic BG 
confirmed 
hypoglycaemia
Yes
No
Severe or 
BG confirmed 
symptomatic 
hypoglycaemia
BG confirmed 
hypoglycaemia
Severe or BG 
confirmed 
hypoglycaemia
Note: Glucose measurements are performed with capillary blood calibrated to plasma equivalent glucose values
BG: blood glucose  PG: plasma glucose  SMPG: Self-measured plasma glucose  
Subject 
able to 
treat him/
herself
Severe 
hypoglycaemia
(ADA 2013)
Figure 17–1
Novo Nordisk classification of hypoglycaemia
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
95 of 113
ADA classification34 of hypoglycaemia 
!
Severe hypoglycaemia: An episode requiring assistance of another person to actively 
administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose 
concentrations may not be available during an event, but neurological recovery following 
the return of PG to normal is considered sufficient evidence that the event was induced by a 
low PG concentration.
!
Asymptomatic hypoglycaemia: An episode not accompanied by typical symptoms of 
hypoglycaemia, but with a measured PG concentration ≤ 3.9 mmol/L (70 mg/dL).
!
Documented symptomatic hypoglycaemia: An episode during which typical symptoms of 
hypoglycaemia are accompanied by a measured PG concentration ≤ 3.9 mmol/L (70 
mg/dL).
!
Pseudo-hypoglycaemia: An episode during which the person with diabetes reports any of the 
typical symptoms of hypoglycaemia with a measured PG concentration > 3.9 mmol/L (70 
mg/dL) but approaching that level.
!
Probable symptomatic hypoglycaemia: An episode during which symptoms of 
hypoglycaemia are not accompanied by a PG determination but that was presumably caused 
by a PG concentration ≤ 3.9 mmol/L (70 mg/dL).
Hypoglycaemic 
episode 
PG ≤ 3.9 mmol/L 
(70 mg/dL) 
or 
Alleviation of 
symptoms 
or
Seizure, coma or 
fatal 
SMPG
measurement
Asymptomatic 
hypoglycaemia
Documented 
symptomatic 
hypoglycaemia
Pseudo-
hypoglycaemia
Probable 
symptomatic 
hypoglycaemia
No
Yes
No measurement 
with symptoms
PG > 3.9 mmol/L 
(70 mg/dL)
with symptoms
PG ≤3.9 mmol/L 
(70 mg/dL)
with symptoms
PG ≤3.9 mmol/L 
(70 mg/dL)
without symptoms
No
Yes
Note: Glucose measurements are performed with capillary blood calibrated to plasma equivalent glucose values
PG: plasma glucose  SMPG: Self-measured plasma glucose  
Subject 
able to 
treat him/
herself
Severe 
hypoglycaemia
(ADA 2013)
Figure 17–2
ADA classification of hypoglycaemia
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
96 of 113
Treatment emergent hypoglycaemic episodes are presented in terms of the number of subjects with 
at least one event (N), the percentage of subjects with at least one event (%), the number of events 
(E) and the event rate per 100 years of exposure (R). Separate summaries are made by severity 
considering all episodes, nocturnal and daytime episodes using Novo Nordisk and ADA classified 
episodes. All episodes will also be summarised by category, including summaries in relation to time 
since start of meal, as occurring during1, 2, and 4 hours after start of meal, and from 2 hours 
(exclusive) to 4 hours (inclusive) after start of meal, respectively.
The number of treatment emergent severe or BG confirmed hypoglycaemic episodes (all, daytime, 
nocturnal, 1 hour, 2 hours, 4 hours and from 2 hours (exclusive) to 4 hours (inclusive) after start of 
the meal) will be analysed based on the FAS using a negative binomial regression model with a log-
link function and the logarithm of the time period in which a hypoglycaemic episode is considered 
treatment emergent as offset. The model will include treatment, region and metformin use at 
baseline (Yes/No) as factors. To the extent where data allow, separate analysis will be performed 
for severe hypoglycaemic episodes.
Change from baseline in clinical evaluations 16 weeks after randomisation:
Physical examination
The physical examination parameters (head, ears, eyes, nose, throat, neck, respiratory system, 
cardiovascular system, gastrointestinal system incl. mouth, musculoskeletal system, central and 
peripheral nervous system, skin), and their change from baseline, will be summarised descriptively
using the on-treatment period. All findings will be listed.
Vital signs
Vital signs include diastolic blood pressure, systolic blood pressure and pulse. The measurements 
will be summarised descriptively using the on-treatment period and both actual values as mean 
change and change from baseline.
Electrocardiogram
ECG findings will be summarised descriptively using the on-treatment period and including 
summaries of the change from baseline. Change from baseline will be summarised as 
normal/abnormal not clinically significant/abnormal clinically significant categorisation in shift 
tables.
Fundoscopy/fundus photography
Fundoscopy/fundus photography findings will be summarised descriptively using the on-treatment 
period and including summaries of the change from baseline. Change from baseline will be 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
97 of 113
summarised as normal/abnormal not clinically significant/abnormal clinically significant 
categorisation in shift tables.
Change from baseline in clinical laboratory assessments 16 weeks after randomisation
Change from baseline 16 weeks after randomisation in central laboratory assessments:
!
Haematology (erythrocytes, haematocrit, haemoglobin, leucocytes, thrombocytes)
!
Biochemistry (ALT, AST, albumin, alkaline phosphatase, creatinine, potassium, sodium, 
total bilirubin)
Individual laboratory values will be compared to their relevant reference range (when existing) and 
flagged as being below or above the range. The measurements and their change from baseline will 
be summarised descriptively using the on-treatment period. Change from baseline will be 
summarised both the actual values and the low/normal/high categorisation in shift tables.
Change from baseline in body weight and body mass index 16 weeks after randomisation
The measurements will be summarised descriptively using the on-treatment period and the actual 
values as mean change.
Change from baseline in body weight will be analysed based on all planned post baseline 
measurements until or at 16 weeks after randomisation using a statistical model similar to 1) except 
with the corresponding baseline measurement as covariate.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
98 of 113
18 Ethics
18.1
Benefit-risk assessment of the trial
All subjects included in the trial will be treated with basal-bolus regimen with insulin degludec as 
the basal insulin. Inclusion and exclusion criteria have been chosen to ensure that subjects enrolling 
in the trial have T2DM at a stage where basal-bolus treatment is needed (i.e. subjects must have 
been diagnosed with T2DM for 10 years or more and must have been on a basal-bolus treatment 
regimen at least 365 days prior to screening). 
Subjects taking metformin at the enrolment in the trial should continue the metformin treatment 
unchanged. Metformin plus basal/bolus insulin is a recommended treatment for subjects with 
T2DM9 and the combination of metformin and basal-bolus insulin therapy with faster aspart or 
NovoRapid® as the bolus insulin was included in the phase 3A faster aspart trials in T2DM. 
The most common side effect of all available insulin preparations is hypoglycaemia. The 
investigator will explain to the subject how they should check their BG with the BG meter provided 
by Novo Nordisk and what precautions to take in case of low BG measurement.
Trial products will be provided by Novo Nordisk free of charge during the trial. When treatment 
with trial products ends, the subject and investigator will decide on the best available treatment on 
the market. Novo Nordisk will not offer any free medications after the completion of the trial.
Summary of clinical pharmacology
The pharmacokinetic and pharmacodynamic profiles of faster aspart consistently demonstrated a 
left shift compared to that of NovoRapid® in subjects with T1DM and the profiles for faster aspart 
and NovoRapid® were similar in overall shape. Faster aspart produced a faster onset of exposure 
and increased initial absorption rate compared to NovoRapid® resulting in a faster onset of action 
and increased early glucose-lowering effect. Overall, the differences in the pharmacokinetic and 
pharmacodynamic properties for faster aspart compared to NovoRapid® were consistent across 
trials.22 No safety concerns were raised during any of the trials. 
Similar clinical pharmacology trials have not been performed in subjects with T2DM, however the 
phase 3A programme for faster aspart included trials in bolus naïve T2DM subjects. Non-inferiority 
to NovoRapid® with regard to HbA1c change from baseline was demonstrated. In subjects with 
T2DM faster aspart statistically significantly improved control of the 1-hour PPG increment when 
compared to NovoRapid®.22 No safety issues for faster aspart have been identified based on data 
from the clinical development programme, and the safety profile is similar to NovoRapid®.22
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
99 of 113
Clinical benefits and risk considerations for the trial
The purpose of this trial is to confirm the effect and compare safety of faster aspart compared to 
NovoRapid® both in combination with insulin degludec with or without metformin in subjects with 
T2DM treated with a basal-bolus regimen.
For the individual subjects, the personal health-related benefits are related to the medical 
examination and the benefit from an intensified treatment regimen anticipated to be better than or 
equal to the treatment they receive at the time they enter the trial. However, subjects will have to 
spend some extra time monitoring and recording data and on additional visits to the clinic and 
phone contacts.
The very high frequency of contacts between the subject and the investigator and the thorough 
evaluation of SMPG values will provide the opportunity for optimising the titration of basal and 
bolus insulin based on SMPG values and thereby may contribute to obtaining improved HbA1c
results. All subjects will have reinforced dietary training including simple carbohydrate counting.
For the individual subjects, the anticipated risks include hypoglycaemia, hyperglycaemia, systemic 
allergic reactions, injection site reactions, lipodystrophy, and antibody development. The risks will 
be mitigated by the close supervision of the subjects and the frequent measurements of BG levels.
A consequence of the pharmacodynamics of rapid-acting insulin analogues is that if hypoglycaemia 
occurs, it may occur earlier after an injection than with soluble human insulin. A phase 3A trial with 
faster aspart in T2DM showed a slight shift in distribution of the occurrence of hypoglycaemic 
episodes in relation to a meal when comparing to NovoRapid®. A statistical significant higher rate 
of hypoglycaemic episodes was seen during the first 2 hours after a meal for faster aspart. This is 
not unexpected and reflects the pharmacokinetic and pharmacodynamic properties of faster aspart.22
All treatments are contraindicated in case of hypersensitivity to the active substances or any of the 
excipients. The risk of hypersensitivity is partly mitigated by excluding subject with known 
hypersensitivity towards any trials products or related products.
Injection site reactions can occur. The nature of the injection site reactions is expected to be mild, 
transient, and more of a visual character and is not expected to be of concern to the subject’s safety. 
Lipodystrophy (including lipohypertrophy, lipoatrophy) at the injection site can occur. Continuous 
rotation of the injection site within the particular injection area may help to reduce the risk of 
developing these reactions.
The blood samples during meal tests might be inconvenient to the subjects, but are not of any safety 
concern.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
100 of 113
Subjects in this trial will be using bolus and basal insulin administered via two differently colour-
coded prefilled pens. This colour difference will help the subject to distinguish between the pens 
and thereby minimise the risk of medication errors with regard to mixing up the pens used for basal 
and bolus injection. Subjects will be trained in distinguishing between the pens. It is expected that 
the risk of mixing up basal and bolus insulin in this trial is similar to other clinical trials.
No maximum dose of insulin is specified as doses are titrated individually. All subjects will perform 
4-point profiles on a daily basis throughout the trial for safety purposes and for the purpose of 
insulin titration.
Conclusion
Subjects in this trial will benefit from an intensified insulin treatment in a basal-bolus regimen in a 
treat-to-target setting under close supervision.
The safety profile of insulin aspart is well established from the market use of NovoRapid®. The data 
available for faster aspart in non-clinical and clinical studies taken together with review of the 
additional excipients in the faster aspart formulation have not revealed any safety issues that would 
prohibit the administration of faster aspart formulations in accordance with this trial.
It is therefore concluded that the clinical benefits from the trial as well as the contribution to the 
development of a new faster aspart outweigh the potential risks of participating in this trial.
18.2
Informed consent 
In seeking and documenting informed consent, the investigator must comply with applicable 
regulatory requirement(s) and adhere to ICH GCP1 and the requirements in the Declaration of 
Helsinki.2
Before any trial-related activity, the investigator must give the subject verbal and written 
information about the trial and the procedures involved in a form that the subject can read and 
understand. 
The subjects must be fully informed of their rights and responsibilities while participating in the 
trial as well as possible disadvantages of being treated with the trial products.
The investigator must ensure the subject ample time to come to a decision whether or not to 
participate in the trial. 
A voluntary, signed and personally dated informed consent must be obtained from the subject 
before any trial-related activity.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
101 of 113
The responsibility for seeking informed consent must remain with the investigator, but the 
investigator may delegate the task to a medically qualified person, in accordance with local 
requirements. The written informed consent must be signed and personally dated by the person who 
seeks the informed consent before any trial-related activity.
If information becomes available that may be relevant to the subject’s willingness to continue 
participating in the trial, the investigator must inform the subject in a timely manner, and a revised 
written subject information must be provided and a new informed consent must be obtained.
18.3
Data handling
If the subject withdraws from the trial or is lost to follow-up, then the subject’s data will be handled 
as follows:
!
Data already collected and any data collected at the end-of-trial visit including follow-up 
visits will be retained by Novo Nordisk, entered into the database and used for the clinical 
trial report. 
!
Safety events will be reported to Novo Nordisk and regulatory authorities according to 
local/national requirements.
If data is used, it will always be in accordance with local regulations and IRBs/IECs.
18.4
Information to subjects during trial
The site will be offered a communication package to the subject during the conduct of the trial. The 
package content is issued by Novo Nordisk. The communication package will contain the letters 
intended for distribution to the subjects. The letters will be translated and adjusted to local 
requirements and distributed to the subject at the discretion of the investigator. The subject may 
receive a “welcome to the trial letter” and a “thank you for your participation letter” after 
completion of the trial. Further the subject may receive letters during the trial.
All written information to subjects must be sent to IRB/IEC for approval/favourable opinion and to 
regulatory authorities for approval or notification according to local regulations.
18.5
Premature termination of the trial and/or trial site
Novo Nordisk, the IRBs/IECs or a regulatory authority may decide to stop the trial, part of the trial 
or a trial site at any time, but agreement on procedures to be followed must be obtained.
If the trial is suspended or prematurely terminated, the investigator must inform the subjects 
promptly and ensure appropriate therapy and follow-up. The investigator and/or Novo Nordisk must 
also promptly inform the regulatory authorities and IRBs/IECs and provide a detailed written 
explanation. 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
102 of 113
If, after the termination of the trial, the benefit-risk analysis changes, the new evaluation must be 
provided to the IRBs/IECs in case it has an impact on the planned follow-up of subjects who have 
participated in the trial. If it has an impact, the actions needed to inform and protect the subjects 
should be described.
19 Protocol compliance
19.1
Protocol deviations
Deviations from the protocol should be avoided.
If deviations do occur, the investigator must inform the monitor and the implications of the 
deviation must be reviewed and discussed.
Deviations must be documented and explained in a protocol deviation by stating the reason, date, 
and the action(s) taken. Some deviations, for which corrections are not possible, can be 
acknowledged and confirmed via edit checks in the eCRF or via listings from the trial database.
Documentation on protocol deviations must be kept in the investigator trial master file and sponsor 
trial master file.
19.2
Prevention of missing data
The importance of subject retention will be addressed by Novo Nordisk in the training and 
communication with the trial sites.
The subjects will be carefully informed about the trial procedures before signing informed consent, 
so that they know the implications of participating in the trial. The run-in period in this trial will 
reduce the likelihood of drop-outs as only those who adhere to the protocol requirements will 
undergo randomisation. Subjects will during the run-in period get an understanding of what is 
expected from them when taking part in the trial and thereby minimise discontinuation from trial 
product post randomisation. In addition, only absolutely necessary criteria for premature 
discontinuation of trial products primarily focusing on subjects safety are included and thereby 
reducing the number of discontinuations and limiting the amount of missing data.
Close surveillance of subject retention will be performed throughout the trial by Novo Nordisk with 
focus on reasons for premature discontinuation of trial products or withdrawal of consent to secure 
early mitigations in collaboration with the trial sites.
The subjects must be instructed to complete their diary ongoing according to the protocol. Missing 
data will not be recorded retrospectively due to the decreased validity of such data36, 37; however a 7 
days’ timeline is applied for reporting of missing hypoglycaemic episode, The subject will be 
retrained in correct completion of the diary if missing data is identified.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
103 of 113
The investigator will make every effort to ensure that all assessments are performed and data is 
collected. If missing data does occur the reason will be collected via the protocol deviation process, 
see section 19.1. Novo Nordisk will monitor protocol deviations on an on-going basis throughout 
the trial followed by appropriate actions (e.g. re-training of site staff).
20 Audits and inspections
Any aspect of the clinical trial may be subject to audits conducted by Novo Nordisk or inspections 
from domestic or foreign regulatory authorities or from IRBs/IECs. Audits and inspections may 
take place during or after the trial. The investigator and the site staff as well as Novo Nordisk staff 
have an obligation to cooperate and assist in audits and inspections. This includes giving auditors 
and inspectors direct access to all source documents and other documents at the trial site relevant to 
the clinical trial. This includes permission to examine, analyse, verify and reproduce any record(s) 
and report(s) that are relevant to the evaluation of the trial.
21 Critical documents
Before a trial site is allowed to start screening subjects, written notification from Novo Nordisk 
must be received and the following documents must be available to Novo Nordisk:
!
Regulatory approval and/or acknowledgement of notification as required 
!
Approval/favourable opinion from IRBs/IECs clearly identifying the documents reviewed as 
follows: protocol, any protocol amendments, subject information/informed consent form, 
any other written information to be provided to the subject and subject recruitment materials
!
List of IRB/IEC members and/or constitution (or a general assurance number/statement of 
compliance)
!
Curricula vitae of investigator and sub-investigator(s) (current, dated and signed - must 
include documented GCP training or a certificate)
!
Signed receipt of IB
!
Signed and dated Agreement on Protocol
!
Signed and dated Agreement on Protocol Amendment, if applicable
!
Contract, signed by the investigator and/or appropriate parties on behalf of the investigator’s 
site and Novo Nordisk
!
Source document agreement
!
Central laboratory certification and normal ranges
!
Insurance statement, if applicable
!
Financial disclosure form from investigator and sub-investigator(s)
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
104 of 113
!
For US trial sites: verification under disclosures per Code of Federal Regulations (CFR) of 
Financial Conflict of Interest
!
For US trial sites: FDA form 1572 must be completed and signed by the investigator at each 
site
FDA form 1572:
For US sites:
!
Intended for US sites
!
Conducted under the Investigational new drug (IND)
!
All US investigators, as described above, will sign FDA Form 1572
For sites outside the US:
!
Intended for participating sites outside of the US
!
Not conducted under the Investigational new drug (IND)
!
All investigators outside of the US will not sign FDA form 1572
Novo Nordisk will analyse and report data from all sites together if more than one site is involved in 
the trial.
By signing the protocol agreement, each investigator agrees to comply fully with ICH GCP1,
applicable regulatory requirements and the Declaration of Helsinki.2
By signing the protocol agreement, each investigator also agrees to allow Novo Nordisk to make 
investigator’s name and information about site name and address publically available if this is 
required by national or international regulations.
22 Responsibilities
The investigator is accountable for the conduct of the trial at his/her site and must ensure adequate 
supervision of the conduct of the trial at the trial site. If any tasks are delegated, the investigator 
must maintain a log of appropriately qualified persons to whom he/she has delegated specified trial-
related duties. The investigator must ensure that there is adequate and documented training for all 
staff participating in the conduct of the trial. It is the investigator’s responsibility to supervise the 
conduct of the trial and to protect the rights, safety, and well-being of the subjects.
A qualified physician, who is an investigator or a sub-investigator for the trial, must be responsible 
for all trial-related medical decisions.
The investigator will follow instructions from Novo Nordisk when processing data.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
105 of 113
The investigator is responsible for filing essential documents (i.e. those documents which 
individually and collectively permit evaluation of the conduct of a trial and the quality of the data 
produced) in the investigator trial master file. The documents including the subject identification 
code list must be kept in a secure locked facility, so no unauthorized persons can get access to the 
data.
The investigator will take all necessary technical and organisational safety measures to prevent 
accidental or wrongful destruction, loss or deterioration of data. The investigator will prevent any 
unauthorised access to data or any other processing of data against applicable law. The investigator 
must be able to provide the necessary information or otherwise demonstrate to Novo Nordisk that 
such technical and organisational safety measures have been taken.
During any period of unavailability, the investigator must delegate responsibility for medical care of 
subjects to a specific qualified physician who will be readily available to subjects during that time.
If the investigator is no longer able to fulfil the role as investigator (e.g. if he/she moves or retires), 
a new investigator will be appointed in consultation with Novo Nordisk.
The investigator and other site personnel must have sufficient English skills according to their 
assigned task(s).
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
106 of 113
23 Reports and publications
The information obtained during the conduct of this trial is considered confidential, and may be 
used by or on behalf of Novo Nordisk for regulatory purposes as well as for the general 
development of the trial product. All information supplied by Novo Nordisk in connection with this 
trial shall remain the sole property of Novo Nordisk and is to be considered confidential 
information. 
No confidential information shall be disclosed to others without prior written consent from Novo 
Nordisk. Such information shall not be used except in the performance of this trial. The information 
obtained during this trial may be made available to other physicians who are conducting other 
clinical trials with the trial product, if deemed necessary by Novo Nordisk. Provided that certain 
conditions are fulfilled, Novo Nordisk may grant access to information obtained during this trial to 
researchers who require access for research projects studying the same disease and/or trial product 
studied in this trial.
Novo Nordisk may publish on its clinical trials website a redacted clinical trial report for this trial.
One investigator will be appointed by Novo Nordisk to review and sign the clinical trial report 
(signatory investigator) on behalf of all participating investigators. The signatory investigator will 
be appointed based upon the criteria defined by the International Committee of Medical Journal 
Editors for research publications.42
23.1
Communication of results
Novo Nordisk commits to communicating, and otherwise making available for public disclosure, 
results of trials regardless of outcome. Public disclosure includes publication of a paper in a 
scientific journal, abstract submission with a poster or oral presentation at a scientific meeting, or 
disclosure by other means.
The results of this trial will be subject to public disclosure on external web sites according to 
international and national regulations, as reflected in the Novo Nordisk Code of Conduct for 
Clinical Trial Disclosure.28
Novo Nordisk reserves the right to defer the release of data until specified milestones are reached, 
for example when the clinical trial report is available. This includes the right not to release the 
results of interim analyses, because the release of such information may influence the results of the 
entire trial.
At the end of the trial, one or more scientific publications may be prepared collaboratively by the 
investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or 
communication for up to 60 days to protect intellectual property.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
107 of 113
In all cases the trial results will be reported in an objective, accurate, balanced and complete 
manner, with a discussion of the strengths and limitations. All authors will be given the relevant 
statistical tables, figures, and reports needed to evaluate the planned publication. In the event of any 
disagreement on the content of any publication, both the investigators’ and Novo Nordisk opinions 
will be fairly and sufficiently represented in the publication.
Where required by the journal, the investigator from each trial site will be named in an 
acknowledgement or in the supplementary material, as specified by the journal. 
Novo Nordisk maintains the right to be informed of plans by any investigator to publish and to 
review any scientific paper, presentation, communication or other information concerning the 
investigation described in this protocol. Any such communication must be submitted in writing to 
Novo Nordisk before submission for comments. Comments will be given within four weeks from 
receipt of the planned communication.
Authorship
Authorship of publications should be in accordance with the Uniform Requirements of the 
International Committee of Medical Journal Editors42 (sometimes referred to as the Vancouver 
Criteria).
Site-specific publication(s) by investigator(s)
For a multi-centre clinical trial, analyses based on single-site data usually have significant statistical 
limitations and frequently do not provide meaningful information for healthcare professionals or 
subjects, and therefore may not be supported by Novo Nordisk. It is a Novo Nordisk policy that 
such individual reports do not precede the primary manuscript and should always reference the 
primary manuscript of the trial.
Novo Nordisk reserves the right to prior review of such publications. Further to allow for the 
primary manuscript to be published as the first, Novo Nordisk asks for deferment of publication of 
individual site results until the primary manuscript is accepted for publication. As Novo Nordisk 
wants to live up to the industry publication policy, submission of a primary publication will take 
place no later than 18 months after trial completion. 
23.2
Investigator access to data and review of results
As owner of the trial database, Novo Nordisk has the discretion to determine who will have access 
to the database. 
Individual investigators will have their own research subjects' data, and will be provided with the 
randomisation code after results are available.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
108 of 113
24 Retention of clinical trial documentation
24.1
Retention of clinical trial documentation
Subject’s medical records must be kept for the maximum period permitted by the hospital, 
institution or private practice.
The investigator must agree to archive the documentation (this includes both electronic and paper-
based records) pertaining to the trial in an archive after completion or discontinuation of the trial if 
not otherwise notified. The investigator should not destroy any documents without prior permission 
from Novo Nordisk. If the investigator cannot archive the documents at the trial site, Novo Nordisk 
can refer the investigator to an independent archive provider that has a system in place to allow only 
the investigator to access the files.
The investigator must be able to access his/her trial documents without involving Novo Nordisk in 
any way. Site-specific CRFs and other subject data (in an electronic readable format or as paper 
copies or prints) will be provided to the investigator before access is revoked to the systems and/or 
electronic devices supplied by Novo Nordisk. These data must be retained by the trial site. If the 
provided data (e.g. the CD-ROM) is not readable during the entire storage period, the investigator 
can request a new copy. A copy of all data will be stored by Novo Nordisk.
Novo Nordisk will maintain Novo Nordisk documentation pertaining to the trial for at least 20 years 
after discontinuation of the marketing authorisation, termination of the trial or cancellation of the 
research project whichever is longest.
The files from the trial site/institution must be retained for 15 years after end of trial as defined in 
Section 7, or longer if required by local regulations or Novo Nordisk. In any case trial files cannot 
be destroyed until the trial site/institution is notified by Novo Nordisk. The deletion process must 
ensure confidentiality of data and must be done in accordance with local regulatory requirements.  
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
109 of 113
25 Institutional Review Boards/Independent Ethics Committees and 
regulatory authorities
IRB/IEC:
Written approval or favourable opinion must be obtained from IRB/IEC prior to commencement of 
the trial.
During the trial, the investigator or Novo Nordisk, as applicable, must promptly report the 
following to the IRB/IEC, in accordance with local requirements: updates to IB, unexpected SAEs 
where a causal relationship cannot be ruled out, protocol amendments according to local
requirements, deviations to the protocol implemented to eliminate immediate hazards to the 
subjects, new information that may affect adversely the safety of the subjects or the conduct of the 
trial (including new benefit-risk analysis in case it will have an impact on the planned follow-up of 
the subjects), annually written summaries of the trial status, and other documents as required by the 
local IRB/IEC.
The investigator must ensure submission of the clinical trial report synopsis to the IRB/IEC.
Protocol amendments must not be implemented before approval or favourable opinion according to 
local regulations, unless necessary to eliminate immediate hazards to the subjects.
The investigator must maintain an accurate and complete record of all submissions made to the 
IRB/IEC. The records must be filed in the investigator trial master file and copies must be sent to 
Novo Nordisk.
Regulatory Authorities:
Regulatory authorities will receive the clinical trial application, protocol amendments, reports on 
SAEs, and the clinical trial report according to national requirements.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
110 of 113
26 Indemnity statement
Novo Nordisk carries product liability for its products, and liability as assumed under the special 
laws, acts and/or guidelines for conducting clinical trials in any country, unless others have shown 
negligence.
Novo Nordisk assumes no liability in the event of negligence, or any other liability of the sites or 
investigators conducting the trial, or by persons for whom the said site or investigator are 
responsible.
Novo Nordisk accepts liability in accordance with:
Poland: Novo Nordisk carries liability for the trial exclusively in the scope defined by the 
applicable laws and in particular by the Civil Code and the Pharmaceutical Law dated 6 September 
2001 (uniform version Journal of Laws of 2008 No. 45 item 271 with amendments). In order to 
support potential claims for liability attributable to the trial, Novo Nordisk and the investigators are 
covered by the insurance policy issued according to applicable Polish law.
Russia: Federal law of 12 April 2010 No. 61-FZ ‘On Medicinal Drugs’ Circulation and Ministry of 
Healthcare of Russian Federation’ order of 01 April 2016 No. 200n “Approval of rules of good 
clinical practice.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
111 of 113
27 References
1.
International Conference on Harmonisation. ICH Harmonised Tripatite Guideline. Guideline 
for Good Clinical Practise E6(R2), Step 4. 09 Nov 2016.
2.
World Medical Association. Declaration of Helsinki. Ethical Principles for Medical 
Research Involving Human Subjects. Last amended by the 64th WMA General Assembly, 
Fortaleza, Brazil. October 2013.
3.
Diabetes Control and Complications Trial Research Group. The effect of intensive treatment 
of diabetes on the development and progression of long-term complications in insulin-
dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. 
N Engl J Med. 1993;329(14):977-86.
4.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional 
treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK 
Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837-53, Erratum 
1999; 354: 602.
5.
Woerle HJ, Neumann C, Zschau S, Tenner S, Irsigler A, Schirra J, et al. Impact of fasting 
and postprandial glycemia on overall glycemic control in type 2 diabetes - Importance of 
postprandial glycemia to achieve target HbA1c levels. Diabetes Research and Clinical 
Practice. 2007;77(2):280-5.
6.
International Diabetes Federation Guideline Development G. Guideline for management of 
postmeal glucose in diabetes. Diabetes Res Clin Pract. 2014;103(2):256-68.
7.
Leiter LA, Ceriello A, Davidson JA, Hanefeld M, Monnier L, Owens DR, et al. Postprandial 
glucose regulation: New data and new implications. Clin Ther. 2005;27(Suppl B):S42-S56.
8.
Brange J, Owens DR, Kang S, Volund A. Monomeric Insulins and Their Experimental and 
Clinical Implications. Diabetes Care. 1990;13(9):923-54.
9.
Lindholm A, McEwen J, Riis AP. Improved postprandial glycemic control with insulin 
aspart. A randomized double-blind cross-over trial in type 1 diabetes. Diabetes Care. 
1999;22(5):801-5.
10.
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. 
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position 
statement of the American Diabetes Association (ADA) and the European Association for 
the Study of Diabetes (EASD). Diabetologia. 2012;55(6):1577-96.
11.
Meneghini L, Mersebach H, Kumar S, Svendsen AL, Hermansen K. A comparison of two 
intensification regimens with rapid-acting insulin aspart in type 2 diabetes inadequately 
controlled by once-daily insulin detemir and oral antidiabetes drugs: the STEP-Wise 
randomized study. Endocr Pract. 2011:727-36.
12.
Liebl A, Prager R, Binz K, Kaiser M, Bergenstal R, Gallwitz B, et al. Comparison of insulin 
analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a 
randomized controlled trial. Diabetes Obes Metab. 2009;11(1):45-52.
13.
Garber AJ, King AB, Del Prato S, Sreenan S, Balci MK, Munoz-Torres M, et al. Insulin 
degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment 
with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, 
randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379(9825):1498-
507.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
112 of 113
14.
Home PD, Lindholm A, Riis A, European Insulin Aspart Study Group. Insulin aspart vs. 
human insulin in the management of long-term blood glucose control in Type 1 diabetes 
mellitus: a randomized controlled trial. Diabet Med. 2000;17(11):762-70.
15.
Raskin P, Riis A, Guthrie RA, Jovanovic L, Leiter L. Use of insulin aspart, a fast-acting 
insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. 
Diabetes Care. 2000;23(5):583-8.
16.
Gallagher A, Home PD. The effect of improved post-prandial blood glucose control on post-
prandial metabolism and markers of vascular risk in people with Type 2 diabetes. Diabetes 
Res Clin Pract. 2005;67(3):196-203.
17.
Perriello G, Pampanelli S, Porcellati F, Avogaro A, Bosi E, Petrella G, et al. Insulin aspart 
improves meal time glycaemic control in patients with Type 2 diabetes: a randomized, 
stratified, double-blind and cross-over trial. Diabet Med. 2005;22(5):606-11.
18.
Bretzel RG, Arnolds S, Medding J, Linn T. A direct efficacy and safety comparison of 
insulin aspart, human soluble insulin, and human premix insulin (70/30) in patients with 
type 2 diabetes. Diabetes Care. 2004;27(5):1023-7.
19.
Novo Nordisk A/S. NovoRapid® (insulin aspart), EU Summary of Product Characteristics 
(SmPC). 15 Nov 2016.
20.
Novo Nordisk A/S. NovoLog (insulin aspart), US Prescribing Information (PI). 07 Oct 
2016.
21.
Novo Nordisk A/S. Fiasp (insulin aspart), EU Summary of Product Characteristics (SmPC). 
03 Feb 2017.
22.
Novo Nordisk A/S. Investigator's Brochure, Faster-acting Insulin Aspart (9th Edition). 2016.
23.
Novo Nordisk A/S. Tresiba® (insulin degludec) EU Summary of Product Characteristics 
(SmPC). August 2015.
24.
Novo Nordisk A/S. Investigator's Brochure, insulin degludec (Tresiba®), project NN1250, 
(edition 12). 14 Dec 2016.
25.
European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). 
Guideline on clinical investigation of medicinal products in the treatment or prevention of 
diabetes mellitus (CPMP/EWP/1080/00 Rev. 1). Adoption by CHMP. 14 May 2012.
26.
U.S. Department of Health and Human Services, Food and Drug Administration. Guidance 
for Industry. Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment 
and Prevention, Draft Guidance. 2008.
27.
Rodbard HW, Visco VE, Andersen H, Hiort LC, Shu DH. Treatment intensification with 
stepwise addition of prandial insulin aspart boluses compared with full basal-bolus therapy 
(FullSTEP Study): a randomised, treat-to-target clinical trial. Lancet Diabetes Endocrinol. 
2014;2(1):30-7.
28.
Novo Nordisk A/S. http://www.novonordisk-trials.com/website/content/how-we-disclose-
trial-information.aspx.
29.
De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Clinical trial 
registration: a statement from the International Committee of Medical Journal Editors. N 
Engl J Med. 2004;351(12):1250-1.
30.
U.S. Food and Drug Administration. Food and Drug Administration Amendments Act of 
2007 as amended by the Final Rule "Clinical Trials Registration and Results Information 
Submission". 21 September 2017.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
113 of 113
31.
The European Parliament and the Council of the European Council. Directive 2001/20/EC 
of the European Parliament and of the Councill of 4 April 2001 on the approximation of the
laws, regulations and administrative provisions of the Member States relating to the 
implementation of good clinical practice in the conduct of clinical trials on medicinal 
products for human use, article 11. Official Journal of the European Communities. 1 May 
2001.
32.
The European Parliament and the Council of the European Council. Regulation (EC) No 
726/2004 of the European Parliament and of the Council of 31 March 2004 laying down 
Community procedures for the authorisation and supervision of medicinal products for 
human and veterinary use and establishing a European Medicines Agency, article 57. 
Official Journal of the European Communities. 2004.
33.
Clarke WL, Cox DJ, Gonder-Frederick LA, Julian D, Schlundt D, Polonsky W. Reduced 
awareness of hypoglycemia in adults with IDDM. A prospective study of hypoglycemic 
frequency and associated symptoms. Diabetes Care. 1995;18(4):517-22.
34.
Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al. Hypoglycemia 
and diabetes: a report of a workgroup of the American Diabetes Association and the 
Endocrine Society. Diabetes Care. 2013;36(5):1384-95.
35.
McAulay V, Deary IJ, Frier BM. Symptoms of hypoglycaemia in people with diabetes. 
Diabet Med. 2001;18(9):690-705.
36.
U.S. Department of Health and Human Services, Food and Drug Administration. Guidance 
for Industry. Patient-Reported Outcome Measures: Use in Medical Product Development to 
Support Labeling Claims. December 2009.
37.
Stull DE, Leidy NK, Parasuraman B, Chassany O. Optimal recall periods for patient-
reported outcomes: challenges and potential solutions. Curr Med Res Opin. 2009;25(4):929-
42.
38.
European Commission. The Rules Governing Medicinal Products in the European Union, 
Volume 4, Annex 13, Investigational Medicinal Products. Brussels, February 2010.
39.
International Conference of Harmonisation. ICH Harmonised Tripartite Guideline E9. 
Statistical Principles for Clinical Trials, Step 4 Version. 5 Feb 1998.
40.
Koch GG. Comments on 'Current issues in non-inferiority trials' by Thomas R. Fleming, 
Statistics in Medicine, DOI: 10.1002/sim.2855. Stat Med. 2008;27(3):333-42.
41.
Schwartz NS, Clutter WE, Shah SD, Cryer PE. Glycemic thresholds for activation of 
glucose counterregulatory systems are higher than the threshold for symptoms. J Clin Invest. 
1987;79(3):777-81.
42.
International Committee of Medical Journal Editors. Recommendations for the Conduct, 
Reporting, Editing and Publication of Scholarly Work in Medical Journals; current version 
available at www.icmje.org.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
1 of 112
Protocol
Trial ID:NN1218-4113
Updated protocol including:
Protocol, final version 2.0 dated 28 March 2017
Global Amendment no. 1 version 1.0 dated 09 June 2017
Global Amendment no. 2 version 1.0 dated 23 February 2018
Efficacy and Safety of Fast-acting Insulin Aspart Compared to 
NovoRapid® both in Combination with Insulin Degludec with or 
without Metformin in Adults with Type 2 Diabetes (onset® 9)
Trial phase: 3b
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
2 of 112
Table of Contents
Page
Table of Contents........................................................................................................................................2
Table of Figures ..........................................................................................................................................5
Table of Tables............................................................................................................................................5
1
Summary..............................................................................................................................................8
2
Flow chart ..........................................................................................................................................11
3
Background information and rationale for the trial.........................................................................14
3.1
Background information..........................................................................................................14
3.1.1
Therapeutic Area ...................................................................................................14
3.1.2
NovoRapid® (Insulin aspart)...................................................................................15
3.1.3
Fast-acting insulin aspart........................................................................................15
3.1.4
Insulin degludec.....................................................................................................17
3.2
Rationale for the trial...............................................................................................................17
4
Objectives and endpoints...................................................................................................................18
4.1
Objectives...............................................................................................................................18
4.2
Endpoints................................................................................................................................18
4.2.1
Primary endpoint ...................................................................................................18
4.2.2
Secondary endpoints ..............................................................................................18
4.2.2.1
Confirmatory secondary endpoints ...................................................18
4.2.2.2
Supportive secondary endpoints .......................................................19
5
Trial design ........................................................................................................................................21
5.1
Type of trial ............................................................................................................................21
5.2
Rationale for trial design .........................................................................................................22
5.2.1
Rational for choice of non-inferiority margin .........................................................22
5.3
Treatment of subjects ..............................................................................................................22
5.4
Treatment after discontinuation of trial products......................................................................23
5.5
Rationale for treatment............................................................................................................23
6
Trial population .................................................................................................................................25
6.1
Number of subjects .................................................................................................................25
6.2
Inclusion criteria .....................................................................................................................25
6.3
Exclusion criteria ....................................................................................................................26
6.4
Run-in period exclusion criteria...............................................................................................27
6.5
Randomisation criterion ..........................................................................................................28
6.6
Criteria for premature discontinuation of trial products............................................................28
6.7
Withdrawal from trial..............................................................................................................29
6.8
Subject replacement ................................................................................................................29
6.9
Rationale for trial population...................................................................................................29
7
Milestones...........................................................................................................................................31
8
Methods and assessments ..................................................................................................................32
8.1
Visit procedures ......................................................................................................................32
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
3 of 112
8.1.1
Screening (Visit 1).................................................................................................32
8.1.2
Run-in ...................................................................................................................33
8.1.3
Randomisation.......................................................................................................33
8.1.4
Phone contacts.......................................................................................................34
8.1.5
Fasting visits..........................................................................................................34
8.1.6
Rescheduled visits..................................................................................................34
8.1.7
End of treatment ....................................................................................................34
8.1.8
Follow-up period ...................................................................................................35
8.1.9
Premature discontinuation of trial products.............................................................35
8.1.10
Withdrawal from trial.............................................................................................36
8.1.10.1
Lost to follow-up..............................................................................37
8.1.11
Review of results ...................................................................................................37
8.2
Subject related information/assessments..................................................................................38
8.2.1
Demography ..........................................................................................................38
8.2.2
Diabetes history and diabetes complications...........................................................38
8.2.3
Hypoglycaemia unawareness .................................................................................38
8.2.4
Concomitant illness and medical history.................................................................38
8.2.5
Concomitant medication ........................................................................................39
8.2.6
Concomitant medication (diabetes) ........................................................................39
8.2.7
Childbearing potential............................................................................................40
8.2.8
Tobacco use...........................................................................................................40
8.3
Efficacy assessments...............................................................................................................41
8.3.1
Meal test................................................................................................................41
8.3.2
Discontinuation of MyGlucoHealth BG-meter and electronic diary ........................44
8.3.3
Self-measured plasma glucose................................................................................44
8.3.4
Insulin dose ...........................................................................................................46
8.4
Safety assessments ..................................................................................................................47
8.4.1
Adverse events.......................................................................................................47
8.4.1.1
Medication error...............................................................................47
8.4.1.2
Adverse events requiring additional data collection ..........................48
8.4.2
Hypoglycaemic episodes........................................................................................48
8.4.3
Eye examination ....................................................................................................51
8.4.4
Electrocardiogram – 12 lead...................................................................................51
8.4.5
Body measurements...............................................................................................52
8.4.6
Physical examination .............................................................................................52
8.4.7
Vital signs..............................................................................................................53
8.5
Laboratory assessments...........................................................................................................53
8.5.1
Laboratory assessments for efficacy.......................................................................54
8.5.2
Laboratory assessments for safety ..........................................................................55
8.6
Other assessments ...................................................................................................................56
8.6.1
Dietary training in simple carbohydrate counting ...................................................56
8.6.2
Training in the pen injector ....................................................................................56
8.6.3
Diary .....................................................................................................................56
8.7
Subject compliance .................................................................................................................57
9
Trial supplies......................................................................................................................................59
9.1
Trial products..........................................................................................................................59
9.2
Labelling.................................................................................................................................59
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
4 of 112
9.3
Storage....................................................................................................................................60
9.4
Drug accountability and destruction ........................................................................................60
9.5
Auxiliary supplies ...................................................................................................................61
10
Interactive voice/web response system ..............................................................................................61
11
Randomisation procedure and breaking of blinded codes................................................................62
11.1
Breaking of blinded codes .......................................................................................................62
12
Adverse events, technical complaints and pregnancies.....................................................................63
12.1
Definitions ..............................................................................................................................63
12.1.1
Adverse event ........................................................................................................63
12.1.2
Serious adverse event.............................................................................................64
12.1.3
Non-serious adverse event......................................................................................65
12.1.4
Medication errors...................................................................................................65
12.1.5
Adverse events requiring additional data collection................................................65
12.1.6
Technical complaints .............................................................................................66
12.2
Reporting of adverse events.....................................................................................................66
12.3
Follow-up of adverse events....................................................................................................68
12.4
Technical complaints and technical complaint samples............................................................69
12.4.1
Reporting of technical complaints ..........................................................................69
12.4.2
Collection, storage and shipment of technical complaint samples ...........................70
12.5
Pregnancies in female subjects ................................................................................................71
12.6
Precautions and/or overdose....................................................................................................72
12.7
Committees related to safety ...................................................................................................72
12.7.1
Novo Nordisk safety committee .............................................................................72
13
Case report forms ..............................................................................................................................73
13.1
Corrections to case report forms..............................................................................................73
13.2
Case report form flow .............................................................................................................74
14
Monitoring procedures ......................................................................................................................74
15
Data management ..............................................................................................................................75
16
Computerised systems .......................................................................................................................76
17
Statistical considerations ...................................................................................................................77
17.1
Sample size calculation ...........................................................................................................79
17.2
Definition of analysis sets........................................................................................................81
17.3
Primary endpoint.....................................................................................................................81
17.4
Secondary endpoints ...............................................................................................................85
17.4.1
Confirmatory secondary endpoints.........................................................................85
17.4.2
Supportive secondary endpoints .............................................................................87
17.4.2.1
Efficacy endpoints............................................................................87
17.4.2.2
Safety endpoints...............................................................................91
18
Ethics..................................................................................................................................................97
18.1
Benefit-risk assessment of the trial ..........................................................................................97
18.2
Informed consent ....................................................................................................................99
18.3
Data handling........................................................................................................................100
18.4
Information to subjects during trial........................................................................................100
18.5
Premature termination of the trial and/or trial site..................................................................100
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
5 of 112
19
Protocol compliance.........................................................................................................................101
19.1
Protocol deviations................................................................................................................101
19.2
Prevention of missing data ....................................................................................................101
20
Audits and inspections .....................................................................................................................102
21
Critical documents...........................................................................................................................102
22
Responsibilities.................................................................................................................................103
23
Reports and publications .................................................................................................................105
23.1
Communication of results......................................................................................................105
23.2
Investigator access to data and review of results ....................................................................106
24
Retention of clinical trial documentation........................................................................................107
24.1
Retention of clinical trial documentation ...............................................................................107
25
Institutional Review Boards/Independent Ethics Committees and regulatory authorities ...........108
26
Indemnity statement ........................................................................................................................109
27
References ........................................................................................................................................110
Appendix A
Titration Guideline
Attachment I  Global list of key staff and relevant departments and suppliers 
Attachment II
Country list of key staff and relevant departments, if applicable for the individual country
Table of Figures
Page
Figure 5–1
Trial Design. ......................................................................................................................21
Figure 12–1
Reporting of AEs ...............................................................................................................67
Figure 17–1
Novo Nordisk classification of hypoglycaemia ...................................................................93
Figure 17–2
ADA classification of hypoglycaemia.................................................................................94
Table of Tables
Page
Table 8–1
Meal test schedule..............................................................................................................43
Table 8–2
7-point SMPG profiles with additional 9-point SMPG profile.............................................46
Table 9–1
Trial products.....................................................................................................................59
Table 9–2
Storage conditions..............................................................................................................60
Table 17–1
Specifications assumed for sample size calculations ...........................................................80
Table 17–2
Sensitivity of sample size to power.....................................................................................80
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
6 of 112
List of abbreviations
ADA
American Diabetes Association
AE
adverse event
ALT
alanine aminotransferase
AST
aspartate aminotransferase
BG
Blood glucose
CRF
case report form
DUN
dispensing unit number
ECG
electrocardiogram
eCRF
electronic case report form
eDiary
electronic diary 
FAS
full analysis set
FDA
U.S. Food and Drug Administration
FPG
fasting plasma glucose
GCP
Good Clinical Practice
GLP-1
glucagon-like peptide-1
HbA1c
glycosylated haemoglobin
IB
Investigator’s Brochure
ICH
International Conference on 
Harmonisation of Technical 
Requirements for Registration of 
Pharmaceuticals for Human Use
IEC
independent ethics committee
IMP
investigational medicinal product
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
7 of 112
IRB
institutional review board
IWRS
interactive voice/web response 
system
LPLV
last patient last visit
NIMP
non-investigational medicinal 
product
OAD
oral antidiabetic drug
PG
plasma glucose
PPG
postprandial glucose
PP
per protocol
SAE
serious adverse event
SmPC
summary of product characteristics
SMPG
self-measured plasma glucose
SUSAR
suspected unexpected serious adverse 
reaction
T1DM
Type 1 diabetes mellitus
T2DM
Type 2 diabetes mellitus
TEAE
Treatment Emergent Adverse Event 
TMM
Trial Materials Manual
UTN
Universal Trial Number
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
8 of 112
1
Summary
Objective(s) and endpoint(s):
Primary objective
To confirm the effect in terms of glycaemic control of treatment with fast-acting insulin aspart 
compared to NovoRapid® both in combination with insulin degludec with or without metformin in 
adults with type 2 diabetes mellitus treated with a basal-bolus regimen, using a non-inferiority 
approach.
Secondary objectives
To confirm superiority of fast-acting insulin aspart compared to NovoRapid® both in combination 
with insulin degludec with or without metformin in adults with type 2 diabetes mellitus treated with 
a basal-bolus regimen in terms of:
!
Postprandial glucose regulation
!
Overall glycaemic control 
!
Postprandial glucose excursions 
To compare the safety of fast-acting insulin aspart to NovoRapid® both in combination with insulin 
degludec with or without metformin in adults with type 2 diabetes mellitus treated with a basal-
bolus regimen.
Primary endpoint
Change from baseline in HbA1c 16 weeks after randomisation
Key secondary endpoints
Confirmatory secondary endpoints:
!
Change from baseline in 1-hour postprandial glucose increment 16 weeks after 
randomisation (meal test)
!
Change from baseline in 1,5-anhydroglucitol 16 weeks after randomisation
Trial design:
This is a phase 3b, 16-week, multicentre, multinational, 1:1 randomised, double-blind, active 
controlled, treat-to-target, parallel group trial with a 12-week run-in period comparing the effect and 
safety of fast-acting insulin aspart to NovoRapid® both in combination with insulin degludec with 
or without metformin in subjects with type 2 diabetes mellitus treated with a basal-bolus regimen. 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
9 of 112
The trial includes two blinded dosing arms - mealtime fast-acting insulin aspart and mealtime 
NovoRapid®.
Trial population:
A total of 1803 subjects with Type 2 diabetes mellitus are planned to be screened and 1072 are 
planned to be randomised.
Key inclusion criteria:
!
Male or female, age ≥ 18 years at the time of signing informed consent.
!
Diagnosed with type 2 diabetes mellitus≥ 10 years prior to screening (Visit 1).
!
Treated with a basal-bolus insulin regimen ≥ 1 year prior to the day of screening (Visit 1). A 
basal-bolus insulin regimen is defined as basal insulin once or twice daily and bolus insulin 
analogue taken with meals at least 3 times daily. Treatment with premixed insulin or soluble 
insulin combination is not considered a basal-bolus regimen.
!
Treated with or without oral antidiabetic drugs including extended release formulations.
!
HbA1c 7.0-10.0% (both inclusive) as assessed by central laboratory at screening (Visit 1).
Key exclusion criteria:
!
Any of the following: myocardial infarction, stroke, hospitalization for unstable angina or 
transient ischaemic attack within the past 180 days prior to the day of screening (Visit 1). 
!
Subjects presently classified as being in New York Heart Association (NYHA) Class IV. 
!
Planned coronary, carotid or peripheral artery revascularisation known on the day of 
screening (Visit 1).
!
Treatment with injectable GLP-1 receptor agonists in a period of 90 days prior to screening 
(Visit 1). 
!
Anticipated initiation or change in concomitant medications (for more than 14 consecutive 
days) known to affect weight or glucose metabolism (e.g. treatment with orlistat, thyroid 
hormones, or corticosteroids).
Randomisation criterion:
!
HbA1c ≤ 9.0% measured by the central laboratory at Visit 13 (week -1).
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
10 of 112
Key Assessments:
!
HbA1c
!
Postprandial glucose increment (meal test)
!
1,5-anhydroglucitol 
!
Hypoglycaemic episodes
!
Adverse events
Trial product(s):
Investigational medicinal products:
!
Test products: 
o
Fast-acting insulin aspart, 100 U/mL solution for subcutaneous injection, 3 mL 
PDS290 pen injector (blinded) 
o
Insulin degludec, 100U/mL solution for subcutaneous injection, 3 mL PDS290 pen 
injector 
!
Reference therapy: 
o
Insulin aspart (NovoRapid®), 100 U/mL solution for subcutaneous injection, 3 mL 
PDS290 pen injector (blinded)
Other medicinal products: 
!
Rapid acting insulin analogues (NovoRapid® or marketed formulations of insulin lispro or 
insulin glulisine) during run-in period
!
Metformin, tablets for oral use
CONFIDENTIAL


Protocol
UTN: U1111-1180-0636
Date:
23 February 2018
Status:
Final
1RYR1RUGLVN
Trial ID: NN1218-4113
EudraCT no.: 2016-000878-38
Version:
4.0
Page:
11 of 112
2
Flow chart
NN1218-4113
Protocol section
Screening
12-week run-in period
Randomisation
16- week treatment period
Blinded trial product
End of treatment
Premature 
discontinuation
Follow-up 1
Follow-up 2
Visit (V)
Phone contact (P)
V1
V2
P3
P4
V5
P6
P7
P8
V9
P10
P11
P12
V13
V14
P15
V16
P17
V18
P19
P20
P21
V22
P23
P24
P25
V26
P27
P28
P29
V30
V30A
V31
P32
Time of visit (weeks)
-14
-12
-11
-10
-9
-8
-7
-6
-5
-4
-3
-2
-1
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
+7 
days
+30
days
Visit window (days)
+10
±3
±3
±3
±3
±3
±3
±3
0
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
+10
+5
SUBJECT RELATED INFO/ASSESSMENTS
Informed consent
18.2
X
In/exclusion criteria
6.2 6.3
X
X
Run-in period exclusion criteria
6.4
X
X
X
X
X
X
X
Randomisation criterion
6.5
X
Randomisation
8.1.3
X
Criteria for premature discontinuation of trial 
products
6.6
X
X
X
X
X
X
X
X
X
Demography 
8.2.1
X
Tobacco use
8.2.8
X
Diabetes history and diabetes complications
8.2.2, 
8.2.6
X
Hypoglycaemia unawareness 
8.2.3
X
Concomitant illness and medical history
8.2.4
X
Concomitant medication
8.2.5
8.2.6
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Child-bearing potential
8.2.7
X
EFFICACY
Meal test
8.3.1
X
X
X
4-point profile (SMPG)
8.3.3
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
7-9-7-point profile (SMPG)
8.3.3
X
X
X
X
1,5-anhydroglucitol
8.5.1
X
X
X
X
X
X
Fasting plasma glucose
8.5.1
X
X
X
X


Protocol
UTN: U1111-1180-0636
Date:
23 February 2018
Status:
Final
1RYR1RUGLVN
Trial ID: NN1218-4113
EudraCT no.: 2016-000878-38
Version:
4.0
Page:
12 of 112
NN1218-4113
Protocol section
Screening
12-week run-in period
Randomisation
16- week treatment period
Blinded trial product
End of treatment
Premature 
discontinuation
Follow-up 1
Follow-up 2
Visit (V)
Phone contact (P)
V1
V2
P3
P4
V5
P6
P7
P8
V9
P10
P11
P12
V13
V14
P15
V16
P17
V18
P19
P20
P21
V22
P23
P24
P25
V26
P27
P28
P29
V30
V30A
V31
P32
Time of visit (weeks)
-14
-12
-11
-10
-9
-8
-7
-6
-5
-4
-3
-2
-1
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
+7 
days
+30
days
Visit window (days)
+10
±3
±3
±3
±3
±3
±3
±3
0
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
+10
+5
HbA1c
8.5.1
X
X
X
X
X
X
X
X
X
X
Fasting C-peptide
8.5.1
X
Lipids
8.5.1
X
X
X
X
X
SAFETY
Adverse events
8.4.1, 
12
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Injection site reactions 
8.4.1.2
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Hypoglycaemic episodes
8.4.2
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Technical complaints
12.1.6
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Body weight
8.4.5
X
X
X
Height
8.4.5
X
Physical examination
8.4.6
X
X
X
X
Vital signs
8.4.7
X
X
X
X
Eye examination
0
X
X
X
X
ECG
8.4.4
X
X
X
X
Biochemistry
8.5.2
X
X
X
X
X
Haematology
8.5.2
X
X
X
X
X
Pregnancy test
8.5.2
X
X
X
X
TRIAL MATERIAL
Dispensing visit
9.4
X
X
X
X
X
X
X
X
X
New (prescribed) dose of trial insulin
8.3.4
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Dosing (Start/stop date of trial insulin)
8.3.4
X
X
X
X
X
Insulin dose of basal and bolus insulin each day
8.3.4
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Drug accountability 
9.4
X
X
X
X
X
X
X
X
X
X
X


Protocol
UTN: U1111-1180-0636
Date:
23 February 2018
Status:
Final
1RYR1RUGLVN
Trial ID: NN1218-4113
EudraCT no.: 2016-000878-38
Version:
4.0
Page:
13 of 112
NN1218-4113
Protocol section
Screening
12-week run-in period
Randomisation
16- week treatment period
Blinded trial product
End of treatment
Premature 
discontinuation
Follow-up 1
Follow-up 2
Visit (V)
Phone contact (P)
V1
V2
P3
P4
V5
P6
P7
P8
V9
P10
P11
P12
V13
V14
P15
V16
P17
V18
P19
P20
P21
V22
P23
P24
P25
V26
P27
P28
P29
V30
V30A
V31
P32
Time of visit (weeks)
-14
-12
-11
-10
-9
-8
-7
-6
-5
-4
-3
-2
-1
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
+7 
days
+30
days
Visit window (days)
+10
±3
±3
±3
±3
±3
±3
±3
0
±3
±3
±3
±3
±3
±3
±3
±3
±3
±3
+10
+5
IWRS call
10
X
X
X
X
X
X
X
X
X
X
X
X
BG-meter start datea
8.3.2
(X)
(X)
(X)
(X)
(X)
(X)
(X)
(X)
(X)
(X)
(X)
(X)
(X)
(X)
(X)
(X)
(X)
(X)
(X)
(X)
(X)
REMINDERS
Handout ID card
8.1.1
X
Confirmation of unchanged metformin
8.2.5
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Attend visit fasting
8.1.5
X
X
X
X
Training in carbohydrate counting
8.6.1
X
X
X
X
Handout direction for use
9.2
X
Training in trial product and pen handling
8.6.2
X
X
X
X
X
X
Handout pen differentiation guide
9.2
X
Training in pen differentiation
8.6.2
X
X
X
Handout and instruct in diary
8.6.3
X
X
X
X
X
X
X
X
X
X
X
X
Handout and instruct in BG meter usea
8.3.2, 
8.3.3
X
(X)
(X)
(X)
(X)
(X)
(X)
(X)
(X)
(X)
(X)
(X)
Handout and instruct in subject mealtime insulin 
dose adjustment guide
8.3.4
X
Diary collection
8.6.3
X
X
X
X
X
X
X
X
X
X
X
End of treatment
8.1.7
X
X
End of trial
X
a (X) is only applicable for subjects who have used the glycaemic data collection system (the combination of the MyGlucoHealth Wireless BG-meter and an electronic 
diary) section 8.3.2.


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
14 of 112
3
Background information and rationale for the trial
The trial will be conducted in compliance with this protocol, ICH GCP1 and applicable regulatory 
requirements, and in accordance with the Declaration of Helsinki.2
In this document, the term investigator refers to the individual responsible for the overall conduct of 
the clinical trial at a trial site.
3.1
Background information
Improvement in long-term glucose control, as obtained with intensified insulin therapy, may reduce 
the incidence of complications and delay the progression of existing complications in people with 
Type 1 Diabetes Mellitus (T1DM) and Type 2 Diabetes Mellitus (T2DM).3, 4 Postprandial 
hyperglycaemia contributes significantly to the glycosylated haemoglobin (HbA1c) level and its 
control is thus essential for achieving the HbA1c target level.5 Postprandial hyperglycaemia is 
associated with increased risk of micro- and macro-vascular complications.6 Lowering of 
postprandial hyperglycaemia may reduce the progression of atherosclerosis and cardiovascular 
events in patients with T2DM.7
Basal-bolus insulin therapy aims at mimicking the physiological insulin response in the healthy 
state to the largest possible extent. For that purpose, rapid-acting insulin analogues were developed 
to more effectively control the postprandial glucose (PPG) excursions than subcutaneously injected 
human regular insulin, primarily through offering a faster onset and shorter duration of action.8
However, unmet needs exist within prandial insulin therapy for people with diabetes. The current 
insulin analogues are not able to match the speed of the normal physiological postmeal insulin 
secretion, leading to suboptimal control of blood glucose (BG), and exogenous insulin with a faster 
glucose lowering effect is needed for tighter PPG control. In addition, a faster glucose lowering 
effect is also likely to offer greater flexibility in the time of dosing around meals thus increasing 
convenience for the patients and may allow the patients to better match the insulin taken to the 
meal.9
For an assessment of benefits and risks of the trial, see Section 18.1
3.1.1
Therapeutic Area
Due to the progressive nature of T2DM, many patients are likely to be candidates for intensified 
insulin therapy. Prandial insulin supplementation is recommended by European Association for the 
Study of Diabetes (EASD)/American Diabetes Association (ADA) guidelines10 for treatment 
intensification in patients with T2DM who do not reach HbA1c target below 7.0% on oral 
antidiabetic drugs (OADs) and basal insulin alone. The recommendation is a stepwise addition of 
bolus insulin when significant PPG excursions occur. A trial investigating step-wise addition of 
bolus insulin (basal-plus regimen) showed that around 75% of patients enrolled in the trial needed 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
15 of 112
three boluses after 36 weeks of treatment.11 Results from the PREFER trial indicated that one-third 
of the total prandial insulin dose is delivered with each meal in the majority of patients achieving 
HbA1c ≤7.0%.12 When used as part of a basal-bolus regimen in patients with T2DM who had 
previously received other insulin and/or OAD regimens, insulin aspart in combination with insulin 
degludec was a safe, well tolerated and effective treatment associated with clinically relevant 
reductions in hyperglycaemia.13
3.1.2
NovoRapid® (Insulin aspart)
Insulin aspart is currently marketed worldwide as NovoRapid® (in US it is NovoLog®) and is a 
rapid-acting insulin analogue indicated for the treatment of diabetes. In the remainder of this 
protocol the name NovoRapid® will be applied for the marketed formulation of insulin aspart.
Insulin aspart is homologous to human insulin, with the exception of the substitution of proline with 
aspartic acid at position B28. The rapid action of insulin aspart is related to a weakened tendency of 
the insulin molecules to self-associate due to this modification and thereby is related to faster 
absorption as compared with regular human insulin. Compared with human insulin, NovoRapid®
has a faster onset and a shorter duration of action, resulting in superior postmeal glucose control by 
means of lowering total glucose excursion following a meal, both in subjects with T1DM3, 14, 15 and 
in subjects with T2DM.16-18 This also allows NovoRapid® to be injected immediately before a meal, 
in contrast to regular human insulin which should be injected 30 minutes prior to the meal.
For further details, please refer to the current version of the NovoRapid® EU Summary of Product 
Characteristics19(SmPC) and the U.S. NovoLog® Label Information20.
3.1.3
Fast-acting insulin aspart
Fast-acting insulin aspart (faster aspart) (markedet as Fiasp®) is insulin aspart in a new formulation. 
Faster aspart is being developed with the objective of achieving an increased early absorption of 
insulin aspart compared to NovoRapid® thereby providing a faster insulin action. Faster aspart aims 
at approaching the physiological prandial insulin secretion pattern better than currently available 
treatment and thereby more effectively controlling the PPG excursions and achieving a better PPG
control and increased flexibility in the time of dosing around meals compared with NovoRapid®. 
Results from clinical pharmacology trials in adults comparing pharmacokinetic and 
pharmacodynamic properties of faster aspart and NovoRapid® have shown that faster aspart resulted 
in an earlier onset of appearance and a greater early exposure to insulin aspart than NovoRapid® in 
subjects with T1DM, with the largest difference found within the first 15 minutes after injection. 
Faster aspart also resulted in a greater early glucose-lowering effect than NovoRapid®, but no 
statistically significant difference between faster aspart and NovoRapid® in total glucose-lowering 
effect.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
16 of 112
In a therapeutic confirmatory basal-bolus trial in adult subjects with T1DM, faster aspart taken with 
the meal in combination with Levemir® effectively improved glycaemic control and the reduction in 
HbA1c was statistically significantly larger than with NovoRapid®. Mealtime faster aspart provided 
superior PPG control compared to NovoRapid® based on 2-hour PPG increment during a meal test. 
A statistically significant difference was also demonstrated for 1-hour PPG increment (meal test) in 
favour of mealtime faster aspart. No statistically significant difference was seen in overall rate of 
severe or BG confirmed hypoglycaemic episodes between mealtime faster aspart and NovoRapid®. 
The rate during the first one hour after start of a meal, constituting a smaller fraction of all severe or 
BG confirmed hypoglycaemic episodes, was statistically significantly higher for faster aspart 
compared to NovoRapid®. The overall safety profile for faster aspart and NovoRapid® was similar 
and as expected for insulin aspart.
In a therapeutic confirmatory basal-bolus trial in adult subjects with T2DM, adding and titrating 
mealtime faster aspart in combination with insulin glargine also effectively improved glycaemic 
control and non-inferiority to NovoRapid® regarding HbA1c change from baseline was confirmed. A 
statistically significant benefit in 2-hour PPG increment (meal test) could not be confirmed for 
faster aspart compared to NovoRapid®. A statistically significant difference was demonstrated for 
1-hour PPG increment (meal test) in favour of faster aspart compared to NovoRapid®. No 
statistically significant difference was seen in overall rate of severe or BG confirmed 
hypoglycaemic episodes between faster aspart and NovoRapid®. The rate during the first two hours 
after start of a meal, constituting a small fraction of all severe or BG confirmed hypoglycaemic 
episodes, was statistically significantly higher for faster aspart compared to NovoRapid®. The 
overall safety profile for faster aspart and NovoRapid® was similar and as expected for insulin 
aspart.
The safety profile of faster aspart is expected to be similar to that of NovoRapid®. The insulin aspart 
molecule has a well-known safety profile based on more than 15 years of clinical experience. 
Compared to NovoRapid® faster aspart contains excipients which results in a faster initial 
absorption of insulin aspart following subcutaneous injection. The added excipients are included in 
the U.S. Food and Drug Administration’s (FDA) list for approved drug products for injections, and 
no toxicological concerns have been predicted from subcutaneous use in humans at the proposed 
concentrations. For further details, please refer to the current version of the Fiasp® SmPC21. If not 
approved in the country of interest detailed information for faster aspart is available in the current 
edition of the Investigator’s Brochure (IB)22 and any updates hereof.
At the time of this protocol issuance, faster aspart is approved in EU, US and Canada among others.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
17 of 112
3.1.4
Insulin degludec
Insulin degludec (marketed as Tresiba®) is a basal insulin with an ultra-long duration of action for 
once-daily subcutaneous administration at any time of the day, preferably at the same time every 
day. After subcutaneous injection, soluble and stable multi-hexamers are formed creating a depot of 
insulin in the subcutaneous tissue. Insulin degludec monomers gradually separate from the multi-
hexamers thus resulting in a slow and continuous delivery of insulin degludec into the circulation, 
leading to the observed ultra-long pharmacokinetic and pharmacodynamic profiles and thereby a 
flat and stable glucose-lowering effect. The duration of action of insulin degludec is beyond 42 
hours within the therapeutic dose range.
For further details please refer to the current version of the Tresiba® SmPC23. If not approved in the 
country of interest detailed information for insulin degludec is available in the current edition and 
any updates of the IB24.
At the time of this protocol issuance, insulin degludec is approved in more than 70 countries 
including US, EU, Canada and Japan.
3.2
Rationale for the trial
The purpose of this trial is to confirm the effect and compare safety of faster aspart compared to 
NovoRapid® both in combination with insulin degludec with or without metformin in subjects with 
T2DM treated with a basal-bolus regimen. This trial will provide new information in subjects with 
T2DM already treated with a basal-bolus regimen as this was not studied in the phase 3a
programme.
In the European Medicines Agency (EMA) and FDA note for guidance on clinical investigation of 
medicinal products for the treatment of diabetes, HbA1c is considered the most widely accepted 
measure of overall, long-term glucose control. Consequently, HbA1c will be included as the primary 
endpoint.25, 26
The trial is intended to confirm that administration of faster aspart gives overall glycaemic control 
non-inferior to NovoRapid® and to confirm that faster aspart, with its faster onset of action, is 
capable of demonstrating superior control of postprandial glucose regulation and excursions as well 
as a greater reduction in HbA1c in subjects with T2DM.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
18 of 112
4
Objectives and endpoints
4.1
Objectives
Primary objective
To confirm the effect in terms of glycaemic control of treatment with faster aspart compared to 
NovoRapid® both in combination with insulin degludec with or without metformin in adults with 
T2DM treated with a basal-bolus regimen, using a non-inferiority approach.
Secondary objectives
To confirm superiority of faster aspart compared to NovoRapid® both in combination with insulin 
degludec with or without metformin in adults with T2DM treated with a basal-bolus regimen in 
terms of:
!
Postprandial glucose regulation
!
Overall glycaemic control 
!
Postprandial glucose excursions 
To compare the safety of faster aspart to NovoRapid® both in combination with insulin degludec 
with or without metformin in adults with T2DM treated with a basal-bolus regimen.
4.2
Endpoints
Baseline is defined as randomisation (Visit 14) 
4.2.1
Primary endpoint
Change from baseline in HbA1c 16 weeks after randomisation
4.2.2
Secondary endpoints
4.2.2.1
Confirmatory secondary endpoints
!
Change from baseline in 1-hour PPG increment 16 weeks after randomisation (meal test)
!
Change from baseline in 1,5-anhydroglucitol 16 weeks after randomisation
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
19 of 112
4.2.2.2
Supportive secondary endpoints
Supportive secondary efficacy endpoints
!
Change from baseline in fasting plasma glucose (FPG) 16 weeks after randomisation
!
If a subject achieves HbA1c targets 16 weeks after randomisation:
o
HbA1c < 7.0% 
o
HbA1c < 7.0% without severe hypoglycaemia
!
Change from baseline in 30- minutes, 1- hour,  2- hour, 3- hour and 4- hour PPG and 30-
minutes, 2- hour, 3- hour and 4- hour PPG increment 16 weeks after randomisation (meal 
test)
!
Change from baseline in endpoints derived from the 7-9-7-point self-measured plasma 
glucose (SMPG) profile 16 weeks after randomisation:
o
Mean of the 7-9-7-point profile
o
Postprandial glucose and PPG increment (mean, breakfast, lunch, main evening meal)
o
Fluctuation in 7-9-7-point profile
o
Change in the nocturnal SMPG measurements
!
If a subject achieves PPG target (overall mean of daily PPG measurements in 7-9-7-point 
SMPG profile) 16 weeks after randomisation:
o
Overall PPG (1 hour) ≤7.8 mmol/L [140 mg/dL]
o
Overall PPG (1 hour) ≤7.8 mmol/L [140 mg/dL] without severe hypoglycaemia
!
Insulin dose (Units/day and Units/kg/day; total basal, total bolus and individual meal insulin 
dose) 16 weeks after randomisation
!
Change from baseline in lipids-lipoproteins profile 16 weeks after randomisation (total 
cholesterol, high density lipoproteins (HDL) cholesterol, low density lipoproteins (LDL) 
cholesterol)
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
20 of 112
Supportive secondary safety endpoints
!
Number of treatment emergent adverse events (AEs) during 16 weeks after randomisation
!
Number of treatment emergent injection site reactions during 16 weeks after randomisation
!
Number of treatment emergent hypoglycaemic episodes classified both according to the
ADA definition and Novo Nordisk definition during 16 weeks after randomisation
o
Overall
o
Daytime hypoglycaemic episodes
o
Nocturnal hypoglycaemic episodes (00:01-05:59 – inclusive)
o
Hypoglycaemic episodes from start of meal until 1, 2, 4 hours and from 2 hours 
(exclusive) to 4 hours (inclusive) after start of meal
!
Change from baseline in clinical evaluations 16 weeks after randomisation:
o
Physical examination
o
Vital signs (diastolic blood pressure, systolic blood pressure and pulse)
o
Electrocardiogram 
o
Fundoscopy/fundus photography
!
Change from baseline in central laboratory assessments 16 weeks after randomisation:
o
Haematology (erythrocytes, haematocrit, haemoglobin, leucocytes, thrombocytes)
o
Biochemistry (alanine aminotransferase (ALT), aspartate aminotransferase (AST), 
albumin, alkaline phosphatase, creatinine, potassium, sodium, total bilirubin)
!
Change from baseline in body weight and body mass index 16 weeks after randomisation
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
21 of 112
5
Trial design
5.1
Type of trial
This is a phase 3b, 16-week, multicentre, multinational, 1:1 randomised, double-blind, active 
controlled, treat-to-target, parallel group trial with a 12-week run-in period comparing the effect and 
safety of faster aspart to NovoRapid® both in combination with insulin degludec with or without 
metformin in subjects with T2DM treated with a basal-bolus regimen. 
Figure 5–1
Trial Design.
The trial design is summarised in Figure 5–1. The total duration of the trial is approximately 34 
weeks divided into the following periods:
!
An approximately 2-week screening period
!
A 12-week run-in period primarily for optimisation of the basal insulin and subject training
!
A 16-week treatment period
!
A 30-day follow-up period: FU1; 7 days after end of treatment and FU2; 30 days after end 
of treatment 
The trial includes a screening period followed by weekly visits/phone contacts during the trial. At 
Visit 2, all eligible subjects will be enrolled in a 12-week run-in period. After the run-in period, 
subjects eligible for randomisation (HbA1c ≤ 9.0% measured at Visit 13) will be randomised (1:1) to 
receive double blinded treatment with either faster aspart or NovoRapid® both in combination with 
once daily insulin degludec with or without metformin.  
   -14    -12 weeks
       
                    
0
                 
                                        
  16 weeks +7d+30d   
Screening
Randomisation
Faster aspart + insulin degludec ± metformin
NovoRapid
® + insulin degludec ± metformin 
End of 
treatment
Basal titration
Bolus titration
Bolus insulin analogue + insulin 
degludec ± metformin
FU1   FU2
12-week run-in period
16-week treatment 
period
HbA1c ≤9.0 % 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
22 of 112
All subjects will have a standardised meal test at baseline (Visit 14 before randomisation) and at 
end of treatment (Visit 30). The meal test will be described in more details in section 8.3.1.
After the 16-week treatment period, each subject will have a 30-day safety follow-up period.
5.2
Rationale for trial design
The 12-week run-in period has been included to ensure the subjects are being trained in the trial 
procedures and that the basal insulin titration is optimised. A 16-week treatment period is needed to 
obtain valid and adequate efficacy and safety data. 
The rational for the simple carbohydrate counting (carbohydrate awareness) is to ensure that 
subjects are able to better control the carbohydrate amount of their meals aiming at a similar 
carbohydrate intake between days as a supplement to the algorithm based titration.
The rationale for the meal test is to evaluate PPG regulation after a standardised meal when 
injecting faster aspart compared to NovoRapid®.
The treat-to-target approach, and thereby the very high frequency of contacts, has been chosen in 
order to ensure optimal titration of faster aspart and NovoRapid®.
The 7-day follow-up visit and 30-day follow up contact are introduced in order to collect 
information on AEs occurring in the follow-up period.
5.2.1
Rational for choice of non-inferiority margin 
In a recently finalised faster aspart trial (NN1218-4049, data on file) with a bolus insulin naïve 
T2DM adult population comparing a basal insulin treatment in addition to metformin to a full basal-
bolus insulin treatment in addition to metformin the estimated treatment effect in change from 
baseline HbA1c was - 0.94% [-1.17; -0.72]. In this trial the addition of 3 times daily faster aspart led 
to a reduction in HbA1c of 1.16% after 18 weeks of treatment. In a similar phase 4 trial27
investigating the stepwise addition of NovoRapid® to a full basal-bolus regimen in bolus naïve 
T2DM adults the observed reduction in HbA1c after 21 weeks of treatment was 1.15% (data ANA-
3786, data on file) with 3 times daily NovoRapid® added to basal insulin. This gives some 
indication that the effect of NovoRapid® versus placebo would be close to the 0.94% observed in 
trial NN1218-4049. Thus using a non-inferiority margin of 0.4%, one of the suggested margins in 
the FDA guidance26, an improvement of approximately 0.54% would have been preserved using the 
0.4% non-inferiority margin.
5.3
Treatment of subjects
At Visit 2, all eligible subjects will be enrolled in a run-in period where all subjects will be 
transferred from their pre-trial basal insulin treatment to insulin degludec once daily. They must 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
23 of 112
continue their pre-trial bolus insulin analogue with or without metformin. All OADs, except for 
metformin must be stopped at Visit 2. For subjects treated with metformin prior to the trial, they 
should continue with their pre-trial dose of metformin. The dose and dosing frequency of metformin 
should not be changed at any time during the trial, unless due to safety concerns. Initiation of any 
other diabetes treatmentis not allowed during the screening, run-in or treatment period and must be 
reported (see section 8.2.6).This includes metformin for subjects not treated with metformin prior 
to the trial. During the run-in period, the investigator will focus on optimising the basal insulin 
treatment using a treat-to-target approach following the titration guideline (Appendix A). The bolus 
insulin will not be titrated during the run-in period unless the investigator finds it necessary to 
adjust the bolus insulin for safety reasons. All subjects will receive dietary training regarding simple 
carbohydrate counting (carbohydrate awareness) in the run-in period.
All subjects should consume 3 main meals (breakfast, lunch and dinner) daily throughout the trial.
In the treatment period, eligiblesubjects must discontinue their pre-trial bolus insulin analogue and 
will receive double blinded treatment with either fasteraspart or NovoRapid®both in combination 
with once daily insulin degludec with or without metformin. The investigator should focus on 
optimising the bolus insulintreatment following thebolus dosing algorithm as described in the 
titration guideline (Appendix A). Surveillance of insulin titration will be performed by Novo 
Nordisk.
The maximum duration of treatment will be 28weeks. No maximum dose is specified. Doses are 
adjusted according to SMPGvalues (Appendix A).
Use of flash glucose monitoring or a real time continuous glucose monitoring system is not allowed 
throughout the trial.
5.4
Treatment after discontinuation of trial products
When discontinuing trial products, the subject should be switched to a suitable marketed product at 
the discretion of the investigator. Doses of subsequent antidiabetic treatment should be carefully 
titrated based on BG measurements, considering the stable effect and long half-life of insulin 
degludec.
5.5
Rationale for treatment
Based on the currently available pharmacokinetic data on faster aspart, it is anticipated that 
treatment with faster aspart as a mealtime insulin will enable insulin therapy to more closely 
approach a physiologic insulin secretory pattern. Consequently, the PPG excursions may be more 
effectively controlled. For further details, please refer to the current version of the faster aspart 
SmPC21 or IB.22
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
24 of 112
NovoRapid® will be used as a comparator to faster aspart in order to compare the effect and safety 
of faster aspart to the currently marketed insulin aspart formulation. As this is a double-blind trial, 
NovoRapid® and faster aspart will be titrated following the same recommendations.
Insulin degludec has been chosen as the basal insulin because it is a once-daily basal insulin and as 
effect and safety has been confirmed in adult subjects. The flat and stable glucose-lowering effect of 
insulin degludec makes it optimal when assessing the properties of bolus insulin (faster aspart 
compared to NovoRapid®).
Combination of insulin treatment with metformin is associated with better glycaemic control, fewer 
hypoglycaemic events, and less weight gain than treatment with insulin alone, therefore metformin 
should be continued when type 2 patients are on insulin therapy.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
25 of 112
6
Trial population
6.1
Number of subjects 
Number of subjects planned to be screened: 1803
Number of subjects planned to be included in the run-in period: 1262
Number of subjects planned to be randomised: 1072
A screening failure rate of approximately 30% and a run-in failure rate of approximately 15% are 
anticipated for this trial.
6.2
Inclusion criteria
For an eligible subject, all inclusion criteria must be answered “yes”. 
1. Informed consent obtained before any trial-related activities. Trial-related activities are any 
procedures that are carried out as part of the trial, including activities to determine suitability 
for the trial. 
2. Male or female, age ≥ 18 years at the time of signing informed consent.
3. Diagnosed with type 2 diabetes mellitus ≥ 10 years prior to screening (Visit 1).
4. Treated with a basal-bolus insulin regimen ≥ 1 year prior to the day of screening (Visit 1). A 
basal-bolus insulin regimen is defined as basal insulin once or twice daily and bolus insulin 
analogue taken with meals at least 3 times daily. Treatment with premixed insulin or soluble 
insulin combination is not considered a basal-bolus regimen.
5. Treated with or without oral antidiabetic drugs including extended release formulations. 
6. HbA1c 7.0-10.0% (both inclusive) as assessed by central laboratory at screening (Visit 1).
7. Able and willing to adhere to the protocol including performance of SMPG profiles and 
meal test.
8. Able and willing to consume 3 main meals (breakfast, lunch and dinner) daily throughout 
the trial.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
26 of 112
6.3
Exclusion criteria
For an eligible subject, all exclusion criteria must be answered “no”. 
1. Known or suspected hypersensitivity to trial product(s) or related products.
2. Previous participation in this trial. Participation is defined as signed informed consent. 
3. Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing 
potential and not using an adequate contraceptive method (adequate contraceptive measure 
as required by local regulation or practice). 
For Bulgaria, Czech Republic, Germany, Greece, Italy, Poland, Romania and Spain: The 
following contraceptive measures are considered adequate: 
o
combined (estrogen and progestogen containing) hormonal contraception associated 
with inhibition of ovulation (oral, transdermal or intravaginal)
o
progestogen-only hormonal contraception associated with inhibition of ovulation
(oral, injectable or implantable)
o
intrauterine device
o
intrauterine hormone-releasing system
o
sexual abstinence
o
vasectomised partner
o
double barrier method (a combination of male condom with either cap, diaphragm or 
sponge with spermicide)
4. Participation in any clinical trial of an approved or non-approved investigational medicinal 
product within 30 days before screening (Visit 1). Clinical trials do not include non-
interventional studies.
5. Any disorder, except for conditions associated with type 2 diabetes mellitus, which in the 
investigator’s opinion might jeopardise subject’s safety or compliance with the protocol.
6. Any of the following: myocardial infarction, stroke, hospitalization for unstable angina or 
transient ischaemic attack within the past 180 days prior to the day of screening (Visit 1). 
7. Subjects presently classified as being in New York Heart Association (NYHA) Class IV. 
8. Planned coronary, carotid or peripheral artery revascularisation known on the day of 
screening (Visit 1).
9. Inadequately treated blood pressure defined as Grade 3 hypertension or higher (Systolic 
≥180 mmHg or diastolic ≥110 mmHg) at screening (Visit 1).
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
27 of 112
10. Treatment with injectable GLP-1 receptor agonists in a period of 90 days prior to screening 
(Visit 1). 
11. Anticipated initiation or change in concomitant medications (for more than 14 consecutive 
days) known to affect weight or glucose metabolism (e.g. treatment with orlistat, thyroid 
hormones, or corticosteroids).
12. Proliferative retinopathy or maculopathy requiring acute treatment. Verified by fundus 
photography or pharmacologically dilated fundoscopy performed within the past 90 days 
prior to Visit 2.
13. Presence or history of malignant neoplasms within the past 5 years prior to the day of 
screening (Visit 1). Basal and squamous cell skin cancer and any carcinoma in-situ is 
allowed. 
14. For subjects treated with metformin: Any contraindications or restrictions to use of 
metformin (according to local labelling) at investigator’s discretion.
6.4
Run-in period exclusion criteria
The subject must be withdrawn from the trial during the run-in period if the following applies after 
screening (Visit 1), and before or at randomisation (Visit 14): 
1. Included in the trial in violation of the inclusion and/or exclusion criteria.
2. Pregnancy
3. Intention of becoming pregnant
4. Simultaneous participation in another clinical trial of an approved or non-approved 
investigational medicinal product.
5. Any of the following: myocardial infarction, stroke, hospitalization for unstable angin a or 
transient ischaemic attack.
6. Planned coronary, carotid or peripheral artery revascularisation.
7. Any disorder which in the investigator’s opinion might jeopardise subject’s safety.
8. Inability or lack of willingness to adhere to the protocol, based on the investigator’s 
judgement.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
28 of 112
6.5
Randomisation criterion
To be randomised, the randomisation criterion must be answered “yes”.
1. HbA1c ≤ 9.0% measured by the central laboratory at Visit 13 (week -1).
6.6
Criteria for premature discontinuation of trial products
Efforts must be made so that subjects attend and complete all scheduled visit procedures. Subjects 
should stay in the trial irrespective of lack of adherence to randomised treatment, lack of adherence 
to visit schedule or missing assessments. Only subjects who decline any further contact with the site 
in relation to the trial will be considered as withdrawn from the trial (see Section 6.7).
The subject may be prematurely discontinued from trial products at the discretion of the investigator 
due to a safety concern.
The subject must be prematurely discontinued from trial products if the following applies after 
randomisation:
1. Included in the trial in violation of the inclusion and/or exclusion criteria and/or randomised 
in violation of the randomisation criterion.
2. Pregnancy 
3. Intention of becoming pregnant
4. Simultaneous participation in another clinical trial of an approved or non-approved 
investigational medicinal product
5. Lack of efficacy defined as fulfilment of all 4 below criteria:
!
No reduction in HbA1c measured by central laboratory from screening (Visit 1) to visit 
18, 22 or 26 AND
!
A daily average of 4-point SMPG readings (before breakfast, before lunch, before dinner 
and at bed time) on 3 consecutive days higher than 240 mg/dL (13.3 mmol/L) within the 
last two weeks period AND
!
A confirmatory FPG exceeding 240 mg/dL (13.3 mmol/L) or a confirmatory random PG 
exceeding 300 mg/dL (16.7 mmol/L) measured by central laboratory AND
!
No treatable intercurrent cause (e.g. non-compliance) for the hyperglycaemia at the 
investigator’s judgment
6. Unacceptable adverse event (including toxicity) that cannot be solved by any medical 
intervention or considered as non-acceptable risk at the investigator's judgment.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
29 of 112
See Section 8.1.9 for procedures to be performed for subjects discontinuing trial products
prematurely.
6.7
Withdrawal from trial
The subject may withdraw consent at will at any time.
A subject is considered withdrawn from trial if the following applies before Visit 30:
!
Subject is lost to follow up (see Section 8.1.10))
!
Subject withdraws consent 
!
Death
Subjects withdrawing from trial before randomisation are considered screening or run-in failures.
If the subject considers withdrawing consent the investigator must underline to the subject the 
importance of continuing in the trial despite trial product discontinuation. If the subject agrees to 
discontinue trial products but to stay in the trial, procedures described in section 8.1.9 must be 
followed. 
See Section 8.1.10 for procedures to be performed for subjects withdrawing consent after 
randomisation. 
6.8
Subject replacement
Subjects who discontinue trial products prematurely or withdraw from trial will not be replaced.
6.9
Rationale for trial population 
The trial population consists of adult subjects with T2DM who have been treated with a basal-bolus 
insulin regimen for at least 365 days, but are not optimally controlled as demonstrated by an HbA1c
≥ 7.0%, and may benefit from intensified insulin titration using a treat-to-target approach. The 
subjects need to have had T2DM for at least 10 years to ensure more progressed disease requiring a 
full basal bolus insulin supplementation. The subjects need to be on a basal-bolus insulin regimen 
for at least 365 days in order to ensure that they have been adequately educated and are familiar 
with using the intensive regimen required in this trial. This will also help to avoid including newly 
diagnosed patients that could enter in the metabolic remission period.
Subjects with an HbA1c > 10% are not included in this trial. This is because the trial protocol 
requires strict adherence and good subject compliance and a likely cause of elevated HbA1c > 10% 
in a diabetic subject is poor compliance with treatment regimens or an atypical course of the 
disease. The upper HbA1c limit is also expected to select a population that can achieve adequate 
basal insulin coverage in the 12-week run-in basal insulin titration period. Subjects in good 
glycaemic control defined as HbA1c <7.0 % may not benefit from this trial and hence the lower cut-
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
30 of 112
off value has been chosen. Subjects with an HbA1c > 9% are not eligible to be randomised into the 
treatment period of the trial. This is because the trial protocol requires strict adherence and good 
subject compliance, a likely cause of HbA1c> 9% after 12-week basal insulin titration period is poor 
compliance with treatment regimens or an atypical course of the disease.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
31 of 112
7
Milestones
Planned duration of recruitment period: 36 weeks
End of trial is defined as last patient last visit (LPLV) .
Recruitment:
The screening and randomisation rate will be followed closely via the interactive voice/web 
response system (IWRS) in order to estimate when to stop screening. All investigators will be 
notified immediately when the recruitment period ends, after which no further subjects may be 
screened and the IWRS will be closed for further screening. All subjects screened during the 
recruitment period and found eligible for randomisation can be randomised within the timelines 
specified in the flow chart (see Section 2).
Trial registration:
Information of the trial will be disclosed at clinicaltrials.gov and novonordisk-trials.com. According 
to the Novo Nordisk Code of Conduct for Clinical Trial Disclosure28, it will also be disclosed 
according to other applicable requirements such as those of the International Committee of Medical 
Journal Editors (ICMJE)29, the FDA Amendment Act (FDAAA)30, European Commission 
Requirements31, 32 and other relevant recommendations or regulations. If a subject requests to be 
included in the trial via the Novo Nordisk e-mail contact at these web sites, Novo Nordisk may 
disclose the investigator’s contact details to the subject. As a result of increasing requirements for 
transparency, some countries require public disclosure of investigator names and their affiliations.
Primary Completion Date is the last assessment of the primary endpoint, and is for this protocol last 
subject first visit + 30 weeks corresponding to Visit 30. If the last subject is withdrawn/dropout 
early the Primary Completion Date is the date when the last subject would have completed Visit 30. 
The Primary Completion Date determines the deadline for results disclosure at clinicaltrials.gov
according to FDAAA.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
32 of 112
8
Methods and assessments
8.1
Visit procedures
The following sections describe the assessments and procedures. These are also included in the flow 
chart (see Section 2).
8.1.1
Screening (Visit 1)
Informed consent must be obtained before any trial related activity, see Section 18.2.
All subjects must be provided with a copy of their own signed and dated informed consent form.
Subjects will continue on their current diabetes treatment until start of run-in period (Visit 2) and 
they will not be supplied with any trial products until then.
The investigator must keep a subject screening log, a subject identification code list and a subject 
enrolment log. Only subjects who have signed the informed consent form should be included on the 
logs. The subject screening log and subject enrolment log may be combined in one log.
At screening, subjects will be provided with a card stating that they are participating in a trial and 
giving contact address(es) and telephone number(s) of relevant trial site staff. Subjects should be 
instructed to return the card to the investigator at the last trial visit or to destroy the card after the 
last visit.
Each subject will be assigned a unique 6-digit subject number which will remain the same 
throughout the trial. A screening session must be performed in the IWRS.
Screening failures
For screening failures the screening failure form in the electronic case report form (eCRF) must be 
completed with the reason for not continuing in the trial. Serious AEs (SAEs) from screening 
failures must be transcribed by the investigator into the eCRF. Follow-up on SAEs must be carried 
out according to Section 12.
A screening failure session must be made in the IWRS. When data has been monitored and queries 
have been resolved the case book must be signed.
Re-screening is NOT allowed if the subject has failed one of the inclusion, exclusion or 
randomisation criteria, this includes re-sampling if the subject has failed one of the inclusion,
exclusion or randomisation criteria related to laboratory parameters.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
33 of 112
8.1.2
Run-in
If the subject is found eligible to continue in the trial the subject will enter a run-in period. Visit 2 
can take place as soon as the subject has been found eligible and must take place no later than 17 
days after screening. 
In- or exclusion criteria must not be ticked “Yes” or “No” in the eCRF before source data is 
available. In case source data is not available “Result pending” must be chosen. This is particularly 
relevant for lab samples and in some cases the ECG (electrocardiogram) and eye examination 
result. The results of all the screening assessments must be available (including central laboratory 
results) and must have been reviewed by the investigator before the subject can enter the run-in 
period.
At start of the run-in period (Visit 2), the subject will receive the basal insulin trial product (Insulin 
degludec). The subjects must be trained in how to handle the insulin pen injectors (see section 
8.6.2). Training may be repeated during the trial if necessary. First date of trial product (basal 
insulin) must be recorded in the eCRF.
A run-in dispensing session must be performed in the IWRS. A drug accountability session 
confirming dispensing of allocated trial product should also be performed when dispensing trial 
product.
The BG meter and diary should be provided to the subjects at Visit 2. Subjects must be trained in 
use of the BG meter and completion of the diary. 
Run-in failures
If the subject is not eligible to be randomised (i.e. has met one of the run-in period exclusion 
criteria, has not met the randomisation criterion or withdraw from trial before randomisation) then 
the subject will be considered a run-in failure. Consequently, a run-in failure session must be made 
in the IWRS system and a run-in failure form must be completed in the eCRF together with the 
reason for not continuing in the trial. The last date of trial product must be captured in the eCRF. 
No follow-up visit should take place and no additional assessments are needed. The diary should be 
returned to the site.SAEs and non-serious AEs from run-in failures must be recorded by the 
investigator in the eCRF. Follow-up of AEs must be carried out according to section 12.3.
When data has been monitored and queries have been resolved the case book must be signed in the 
eCRF.
8.1.3
Randomisation 
If the subject meets the randomisation criterion as measured at Visit 13, then the subject will at 
Visit 14 be randomised into one of the two treatment arms using an IWRS randomisation session. A 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
34 of 112
drug accountability session confirming dispensing of allocated trial products should also be 
performed when dispensing trial products.
First date of the randomised trial product (bolus insulin) must be recorded in the eCRF.
The subject must attend randomisation visit fasting. For definition of fasting, please see section 
8.1.5.
Investigator must hand out the subject mealtime insulin dose adjustment guide and instruct subjects
how to self-titrate (section 8.3.4 and Appendix A).
8.1.4
Phone contacts
Before any phone contact, both the investigator and subject should agree on the timing and direction 
of the call. The investigator remains responsible for ensuring that the phone contacts occur even if it 
is agreed that the subject should call the site. A phone contact may be converted to a site visit if 
needed.
8.1.5
Fasting visits
The subjects must attend the visits specified in the flowchart (section 2) in a fasting condition. 
Fasting is defined as at least eight hours without drink or food intake prior to the visit except for 
water.
Insulin dosing (including basal insulin) and medication which should be taken with or after a meal 
should be withheld until blood sampling has been performed. If a subject attends the visit non-
fasting, then the subject’s blood samples, meal test and body weight measurement must be re-
scheduled within the visit window and at Visit 14 before randomisation to trial product.
8.1.6
Rescheduled visits
The date of the rescheduled assessment in the eCRF should reflect the actual date of the rescheduled 
assessment (i.e. the actual visit date will differ from the assessment date under the same visit).
8.1.7
End of treatment
At end of treatment trial products must be discontinued and a completion IWRS session must be 
performed. Last date on the basal and bolus trial insulin must be recorded in eCRF.
The subject must be switched to a suitable marketed product at the discretion of the investigator and 
this product must be recorded on the concomitant medication (diabetes) form in eCRF, as described 
in section 8.2.6.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
35 of 112
8.1.8
Follow-up period
The follow-up visit 1 (FU1) is a site visit and must take place 7-17 days after the end of treatment 
visit. Follow-up contact 2 (FU2) is a phone contact and must take place 30-35 days after the end of 
treatment visit.
Follow-up visit 1
The following data will be collected:
!
AEs 
!
Concomitant medication
!
Current diabetes medication
!
Hypoglycaemic episodes
!
Additional information on injection site reactions
Follow-up contact 2
The following data will be collected:
!
AEs
!
Concomitant medication
!
Current diabetes medication
!
Hypoglycaemic episodes
8.1.9
Premature discontinuation of trial products
If a subject prematurely discontinues trial products after randomisation (Visit 14), the investigator 
must undertake procedures similar to those for Visit 30 as soon as possible, also called Visit 30A 
(see flowchart section 2). 
Premature discontinuation of trial products must be registered in IWRS . This must be performed at 
least 4 days prior to Visit 30A to ensure scheduling of the 7-9-7-point SMPG profile on the three 
days prior to Visit 30A. Subjects should perform this 7-9-7 point SMPG profile before 
discontinuing trial products.
At Visit 30A subjects must undergo the meal test before discontinuing trial products. The meal test 
should be performed with bolus trial insulin. If it is not feasible due to safety reasons including 
pregnancy as judged by the investigator the meal test should be performed with the marketed bolus 
product the subject is switched to. 
The primary reason for premature discontinuation of trial products must be specified in the eCRF, 
and final drug accountability must be performed. A treatment discontinuation session must be made 
in the IWRS after the final meal test.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
36 of 112
The subject should be switched to a suitable marketed product at the discretion of the investigator. 
The medication should be recorded on the concomitant medication (diabetes) form in the eCRF, as 
described in section 8.2.6 at each contact after trial product discontinuation.
The subject should also complete the follow-up visits (FU1 and FU2) 7 days and 30 days after 
discontinuation of trial product. Visit 31 (FU1) can be converted into a phone contact as the diary 
can be collected at the next site visit for the subjects that discontinue trial products prematurely.
In addition, subjects prematurely discontinued from trial products should continue with the per
protocol planned visits at 4 (Visit 18), 8 (Visit 22), 12 (Visit 26), 16 (Visit 30) weeks after 
randomisation depending on when the subject discontinues trial products. The meal test at Visit 30
should be done with the subjects’ currently prescribed insulin treatment with the same bolus insulin 
dose as at baseline. 
The following assessments are not applicable for subjects that prematurely discontinue trial 
products: 4 point profiles, daily doses of trial insulin, time of injection, dose recommendation, 
reason for deviation and collection of technical complaints.
In the following situations, only one visit should take place:
!
If Visit 30A is within 2 weeks of one of the per protocol planned visits, only Visit 30A 
should be performed
!
If any per protocol planned visit and the windows of a follow-up visit are overlapping 
according to visit schedule, only the per protocol planned visit should be performed
It should be documented in the medical records if subject refuses to attend a visit from Visit 30A 
and onwards.A subject that permanently discontinues trial product before the End of Treatment visit 
(V30), will be considered to be a treatment non-completer. 
Diary records after premature discontinuation of trial products
Date, actual clock time and value of the SMPG measurements performed as part of the 7-9-7-point 
profiles on the three consecutive days prior Visit 30A, Visit 22 and Visit 30 must be transcribed to 
the eCRF. Additionally, hypoglycaemic episodes must be recorded in the diary and transcribed to 
the eCRF.
8.1.10
Withdrawal from trial
If a subject withdraws consent, the investigator must aim to undertake procedures similar to those 
for Visit 30 including the meal test, as soon as possible, also called Visit 30A. The investigator must 
encourage the subjects to undergo the meal test at Visit 30A. The meal test must be performed with 
bolus trial insulin according to randomisation. If it is not feasible due to safety reasons including 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
37 of 112
pregnancy as judged by the investigator the meal test should be performed with the marketed bolus 
product the subject is switched to.
If the subject agrees, the investigator must aim to perform the follow up visits (FU1 and FU2) 7 and 
30 days after discontinuation of trial product.
In case a premature discontinuation of trial product subject chooses to withdraw consent from trial 
after completing Visit 30A, FU1 and FU2, the investigator must encourage the subjects to undergo 
procedures of Visit 30, as soon as possible, whereas FU1 and FU2 are not to be completed again.
The end of treatment and end of trial form in the eCRF must be completed, and final drug 
accountability must be performed even if the subject is not able to come to the trial site. A treatment 
discontinuation session must be made in the IWRS. The case book must be signed.
Although a subject is not obliged to give his/her reason(s) for withdrawing consent, the investigator 
must make a reasonable effort to ascertain the reason(s), while fully respecting the subject’s rights. 
Where the reasons are obtained, the primary reason for withdrawing consent must be specified in 
the eCRF.
A subject that is withdrawn from trial before the End of Treatment Visit (V30), will be considered 
to be a treatment non-completer and a trial non-completer. 
8.1.10.1
Lost to follow-up
The following actions must be taken in relation to a subject who fails to attend the site for a 
required visit:
!
The site must attempt to contact the subject and reschedule the missed visit as soon as 
possible
!
The site must re-train the subject in the importance of maintaining the scheduled visits 
In cases in which the subject is deemed lost to follow-up the investigator must make every effort to 
regain contact with the subject (e.g. telephone calls to friends or family members, e-mails or 
certified letter to the subject as applicable). These contact attempts must be documented in the 
subject’s medical records. Should the subject continue to be unreachable, only then will he/she be 
considered to have withdrawn from the trial with the primary reason being “lost to follow -up”.
8.1.11
Review of results
Review of ECG results, eye examination report, laboratory reports, data entered in the diaries etc. 
must be documented either on the documents, printouts or in the subject’s medical record.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
38 of 112
If clarification of entries or discrepancies in the diary is needed, the subject must be questioned and 
a conclusion made in the subject’s medical record. Care must be taken not to bias the subject. Any 
discrepancies or missing data points available elsewhere related to a 7-9-7 point profile or 
hypoglycaemic episodes must be corrected or added.
8.2
Subject related information/assessments 
8.2.1
Demography
Demography will be recorded at screening and consists of:
!
Date of birth (according to local regulation)
!
Sex
!
Ethnicity (according to local regulation)
!
Race (according to local regulation)
8.2.2
Diabetes history and diabetes complications 
Diabetes history and diabetes complications will be recorded at screening and consists of:
!
Date of diagnosis of T2DM
!
Information regarding diabetes complications including date of onset
–
Diabetic retinopathy
–
Diabetic neuropathy
–
Diabetic nephropathy
–
Macroangiopathy (including peripheral vascular disease)
8.2.3
Hypoglycaemia unawareness 
Information on hypoglycaemia unawareness will be recorded at screening according to Clarke’s 
questionnaire, question 8.33
The investigator must ask the subject in the following way: “To what extent can you tell by your 
symptoms that your blood glucose is low?” The subject can answer never, rarely, sometimes, often 
or always.
Subjects answering ‘never, rarely or sometimes’ are considered as having impaired awareness of 
hypoglycaemia.
8.2.4
Concomitant illness and medical history
–
A concomitant illness is any illness that is present at the start of the trial (i.e. at the first 
visit (Visit 1)) or found as a result of a screening procedure or other trial procedures 
performed before exposure to trial product. 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
39 of 112
T2DM and diabetes complications should be reported separately in the Diabetes History/Diabetes 
Complications Form in the eCRF.
Medical history is a medical event that the subject has experienced in the past. Only relevant 
medical history, as judged relevant by the investigator, should be reported. 
The information collected for concomitant illness and medical history should include diagnosis, 
date of onset and date of resolution or continuation, as applicable.
Any change to a concomitant illness should be recorded during the trial. A clinically significant 
worsening of a concomitant illness must be reported as an AE.
It must be possible to verify the subject’s medical history in source documents such as subject’s 
medical record. If a subject is not from the investigators own practice; the investigator must make 
reasonable effort to obtain a copy of subject’s medical record from relevant party e.g. primary 
physician. The investigator must document any attempt to obtain external medical information by 
noting the date(s) when information was requested and who has been contacted.
8.2.5
Concomitant medication
A concomitant medication is any medication, other than the trial product(s), which is taken during 
the trial, including the screening, run-in, treatment and follow-up periods.
Details of any concomitant medication must be recorded at Visit 1. Changes in concomitant 
medication must be recorded at each visit as they occur. 
The information collected for each concomitant medication includes trade name or generic name, 
indication, start date and stop date or continuation. 
If a change is due to an AE, then this must be reported according to Section 12. If the change 
influences the subject’s eligibility to continue in the trial, the monitor must be informed.
8.2.6
Concomitant medication (diabetes)
Any diabetes medication other than the trial product(s) which is taken during the trial, including the 
screening, run-in, treatment and follow-up periods must be recorded in a separate concomitant 
medication (diabetes) form in the eCRF including the trade name or generic name, total daily dose, 
frequency, start date and stop date or continuation. For subjects treated with metformin it is the start 
date and dose of last stable metformin dose which should be reported.
At the run-in visit (Visit 2) basal insulin and all OADs except for metformin must be discontinued 
and a stop date recorded. For subjects treated with metformin, investigator should at each weekly 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
40 of 112
contact (visit or phone contact), confirm with the subject that dose and frequency of metformin has 
been unchanged. This should be documented in the medical records. 
At the randomisation visit (Visit 14) pre-trial bolus insulin must be discontinued and a stop date 
recorded.
It is important to ensure subjects adhere to treatment. Therefore, during the treatment period (from 
randomisation to End of Treatment) the investigator must also at each weekly contact (visit or 
phone contact), evaluate if the subject has taken any ancillary treatment since last contact. 
Ancillary treatment is defined as any diabetes medication - other than randomised treatment (trial 
products in the basal-bolus regimen with or without metformin) initiated in case of unsatisfactory 
glycaemic control. It should be registered as such on the concomitant medication (diabetes) form in 
the eCRF. For subjects not treated with metformin prior to the randomisation, initiation of long term 
use of metformin is considered as ancillary treatment. A medication error (Section 8.4.1.1) is as 
such not considered as ancillary treatment.
8.2.7
Childbearing potential
It must be recorded in the eCRF whether female subjects are of childbearing potential. Reason for 
not being of childbearing potential must be documented in the medical records. 
Pregnancy testing must be performed on female subjects of childbearing potential as described in 
Section 8.5.2. Female subjects of childbearing potential must be instructed to use adequate 
contraceptive methods throughout the trial and until 1 week after end of treatment.
Female of non-childbearing potential is defined as:
!
Female who has undergone a hysterectomy, bilateral oophorectomy or bilateral tubal 
ligation 
!
Postmenopausal defined as no menses for 12 months without an alternative medical cause
!
Other medical reasons preventing childbearing potential 
8.2.8
Tobacco use
Details of tobacco use must be recorded at Visit 1. Smoking is defined as smoking at least one 
cigarette or equivalent daily. 
Smoking status:
!
Never smoked
!
Previous smoker
!
Current smoker
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
41 of 112
8.3
Efficacy assessments
8.3.1
Meal test
The subject will undergo a standardised liquid meal test at two visits (see flowchart section 2) and 
will have their 30 minute and 1, 2, 3 and 4 hour PPG measured. The total duration of the meal test is 
expected to be up to 6 hours including preparations. During that time 6 blood samples will be 
drawn, as specified in the Table 8–1. 
Before initiation of the meal test 
The subject should be instructed to: 
!
Follow normal routine regarding eating and exercise habits on the day prior to the meal test
!
Refrain from intake of alcohol and use of medications that affect motility (i.e. prokinetics, 
anticholinergics, tricyclic antidepressants) on the day prior to the meal test, unless the 
subject was on this medication at trial entry and does not change the product or product dose
!
Remember to bring their current/trial bolus and basal insulin, diary and BG meter to the 
meal test visits
!
Attend the meal test visits in a fasting condition. For definition of fasting, please refer to 
section 8.1.5. If subjects are normally dosing basal insulin in the morning, it is important 
they wait until after completion of the meal test
!
Achieve an SMPG value within a range of 4.0-8.8 mmol/L [71-160 mg/dL] before 
beginning the meal test. The SMPG value should be verified at the site before starting the 
meal test.
The meal test should be re-scheduled within the visit window and at Visit 14 before randomisation 
to trial product in case:
!
any hypoglycaemic episode occurs from midnight before the meal test 
!
the subject is not fasting or 
!
the SMPG value is outside the range.
At Visit 14 (randomisation visit) the investigator must evaluate if the subject is eligible to continue 
in the trial before the meal test is performed. Only subjects eligible for randomisation should have 
the Visit 14 meal test performed.
Bolus insulin dose and meal test carbohydrate calculation
The standardised liquid meal will be provided by Novo Nordisk. The volume of the liquid meal 
should be measured out by the investigator to be the equivalent to 78 grams of digestible 
carbohydrates (total carbohydrate content minus fibre). 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
42 of 112
At the baseline meal test, the bolus insulin dose should be calculated by the investigator by dividing 
the digestible carbohydrate content of the standardised meal by a calculated insulin:carbohydrate 
ratio. The insulin:carbohydrate ratio in this trial is calculated by dividing 500 by the total daily dose 
(taken from the day before) of both basal and bolus insulin. The calculated dose should be rounded 
to the nearest whole unit. 
Same bolus insulin dose will be used for the meal test at end of treatment. The insulin should be 
administered subcutaneously in the abdomen in accordance with Table 8–1.
Initiation of meal test
The subject’s body weight must be measured before start and a blood sample must be drawn two 
minutes before intake of the standardised meal. 
For the meal test at Visit 14 the subject must receive the bolus insulin that was also used in the run-
in period. 
For the meal test at Visit 30 the subject should receive the bolus trial insulin they were randomised 
to and have used throughout the treatment period. If subject has been prematurely discontinued they 
should perform a meal test both at Visit 30A and again at Visit 30; the meal test at Visit 30 should 
be performed with the marketed bolus product the subject was switched to. 
The start of consumption of the liquid meal is defined as time point 0. The subject must consume
the liquid meal as quickly as possible and within 12 minutes. The investigator should confirm that 
the subject consumed the required volume of the standardised liquid meal in the eCRF.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
43 of 112
Table 8–1
Meal test schedule
Time point 
(minutes)
Blood 
sample 
SMPG 
values 
Standardised meal
Bolus insulin injection
Before start 
of meal test
X (within target 
range 4.0-8.8 
mmol/L [71-160 
mg/dL])
-2
X
0
X (as appropriate 
to ensure 
subject’s safety)
X
X
Insulin injection at the start of the meal
30
X
60
X
120
X
180
X
240
X
End of meal 
test
X (for subject’s 
safety)
Conduct of meal test
The subject should stay in the clinic to have the blood samples drawn after 30 minutes, 1, 2, 3 and 4 
hours from the start of the standardised meal, as detailed in Table 8–1. The samples will be 
analysed by the central laboratory.
During the meal test the subject should be resting in a chair. No smoking or intake of food and 
liquids will be allowed during the meal test, except for water consumption which is allowed two 
hours after intake of the standardised meal.
If SMPG values ≤3.9 mmol/L [70 mg/dL] are measured, then the hypoglycaemia should be treated 
with glucose rescue treatment according to local practice and the meal test should continue 
according to the investigator’s discretion. The hypoglycaemic episode must be reported. Please see 
section 8.4.2. 
After the end of the meal test, the investigator should make sure that the subject is safe to leave the 
site by performing an additional SMPG measurement.
Only after the meal test at Visit 14 is completed, the subject will be allowed to start treatment with 
randomised trial product. 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
44 of 112
Data collection
The following must be recorded in relation to the meal test: 
!
Fasting status
!
SMPG value measured before the meal test and within allowed ranges and the time of the 
measurement
!
Actual clock start and end time of standardised meal
!
Volume of meal consumed
!
Confirmation that the subject consumed the required volume of the standardised meal
!
Batch number of the standardised meal consumed
!
Actual clock time and dose of bolus insulin 
!
Actual clock time of blood samples
!
Hypoglycaemic episodes, if relevant
o
SMPG value, time of intervention and amount of glucose rescue treatment and 
hypoglycaemic episode form
Laboratory results from meal test data will be loaded directly into the trial database by the central 
laboratory. The meal test results will not be provided to the investigator until after LPLV in order to 
keep the blinding of the subject and investigator.
8.3.2
Discontinuation of MyGlucoHealth BG-meter and electronic diary
This section applies to subjects enrolled prior to implementation of Global Protocol Amendment no. 
2.0. Subjects who have used the glycaemic data collection system (the combination of the 
MyGlucoHealth Wireless BG-meter and an electronic diary (eDiary)) have been instructed to 
discontinue this system and use an alternative BG-meter until a new trial BG-meter and paper diary 
is provided by Novo Nordisk.
The following must be recorded by the investigator in the eCRF:
!
Start date of new trial BG-meter
8.3.3
Self-measured plasma glucose
At Visit 2, subjects will be provided with a BG meter including ancillaries as well as instructions 
for use, if needed. The subjects will be instructed in how to use the device.
The subjects should be instructed how to record the results of the SMPG values including a 7-9-7 
point profile in the diaries. Data from the diary must be transcribed into the eCRF during or 
following the contact. If obtained via phone and a discrepancy is later detected, the values in the 
eCRF must be corrected. 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
45 of 112
Occasional review by the investigator of the values stored in the memory of the BG-meter and 
correct reporting of these in the diary is advised in order to ensure adequacy of the data reported in 
the trial database.
The BG meters use test strips calibrated to plasma values. Therefore, all measurements performed 
with capillary blood are automatically calibrated to plasma equivalent glucose values, which will be 
shown on the display. 
Only the BG meter provided by Novo Nordisk should be used for the measurements required in the 
protocol.
4-point self-measured plasma glucose profile 
The 4-point SMPG profile will be recorded for insulin titration purposes. Subjects will be instructed 
to perform 4-point profiles every day from Visit 2 to Visit 30 for titration purposes. The 
measurements should be performed at the following time points:
!
Before breakfast
!
Before lunch
!
Before main evening meal (dinner)
!
At bedtime
For SMPG measurements actual clock time, time point (e.g. before breakfast), date and value 
should be recorded in the diary.
SMPG values measured before breakfast, lunch, main evening meal, and at bedtime should be 
performed before any injection of bolus insulin and just before the start of the meal (breakfast, 
lunch or main evening meal). SMPG values measured before breakfast should be performed in a 
fasting condition. The 4-point profile is part of the 7- or 9-point profiles which are measured prior 
to selected site visits.
7-9-7 point self-measured plasma glucose profile
The 7- and 9-point SMPG profiles will be used for titration purposes and evaluation of the effect of 
the trial. The subject will be instructed to perform a 7-9-7 point profile on the 3 consecutive days 
just before selected visits as outlined in the flowchart in section 2. See Table 8–2 (7-point profiles 
indicated as X and the 9-point profile indicated as √). 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
46 of 112
Table 8–2
7-point SMPG profiles with additional 9-point SMPG profile
Time point
Day -3
7-point 
profile
Day -2
9-point 
profile
Day -1
7-point 
profile
Before breakfast
X
∀
∀ #X)a
60 minutes after the start of 
breakfast
X
∀ 
X
Before lunch
X
∀ 
X
60 minutes after the start of 
lunch
X
∀ 
X
Before main evening meal
X
∀ 
X
60 minutes after the start of 
main evening meal
X
∀ 
X
At bedtime
X
∀ 
X
At 4 am
∀ 
aThe last SMPG in the 9-point profile and the first SMPG of the 7-point profile on day-1 are overlapping.
For SMPG measurements actual clock time, time point (e.g. before breakfast), date and value
should be recorded in the diary. SMPG values measured before breakfast, lunch and main evening 
meal and at bedtime should be performed before any insulin injection and just before the start of the 
meal (breakfast, lunch or main evening meal). SMPG values measured before breakfast should be 
performed in a fasting condition.
The measurements will be used to evaluate the glucose profile.
8.3.4
Insulin dose
The subject should be instructed to report the following concerning dosing of trial products in the 
diary:
!
Date, actual clock time and dose of basal and bolus insulin on a daily basis from Visit 2 to 
Visit 30.
!
Date, actual clock time, and dose for other (extra) bolus insulin administration as well as 
time and type of previous main meal and reason for the extra bolus from Visit 2 to Visit 30.
Data from the diary must be transcribed into the eCRF during or following the contact. If obtained 
via phone and a discrepancy is later detected, the values in the eCRF must be corrected. 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
47 of 112
Dosing and dose adjustment (new dose)
The recommended insulin doses will be calculated in the eCRF based on recommendations from the 
Insulin Titration Guideline (see Appendix A). At each visit/phone contact the investigator will 
titrate the subject’s insulin doses by making prescribed dose adjustments based on the 
recommendation from the eCRF if applicable and provide the new prescribed dose to the subject. 
Investigator must hand out the subject mealtime insulin dose adjustment guide at Visit 14 and 
should instruct subjects to perform self-titration of bolus (mealtime) trial insulin between the 
scheduled visits/phone contacts from Visit 14 to Visit 30. 
The investigator should record the following in the eCRF:
!
Prescribed doses of trial products
!
Reason for deviating in dose adjustments from the titration guideline, if applicable
The subject should report the following in the diary: 
!
Dose adjustment of bolus trial insulin 
8.4
Safety assessments  
In case of an abnormal and clinically significant finding, the investigator must record the finding on 
the concomitant illness form if it is present at screening. Any new finding fulfilling the definition 
stated in section 12 during the trial and any clinically significant worsening from baseline must be 
reported as an AE.
8.4.1
Adverse events
Adverse events (AEs) must be reported at each visit in accordance with the procedures outlined in 
Section 12.
8.4.1.1
Medication error
If a medication error is observed during the trial, the following information is required and a 
specific event form must be completed in the eCRF in addition to the AE form:
!
Trial product(s) involved
!
Classification of medication error
!
Whether the subject experienced any hypoglycaemic episode and/or AEs as a result of the 
medication error
!
Suspected primary reason for the medication error
For definition of medication errors, see Section 12.1.4.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
48 of 112
8.4.1.2
Adverse events requiring additional data collection
For some AEs additional data collection is required and specific event forms must be completed in 
the eCRF in addition to the AE form. 
In case any of these events fulfil the criteria for a SAE, please report accordingly, see Section 12.
Injection site reaction
If an event of injection site reaction is observed the following additional information must be 
obtained if available on the injection site reaction form:
!
Type of reaction – local or generalised
!
Symptoms associated with the event
!
Treatment given for the event
!
Association with the trial product(s)
!
Relevant risk factors associated with the event
The investigator has to evaluate whether further actions are needed (e.g. extra visits, supervised 
injection, premature discontinuation of trial product s, dermatologist consultation).
If any injection site reactions occur after Visit 31 they should still be recorded as AEs, but the 
additional data collection on the specific event form in the eCRF is not required.
8.4.2
Hypoglycaemic episodes
Plasma glucose should always be measured and recorded when a hypoglycaemic episode is 
suspected. 
All plasma glucose (PG) values:
!
≤ 3.9 mmol/L (70 mg/dL) or 
!
> 3.9 mmol/L (70 mg/dL) occurring in conjunction with hypoglycaemic symptoms 
should be reported in the diary by the subject from Visit 2 to Visit 32 (FU2) and in the eCRF by the 
investigator according to the instructions below. 
Upon onset of a hypoglycaemic episode the subject is recommended to measure PG every 15 
minutes until the SMPG value is >3.9 mmol/L (70 mg/dL) and/or symptoms have been resolved in 
accordance to current guidelines.34
A SMPG value ≤3.9 mmol/L (70 mg/dL) or hypoglycaemic symptoms must trigger a 
hypoglycaemic episode form to be completed by the subject. Repeated SMPG measurements and/or 
symptoms, occurring within a period of 60 minutes after onset on a hypoglycaemic episode, will by 
default be considered as one hypoglycaemic episode until a succeeding SMPG value is >3.9 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
49 of 112
mmol/L (70 mg/dL) and/or symptoms have been resolved and should be reported on one 
hypoglycaemic episode form. SMPG measurements ≤3.9 mmol/L (70 mg/dL) or hypoglycaemic 
symptoms after the 60 minutes period shall trigger the reporting of a new hypoglycaemia episode 
and prompt the subject to fill out a new hypoglycaemic episode form until a succeeding 
measurement is >3.9 mmol/L (70 mg/dL) and/or symptoms have been resolved.
In case of several low SMPG values within the 60 minutes interval, the lowest value is the one that 
will be reported as the SMPG value for the hypoglycaemic episode but the start time of the episode 
will remain as the time for the first SMPG value and/or symptom.
The record should include the following information:
!
Start date and time of the hypoglycaemic episode 
!
The PG level before treating the episode (if available) and any follow up measurements. 
The lowest value measured during the hypoglycaemic episode will be reported as the PG
value for the episode, the remaining values will be kept as source data in the diary.
!
Whether the episode was symptomatic (Yes/No)
A hypoglycaemic episode starting without symptoms should be updated to symptomatic if 
the subject experiences symptoms later during the episode. 
!
Whether the subject was able to treat him/herself
!
If the severity of a hypoglycaemic episode aggravates, only one hypoglycaemic episode 
should be reported reflecting the most severe degree of hypoglycaemia.Date, time and dose 
of last bolus insulin administration prior to the episode 
!
Date, time and dose of last basal administration prior to the episode 
!
Date and time of last main meal (not including snacks) prior to the episode
!
Whether the episode occurred in relation to physical activity
!
Change in any concomitant illness
!
Any sign of fever and/or other acute disease 
!
Whether the subject was asleep when the episode occurred
–
If yes, whether the symptoms of the episode woke up the subject
The answer to the question: "Was the subject able to treat him/herself?" must be answered "No" for 
an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or 
take other corrective actions. Plasma glucose concentrations may not be available during an event, 
but neurological recovery following the return of PG to normal is considered sufficient evidence 
that the event was induced by a low PG concentration.34
Oral carbohydrates must not be given if the subject is unconscious.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
50 of 112
If the question "Was the subject able to treat him/herself?" is answered "No", the following 
information should be recorded by the subject:
!
Who assisted in the treatment of the hypoglycaemic episode (i.e. medical person or non-
medical person)?
!
Where the treatment was administered (in clinic/emergency room/hospital or other. If the 
subject was treated in clinic/emergency room/hospital, whether they were transported in an 
ambulance or not)
!
Type of treatment provided by another person (i.e. oral carbohydrates, glucagon, IV glucose 
or other)
!
Were symptoms alleviated after administration of treatment?
!
Factors contributing to the episode (i.e. physical activity, missed meal, diet change, 
medication error (i.e. overdose, mix-up between products, incorrect use of device), 
miscalculation of dose of antidiabetic medication, other factors not listed or unknown)
!
Did the subject experience seizure?
!
Was the subject unconscious/comatose? 
!
Did the subject experience any of the following symptoms35 (layman term used in the diary
is specified in brackets if different from the protocol term)? 
–
Autonomic: sweating, trembling, hunger or palpitations (rapid or irregular heart beat)
–
Neuroglycopenic: confusion, drowsiness, speech difficulty, visual disturbances, odd 
behaviour, impaired balance or incoordination (reduced ability to coordinate movement)
–
General malaise: headache or malaise (feeling discomfort/unease)
!
Other symptoms 
The investigator must review the diary for low SMPG values not reported as hypoglycaemic 
episodes. The subject must be questioned whether any of the low values were severe, i.e. whether 
the subject was able to self-treat or not. If the subject was not able to self-treat, it has to be reported 
as a severe hypoglycaemic episode.Low SMPG values for non-severe hypoglycaemic episodes not 
having a hypoglycaemic episode form completed within 7 days since the SMPG measurement 
should be reported on a hypoglycaemic episode form with as much information as possible. Novo 
Nordisk will not query for additional data except for the start date, SMPG value and whether the 
subject was able to self-treat due to decreased validity of such data.36, 37
The subject must be re-trained in how to report hypoglycaemic episodes if the investigator identifies 
low SMPG values not reported as hypoglycaemic episodes.
If the hypoglycaemic episode fulfils the criteria for an SAE then an AE form and a safety 
information form (SIF) must also be filled in the eCRF, see Section 12. One AE-form and SIF can 
cover several hypoglycaemic episode forms if the subject has not recovered between the episodes.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
51 of 112
8.4.3
Eye examination
Fundus photography/pharmacologically dilated fundoscopy must be performed by the investigator, 
a local ophthalmologist, or an optometrist according to local practice. The result of the fundus 
photography/pharmacologically dilated fundoscopy must be interpreted locally by the investigator. 
To document this, the investigator must sign and date the result page or write the interpretation in 
the subject’s medical records. 
The evaluation must follow the categories:
!
Normal
!
Abnormal
–
Was the result clinically significant? (Yes/No)
Abnormal and clinically significant findings must be recorded as described in Section 8.4.
If a fundus photography/pharmacologically dilated fundoscopy has been performed within 90 days 
before Visit 2 and if the results are available at Visit 2, then the procedure does not need to be 
repeated. If performed before the subject consents to participate in the trial, it must also be stated in 
the subject’s medical records that this procedure was not performed in relation to the trial.
The eye examination must be performed prior to administration of bolus trial insulin at Visit 14 (the 
results do not need to be available for randomisation). An eye examination performed within 14 
days prior to randomisation is acceptable.
Eye examination obtained within 21 days prior to Visit 30 is acceptable if the result is available at 
the visit.
For subjects prematurely discontinued trial products: eye examination performed 21 days in 
advance of Visit 30A are acceptable if the results are available at the scheduled visits. However eye 
examination performed at Visit 14 cannot be accepted for the Visit 30A.
8.4.4
Electrocardiogram – 12 lead
An electrocardiogram (ECG)-12 lead must be performed locally. The ECG must be interpreted by 
the investigator, and documented by investigator signature and date on the ECG print-out or write 
the interpretation of the ECG in the subject’s medical records.
The evaluation must follow the categories:
!
Normal
!
Abnormal
–
Was the result clinically significant? (Yes/No)
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
52 of 112
Abnormal and clinically significant findings must be recorded as described in Section 8.4
If an ECG-12 lead has already been performed within 21 days before screening (Visit 1), and if the 
results are available at the screening visit, the procedure does not need to be repeated. If performed 
before the subject consents to participate in the trial it must also be stated in the subject’s medical 
records that this procedure was not performed in relation to the trial.
ECGs performed 21 days in advance of Visit 14 and Visit 30 are acceptable if the results are 
available at the scheduled visits.
For subjects prematurely discontinued trial products: ECGs performed 21 days in advance of Visit 
30A are acceptable if the results are available at the scheduled visits. However ECGs performed at 
Visit 14 cannot be accepted for the Visit 30A.
8.4.5
Body measurements
Height (without shoes) will be measured at site in centimetres (cm) or inches (in) and recorded to 
one decimal place in the eCRF.
Body weight should be measured in kilograms (kg) or pounds (lb) without overcoat and shoes, and 
wearing only light clothing. Body weight must be measured prior to the start of the meal test at 
Visit 14 and Visit 30.
Body weight will be recorded to one decimal place. The body weight should be assessed on the 
same weighing scale equipment throughout the trial, if possible. 
BMI will automatically be calculated by the eCRF.
8.4.6
Physical examination
Physical examination will include examination of:
!
the respiratory system
!
the cardiovascular system
!
the central and peripheral nervous system
!
the gastrointestinal system, including the mouth
!
the musculoskeletal system
!
the skin
!
the head, ears, eyes, nose, throat and neck
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
53 of 112
The results must be transcribed to the eCRF as:
!
Normal
!
Abnormal
–
Was the result clinically significant? (Yes/No)
Abnormal and clinically significant findings must be recorded as described in Section 8.4
8.4.7
Vital signs
Diastolic blood pressure, systolic blood pressure and pulse should be assessed while the subject is in 
a sitting position after five minutes of rest. If the subject is using antihypertensive medication to 
control the blood pressure, then the medication should be taken as usual prior to assessing vital 
signs. 
At screening (Visit 1) blood pressure needs to be measured three times and all values should be 
recorded in the eCRF. The mean value will be calculated by the eCRF, and must be used to assess 
the relevant exclusion criterion; please see section 6.3.
Abnormal and clinically significant findings must be recorded as described in Section 8.4
8.5
Laboratory assessments
Except for urine pregnancy testing, which will be performed locally, all laboratory analyses will be 
performed by a central laboratory contracted by Novo Nordisk. The central laboratory will provide 
all laboratory supplies for the sampling and transportation of all blood and urine samples taken 
during the trial.
A detailed description of the procedures for obtaining the samples, handling, storage, and shipment 
of the samples are specified in a trial-specific laboratory manual provided to the sites by the central 
laboratory. Information regarding laboratory materials such as tubes and labels are also described. 
Laboratory samples can be drawn on another day than on the day of the actual visit, as long as it is 
within the visit window, as stated in the flowchart in section 2. 
If laboratory samples need to be retaken due to missing result(s) (e.g. haemolysed, sample leaked 
during transit, sample not being conclusive, lost in transit, etc.), the subject should be called in for 
resampling. Please see the laboratory manual for further guidance.
Samples will be coded in order to keep subject’s identity anonymous. 
The laboratory provides results to the trial sites in the units preferred by the trial sites while the 
results that are transferred to the trial database will always be in SI units.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
54 of 112
The laboratory equipment may provide analyses not requested in the protocol but produced 
automatically in connection with the requested analyses according to specifications in the laboratory 
standard operating procedures. Such data will not be transferred to the trial database, but abnormal 
values will be reported to the investigator. The investigator must review all laboratory results for 
concomitant illnesses and AEs and report these according to Section 8.2.4 and Section 12. Review 
of laboratory reports must be documented either on the documents and/or in the subject's medical 
record.
Only laboratory samples specified in the protocol must be sent to the central laboratory for analysis; 
if additional laboratory sampling is needed, e.g. to follow up on AEs, this must be done at a local 
laboratory.
Laboratory samples will be destroyed on an ongoing basis and no later than at finalisation of the 
clinical trial report.
8.5.1
Laboratory assessments for efficacy
Glucose metabolism 
Plasma glucose will be measured during the meal test. See section 8.3.1.
FPG is measured in order to evaluate metabolic control. The subject must attend these visits fasting. 
For definition of fasting, see Section 8.1.5.
A FPG result ≤3.9 mmol/L (70 mg/dL) should not be reported as a hypoglycaemic episode but as a 
clinical laboratory AE (CLAE) at the discretion of the investigator (see Section 12.1.1). 
The level of 1,5-anhydroglucitol (GlycoMark) is measured in order to evaluate post prandial 
glucose excursions. 
Blood samples will be drawn to determine the HbA1c level in order to evaluate metabolic control. 
Fasting C-peptide is measured at randomisation in order to reflect endogenous insulin secretion.
Lipids
Blood samples for lipids will be analysed to determine:
!
Total cholesterol
!
High density lipoprotein (HDL) cholesterol
!
Low density lipoprotein (LDL) cholesterol
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
55 of 112
8.5.2
Laboratory assessments for safety
Biochemistry
Blood samples for biochemistry will be analysed to determine:
!
ALT
!
AST
!
albumin
!
alkaline phosphatase
!
creatinine
!
potassium
!
sodium
!
total bilirubin
!
total protein
!
eGFR(estimated glomerular filtration rate) at screening
eGFR will be calculated by the central laboratory based on the creatinine value using the CKD-EPI 
equation which may help evaluate exclusion criteria 14 according to local label.33
Haematology
Blood samples for haematology will be analysed to determine:
!
erythrocytes
!
haematocrit
!
haemoglobin
!
leucocytes
!
thrombocytes 
Pregnancy testing
For females of childbearing potential (see section 8.2.7), a blood human Chorion Gonadotropin 
(hCG) pregnancy test will be performed at the visits indicated in the flowchart in section 2. In 
addition, urine pregnancy tests will be performed locally during the trial if pregnancy is suspected
or if required by local law. A positive urine test should be followed by a confirmatory serum-hCG 
(central laboratory).
The central laboratory will provide the pregnancy kits for urine testing performed locally at the site.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
56 of 112
8.6
Other assessments
8.6.1
Dietary training in simple carbohydrate counting
During the run-in period all subjects should have dietary training regarding simple carbohydrate 
counting (e.g. sessions with a diabetes educator, dietician or qualified site staff) to improve 
subject’s carbohydrate awareness and understanding of their eating habits effect on their diabetes. It 
is the investigator’s responsibility to ensure that the subject is adequately trained and has a 
satisfactory knowledge in:
!
Recognition of carbohydrates in commonly eaten foods 
!
Ability to count the carbohydrate content in typical portions of simple foods
!
Ability to interpret a nutrition label for carbohydrate content 
!
Glycaemic targets 
!
Preventing and treating hypoglycaemia using carbohydrate foods
!
Ability to sum the carbohydrate content of a meal 34
A 3x24-hour meal record should be filled in by the subject prior to the visits indicated in the 
flowchart (Section 2) in order to evaluate the subject’s ability to count the carbohydrate content of 
the meal. The meal records will not be collected by the sponsor.
8.6.2
Training in the pen injector
The subjects must be trained in how to handle the pen injector when handed out the first time. 
Training must be repeated according to flowchart (Section 2) in order to ensure correct use of the 
pen injector. The following should be emphasised:
!
Always use a new needle for each injection as this will prevent contamination and blocked 
needles
!
Remember to prime the pen to ensure product flow 
!
The needle should be kept in the skin while counting slowly to 6 after the dose counter has 
returned to zero after injection. If the needle is removed too early then the full dose may not 
have been delivered.
!
Always check that the correct insulin pen is used (bolus or basal) e.g. by colour coding and 
label. Use the pen differentiation guide as a reference.
!
In-use time and storage conditions of pen-injectors (Section 9.3).
8.6.3
Diary
At the run-in visit (Visit 2) the subjects will be provided with a diary. The investigator must 
carefully instruct the subject in how to use the diary. At each following site visit the subject will be 
provided with a new diary. The diary must be collected at the next site visit and retained at the site 
as source data in accordance with Section 14. 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
57 of 112
At FU1 the subject should be provided with a diary for collecting hypoglycaemic episodes in the 
remaining follow up period. This diary will not be returned to site by the subject since FU2 is a 
phone contact. Consequently, source data for FU2 is the notes written in subject’s medical record.
All data entered in the diary is considered source data, as described in sections 8.3.3, 8.3.4 and 
8.4.2.
The subjects will be instructed in recording the following in the diary:
!
Daily 4-point profiles
!
Date, dose, clock time and time point of bolus insulin
!
Date, dose and time of basal insulin
!
7-9-7- profiles (before visits 14, 22, 30 and 30A)
!
Date of first basal dose of trial product (V2)
!
Date of first bolus dose of trial product (V14)
!
Date of last dose of trial product (V30)
!
Hypoglycaemic episodes as described in section 8.4.2
The investigator is allowed to record the following in the diary:
!
prescribed doses of trial insulin
!
time and date of next visit and/or phone contact
!
subject ID and site contact details
Diaries must be reviewed by the investigator to ensure that AEs, including any overall change in 
health and concomitant medication, are reported. The review must be documented on the front page 
of the diary and data must be transcribed into the eCRF.
Selected titration data (e.g. certain SMPGs and dose data) will only be used during the trial for 
central titration surveillance, to ensure compliance with the titration guideline (Appendix A), and 
will not be reported in the CTR. All data will be stored by Novo Nordisk (Section 24).
Diary records after premature discontinuation of trial product:
The Subject will be handed out premature discontinuation diaries at visit 30A to record the 
following:
!
Hypoglycaemic episodes
!
7-9-7- profiles (visit 22 and 30)
8.7
Subject compliance
Throughout the trial, the investigator will remind the subjects to follow the trial procedures and 
requirements to ensure subject compliance. In addition, subject compliance will be assessed by 
monitoring of drug accountability at specified visits, please refer to the flow chart (Section 2). The 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
58 of 112
unused amount of investigational medicinal product (IMP) will be assessed against the dispensed 
amount and, in case of discrepancies, the subject must be asked to clarify.
If a subject is found to be non-compliant, the investigator will remind the subject of the importance 
of following the instructions given including taking the trial products as prescribed.
The investigator will at each weekly contact (visit or phone contact) assess the subject’s compliance 
by evaluating the glycaemic control, adherence to treatment and the visit schedule and completion 
of the subject’s diary including the SMPG profiles, dose and hypoglycaemia reporting.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
59 of 112
9
Trial supplies
Trial supplies comprise trial products and auxiliary supplies. Additional details regarding trial 
supplies can be found in the Trial Materials Manual (TMM).
Trial products must not be dispensed to any person not included in the trial.
Trial product must not be used, if it does not appear clear and colourless.
9.1
Trial products
The following trial products will be provided by Novo Nordisk A/S, Denmark:
Table 9–1
Trial products
Trial product
Strength
Dosage form
Route of 
administration
Container/
delivery device
Faster aspart, 
(IMP), test product
100 U/ml 
Solution for 
injection
Subcutaneously
3 ml prefilled 
pen
Insulin aspart 
(NovoRapid®)
(IMP), reference therapy
Insulin degludec
(IMP), test product
100 U/ml
Solution for 
injection
Subcutaneously
3 ml prefilled 
pen
The following non-investigational medicinal products (NIMP) will not be provided by Novo 
Nordisk. However, they will be reimbursed if required according to local regulations.
!
Rapid acting insulin analogues (NovoRapid® or marketed formulations of insulin lispro or 
insulin glulisine) in the run-in period
!
Metformin, tablets for oral use
The comparator and active drug are visually identical.
9.2
Labelling
The trial products will be labelled in accordance with Annex 13 38, local regulations and trial 
requirements.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
60 of 112
Each trial site will be supplied with sufficient trial products for the trial on an on-going basis 
controlled by the IWRS. Trial product will be distributed to the trial sites according to enrolment 
and randomisation.
The investigator must document that direction for use is given to the subject orally and in writing at 
the first dispensing visit (Visit 2). Additionally, the pen differentiation guide must be provided to 
subjects at randomisation (Visit 14). Direction for use and pen differentiation guide can be provided 
as needed at the following dispensing visits.
9.3
Storage 
Table 9–2
Storage conditions
Trial product
Storage conditions
(not-in-use)
In-use conditions
In-use timea
Faster aspart
Store in refrigerator
(2°C – 8°C)
Do not freeze
Protect from light
Store below 30°C
Do not refrigerate
Do not freeze
Protect from light
Use within 4 
weeks
Insulin aspart
(NovoRapid®)
Insulin degludec 
Store in refrigerator
(2°C – 8°C)
Do not freeze
Protect from light
Do not store above 30°C
Protect from light
Can be stored in refrigerator 
(2°C – 8°C)
Do not freeze
Use within 8
weeks
a In-use time starts when first dose is taken
The investigator must ensure that trial product is kept under proper storage conditions and record 
and evaluate the temperature. The investigator must inform Novo Nordisk immediately if any trial 
product has been stored outside specified conditions (e.g. outside temperature range). Additional 
details regarding handling of temperature deviations can be found in the TMM.
Trial product that has been stored improperly must not be dispensed to any subject before it has 
been evaluated and approved for further use by Novo Nordisk. The investigator must take 
appropriate action to ensure correct storage.
9.4
Drug accountability and destruction
Drug accountability of all trial products received at site is the responsibility of the investigator.
Returned trial product (used/partly used and/or unused), expired or damaged trial product can be 
stored at room temperature and must be stored separately from non-allocated trial product.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
61 of 112
Non-allocated trial products (expired, damaged and available) must be accounted as unused at the 
latest at closure of the trial site.
Subjects are instructed to return all used, partly used and unused trial product at each dispensing 
visit after Visit 2. Please refer to the flowchart (section 2) for timing of the dispensing visits.
Destruction of trial products can be performed on an on-going basis and will be done according to 
local procedures after accountability is finalised and reconciled by the monitor in the IWRS. 
Destruction of products must be documented in the IWRS.
9.5
Auxiliary supplies
The following will be provided by Novo Nordisk:
!
Direction for use for the prefilled pens
!
Novo Nordisk needles
!
Standardised liquid meal (for the meal test)
!
BG meter and strips, lancets and control solution for BG meter
Only needles provided by Novo Nordisk must be used for administration of trial product.
Please refer to the TMM for further auxiliary details.
10
Interactive voice/web response system
A trial-specific IWRS will be set up which can be accessed at any time via the internet or telephone. 
Access to the IWRS must be restricted to and controlled by authorised persons. 
IWRS is used for:
!
Medication arrival
!
Screening
!
Screening failure
!
Run-in dispensing
!
Run-in failure
!
Randomisation
!
Dispensing
!
Dispensing Verification (when barcode scanner is used)
!
Treatment discontinuation 
!
Completion
!
Code break
!
Drug accountability
!
Data change
IWRS user manuals will be provided to each trial site.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
62 of 112
11 Randomisation procedure and breaking of blinded codes
At randomisation (Visit 14) the subject will be randomised to either faster aspart or NovoRapid®, 
both in combination with once daily insulin degludec with or without metformin.
The randomisation will be carried out in a 1:1 manner to the 2 different treatment possibilities 
described below using the IWRS:
!
Faster aspart and insulin degludec with or without metformin
!
NovoRapid® and insulin degludec with or without metformin
The investigator, subject and sponsor will be blinded to the bolus treatment.
11.1
Breaking of blinded codes
The IWRSwill notify Novo Nordisk (monitor and the Global Safety department) immediately after 
the code is broken.
The code for a particular subject may be broken in a medical emergency if knowing the actual 
treatment would influence the treatment of the subject. Whenever a code is broken the person 
breaking the code must print the Code Break Confirmation Notification generated by the IWRS, 
record the reason, and sign and date the document.
When the code is broken, the treatment allocation will be accessible to the investigator and the 
Novo Nordisk Global Safety department.If IWRS is not accessible at the time of code break the 
IWRS helpdesk should be contacted. Contact details are listed in Attachment I.
If the code has been brokenby investigator, the subject must discontinue treatment with trial 
product and a treatment discontinuation session must be completed in IWRS.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
63 of 112
12 Adverse events, technical complaints and pregnancies
12.1
Definitions
12.1.1
Adverse event 
An adverse event (AE) is any untoward medical occurrence in a subject administered a medicinal 
product, and which does not necessarily have a causal relationship with this treatment. 
An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory 
finding), symptom or disease temporally associated with the use of a product, whether or not 
considered related to the product. 
An AE includes:
!
A clinically significant worsening of a concomitant illness.
!
A clinical laboratory AE (CLAE): a clinical laboratory abnormality which is clinically 
significant, i.e. an abnormality that suggests a disease and/or organ toxicity and is of a 
severity that requires active management. Active management includes active treatment or 
further investigations, for example change of medicine dose or more frequent follow -up due 
to the abnormality.
The following should not be reported as AEs:
!
Pre-existing conditions, including those found as a result of screening or other trial 
procedures performed before exposure to trial product (pre-existing conditions should be 
reported as medical history or concomitant illness).
!
Pre-planned procedures unless the condition for which the procedure was planned has 
worsened from the first trial related activity after the subject has signed the informed 
consent.
!
Non-serious hypoglycaemia is an AE, but is reported on a hypoglycaemic episode form 
instead of on an AE form, see Section 8.4.2.
The following three definitions are used when assessing an AE:
!
Severity 
–
Mild – no or transient symptoms, no interference with the subject’s daily activities.
–
Moderate – marked symptoms, moderate interference with the subject’s daily activities.
–
Severe – considerable interference with the subject’s daily activities; unacceptable.
!
Causality 
Relationship between an AE and the relevant trial product(s): 
–
Probable - Good reason and sufficient documentation to assume a causal relationship.
–
Possible - A causal relationship is conceivable and cannot be dismissed.
–
Unlikely - The event is most likely related to aetiology other than the trial product.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
64 of 112
•
Final outcome
–
Recovered/resolved - The subject has fully recovered, or by medical or surgical treatment 
the condition has returned to the level observed at the first trial-related activity after the 
subject signed the informed consent.
–
Recovering/resolving - The condition is improving and the subject is expected to recover 
from the event. This term is only applicable if the subject has completed the trial or has died 
from another AE.
–
Recovered/resolved with sequelae - The subject has recovered from the condition, but 
with lasting effect due to a disease, injury, treatment or procedure. If a sequela meets an 
SAE criterion, the AE must be reported as an SAE.
–
Not recovered/not resolved - The condition of the subject has not improved and the 
symptoms are unchanged, or the outcome is not known.
–
Fatal - This term is only applicable if the subject died from a condition related to the 
reported AE. Outcomes of other reported AEs in a subject before he/she died should be 
assessed as “recovered/resolved”, “recovering/resolving”, “recovered/resolved with 
sequelae” or “not recovered/not resolved”. An AE with fatal outcome must be reported as 
an SAE.
–
Unknown - This term is only applicable if the subject is lost to follow-up.
12.1.2
Serious adverse event
A serious adverse event (SAE) is an experience that at any dose results in any of the following:
!
Death.
!
A life-threateninga experience.
!
In-patient hospitalisationb or prolongation of existing hospitalisation.
!
A persistent or significant disability or incapacityc.
!
A congenital anomaly or birth defect.
!
Important medical events that may not result in death, be life threateninga or require 
hospitalisationb may be considered an SAE when - based on appropriate medical judgement 
- they may jeopardise the subject and may require medical or surgical intervention to 
prevent one of the outcomes listed in the definition of SAEd. 
a. The term “life threatening” in the definition of SAE refers to an event in which the subject was at 
risk of death at the time of the event. It does not refer to an event which hypothetically might have 
caused death if it was more severe.
b. The term “hospitalisation” is used when a subject: 
–
Is admitted to a hospital or in-patient, irrespective of the duration of physical stay, or 
–
Stays at the hospital for treatment or observation for more than 24 hours.
Medical judgement must always be exercised, and when in doubt, the hospital contact should be 
regarded as a hospitalisation. Hospitalisations for administrative, trial related and social purposes do 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
65 of 112
not constitute AEs and should therefore not be reported as AEs or SAEs. Hospital admissions for 
surgical procedures, planned before trial inclusion, are not considered AEs or SAEs.
c. A substantial disruption of a subject’s ability to conduct normal life functions (e.g. following the 
event or clinical investigation the subject has significant, persistent or permanent change, 
impairment, damage or disruption in his/her body function or structure, physical activity and/or 
quality of life).
d. For example intensive treatment in an emergency room or at home of allergic bronchospasm, 
blood dyscrasia or convulsions that do not result in hospitalisation, or development of drug 
dependency or drug abuse.
The following AEs must always be reported as an SAE using the important medical event criterion 
if no other seriousness criteria are applicable:
!
suspicion of transmission of infectious agents via the trial product 
!
risk of liver injury defined as ALT or AST >3 x UNL and total bilirubin >2 x UNL, where 
no alternative aetiology exists (Hy's law).
12.1.3
Non-serious adverse event
A non-serious AE is any AE which does not fulfil the definition of an SAE.
12.1.4
Medication errors
A medication error concerning trial products is defined as:
!
Administration of wrong drug. 
Note: Use of wrong dispensing unit number (DUN) is not considered a medication error unless 
it results in administration of wrong drug.
!
Wrong route of administration, such as intramuscular instead of subcutaneous.
!
Administration of an overdose with the intention to cause harm (e.g. suicide attempt), 
misuse or abuse of trial product.
!
Accidental administration of a lower or higher dose than intended. The administered dose 
must deviate from the intended dose to an extent where clinical consequences for the trial 
subject were likely to happen as judged by the investigator, although they did not 
necessarily occur.
Medication errors must be reported on an AE form and a specific event form, see Section 8.4.1.1.
12.1.5
Adverse events requiring additional data collection
AEs requiring additional data collection are AEs where the additional data will benefit the 
evaluation of the safety of the trial product.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
66 of 112
In this trial the following AEs require the completion of specific event forms in the eCRF
!
Injection site reaction
For details, see Section 8.4.1.2.
12.1.6
Technical complaints
A technical complaint is any written, electronic, or oral communication that alleges product 
(medicine or device) defects. The technical complaint may be associated with an AE, but does not 
concern the AE itself.
Examples of technical complaints:
!
The physical or chemical appearance of trial products (e.g. discoloration, particles or 
contamination)
!
All packaging material including labelling
!
Problems related to devices (e.g. to the injection mechanism, dose setting mechanism, push 
button or interface between the pen and the needle)  
12.2
Reporting of adverse events
All events meeting the definition of an AE must be collected and reported. This includes events 
from the first trial-related activity after the subject has signed the informed consent until the end of 
the post-treatment follow-up period (FU2). For subjects discontinuing trial products prematurely 
this also includes events after the post-treatment follow-up period until the last contact (Visit 30). 
The events must be recorded in the applicable eCRF forms in a timely manner, see timelines below 
and Figure 12–1. 
During each contact with the trial site staff, the subject must be asked about AEs and technical 
complaints, for example by asking: “Have you experienced any problems since the last contact?”
All AEs, either observed by the investigator or subject, must be reported by the investigator and 
evaluated.
All AEs must be recorded by the investigator on an AE form. The investigator should report the 
diagnosis, if available. If no diagnosis is available, the investigator should record each sign and 
symptom as individual AEs using separate AE forms.
For SAEs, a safety information form must be completed in addition to the AE form. If several 
symptoms or diagnoses occur as part of the same clinical picture, one safety information form can 
be used to describe all the SAEs. 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
67 of 112
For all non-serious AEs, the applicable forms should be signed when the event is resolved or at the 
end of the trial at the latest.
Timelines for initial reporting of AEs:
The investigator must complete the following forms in the eCRF within the specified timelines:
!
SAEs: The AE form within 24 hours and the safety information form within 5 calendar
days of the investigator’s first knowledge of the SAE. Both forms must be signed within 7 
calendar days from the date the information was entered in the eCRF. 
For SAEs requiring reporting on a specific event form: In addition to the above the 
specific event form within 14 calendar days from the investigator’s first knowledge of the 
AE.
If the eCRF is unavailable, the concerned AE information must be reported on a paper AE form and 
sent to Novo Nordisk by fax, e-mail or courier within the same timelines as stated above. When the 
eCRF becomes available again, the investigator must enter the information on the form into the 
eCRF.
Contact details (fax, telephone, e-mail and address) are provided in the investigator trial master file. 
AE identified
Does the AE require 
a specific event 
form?
AE form < 24 hours
SIF < 5 calendar days
Specific event form 
For SAEs: 
< 14 calendar days
Is the Adverse Event 
serious or non-
serious?
AE form
Non-serious
Serious
No
Yes
Queries and follow-up 
requests to be resolved 
< 14 calendar days
Timelines are for the completion of forms from the time of investigator’s awareness.
AEs requiring specific event forms are descibed in Section 12.1.4 and 12.1.5.
No additional action
AE: Adverse Event   SIF: Safety Information form
Figure 12–1
Reporting of AEs 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
68 of 112
Novo Nordisk assessment of AE expectedness: 
Novo Nordisk assessment of expectedness is performed according to the following reference 
documents:
!
Faster aspart IB22 current version and any updates thereto.
!
Insulin degludec Company Core Data Sheet current version and any updates thereto.
!
NovoRapid®, Company Core Data Sheet current version and any updates thereto.
Reporting of trial product-related SUSARs by Novo Nordisk:
Novo Nordisk will notify the investigator of trial product-related suspected unexpected serious 
adverse reactions (SUSARs) in accordance with local requirements and ICH GCP.1 In addition, the 
investigator will be informed of any trial-related SAEs that may warrant a change in any trial 
procedure.
In accordance with regulatory requirements, Novo Nordisk will inform the regulatory authorities, 
including EMA, of trial product-related SUSARs. In addition, Novo Nordisk will inform the 
IRBs/IECs of trial product-related SUSARs in accordance with local requirement and ICH GCP1, 
unless locally this is an obligation of the investigator.
Novo Nordisk and non-Novo Nordisk products used as concomitant medication or non-
investigational medicinal product:
If an AE is considered to have a causal relationship with a non-Novo Nordisk and Novo Nordisk 
marketed product used as NIMP (NovoRapid® in run-in period) and metformin or concomitant 
medication in the trial, it is important that the suspected relationship is reported to Novo Nordisk, 
e.g. in the alternative aetiology section on the safety information form. Novo Nordisk may need to 
report this AE to relevant regulatory authorities.
12.3
Follow-up of adverse events
The investigator must record follow-up information by updating the forms in the eCRF. 
Follow-up information must be reported to Novo Nordisk according to the following:
!
SAEs: All SAEs must be followed until the outcome of the event is “recovered/resolved”, 
“recovered/resolved with sequelae” or “fatal”, and until all queries have been resolved. 
Cases of chronic conditions, cancer or AEs ongoing at time of death (where death is due to 
another AE) may be closed with the outcome “recovering/resolving” or “not recovered/not 
resolved”. Cases can be closed with the outcome of “recovering/resolving” when the subject 
has completed the follow-up period and is expected by the investigator to recover.
The SAE follow-up information should only include new (e.g. corrections or additional) 
information and must be reported within 24 hours of the investigator’s first knowledge of the 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
69 of 112
information. This is also the case for previously non-serious AEs which subsequently become 
SAEs. 
!
Non-serious AEs: Non-serious AEs must be followed until the outcome of the event is 
“recovering/resolving”, “recovered/resolved” or “recovered/resolved with sequelae” or until 
the end of the follow-up period stated in the protocol, whichever comes first, and until all 
queries related to these AEs have been resolved. Cases of chronic conditions, cancer or AEs 
ongoing at time of death (where death is due to another AE) may be closed with the 
outcome “recovering/resolving” or “not recovered/not resolved”. Cases can be closed with 
the outcome of “recovering/resolving” when the subject has completed the follow -up period 
and is expected by the investigator to recover.
The investigator must ensure that the recording of the worst case severity and seriousness of an 
event is kept throughout the trial. A worsening of an unresolved AE must be reported as follow up 
with re-assessment of severity and/or seriousness of the event.
Queries or follow-up requests from Novo Nordisk must be responded to within 14 calendar days
from the date of receipt of the request, unless otherwise specified in the follow-up request.
SAEs after end of trial: If the investigator becomes aware of an SAE with a suspected causal 
relationship to the IMP occurring to a subject after the subject has ended the trial, the investigator 
should report this SAE within the same timelines as for SAEs during the trial. 
12.4
Technical complaints and technical complaint samples
12.4.1
Reporting of technical complaints
For Novo Nordisk Products
All technical complaints on any of the following products:
!
Faster aspart, 100 U/mL solution for subcutaneous injection, 3 mL PDS290 pen injector 
(blinded)
!
NovoRapid®, 100 U/mL solution for subcutaneous injection, 3 mL PDS290 pen injector 
(blinded)
!
Insulin degludec, 100U/mL solution for subcutaneous injection, 3 mL PDS290 pen injector 
(open)
!
Novo Nordisk Needles
which occur from the time of first usage of the product until the time of the last usage of the 
product, must be collected and reported to Customer Complaint Center, Novo Nordisk.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
70 of 112
Contact details (fax, e-mail and address) are provided in Attachment I to the protocol.
The investigator must assess whether the technical complaint is related to any AEsand/or SAEs.
Technical complaints must be reported ona separate technical complaint form:
!
One technical complaint form must be completed for each affected DUN
!
If DUN is not available, a technical complaint form for each batch, code or lot number must
be completed
The investigator must complete the technical complaint form in the eCRF within the following 
timelines of the trial site obtaining knowledge of the technical complaint:
!
Technical complaint assessed as related to an SAE within 24 hours
!
All other technical complaints within 5 calendar days
If the eCRF is unavailable or when reporting a technical complaint that is not subject related, the 
information must be provided on a paper form by fax, e-mail or courier to Customer Complaint 
Center, Novo Nordisk, within the same timelines as stated above. When the eCRF becomes 
available again, the investigator must enter the information on the technical complaint form in the 
eCRF.
Only technical complaints related to AEs will be reported in the clinical trial report.
12.4.2
Collection, storage and shipment of technical complaint samples
For Novo Nordisk Products
The investigator must collect the technical complaint sample and notify the monitor within 5 
calendar days of obtaining the sample at trial site. The monitor must coordinate the shipment to 
Customer Complaint Center, Novo Nordisk (the address is provided in Attachment I) and ensure 
that the sample is sent as soon as possible. A copyof the technical complaint form must be included 
in the shipment of the sample. If several samples are returned in one shipment, the individual 
sample and the corresponding technical complaint form must be clearly separated.
The investigator must ensure that the technical complaint sample contains the batch, code or lot 
number and, if available, the DUN. All parts of the DUN should be returned.
If the technical complaint sample is unobtainable, the investigator must specify on the technical 
complaint form why it is unobtainable. 
Storage of the technical complaint sample must be done in accordance with the conditions 
prescribed for the product.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
71 of 112
12.5
Pregnancies in female subjects 
Female subjects must be instructed to notify the investigator immediately if they become pregnant 
during the trial. The investigator must report any pregnancy in subjects who have received trial 
product(s).
The investigator must follow the pregnancy until the pregnancy outcome and the newborn infant is 
one month of age.
The investigator must report information about the pregnancy, pregnancy outcome, and health of 
the newborn infant(s), as well as AEs in connection with the pregnancy, and AEs in the foetus and 
newborn infant.
The following must be collected and reported by the investigator to Novo Nordisk electronically 
(e.g. in PDF format), or by fax or courier:
1. Reporting of pregnancy information
Information about the pregnancy and pregnancy outcome/health of the newborn infant(s) has to 
be reported on Maternal Form 1A and 1B, respectively.
When the pregnancy outcome is abnormal (i.e. congenital anomalies, foetal death including 
spontaneous abortion and/or any anomalies of the foetus observed at gross examination or 
during autopsy), and/or when a congenital anomaly is diagnosed within the first month, further 
information has to be reported for the female subject on Maternal Form 2. In addition, 
information from the male partner has to be reported on the Paternal Form, after an informed 
consent has been obtained from the male partner.
Initial reporting and follow-up information must be reported within 14 calendar days of the 
investigator’s first knowledge of initial or follow-up information.
2. Reporting of AE information
The investigator has to report AEs in connection with the pregnancy as well as in the foetus and 
newborn infant(s). The SAEs that must be reported include abnormal outcome, such as foetal 
death (including spontaneous abortion), and congenital anomalies (including those observed at 
gross examination or during autopsy of the foetus), as well as other pregnancy complications 
fulfilling the criteria of an SAE.
Forms and timelines for reporting AEs:
Non-serious AEs: 
!
AE forma within 14 calendar days of the investigator’s first knowledge of the initial or 
follow-up information to the non-serious AE.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
72 of 112
SAEs: 
!
AE forma within 24 hours of the investigator’s first knowledge of the SAE.
!
Safety information form within 5 calendar days of the investigator’s first knowledge of the 
SAE.
!
SAE follow-up information to the AE form and/or safety information form within 24 
hours of the investigator’s first knowledge of the follow-up information.
a 
It must be clearly stated in the AE diagnosis field on the AE form if the event occurred in 
the subject, foetus or newborn infant. If the AE occurred in the foetus or newborn infant, the AE 
can only be reported on paper AE and safety information form.
Any queries or follow-up requests from Novo Nordisk to non-serious AEs, SAEs and pregnancy 
forms must be responded to by the investigator within 14 calendar days from the date of receipt of 
the request, unless otherwise specified in the follow-up request.
12.6
Precautions and/or overdose
During treatment with insulin, there is a risk of hypoglycaemia (see section 8.4.2). Symptoms of 
hypoglycaemia usually occur suddenly and may include cold sweat, nervousness or tremor, anxious 
feelings, unusual tiredness, confusion, difficulty in concentration, excessive hunger, temporary 
vision changes, headache, nausea, and palpitation. Prolonged or severe hypoglycaemia can lead to a 
loss of self-control, spasms, and/or unconsciousness and, in extreme cases, death.
Asymptomatic hypoglycaemia and symptoms of hypoglycaemia should be treated with 
carbohydrates. Mild to moderate symptoms can be treated by ingestion of carbohydrate (for 
example, juice). Severe hypoglycaemia resulting in the loss of consciousness should be treated with 
parenteral glucose, glucagon or dextrose.
For further details, please refer to the current version of faster aspart IB22, Insulin degludec IB24 and 
for NovoRapid®, please refer to the current versions of the SmPC19 or U.S. Novolog® Label 
Information.20
12.7
Committees related to safety
12.7.1
Novo Nordisk safety committee
Novo Nordisk will constitute an internal faster aspart safety committee to perform ongoing safety 
surveillance. The faster aspart safety committee may recommend unblinding of any data for further 
analysis, and in this case an independent ad hoc group will be established in order to maintain the
blinding of the trial personnel.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
73 of 112
13 Case report forms 
Novo Nordisk will provide a system for the eCRF. This system and support services to the system 
will be provided by an external supplier.
Ensure that all relevant questions are answered, and that no empty data field exists. If a test or an 
assessment has not been done and will not be available, or if the question is irrelevant (e.g. is not 
applicable), indicate this according to the data entry instructions.
The following will be provided as paper case report forms (CRFs):
!
Pregnancy forms
The following will be provided as paper CRFs to be used when access to the eCRF is revoked or if 
the eCRF is unavailable:
!
AE forms 
!
Safety information forms
!
Technical complaint forms (also to be used to report complaints that are not subject related 
(e.g. discovered at trial site before allocation)
On the paper CRF forms print legibly, using a ballpoint pen. Ensure that all questions are answered, 
and that no empty data blocks exist. Ensure that no information is recorded outside the data blocks. 
If a test/assessment has not been done and will not be available, indicate this by writing “ND” (not 
done) in the appropriate answer field in the CRF. If the question is irrelevant (e.g. is not applicable) 
indicate this by writing “NA” (not applicable) in the appropriate answer field. Further guidance can 
be obtained from the instructions in the CRF.
The investigator must ensure that all information is consistent with the source documentation. By 
electronically signing the case book in the eCRF, the investigator confirms that the information in 
the eCRF and related forms is complete and correct.
13.1
Corrections to case report forms 
Corrections to the eCRF data may be made by the investigator or the investigator’s delegated staff. 
An audit trail will be maintained in the eCRF application containing as a minimum: the old and the 
new data, identification of the person entering the data, date and time of the entry and reason for the 
correction.
If corrections are made by the investigator’s delegated staff after the date the investigator has signed 
the case book, the case book must be signed and dated again by the investigator.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
74 of 112
13.2
Case report form flow 
The investigator must ensure that data is recorded in the eCRF as soon as possible, preferably 
within 5 days after the visit. Once data has been entered, it will be available to Novo Nordisk for 
data verification and validation purposes. The SMPG values and corresponding insulin doses for 
titration purposes should be entered within 24 hours on week days after the site visit/telephone 
contact throughout the trial.
Site specific eCRF data (in an electronic readable format) will be provided to the trial site before 
access to the eCRF is revoked. This data must be retained at the trial site.
14 Monitoring procedures
Monitoring will be conducted using a risk based approach including risk assessment, monitoring 
plans, centralised monitoring and visits to trial sites. During the course of the trial, the monitor will 
visit the trial site to ensure that the protocol is adhered to, that all issues have been recorded, to 
perform source data verification and to monitor drug accountability. The first monitoring visit will 
be performed as soon as possible after first patient first visit at the trial site and no later than 4 
weeks after. The monitoring visit intervals will depend on the outcome of the centralised
monitoring of the eCRFs (remote assessment of data by Novo Nordisk), the trial site's recruitment 
rate and the compliance of the trial site to the protocol and GCP, but will not exceed 12 weeks until 
LPLV at the trial site.
The monitor must be given direct access to all source documents (original documents, data and 
records). Direct access includes permission to examine, analyse, verify and reproduce any record(s) 
and report(s) that are important to the evaluation of the trial. If the electronic medical record does 
not have a visible audit trail, the investigator must provide the monitor with signed and dated 
printouts. In addition the relevant trial site staff should be available for discussions at monitoring 
visits and between monitoring visits (e.g. by telephone).
All data must be verifiable in source documentation other than the eCRF.
Data collected prior to the discontinuation of the glycaemic data collection system (the combined 
use of the MyGlucoHealth BG-meter and an electronic diary):
Data entered by the subject in the eDiary device will be recorded directly in the device. All data 
entered in the eDiary device will be automatically transferred to a database, where it is kept as a 
certified copy of the source data. Data entered in the device will upon confirmation of a successful 
back-up be deleted from the device. Hence the certified copy in the database is regarded as source 
data. For data entered by the investigator through the webportal the source documentation can be 
the medical records but if entered directly into the webportal, the database is regarded as source 
data. For all data recorded the source document must be defined in a source document agreement at 
each trial site. There must only be one source defined at any time for any data element.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
75 of 112
Source data generated by the trial site can be corrected by another person than the person entering 
the source data if accepted by local regulations; any correction must be explained, signed and dated 
by the person making the correction.
The monitor will ensure that the eCRFs are completed and that paper CRFs are collected.
The following data will be source data verified for screening failures: 
!
Date for obtaining informed consent. 
!
Screen failure date and reason
!
Date of visit
!
Demography (date of birth, sex and race (according to local regulation))
!
Eligibility criteria
!
SAE
Monitors will review the subject’s medical records and other source data to ensure consistency 
and/or identify omissions compared to the eCRF. If discrepancies are found, the investigator must 
be questioned about these.
15 Data management
Data management is the responsibility of Novo Nordisk. Data management may be delegated under 
an agreement of transfer of responsibilities to a contract research organisation (CRO).
Appropriate measures, including encryption of data files containing person identifiable data, will be 
used to ensure confidentiality of subject data, when they are transmitted over open networks.
Data from central laboratories will be transferred electronically. In cases where data is transferred 
via non-secure electronic networks, data will be encrypted during transfer.
The subject and any biological material obtained from the subject will be identified by subject 
number and trial ID. Appropriate measures such as encryption or leaving out certain identifiers will 
be enforced to protect the identity of subjects in all presentations and publications as required by 
local, regional and national requirements.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
76 of 112
16 Computerised systems
Novo Nordisk will capture and process clinical data using computerised systems that are described 
in Novo Nordisk Standard Operating Procedures and IT architecture documentation. The use and 
control of these systems are documented.
Investigators working on the trial may use their own electronic systems to capture source data.
Data collected prior to the discontinuation of the glycaemic data collection system (the combined 
use of the MyGlucoHealth BG-meter and an electronic diary):
The eDiary software and hardware implementation are compliant with the requirements of FDA 21 
CFR Part 11 and ICH E6 (EU directive for personal data protection). After trial finalisation, each 
site will be supplied with long-life DVDs. These DVDs will contain site-specific subject records 
including the subject’s eDiary data and audit trail as well as any data additions and corrections 
made on each form. The eDiary vendor will furthermore retain and securely store copies of all 
archived documents and data for 50 years or as required by local data retention laws for trial data. 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
77 of 112
17 Statistical considerations
If necessary, a statistical analysis plan may be written in addition to the protocol, including a more 
technical and detailed elaboration of the statistical analyses. The statistical analysis plan will be 
finalised before database lock.
General considerations
In general, for endpoints evaluated as a change from baseline and/or where a baseline adjustment is 
made, baseline is defined as information collected at randomisation (Visit 14). In case a 
measurement is not available at randomisation, the most recent measurement prior to randomisation 
will be used as baseline. 
Two observation periods are defined, “in-trial” and “on-treatment”, and it will be specified which 
period each analysis will use.
!
In-trial: The observation period from date of randomisation and until last trial -related 
subject-site contact. The in-trial observation period includes data collected after treatment 
discontinuation.
!
On-treatment: The observation period from date of first dose of randomised 
NovoRapid®/faster aspart and to 7 days after the first occurrence of:
o
The day of last dose of randomised NovoRapid ®/faster aspart
o
The day before initiation of ancillary treatment
All efficacy endpoints will be summarised and analysed using the full analysis set (FAS), unless 
otherwise stated. Safety endpoints will be summarised using the safety analysis set and analysed 
using the FAS. The FAS is defined in section 17.2.
Presentation of results from a statistical analysis will include the estimated mean treatment effects 
(LSMeans) for change from baseline, if applicable. Estimated mean treatment differences (or ratios) 
will be presented together with two-sided 95% confidence interval (CI) for all endpoints analysed 
statistically. 
Data collected before randomisation (Visit 14) will only be summarised descriptively.
The primary objective of the trial is to confirm the effect of treatment with faster aspart compared to 
NovoRapid®, both in combination with insulin degludec with or without metformin in adults with 
T2DM in terms of glycaemic control, using a non-inferiority approach. 
More specifically the upper limit of the 95% confidence interval for the difference between faster
aspart and NovoRapid® should be compared to a non-inferiority margin of 0.4%. If it is below or 
equal to 0.4% non-inferiority will be considered established and effect demonstrated. 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
78 of 112
The trial also aims to confirm superiority of treatment with faster aspart for a number of secondary 
confirmatory endpoints. The family-wise type I error rate will be controlled in the strong sense 
using a hierarchical (fixed sequence) testing procedure. This is based on a priority ordering of the 
null-hypotheses, and testing them in this order using the two-sided 95% confidence interval 
approach until an insignificant result appears. The effect is that rejection of a null hypothesis only 
will be considered for analyses where all previous null-hypotheses have been rejected in favour of 
faster aspart. 
The steps in the hierarchical testing procedure are as follows:
Step 1 (Primary analysis):  HbA1c non-inferiority of faster aspart versus NovoRapid®
Step 2: 1-hour PPG increment (meal test) superiority of faster aspart versus NovoRapid®
Step 3: HbA1c superiority of faster aspart versus NovoRapid®
Step 4: 1,5-anhydroglucitol superiority of faster aspart versus NovoRapid®
Estimands
Primary estimand
The primary estimand is defined as the treatment difference between subjects randomised to faster
aspart and NovoRapid® both in combination with insulin degludec with or without metformin, in 
adults with T2DM not optimally controlled with a basal-bolus regimen assessed by change from 
baseline in HbA1c 16 weeks after randomisation for all randomised subjects regardless of treatment 
discontinuation or use of ancillary treatment.  
The primary estimand assesses the expected benefit a future population with T2DM can achieve if 
prescribed to faster aspart as compared to NovoRapid®. By not putting any restrictions on the 
treatment adherence, this estimand aims at a difference as close as possible to the one that can be 
expected in real-world clinical practice, provided that the treatment adherence and use of ancillary 
treatment reflects clinical practice. Thereby the primary estimand provides a treatment difference 
for clinicians concerning the glycaemic effect of faster aspart compared to NovoRapid® in the day 
to day life in subjects with T2DM in an adult population.
Secondary estimand
A secondary estimand is defined as the treatment difference in change from baseline in HbA1c 16 
weeks after randomisation between treatment with faster aspart and treatment with NovoRapid®
both in combination with insulin degludec with or without metformin in adult subjects with T2DM
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
79 of 112
not optimally controlled with a basal-bolus regimen if all subjects had adhered to randomised 
treatment and did not receive ancillary treatment.  
The condition ‘adhered to randomised treatment and did not receive ancillary treatment’ should be 
interpreted as the exclusion of information collected after initiation of antidiabetic treatment that 
can mask or exaggerate the effect of the initially randomised treatment. Only data collected prior to 
discontinuation of trial product or initiation of ancillary treatment is used to draw inference. This 
avoids confounding effects of ancillary treatment.
The two estimands will be repeated for the confirmatory endpoints
!
Change from baseline in 1-hour PPG increment (meal test) 16 weeks after randomisation
!
Change from baseline in 1,5-anhydroglucitol 16 weeks after randomisation
17.1
Sample size calculation
The sample size is determined to ensure a sufficient power for step 1 and step 2 in the hierarchical 
testing procedure for the primary estimand presented in section 17. The power for step 3 and 4 in 
the hierarchical testing procedure will also be presented. The sample size is determined using a non-
inferiority limit of 0.4% in step 1, which was chosen as described in section 5.2.1. The statistical 
evaluation will be done as described in section 17.3.
In previous confirmatory trials where faster aspart has been investigated, the completion rates have 
been high. Therefore it will be expected that treatment discontinuation might be as low as 10% 
where trial discontinuation constitutes half of these and with similar withdrawal reasons in the 
treatment arms.
Power for the non-inferiority step (Step 1) is based on a t-statistic under the assumption of a one-
sided test of size 2.5% for the FAS. A mean treatment difference of -0.1% for the comparison 
between faster aspart and NovoRapid® in favour of faster aspart is expected. As trials in this 
population where data from treatment withdrawn subjects is retrieved is limited, a conservative 
estimate of the standard deviation (SD) in change from baseline in HbA1c of 0.8% was chosen. The 
power for superiority in step 3 will be calculated using the same assumptions as for step 1 but 
without the non-inferiority margin. 
For determination of power in step 2 in the hierarchical testing, where change from baseline in 1-
hour PPG increment 16 weeks after randomisation is compared between faster aspart and 
NovoRapid® a t-statistic with a two-sided test of size 5% is used, where the treatment difference is 
expected to be at least 0.6 mmol/L [11 mg/dL]. The SD=3.5 mmol/L [63 mg/dL] in change from 
baseline in 1-hour PPG increments 16 weeks after randomisation based on laboratory analysed PG 
in a standardised meal test will be considered reasonable based on trials NN1218-3852 and 
NN1218-3853.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
80 of 112
The power in step 4, where superiority of faster aspart over NovoRapid® in change from baseline in 
1,5-anhydroglucitol 16 weeks after randomisation is tested a t-statistic with a two-sided test of size 
5% is used. The mean treatment difference is expected to be at least 0.2 μg/mL and an SD of 
3.5μg/mL will be used based on trials NN1218-3852 and NN1218-3853.
The power calculations are done using proc power in SAS 9.4. Please refer to Table 17–1 for 
assumptions for the sample size calculation.
Table 17–1
Specifications assumed for sample size calculations
Statistical 
test
Significance 
level
Analysis 
population
Non-inferiority 
margin
SD
Mean 
difference
Randomisation 
scheme
Step 1 2-group t-test
One-sided 2.5 % FAS
0.4 % (absolute)
0.8 %
-0.1 %
1:1
Step 2 2-group t-test
Two-sided 5.0% FAS
NA
3.5 mmol/L
0.6 mmol/L
1:1
Step 3 2-group t-test
Two-sided 5.0% FAS
NA
0.8 %
-0.1 %
1:1
Step 4 2-group t-test
Two-sided 5.0% FAS
NA
3.5 μg/mL
0.2 μg/mL
1:1
In Table 17–2 the sensitivity of the sample size to the power shown for three different sizes of FAS. 
Three different choices of the mean difference are used to calculate the power in step 2.
Table 17–2
Sensitivity of sample size to power
N 
total
N 
per 
arm
Step 
1
Step 2
Step 
3
Step 4
FAS FAS Mean 
diff
(%)
SD
(%)
Power 
(%)
Mean 
diff
(mmol/L)
SD
(mmol/L)
Power 
(%)
Mean 
diff
(%)
SD
(%)
Power 
(%)
Mean
diff
(μg/mL)
SD
(μg/mL)
Power 
(%)
-0.1
0.8
>99.9
0.5
3.5
58.1
-0.1
0.8
47.4
0.2
3.5
13.9
920
460
-0.1
0.8
>99.9
0.6
3.5
73.8
-0.1
0.8
47.4
0.2
3.5
13.9
-0.1
0.8
>99.9
0.7
3.5
85.8
-0.1
0.8
47.4
0.2
3.5
13.9
-0.1
0.8
>99.9
0.5
3.5
64.7
-0.1
0.8
53.4
0.2
3.5
15.5
1072
536
-0.1
0.8
>99.9
0.6
3.5
80.1
-0.1
0.8
53.4
0.2
3.5
15.5
-0.1
0.8
>99.9
0.7
3.5
90.5
-0.1
0.8
53.4
0.2
3.5
15.5
-0.1
0.8
>99.9
0.5
3.5
70.4
-0.1
0.8
58.9
0.2
3.5
17.0
1224
612
-0.1
0.8
>99.9
0.6
3.5
85.0
-0.1
0.8
58.9
0.2
3.5
17.0
-0.1
0.8
>99.9
0.7
3.5
93.8
-0.1
0.8
58.9
0.2
3.5
17.0
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
81 of 112
In conclusion, 1072 subjects in the FAS (536 subjects per group) will ensure a marginal power of 
>99.9% to show non-inferiority in step 1, given that the actual treatment difference is -0.1%, and a 
marginal power of 80.1% to show superiority in step 2, given that the actual treatment difference is 
0.6 mmol/L.
Assuming a screening failure rate of 30% and run-in failure rate of 15%, 1803 subjects should be 
screened for inclusion in the trial.
17.2
Definition of analysis sets
The following analysis sets are defined in accordance with the ICH-E9 guidance 39.
!
Full Analysis Set (FAS) includes all randomised subjects. In exceptional cases, randomised 
subjects may be excluded from the FAS. In such cases, the reason for exclusion will be 
justified and documented. Subjects in the FAS will contribute to the evaluation “as 
randomised”
!
Per Protocol (PP) Analysis Set includes all subjects in the FAS, excluding subjects who:
o
Have violated any inclusion criteria
o
Have fulfilled any exclusion criteria
Subjects in the PP analysis set will contribute to the evaluation “as treated” 
!
Safety Analysis Set includes all subjects receiving at least one dose of randomised 
treatment. Subjects in the safety analysis set will contribute to the evaluation “as treated”. 
Randomised subjects who are lost to follow-up, and where no exposure information of the trial 
product or its comparator is available after randomisation, will be handled as unexposed.
Before data are released for statistical review, a blinded review of all data will take place to identify 
serious non-adherence to the protocol that may potentially affect the results. Furthermore, extreme 
values and outliers will be identified by the statistician during programming and data review, 
according to ICH-E9.39 This will be performed by using a fake randomisation.
The subjects or observations to be excluded, and the reasons for their exclusion must be 
documented and signed by those responsible before database lock. The subjects and observations 
excluded from analysis sets, and the reason for this, will be described in the clinical trial report.
17.3
Primary endpoint
The primary endpoint is change from baseline in HbA1c 16 weeks after randomisation. 
Primary analysis:
1) The primary estimand will be addressed by the below primary analysis on all subjects 
included in the FAS and using the in-trial observation period. Note that if subjects withdraw 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
82 of 112
consent to contribute additional information or are completely lost to follow-up, missing data 
will occur. The primary analysis will be implemented as a statistical model using multiple 
imputations where the subjects without any available HbA1c measurements at scheduled 
visits will have their HbA1c value imputed from the available information from the treatment 
group the subject has been randomised to. Note that this resembles in essence a mixed model 
of repeated measurements analysis. Subjects without any post-randomisation measurements 
contribute to the analysis, as the missing values will be imputed. The analysis will be 
implemented as follows: 
!
In the first step, intermittent missing values are imputed using a Markov Chain 
Monte Carlo method, in order to obtain a monotone missing data pattern. This 
imputation is done for each group separately and 100 copies of the dataset will be 
generated. 
!
In the second step, for each of the 100 copies of the dataset, an analysis of variance 
model with region and metformin use at baseline (Yes/No) as factors and baseline 
HbA1c as covariate is fitted to the change in HbA1c from baseline to week 4 for each 
treatment group separately. The estimated parameters, and their variances, from 
these models are used to impute missing values at week 4 for subjects in each 
treatment group, based on region, metformin use at baseline (Yes/No) and baseline 
HbA1c.
!
In the third step, for each of the 100 copies of the dataset, missing values at week 8 
are imputed in the same way as for week 4. The imputations are based on an analysis
of variance model with region and metformin use at baseline (Yes/No) as factors and 
baseline HbA1c and change from baseline in HbA1c at week 4 as covariates.
!
This stepwise procedure is then repeated sequentially for week 12 and 16.
!
For each of the complete data sets, the change from baseline to week 16 is analysed 
using an analysis of variance model with treatment, region and metformin use at 
baseline (Yes/No) as factors, and baseline HbA1c as a covariate. 
!
The estimates and standard deviations for the 100 data sets are pooled to one 
estimate and associated standard deviation using Rubin’s formula:
m =
1
100
 m


CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
83 of 112
SD =  1
100
 SD



+ 1 + 1
100
1
100 −1
(m −m)


where mi and SDi are the estimated means and standard deviations for the 100 copies 
of the dataset, and mMI and SDMI are the pooled estimates.
!
From mMI  and  SDMI, the 95% confidence interval for the treatment differences is 
calculated. 
Non-inferiority of faster aspart will be considered confirmed if the upper boundary of the two-sided 
95% confidence interval is below or equal to 0.4% or equivalent if the p-value for the one-sided test 
of
H0: D > 0.4%    against   HA: D ≤ 0.4%
is less than or equal to 2.5%, where D is the mean treatment difference (faster aspart minus 
NovoRapid®).
Note that as the anticipated number of subjects discontinuing treatment, but not trial is low, multiple 
imputations based on such subjects is not expected to be suitable.
Provided that the hierarchical testing allows, the evaluation of superiority will be based on the same 
statistical model, as the primary analysis 1). The associated sensitivity analysis that follows will 
investigate the robustness of non-inferiority and superiority (analysis 3b and 3c) as well.
Sensitivity analysis for the primary analysis addressing the primary estimand
All sensitivity analyses for the primary analysis addressing the primary estimand will use the in-trial 
observation period.
2) First the primary analysis in 1) will be repeated, but excluding all factors except from 
treatment in the model. This analysis will explore the influence of the different factors.
3) The primary analysis approach chosen for this trial relies on the assumption that missing data 
is missing at random (MAR). This assumption implies that the HbA1c for subjects leaving the 
trial, after their withdrawal, develops in a similar way as the HbA 1c for similar subjects that 
remain in the trial (not necessarily on treatment) and had similar development of HbA1c
before withdrawal. The MAR assumption may be questionable for subjects withdrawing at 
own will. Therefore the statistical models using multiple imputation will be repeated with the 
following alteration:
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
84 of 112
a) Imputations will be done from the treatment arm that the subject was randomised to and 
a value of 0.4% (non-inferiority margin) is added to the change from baseline in HbA1c
at week 16 for subjects randomised to faster aspart who withdrew from the trial.40
b) Imputations will be done from the comparator arm (NovoRapid®). This will serve as a 
supplementary sensitivity analysis for the superiority analysis. It does not rely on the 
MAR assumption, but assumes that all subjects who withdraw from the trial in the faster
aspart arm shift to NovoRapid®. The imputation will be done conditional on observed 
information for subjects that withdraw from the faster aspart arm such that the treatment 
effect diminishes gradually after trial discontinuation (copy reference/conditional 
imputation). The analysis will use data from the in-trial observation period.
c) Imputation will be done from the comparator arm (NovoRapid ®). This will serve as a 
supplementary sensitivity analysis for the superiority analysis. It does not rely on the 
MAR assumption, but it is assumed that all subjects who withdraw from the trial in the 
faster aspart arm respond at week 16 as if they have been treated with NovoRapid® for 
the entire trial. That is, all collected post-randomisation data for subjects who withdraw 
from the trial in the faster aspart arm will be set to missing. The analysis will use data 
from the in-trial observation period.
Analyses addressing the secondary estimand
All analyses addressing the secondary estimand will use the on-treatment observation period.
4) The secondary estimand will be analysed using the same statistical model using multiple 
imputations as the primary analysis in 1) except using the on-treatment observation period. 
5) A tipping point analysis based on a statistical model using multiple imputation model similar 
to 1), using the on-treatment observation period, will be made. In this analysis observations 
for subjects that discontinue randomised treatment are imputed based on the treatment arm 
they were randomised to and subjects discontinuing treatment in the faster aspart group are 
given a penalty. This is done to investigate the robustness of the conclusion in the p rimary 
analysis with respect to the MAR assumption and mimics a scenario where the HbA1c of the 
subjects discontinuing treatment in the faster aspart groups evolve less favourably than 
predicted. As a first step imputations will be done without penalty assuming MAR in the 
treatment group. Second, the imputed values for week 16 in the faster aspart group will be 
added a penalty. This is done repeatedly, gradually increasing the penalty until the 
conclusion from the non-inferiority analysis no longer holds. This will serve as a sensitivity 
analysis for the non-inferiority analysis and the specific value of the penalty that changes the 
conclusion will be used to evaluate the robustness of the conclusion of the non-inferiority 
analysis.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
85 of 112
6) A tipping point analysis based on a statistical model using multiple imputation, similar to 5) 
but with the modification that subjects discontinuing treatment due to non-eligibility 
(Subjects discontinuing randomised treatment prematurely due to criteria 1, 2, 3, and 4, 
which are defined in section 6.6) in the faster aspart group will not have a penalty added. 
These analyses are motivated by the fact that data from subjects prematurely discontinuing 
randomised treatment due to non-eligibility can reasonably be assumed to be missing 
completely at random. 
7) The same statistical model using multiple imputations as the analysis in 4), but using the PP 
analysis set and analysed using the on-treatment observation period. This analysis will 
investigate the situation that subjects might have deviated from the inclusion and exclusion 
criteria and will serve as sensitivity analysis for the non-inferiority analysis.
17.4
Secondary endpoints
17.4.1
Confirmatory secondary endpoints 
If the effect of treatment with faster aspart can be confirmed in the primary analysis, the trial also 
aims to confirm effect of treatment with faster aspart for a number of secondary confirmatory 
endpoints using a hierarchical (fixed sequence) testing procedure as described in section 17
(General consideration). This is based on a priority ordering of the null-hypotheses, and testing 
them in this order using the two-sided 95% confidence interval approach until an insignificant result 
appears. The effect is that rejection of the null hypothesis only, will be confirmed for endpoints 
where all previous null-hypotheses have been rejected in favour of faster aspart.
The confirmatory secondary endpoints are:
!
Change from baseline in 1-hour PPG increment 16 weeks after randomisation (meal test)
!
Change from baseline in 1,5-anhydroglucitol 16 weeks after randomisation
The steps in the hierarchical testing procedure are as follows:
Step 1 (Primary analysis):  HbA1c non-inferiority of faster aspart versus NovoRapid®
Step 2: 1-hour PPG increment (meal test) superiority of faster aspart versus NovoRapid®
Step 3: HbA1c superiority of faster aspart versus NovoRapid®
Step 4: 1,5-anhydroglucitol superiority of faster aspart versus NovoRapid®
The primary estimand for the primary endpoint will be repeated for the confirmatory secondary 
endpoints, change from baseline in 1-hour PPG increment (meal test) and change from baseline in 
1,5-anhydroglucitol 16 weeks after randomisation. The analyses related to these estimands are 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
86 of 112
defined below and will be used for the decisions to continue or not, throughout the hierarchical 
testing procedure. These analyses will be based on the FAS and use the in-trial observation period.
As sensitivity analysis the secondary analysis 4) will also be repeated for the confirmatory 
secondary endpoints. The analyses will be based on the FAS and using the on-treatment observation 
period.
Change from baseline in 1-hour PPG increment 16 weeks after randomisation (meal test) 
(step 2)
As the second step of the hierarchical testing procedure changes from baseline in 1-hour PPG 
increment (meal test) 16 weeks after randomisation will be tested for superiority of faster aspart 
compared to NovoRapid®.
The 1-hour PPG increment will be analysed based on the laboratory measured values in the meal 
test.
The 1-hour PPG increment endpoint will be analysed using the FAS and the in-trial observation 
period based on a multiple imputation technique where the change from baseline in 1-hour PPG 
increment at week 16 for subjects withdrawn from trial are imputed based on data from trial 
completers in the NovoRapid® arm. Multiple copies (100 copies) of the full dataset will be 
generated by imputing missing values based on estimated parameters as follows: 
!
An analysis of variance model with region and metformin use at baseline (Yes/No) as 
factors and baseline 1-hour PPG increment as covariate is fitted to the change from baseline 
in 1-hour PPG increment at week 16 for the NovoRapid® group only. The estimated 
parameters, and the variance, from this model are used to impute missing values using 
stochastic simulation at week 16 for subjects in both treatment groups in order to generate 
100 complete datasets.
!
For each of the complete data sets, the change from baseline to week 16 is analysed using an 
analysis of variance model with treatment, region and metformin use at baseline (Yes/No) as 
factors, and baseline 1-hour PPG increment as covariate.
!
The estimates and standard deviations for the 100 data sets are pooled to one estimate and 
associated standard deviation using Rubins formula. From this, the pooled estimates and 
95% confidence interval for the treatment difference is calculated.
The superiority will be assessed by comparing the upper limit of the 95% CI to 0. If the upper 95% 
CI is below 0 then superiority will be confirmed.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
87 of 112
Change from baseline in HbA1c 16 weeks after randomisation (step 3)
Step 3 in the hierarchical testing procedure is to confirm superiority of change from baseline HbA1c
16 weeks after randomisation of the effect of treatment with faster aspart compared to NovoRapid®. 
Superiority will be based on the same 95% CI that was used for addressing the primary analysis. 
Superiority will be confirmed if the upper boundary of the two-sided 95% confidence interval of the 
mean treatment difference (faster aspart minus NovoRapid®) is below 0%.
Change from baseline in 1,5-anhydroglucitol 16 weeks after randomisation (step 4)
Step 4 in the hierarchical testing procedure is to confirm superiority of change from baseline 1,5-
anhydroglucitol 16 weeks after randomisation of the effect of treatment with faster aspart compared 
to NovoRapid®. The endpoint will be analysed based on all planned post baseline measurements 
until or at 16 weeks after randomisation using a model similar to the primary analysis 1), but with 
baseline 1,5-anhydroglucitol as covariate. Superiority will be confirmed if the upper boundary of 
the two-sided 95% confidence interval of the mean treatment difference ( faster aspart minus 
NovoRapid®) is below 0.
17.4.2
Supportive secondary endpoints
17.4.2.1
Efficacy endpoints
All endpoints except insulin dose in this section will be assessed using the FAS and the in-trial 
observation period and repeated using the on-treatment observation period. Insulin dose will be 
presented using the safety analysis set and will therefore only use the on-treatment observation 
period.
Change from baseline in FPG 16 weeks after randomisation
Change from baseline in FPG 16 weeks after randomisation will be analysed based on all planned 
post baseline measurements until or at 16 weeks after randomisation using a model similar to 1) 
except with baseline FPG as covariate.
If a subject achieves HbA1c target 16 weeks after randomisation
HbA1c < 7.0%
A dichotomous (responder/non-responder) endpoint will be defined based on whether a Subject has 
met the HbA1c target (HbA1c <7.0%) 16 weeks after randomisation.  
This responder endpoint will be analysed based on a logistic regression model using treatment ,
region and metformin use at baseline (Yes/No) as factors, and baseline HbA1c as covariate. In 
analysis of the in-trial observation period subjects without an HbA1c measurement at week 16 will 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
88 of 112
be treated as non-responders. In the analysis using the on-treatment observation period both subjects
who discontinue randomised treatment or withdraw from trial is included as non-responders.
HbA1c < 7.0% without severe hypoglycaemia
A dichotomous (responder/non-responder) endpoint will be defined based on whether a Subject has 
met the HbA1c target (HbA1c <7.0%) 16 weeks after randomisation without treatment emergent 
severe hypoglycaemic episodes.
This responder endpoint will be analysed based on a logistic regression model using treatment ,
region and metformin use at baseline (Yes/No) as factors and baseline HbA1c as covariate. In the 
analysis of the in-trial observation period subjects without an HbA1c measurement at week 16 will 
be treated as non-responders. In the analysis using the on-treatment observation period both subjects
who discontinue randomised treatment or withdraw from trial will be included as non-responders.
Change from baseline in 30- minutes, 1- hour, 2- hour, 3- hour and 4- hour PPG and 30-
minutes, 2- hour, 3- hour and 4- hour PPG increment 16 weeks after randomisation (meal 
test)
Laboratory measured PG from the meal test will be analysed for 30 minutes, 1-hour, 2-hours, 3-
hours and 4-hours PPG separately. The corresponding PPG increments will be derived separately 
using each PPG measurement minus the pre-prandial PG measurement.
Change from baseline in PPG and PPG increment 16 weeks after randomisation will be analysed 
separately using a model similar to the model used in hierarchical testing procedure step 2 for 1-
hour PPG increment 16 weeks after randomisation (meal test) except with the corresponding 
baseline value as covariate.
Change from baseline in endpoints derived from the 7-9-7-point SMPG profile 16 weeks after 
randomisation
In general, analyses will be based on the entire 7-9-7-point SMPG profile except for the analyses of 
nocturnal endpoints where information in the 9-point SMPG profile will be utilised. 
PPG and PPG increments based on the 7-9-7-point SMPG profiles will be derived separately for PG 
measurements made 1 hour after the meal. In the following section this distinction will be 
considered implicit and without further explanation.
Pre-prandial PG and PPG will be recorded by the subjects as part of the 7-9-7-point SMPG profile 
prior to three defined visits. Individual mean mealtime PPG (post-breakfast, post-lunch, post-main 
evening meal) will be derived from the three profiles. Overall mean PPG will be derived from the 
individual derived mealtime PPG values.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
89 of 112
PPG increment for each meal (breakfast, lunch, main evening meal) will be derived from the 7-9-7-
point SMPG profile as the difference between PPG values and the PG value before meal in each 
separate profile. The mean of the derived increments will then be calculated separately for each 
meal. Mean 1 hour PPG increments over all meals will be derived as the mean of all corresponding 
mean meal increments. 
!
Change from baseline in mean of the 7-9-7-point SMPG profile
The mean of the 7-9-7-point SMPG profile is defined as the area under the curve profile 
divided by the measurement time, and is calculated using the linear trapezoidal technique.
Change from baseline in the mean of the 7-9-7-point SMPG profile 16 weeks after 
randomisation will be analysed based on all planned post baseline measurements until or at 
16 weeks after randomisation using a model similar to 1) except with the corresponding 
baseline value as covariate.
!
Change from baseline in PPG and PPG increment (mean, breakfast, lunch and main evening 
meal)
Change from baseline in PPG and PPG increment endpoints 16 weeks after randomisation 
for mean over all three meals and the individual meals will be analysed separately based on 
all planned post baseline measurements until or at 16 weeks after randomisation using a 
model similar to 1) except with the corresponding baseline value as covariate.
!
Change from baseline in fluctuation in 7-9-7-point SMPG profile
The fluctuation in the 7-9-7-point SMPG profile is defined as:
1
  |() −
|
 

!
where T, PG(t) and 
 denotes the length of the profile, the PG value at time t and the mean 
of the profile, respectively. It will be calculated using the linear trapezoidal technique.
Fluctuation in the 7-9-7-point SMPG profile will be logarithmically transformed and 
analysed based on all planned post baseline measurements until or at 16 weeks after 
randomisation using a model similar to 1) except with the corresponding log-transformed 
baseline value as covariate. Estimated treatment means and the estimated treatment 
differences with corresponding 95% CI will be back-transformed to the original scale, 
resulting in estimated geometric means, a treatment ration and a 95% CI for the treatment 
ratio.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
90 of 112
!
Change from baseline in nocturnal SMPG measurements
Change from baseline in nocturnal SMPG measurements will be assessed by considering the 
difference between PG values available at bedtime, at 4 AM and the before breakfast value 
the following day: (4 AM PG value minus at bedtime PG value), (before breakfast PG value 
minus at bedtime PG value) and (before breakfast PG value minus 4 AM PG value).
Change from baseline in nocturnal SMPG measurements 16 weeks after randomisation will 
be analysed based on all planned post baseline measurements until or at 16 weeks after 
randomisation using a model similar to 1) except with the corresponding baseline values as 
covariate.
If a subject achieves PPG target (based on overall mean of daily PPG measurements in 7-9-7-
point SMPG profile) 16 weeks after randomisation:
Overall PPG (1 hour) ∃7.8 mmol/L [140 mg/dL]
A dichotomous (responder / non-responder) endpoint will be defined based on whether a Subject 
has reached an overall mean 1 hour PPG ∃7.8 mmol/L [140 mg/dL] 16 weeks after randomisation, 
where PPG is derived from the 7-9-7-point SMPG profile. 
This responder endpoint will be analysed based on a logistic regression model using treatment , 
region and metformin use at baseline (Yes/No) as factors, and baseline overall 1-hour mean PPG as 
covariate. In analysis of the in-trial observation period subjects without an overall mean 1 hour PPG 
at week 16 will be treated as non-responder. In the on- treatment observation period analysis both 
subjects who discontinue randomised treatment or withdraw from trial will be included as non-
responders.
Overall PPG (1-hour ) ∃7.8 mmol/L [140 mg/dL] without severe hypoglycaemia
A dichotomous (responder / non-responder) endpoint will be defined based on whether a Subject 
has reached an overall 1-hour PPG ∃7.8 mmol/L [140 mg/dL] 16 weeks after randomisation without 
any treatment emergent severe hypoglycaemic episodes. 
This responder endpoint will be analysed based on a logistic regression model using treatment ,
region and metformin use at baseline (Yes/No) as factors, and baseline mean 1-hour PPG as 
covariate. In analysis of the in-trial observation period subjects without an overall mean 1 hour PPG 
at week 16 will be treated as non-responders. In the on- treatment observation period analysis both 
subjects who discontinue randomised treatment or withdraw from trial will be included as non-
responders. 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
91 of 112
Insulin dose (Units/day and Units/kg/day; total basal, total bolus, total daily insulin dose and 
individual meal insulin dose) 16 weeks after randomisation
The insulin doses will be summarised descriptively by treatment week according to regimen, both 
by meal type and as total daily dose in units and units/kg (total daily and separately for each 
mealtime dose). Insulin doses will be summarised using the on-treatment observation period and 
using the safety analysis set.
Change from baseline in lipids-lipoproteins profile 16 weeks after randomisation
Change from baseline in lipid endpoints (total cholesterol, HDL cholesterol, LDL cholesterol) will 
be logarithmically transformed and analysed separately based on all planned post baseline 
measurements until or at 16 weeks after randomisation using a model similar to 1) except with the 
corresponding log-transformed baseline as covariate. Estimated treatment means and the estimated 
treatment difference with corresponding 95% CI will be back-transformed to the original scale, 
resulting in estimated geometric means, a treatment ratio and a 95% CI for the treatment ratio.
17.4.2.2
Safety endpoints
In terms of AEs, as a minimum, SAEs will be tabulated separately using the in-trial observation 
period.
All events in the in-trial observation period will be listed with information about whether it 
appeared in the on-treatment observation period or not.
Number of treatment emergent adverse events
Adverse events (AEs) will be coded using the Medical Dictionary for Regulatory Activities 
(MedDRA). AEs will be presented based on system organ class and preferred terms.
A Treatment Emergent Adverse Event (TEAE) is defined as an event that has an onset date on or 
after the first day of exposure to randomised treatment, and no later than seven days after the last 
day of exposure to randomised treatment.
TEAEs are summarised descriptively, whereas AEs not defined as treatment emergent are presented 
in listings, including AEs reported in the 30-day follow-up period. The summaries of TEAEs are 
made displaying the number of subjects with at least one event, the percentage of subjects with at 
least one event, the number of events and the event rate per 100 patient years of exposure. These 
summaries are done by seriousness, severity, relation to insulin treatment, relation to technical 
complaint, premature treatment discontinuation due to AEs, AEs leading to withdrawal from trial
and outcome.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
92 of 112
Furthermore, summary tables based on system organ class and preferred terms are made for:
!
All TEAEs
!
Serious TEAEs
!
Possibly and probably related TEAEs
!
Severe TEAEs
!
TEAEs with preferred term that are experienced by at least 5% of the subjects in any 
treatment arm or by at least 5% of all subjects
For AEs where additional information is recorded, this will be listed.
AEs occurring during the run-in period are considered non-treatment emergent and will be 
summarised separately.
Number of treatment emergent injection site reactions
Treatment emergent injection site reactions occurring during the trial will be summarised and listed.
Classification of Hypoglycaemia
Treatment emergent: hypoglycaemic episodes will be defined as treatment emergent if the onset of 
the episode occurs on or after the first day of exposure to randomised treatment, and no later than 
one day after the last day of exposure to randomised treatment.
Nocturnal hypoglycaemic episodes: episodes occurring between 00:01 and 05.59 both inclusive.   
Hypoglycaemic episodes are classified according to the Novo Nordisk classification of 
hypoglycaemia (see Figure 17–1) and the ADA classification of hypoglycaemia (see Figure 17–2).
Novo Nordisk classification of hypoglycaemia
In normal physiology, symptoms of hypoglycaemia occur below a PG level of 3.1 mmol/L (56 
mg/dL).41 Therefore, Novo Nordisk has included hypoglycaemia with PG levels below this cut-off 
point in the definition of BG confirmed hypoglycaemia.
Novo Nordisk uses the following classification (see Figure 17–1) in addition to the ADA 
classification: 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
93 of 112
!
Severe hypoglycaemia according to the ADA classification.34
!
Severe or BG confirmed hypoglycaemia: An episode that is severe according to the ADA 
classification34 or BG confirmed by a PG value <3.1 mmol/L (56 mg/dL) with or without 
symptoms consistent with hypoglycaemia. 
Hypoglycaemic
episode
PG ≤ 3.9 mmol/L 
(70 mg/dL) 
or 
Alleviation of 
symptoms 
or
Seizure, coma or 
fatal 
SMPG
measurement
PG < 3.1 mmol/L
(56 mg/dL)
with symptoms
PG < 3.1 mmol/L
(56 mg/dL)
without
symptoms
Symptomatic BG 
confirmed 
hypoglycaemia
Asymptomatic BG 
confirmed 
hypoglycaemia
Yes
No
Severe or 
BG confirmed 
symptomatic 
hypoglycaemia
BG confirmed 
hypoglycaemia
Severe or BG 
confirmed 
hypoglycaemia
Note: Glucose measurements are performed with capillary blood calibrated to plasma equivalent glucose values
BG: blood glucose  PG: plasma glucose  SMPG: Self-measured plasma glucose  
Subject 
able to 
treat him/
herself
Severe 
hypoglycaemia
(ADA 2013)
Figure 17–1
Novo Nordisk classification of hypoglycaemia
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
94 of 112
ADA classification34 of hypoglycaemia 
!
Severe hypoglycaemia: An episode requiring assistance of another person to actively 
administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose 
concentrations may not be available during an event, but neurological recovery following 
the return of PG to normal is considered sufficient evidence that the event was induced by a 
low PG concentration.
!
Asymptomatic hypoglycaemia: An episode not accompanied by typical symptoms of 
hypoglycaemia, but with a measured PG concentration ≤ 3.9 mmol/L (70 mg/dL).
!
Documented symptomatic hypoglycaemia: An episode during which typical symptoms of 
hypoglycaemia are accompanied by a measured PG concentration ≤ 3.9 mmol/L (70 
mg/dL).
!
Pseudo-hypoglycaemia: An episode during which the person with diabetes reports any of the 
typical symptoms of hypoglycaemia with a measured PG concentration > 3.9 mmol/L (70 
mg/dL) but approaching that level.
!
Probable symptomatic hypoglycaemia: An episode during which symptoms of 
hypoglycaemia are not accompanied by a PG determination but that was presumably caused 
by a PG concentration ≤ 3.9 mmol/L (70 mg/dL).
Hypoglycaemic 
episode 
PG ≤ 3.9 mmol/L 
(70 mg/dL) 
or 
Alleviation of 
symptoms 
or
Seizure, coma or 
fatal 
SMPG
measurement
Asymptomatic 
hypoglycaemia
Documented 
symptomatic 
hypoglycaemia
Pseudo-
hypoglycaemia
Probable 
symptomatic 
hypoglycaemia
No
Yes
No measurement 
with symptoms
PG > 3.9 mmol/L 
(70 mg/dL)
with symptoms
PG ≤3.9 mmol/L 
(70 mg/dL)
with symptoms
PG ≤3.9 mmol/L 
(70 mg/dL)
without symptoms
No
Yes
Note: Glucose measurements are performed with capillary blood calibrated to plasma equivalent gl ucose values
PG: plasma glucose  SMPG: Self-measured plasma glucose  
Subject 
able to 
treat him/
herself
Severe 
hypoglycaemia
(ADA 2013)
Figure 17–2
ADA classification of hypoglycaemia
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
95 of 112
Treatment emergent hypoglycaemic episodes are presented in terms of the number of subjects with 
at least one event (N), the percentage of subjects with at least one event (%), the number of events 
(E) and the event rate per 100 years of exposure (R). Separate summaries are made by severity 
considering all episodes, nocturnal and daytime episodes using Novo Nordisk and ADA classified 
episodes. All episodes will also be summarised by category, including summaries in relation to time 
since start of meal, as occurring during1, 2, and 4 hours after start of meal, and from 2 hours 
(exclusive) to 4 hours (inclusive) after start of meal, respectively.
The number of treatment emergent severe or BG confirmed hypoglycaemic episodes (all, daytime, 
nocturnal, 1 hour, 2 hours, 4 hours and from 2 hours (exclusive) to 4 hours (inclusive) after start of 
the meal) will be analysed based on the FAS using a negative binomial regression model with a log -
link function and the logarithm of the time period in which a hypoglycaemic ep isode is considered 
treatment emergent as offset. The model will include treatment, region and metformin use at 
baseline (Yes/No) as factors. To the extent where data allow, separate analysis will be performed 
for severe hypoglycaemic episodes.
Change from baseline in clinical evaluations 16 weeks after randomisation:
Physical examination
The physical examination parameters (head, ears, eyes, nose, throat, neck, respiratory system, 
cardiovascular system, gastrointestinal system incl. mouth, musculoskeletal system, central and 
peripheral nervous system, skin), and their change from baseline, will be summarised descriptively
using the on-treatment period. All findings will be listed.
Vital signs
Vital signs include diastolic blood pressure, systolic blood pressure and pulse. The measurements 
will be summarised descriptively using the on-treatment period and both actual values as mean 
change and change from baseline.
Electrocardiogram
ECG findings will be summarised descriptively using the on-treatment period and including 
summaries of the change from baseline. Change from baseline will be summarised as 
normal/abnormal not clinically significant/abnormal clinically significant categorisation in shift 
tables.
Fundoscopy/fundus photography
Fundoscopy/fundus photography findings will be summarised descriptively using the on-treatment 
period and including summaries of the change from baseline. Change from baseline will be 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
96 of 112
summarised as normal/abnormal not clinically significant/abnormal clinically significant 
categorisation in shift tables.
Change from baseline in clinical laboratory assessments 16 weeks after randomisation
Change from baseline 16 weeks after randomisation in central laboratory assessments:
!
Haematology (erythrocytes, haematocrit, haemoglobin, leucocytes, thrombocytes)
!
Biochemistry (ALT, AST, albumin, alkaline phosphatase, creatinine, potassium, sodium, 
total bilirubin)
Individual laboratory values will be compared to their relevant reference range (when existing) and 
flagged as being below or above the range. The measurements and their change from baseline will 
be summarised descriptively using the on-treatment period. Change from baseline will be 
summarised both the actual values and the low/normal/high categorisation in shift tables.
Change from baseline in body weight and body mass index 16 weeks after randomisation
The measurements will be summarised descriptively using the on-treatment period and the actual 
values as mean change.
Change from baseline in body weight will be analysed based on all planned post baseline 
measurements until or at 16 weeks after randomisation using a statistical model similar to 1) except 
with the corresponding baseline measurement as covariate.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
97 of 112
18 Ethics
18.1
Benefit-risk assessment of the trial
All subjects included in the trial will be treated with basal-bolus regimen with insulin degludec as 
the basal insulin. Inclusion and exclusion criteria have been chosen to ensure that subjects enrolling 
in the trial have T2DM at a stage where basal-bolus treatment is needed (i.e. subjects must have 
been diagnosed with T2DM for 10 years or more and must have been on a basal-bolus treatment 
regimen at least 365 days prior to screening). 
Subjects taking metformin at the enrolment in the trial should continue the metformin treatment 
unchanged. Metformin plus basal/bolus insulin is a recommended treatment for subjects with 
T2DM9 and the combination of metformin and basal-bolus insulin therapy with faster aspart or 
NovoRapid® as the bolus insulin was included in the phase 3A faster aspart trials in T2DM. 
The most common side effect of all available insulin preparations is hypoglycaemia. The 
investigator will explain to the subject how they should check their BG with the BG meter provided 
by Novo Nordisk and what precautions to take in case of low BG measurement.
Trial products will be provided by Novo Nordisk free of charge during the trial. When treatment 
with trial products ends, the subject and investigator will decide on the best available treatment on 
the market. Novo Nordisk will not offer any free medications after the completion of the trial.
Summary of clinical pharmacology
The pharmacokinetic and pharmacodynamic profiles of faster aspart consistently demonstrated a 
left shift compared to that of NovoRapid® in subjects with T1DM and the profiles for faster aspart 
and NovoRapid® were similar in overall shape. Faster aspart produced a faster onset of exposure 
and increased initial absorption rate compared to NovoRapid® resulting in a faster onset of action 
and increased early glucose-lowering effect. Overall, the differences in the pharmacokinetic and 
pharmacodynamic properties for faster aspart compared to NovoRapid® were consistent across 
trials.22 No safety concerns were raised during any of the trials. 
Similar clinical pharmacology trials have not been performed in subjects with T2DM, however the 
phase 3A programme for faster aspart included trials in bolus naïve T2DM subjects. Non-inferiority 
to NovoRapid® with regard to HbA1c change from baseline was demonstrated. In subjects with 
T2DM faster aspart statistically significantly improved control of the 1-hour PPG increment when 
compared to NovoRapid®.22 No safety issues for faster aspart have been identified based on data 
from the clinical development programme, and the safety profile is similar to NovoRapid ®.22
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
98 of 112
Clinical benefits and risk considerations for the trial
The purpose of this trial is to confirm the effect and compare safety of faster aspart compared to 
NovoRapid® both in combination with insulin degludec with or without metformin in subjects with 
T2DM treated with a basal-bolus regimen.
For the individual subjects, the personal health-related benefits are related to the medical 
examination and the benefit from an intensified treatment regimen anticipated to be better than or 
equal to the treatment they receive at the time they enter the trial. However, subjects will have to 
spend some extra time monitoring and recording data and on additional visits to the clinic and 
phone contacts.
The very high frequency of contacts between the subject and the investigator and the thorough 
evaluation of SMPG values will provide the opportunity for optimising the titration of basal and 
bolus insulin based on SMPG values and thereby may contribute to obtaining improved HbA1c
results. All subjects will have reinforced dietary training including simple carbohydrate counting.
For the individual subjects, the anticipated risks include hypoglycaemia, hyperglycaemia, systemic 
allergic reactions, injection site reactions, lipodystrophy, and antibody development. The risks will 
be mitigated by the close supervision of the subjects and the frequent measurements of BG levels.
A consequence of the pharmacodynamics of rapid-acting insulin analogues is that if hypoglycaemia 
occurs, it may occur earlier after an injection than with soluble human insulin. A phase 3A trial with 
faster aspart in T2DM showed a slight shift in distribution of the occurrence of hypoglycaemic 
episodes in relation to a meal when comparing to NovoRapid®. A statistical significant higher rate 
of hypoglycaemic episodes was seen during the first 2 hours after a meal for faster aspart. This is 
not unexpected and reflects the pharmacokinetic and pharmacodynamic properties of faster aspart.22
All treatments are contraindicated in case of hypersensitivity to the active substances or any of the 
excipients. The risk of hypersensitivity is partly mitigated by excluding subject with known 
hypersensitivity towards any trials products or related products.
Injection site reactions can occur. The nature of the injection site reactions is expected to be mild, 
transient, and more of a visual character and is not expected to be of concern to the subject’s safety. 
Lipodystrophy (including lipohypertrophy, lipoatrophy) at the injection site can occur. Continuous 
rotation of the injection site within the particular injection area may help to reduce the risk of 
developing these reactions.
The blood samples during meal tests might be inconvenient to the subjects, but are not of any safety 
concern.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
99 of 112
Subjects in this trial will be using bolus and basal insulin administered via two differently colour-
coded prefilled pens. This colour difference will help the subject to distinguish between the pens 
and thereby minimise the risk of medication errors with regard to mixing up the pens used for basal 
and bolus injection. Subjects will be trained in distinguishing between the pens. It is expected that 
the risk of mixing up basal and bolus insulin in this trial is similar to other clinical trials.
No maximum dose of insulin is specified as doses are titrated individually. All subjects will perform 
4-point profiles on a daily basis throughout the trial for safety purposes and for the purpose of 
insulin titration.
Conclusion
Subjects in this trial will benefit from an intensified insulin treatment in a basal-bolus regimen in a 
treat-to-target setting under close supervision.
The safety profile of insulin aspart is well established from the market use of NovoRapid ®. The data 
available for faster aspart in non-clinical and clinical studies taken together with review of the 
additional excipients in the faster aspart formulation have not revealed any safety issues that would 
prohibit the administration of faster aspart formulations in accordance with this trial.
It is therefore concluded that the clinical benefits from the trial as well as the contribution to the 
development of a new faster aspart outweigh the potential risks of participating in this trial.
18.2
Informed consent 
In seeking and documenting informed consent, the investigator must comply with applicable 
regulatory requirement(s) and adhere to ICH GCP1 and the requirements in the Declaration of 
Helsinki.2
Before any trial-related activity, the investigator must give the subject verbal and written 
information about the trial and the procedures involved in a form that the subject can read and 
understand. 
The subjects must be fully informed of their rights and responsibilities while participating in the 
trial as well as possible disadvantages of being treated with the trial products.
The investigator must ensure the subject ample time to come to a decision whether or not to 
participate in the trial. 
A voluntary, signed and personally dated informed consent must be obtained from the subject 
before any trial-related activity.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
100 of 112
The responsibility for seeking informed consent must remain with the investigator, but the 
investigator may delegate the task to a medically qualified person, in accordance with local 
requirements. The written informed consent must be signed and personally dated by the person who 
seeks the informed consent before any trial-related activity.
If information becomes available that may be relevant to the subject’s willingness to continue 
participating in the trial, the investigator must inform the subject in a timely manner, and a revised 
written subject information must be provided and a new informed consent must be obtained.
18.3
Data handling
If the subject withdraws from the trial or is lost to follow-up, then the subject’s data will be handled 
as follows:
!
Data already collected and any data collected at the end-of-trial visit including follow-up 
visits will be retained by Novo Nordisk, entered into the database and used for the clinical 
trial report. 
!
Safety events will be reported to Novo Nordisk and regulatory authorities according to 
local/national requirements.
If data is used, it will always be in accordance with local regulations and IRBs/IECs.
18.4
Information to subjects during trial
The site will be offered a communication package to the subject during the conduct of the trial. The 
package content is issued by Novo Nordisk. The communication package will contain the letters 
intended for distribution to the subjects. The letters will be translated and adjusted to local 
requirements and distributed to the subject at the discretion of the investigator. The subject may 
receive a “welcome to the trial letter” and a “thank you for your participation letter” after 
completion of the trial. Further the subject may receive letters during the trial.
All written information to subjects must be sent to IRB/IEC for approval/favourable opinion and to 
regulatory authorities for approval or notification according to local regulations.
18.5
Premature termination of the trial and/or trial site
Novo Nordisk, the IRBs/IECs or a regulatory authority may decide to stop the trial, part of the trial 
or a trial site at any time, but agreement on procedures to be followed must be obtained.
If the trial is suspended or prematurely terminated, the investigator must inform the subjects 
promptly and ensure appropriate therapy and follow-up. The investigator and/or Novo Nordisk must 
also promptly inform the regulatory authorities and IRBs/IECs and provide a detailed written 
explanation. 
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
101 of 112
If, after the termination of the trial, the benefit-risk analysis changes, the new evaluation must be 
provided to the IRBs/IECs in case it has an impact on the planned follow-up of subjects who have 
participated in the trial. If it has an impact, the actions needed to inform and protect the subjects 
should be described.
19 Protocol compliance
19.1
Protocol deviations
Deviations from the protocol should be avoided.
If deviations do occur, the investigator must inform the monitor and the implications of the 
deviation must be reviewed and discussed.
Deviations must be documented and explained in a protocol deviation by stating the reason, date, 
and the action(s) taken. Some deviations, for which corrections are not possible, can be 
acknowledged and confirmed via edit checks in the eCRF or via listings from the trial database.
Documentation on protocol deviations must be kept in the investigator trial master file and sponsor 
trial master file.
19.2
Prevention of missing data
The importance of subject retention will be addressed by Novo Nordisk in the training and 
communication with the trial sites.
The subjects will be carefully informed about the trial procedures before signing informed consent, 
so that they know the implications of participating in the trial. The run-in period in this trial will 
reduce the likelihood of drop-outs as only those who adhere to the protocol requirements will 
undergo randomisation. Subjects will during the run-in period get an understanding of what is 
expected from them when taking part in the trial and thereby minimise discontinuation from trial 
product post randomisation. In addition, only absolutely necessary criteria for premature 
discontinuation of trial products primarily focusing on subjects safety are included and thereby 
reducing the number of discontinuations and limiting the amount of missing data.
Close surveillance of subject retention will be performed throughout the trial by Novo Nordisk with 
focus on reasons for premature discontinuation of trial products or withdrawal of consent to secure 
early mitigations in collaboration with the trial sites.
The subjects must be instructed to complete their diary ongoing according to the protocol. Missing 
data will not be recorded retrospectively due to the decreased validity of such data36, 37; however a 7 
days’ timeline is applied for reporting of missing hypoglycaemic episode, The subject will be 
retrained in correct completion of the diary if missing data is identified.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
102 of 112
The investigator will make every effort to ensure that all assessments are performed and data is 
collected. If missing data does occur the reason will be collected via the protocol deviation process, 
see section 19.1. Novo Nordisk will monitor protocol deviations on an on-going basis throughout 
the trial followed by appropriate actions (e.g. re -training of site staff).
20 Audits and inspections
Any aspect of the clinical trial may be subject to audits conducted by Novo Nordisk or inspections 
from domestic or foreign regulatory authorities or from IRBs/IECs. Audits and inspections may 
take place during or after the trial. The investigator and the site staff as well as Novo Nordisk staff 
have an obligation to cooperate and assist in audits and inspections. This includes giving auditors 
and inspectors direct access to all source documents and other documents at the trial site relevant to 
the clinical trial. This includes permission to examine, analyse, verify and reproduce any record(s) 
and report(s) that are relevant to the evaluation of the trial.
21 Critical documents
Before a trial site is allowed to start screening subjects, written notification from Novo Nordisk 
must be received and the following documents must be available to Novo Nordisk:
!
Regulatory approval and/or acknowledgement of notification as required 
!
Approval/favourable opinion from IRBs/IECs clearly identifying the documents reviewed as 
follows: protocol, any protocol amendments, subject information/informed consent form, 
any other written information to be provided to the subject and subject recruitment materials
!
List of IRB/IEC members and/or constitution (or a general assurance number/statement of 
compliance)
!
Curricula vitae of investigator and sub-investigator(s) (current, dated and signed - must 
include documented GCP training or a certificate)
!
Signed receipt of IB
!
Signed and dated Agreement on Protocol
!
Signed and dated Agreement on Protocol Amendment, if applicable
!
Contract, signed by the investigator and/or appropriate parties on behalf of the investigator’s 
site and Novo Nordisk
!
Source document agreement
!
Central laboratory certification and normal ranges
!
Insurance statement, if applicable
!
Financial disclosure form from investigator and sub-investigator(s)
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
103 of 112
!
For US trial sites: verification under disclosures per Code of Federal Regulations (CFR) of 
Financial Conflict of Interest
!
For US trial sites: FDA form 1572 must be completed and signed by the investigator at each 
site
FDA form 1572:
For US sites:
!
Intended for US sites
!
Conducted under the Investigational new drug (IND)
!
All US investigators, as described above, will sign FDA Form 1572
For sites outside the US:
!
Intended for participating sites outside of the US
!
Not conducted under the Investigational new drug (IND)
!
All investigators outside of the US will not sign FDA form 1572
Novo Nordisk will analyse and report data from all sites together if more than one site is involved in 
the trial.
By signing the protocol agreement, each investigator agrees to comply fully with ICH GCP 1,
applicable regulatory requirements and the Declaration of Helsinki.2
By signing the protocol agreement, each investigator also agrees to allow Novo Nordisk to make 
investigator’s name and information about site name and address publically available if this is 
required by national or international regulations.
22 Responsibilities
The investigator is accountable for the conduct of the trial at his/her site and must ensure adequate 
supervision of the conduct of the trial at the trial site. If any tasks are delegated, the investigator 
must maintain a log of appropriately qualified persons to whom he/she has delegated specified trial-
related duties. The investigator must ensure that there is adequate and documented training for all 
staff participating in the conduct of the trial. It is the investigator’s responsibility to supervise the 
conduct of the trial and to protect the rights, safety, and well-being of the subjects.
A qualified physician, who is an investigator or a sub-investigator for the trial, must be responsible 
for all trial-related medical decisions.
The investigator will follow instructions from Novo Nordisk when processing data.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
104 of 112
The investigator is responsible for filing essential documents (i.e. those documents which 
individually and collectively permit evaluation of the conduct of a trial and the quality of the data 
produced) in the investigator trial master file. The documents including the subject identification 
code list must be kept in a secure locked facility, so no unauthorized persons can get access to the 
data.
The investigator will take all necessary technical and organisational safety measures to prevent 
accidental or wrongful destruction, loss or deterioration of data. The investigator will prevent any 
unauthorised access to data or any other processing of data against applicable law. The investigator 
must be able to provide the necessary information or otherwise demonstrate to Novo Nordisk that 
such technical and organisational safety measures have been taken.
During any period of unavailability, the investigator must delegate responsibility for medical care of 
subjects to a specific qualified physician who will be readily available to subjects during that time.
If the investigator is no longer able to fulfil the role as investigator (e.g. if he/she moves or retires), 
a new investigator will be appointed in consultation with Novo Nordisk.
The investigator and other site personnel must have sufficient English skills according to their 
assigned task(s).
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
105 of 112
23 Reports and publications
The information obtained during the conduct of this trial is considered confidential, and may be 
used by or on behalf of Novo Nordisk for regulatory purposes as well as for the general 
development of the trial product. All information supplied by Novo Nordisk in connection with this 
trial shall remain the sole property of Novo Nordisk and is to be considered confidential 
information. 
No confidential information shall be disclosed to others without prior written consent from Novo 
Nordisk. Such information shall not be used except in the performance of this trial. The information 
obtained during this trial may be made available to other physicians who are conducting other 
clinical trials with the trial product, if deemed necessary by Novo Nordisk. Provided that certain 
conditions are fulfilled, Novo Nordisk may grant access to information obtained during this trial to 
researchers who require access for research projects studying the same disease and/or trial product 
studied in this trial.
Novo Nordisk may publish on its clinical trials website a redacted clinical trial report for this trial.
One investigator will be appointed by Novo Nordisk to review and sign the clinical trial report 
(signatory investigator) on behalf of all participating investigators. The signatory investigator will 
be appointed based upon the criteria defined by the International Committee of Medical Journal 
Editors for research publications.42
23.1
Communication of results
Novo Nordisk commits to communicating, and otherwise making available for public disclosure, 
results of trials regardless of outcome. Public disclosure includes publication of a paper in a
scientific journal, abstract submission with a poster or oral presentation at a scientific meeting, or 
disclosure by other means.
The results of this trial will be subject to public disclosure on external web sites according to 
international and national regulations, as reflected in the Novo Nordisk Code of Conduct for 
Clinical Trial Disclosure.28
Novo Nordisk reserves the right to defer the release of data until specified milestones are reached, 
for example when the clinical trial report is available. This includes the right not to release the 
results of interim analyses, because the release of such information may influence the results of the 
entire trial.
At the end of the trial, one or more scientific publications may be prepared collaboratively by the 
investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or 
communication for up to 60 days to protect intellectual property.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
106 of 112
In all cases the trial results will be reported in an objective, accurate, balanced and complete 
manner, with a discussion of the strengths and limitations. All authors will be given the relevant 
statistical tables, figures, and reports needed to evaluate the planned publication. In the event of any 
disagreement on the content of any publication, both the investigators’ and Novo Nordisk opinions 
will be fairly and sufficiently represented in the publication.
Where required by the journal, the investigator from each trial site will be named in an 
acknowledgement or in the supplementary material, as specified by the journal. 
Novo Nordisk maintains the right to be informed of plans by any investigator to publish and to 
review any scientific paper, presentation, communication or other information concerning the 
investigation described in this protocol. Any such communication must be submitted in writing to 
Novo Nordisk before submission for comments. Comments will be given within four weeks from 
receipt of the planned communication.
Authorship
Authorship of publications should be in accordance with the Uniform Requirements of the 
International Committee of Medical Journal Editors42 (sometimes referred to as the Vancouver 
Criteria).
Site-specific publication(s) by investigator(s)
For a multi-centre clinical trial, analyses based on single-site data usually have significant statistical 
limitations and frequently do not provide meaningful information for healthcare professionals or 
subjects, and therefore may not be supported by Novo Nordisk. It is a Novo Nordisk policy that 
such individual reports do not precede the primary manuscript and should always reference the 
primary manuscript of the trial.
Novo Nordisk reserves the right to prior review of such publications. Further to allow for the 
primary manuscript to be published as the first, Novo Nordisk asks for deferment of publication of 
individual site results until the primary manuscript is accepted for publication. As Novo Nordisk 
wants to live up to the industry publication policy, submission of a primary publication will take 
place no later than 18 months after trial completion. 
23.2
Investigator access to data and review of results
As owner of the trial database, Novo Nordisk has the discretion to determine who will have access 
to the database. 
Individual investigators will have their own research subjects' data, and will be provided with the 
randomisation code after results are available.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
107 of 112
24 Retention of clinical trial documentation
24.1
Retention of clinical trial documentation
Subject’s medical records must be kept for the maximum period permitted by the hospital, 
institution or private practice.
The investigator must agree to archive the documentation (this includes both electronic and paper-
based records) pertaining to the trial in an archive after completion or discontinuation of the trial if 
not otherwise notified. The investigator should not destroy any documents without prior permission 
from Novo Nordisk. If the investigator cannot archive the documents at the trial site, Novo Nordisk 
can refer the investigator to an independent archive provider that has a system in place to allow only 
the investigator to access the files.
The investigator must be able to access his/her trial documents without involving Novo Nordisk in 
any way. Site-specific CRFs and other subject data (in an electronic readable format or as paper 
copies or prints) will be provided to the investigator before access is revoked to the systems and/or 
electronic devices supplied by Novo Nordisk. These data must be retained by the trial site. If the 
provided data (e.g. the CD-ROM) is not readable during the entire storage period, the investigator 
can request a new copy. A copy of all data will be stored by Novo Nordisk.
Novo Nordisk will maintain Novo Nordisk documentation pertaining to the trial for at least 20 years 
after discontinuation of the marketing authorisation, termination of t he trial or cancellation of the 
research project whichever is longest.
The files from the trial site/institution must be retained for 15 years after end of trial as defined in 
Section 7, or longer if required by local regulations or Novo Nordisk. In any case trial files cannot 
be destroyed until the trial site/institution is notified by Novo Nordisk. The deletion process must 
ensure confidentiality of data and must be done in accordance with local regulatory requirements.  
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
108 of 112
25 Institutional Review Boards/Independent Ethics Committees and 
regulatory authorities
IRB/IEC:
Written approval or favourable opinion must be obtained from IRB/IEC prior to commencement of 
the trial.
During the trial, the investigator or Novo Nordisk, as applicable, must promptly report the 
following to the IRB/IEC, in accordance with local requirements: updates to IB, unexpected SAEs 
where a causal relationship cannot be ruled out, protocol amendments according to local 
requirements, deviations to the protocol implemented to eliminate immediate hazards to the 
subjects, new information that may affect adversely the safety of the subjects or the conduct of the 
trial (including new benefit-risk analysis in case it will have an impact on the planned follow-up of 
the subjects), annually written summaries of the trial status, and other documents as required by the 
local IRB/IEC.
The investigator must ensure submission of the clinical trial report synopsis to the IRB/IEC.
Protocol amendments must not be implemented before approval or favourable opinion according to 
local regulations, unless necessary to eliminate immediate hazards to the subjects.
The investigator must maintain an accurate and complete record of all submissions made to the 
IRB/IEC. The records must be filed in the investigator trial master file and copies must be sent to 
Novo Nordisk.
Regulatory Authorities:
Regulatory authorities will receive the clinical trial application, protocol amendments, reports on 
SAEs, and the clinical trial report according to national requirements.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
109 of 112
26 Indemnity statement
Novo Nordisk carries product liability for its products, and liability as assumed under the special 
laws, acts and/or guidelines for conducting clinical trials in any country, unless others have shown 
negligence.
Novo Nordisk assumes no liability in the event of negligence, or any other liability of the sites or 
investigators conducting the trial, or by persons for whom the said site or investigator are 
responsible.
Novo Nordisk accepts liability in accordance with:
Poland: Novo Nordisk carries liability for the trial exclusively in the scope defined by the 
applicable laws and in particular by the Civil Code and the Pharmaceutical Law dated 6 September 
2001 (uniform version Journal of Laws of 2008 No. 45 item 271 with amendments). In order to 
support potential claims for liability attributable to the trial, Novo Nordisk and the investigators are 
covered by the insurance policy issued according to applicable Polish law.
Russia: Federal law of 12 April 2010 No. 61-FZ ‘On Medicinal Drugs’ Circulation and Ministry of 
Healthcare of Russian Federation’ order of 01 April 2016 No. 200n “Approval of rules of good 
clinical practice.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
110 of 112
27 References
1.
International Conference on Harmonisation. ICH Harmonised Tripatite Guideline. Guideline 
for Good Clinical Practise E6(R2), Step 4. 09 Nov 2016.
2.
World Medical Association. Declaration of Helsinki. Ethical Principles for Medical 
Research Involving Human Subjects. Last amended by the 64th WMA General Assembly, 
Fortaleza, Brazil. October 2013.
3.
Diabetes Control and Complications Trial Research Group. The effect of intensive treatment 
of diabetes on the development and progression of long-term complications in insulin-
dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. 
N Engl J Med. 1993;329(14):977-86.
4.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional 
treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK 
Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837-53, Erratum 
1999; 354: 602.
5.
Woerle HJ, Neumann C, Zschau S, Tenner S, Irsigler A, Schirra J, et al. Impact of fasting 
and postprandial glycemia on overall glycemic control in type 2 diabetes - Importance of 
postprandial glycemia to achieve target HbA1c levels. Diabetes Research and Clinical 
Practice. 2007;77(2):280-5.
6.
International Diabetes Federation Guideline Development G. Guideline for management of 
postmeal glucose in diabetes. Diabetes Res Clin Pract. 2014;103(2):256-68.
7.
Leiter LA, Ceriello A, Davidson JA, Hanefeld M, Monnier L, Owens DR, et al. Postprandial 
glucose regulation: New data and new implications. Clin Ther. 2005;27(Suppl B):S42-S56.
8.
Brange J, Owens DR, Kang S, Volund A. Monomeric Insulins and Their Experimental and 
Clinical Implications. Diabetes Care. 1990;13(9):923-54.
9.
Lindholm A, McEwen J, Riis AP. Improved postprandial glycemic control with insulin 
aspart. A randomized double-blind cross-over trial in type 1 diabetes. Diabetes Care. 
1999;22(5):801-5.
10.
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. 
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position 
statement of the American Diabetes Association (ADA) and the European Association for 
the Study of Diabetes (EASD). Diabetologia. 2012;55(6):1577-96.
11.
Meneghini L, Mersebach H, Kumar S, Svendsen AL, Hermansen K. A comparison of two 
intensification regimens with rapid-acting insulin aspart in type 2 diabetes inadequately 
controlled by once-daily insulin detemir and oral antidiabetes drugs: the STEP-Wise 
randomized study. Endocr Pract. 2011:727-36.
12.
Liebl A, Prager R, Binz K, Kaiser M, Bergenstal R, Gallwitz B, et al. Comparison of insulin 
analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a 
randomized controlled trial. Diabetes Obes Metab. 2009;11(1):45-52.
13.
Garber AJ, King AB, Del Prato S, Sreenan S, Balci MK, Munoz-Torres M, et al. Insulin 
degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment 
with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, 
randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379(9825):1498-
507.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
111 of 112
14.
Home PD, Lindholm A, Riis A, European Insulin Aspart Study Group. Insulin aspart vs. 
human insulin in the management of long-term blood glucose control in Type 1 diabetes 
mellitus: a randomized controlled trial. Diabet Med. 2000;17(11):762-70.
15.
Raskin P, Riis A, Guthrie RA, Jovanovic L, Leiter L. Use of insulin aspart, a fast-acting 
insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. 
Diabetes Care. 2000;23(5):583-8.
16.
Gallagher A, Home PD. The effect of improved post-prandial blood glucose control on post-
prandial metabolism and markers of vascular risk in people with Type 2 diabetes. Diabetes 
Res Clin Pract. 2005;67(3):196-203.
17.
Perriello G, Pampanelli S, Porcellati F, Avogaro A, Bosi E, Petrella G, et al. Insulin aspart 
improves meal time glycaemic control in patients with Type 2 diabetes: a randomized, 
stratified, double-blind and cross-over trial. Diabet Med. 2005;22(5):606-11.
18.
Bretzel RG, Arnolds S, Medding J, Linn T. A direct efficacy and safety comparison of 
insulin aspart, human soluble insulin, and human premix insulin (70/30) in patients with 
type 2 diabetes. Diabetes Care. 2004;27(5):1023-7.
19.
Novo Nordisk A/S. NovoRapid® (insulin aspart), EU Summary of Product Characteristics 
(SmPC). 15 Nov 2016.
20.
Novo Nordisk A/S. NovoLog (insulin aspart), US Prescribing Information (PI). 07 Oct 
2016.
21.
Novo Nordisk A/S. Fiasp (insulin aspart), EU Summary of Product Characteristics (SmPC). 
03 Feb 2017.
22.
Novo Nordisk A/S. Investigator's Brochure, Faster-acting Insulin Aspart (9th Edition). 2016.
23.
Novo Nordisk A/S. Tresiba® (insulin degludec) EU Summary of Product Characteristics 
(SmPC). August 2015.
24.
Novo Nordisk A/S. Investigator's Brochure, insulin degludec (Tresiba®), project NN1250, 
(edition 12). 14 Dec 2016.
25.
European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). 
Guideline on clinical investigation of medicinal products in the treatment or prevention of 
diabetes mellitus (CPMP/EWP/1080/00 Rev. 1). Adoption by CHMP. 14 May 2012.
26.
U.S. Department of Health and Human Services, Food and Drug Administration. Guidance 
for Industry. Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment 
and Prevention, Draft Guidance. 2008.
27.
Rodbard HW, Visco VE, Andersen H, Hiort LC, Shu DH. Treatment intensification with 
stepwise addition of prandial insulin aspart boluses compared with full basal-bolus therapy 
(FullSTEP Study): a randomised, treat-to-target clinical trial. Lancet Diabetes Endocrinol. 
2014;2(1):30-7.
28.
Novo Nordisk A/S. http://www.novonordisk-trials.com/website/content/how-we-disclose-
trial-information.aspx.
29.
De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Clinical trial 
registration: a statement from the International Committee of Medical Journal Editors. N 
Engl J Med. 2004;351(12):1250-1.
30.
U.S. Food and Drug Administration. Food and Drug Administration Amendments Act of 
2007 as amended by the Final Rule "Clinical Trials Registration and Results Information 
Submission". 21 September 2017.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
112 of 112
31.
The European Parliament and the Council of the European Council. Directive 2001/20/EC 
of the European Parliament and of the Councill of 4 April 2001 on the approximation of the 
laws, regulations and administrative provisions of the Member States relating to the 
implementation of good clinical practice in the conduct of clinical trials on medicinal 
products for human use, article 11. Official Journal of the European Communities. 1 May 
2001.
32.
The European Parliament and the Council of the European Council. Regulation (EC) No 
726/2004 of the European Parliament and of the Council of 31 March 2004 laying down 
Community procedures for the authorisation and supervision of medicinal products for 
human and veterinary use and establishing a European Medicines Agency, article 57. 
Official Journal of the European Communities. 2004.
33.
Clarke WL, Cox DJ, Gonder-Frederick LA, Julian D, Schlundt D, Polonsky W. Reduced 
awareness of hypoglycemia in adults with IDDM. A prospective study of hypoglycemic 
frequency and associated symptoms. Diabetes Care. 1995;18(4):517-22.
34.
Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al. Hypoglycemia
and diabetes: a report of a workgroup of the American Diabetes Association and the 
Endocrine Society. Diabetes Care. 2013;36(5):1384-95.
35.
McAulay V, Deary IJ, Frier BM. Symptoms of hypoglycaemia in people with diabetes. 
Diabet Med. 2001;18(9):690-705.
36.
U.S. Department of Health and Human Services, Food and Drug Administration. Guidance 
for Industry. Patient-Reported Outcome Measures: Use in Medical Product Development to 
Support Labeling Claims. December 2009.
37.
Stull DE, Leidy NK, Parasuraman B, Chassany O. Optimal recall periods for patient-
reported outcomes: challenges and potential solutions. Curr Med Res Opin. 2009;25(4):929-
42.
38.
European Commission. The Rules Governing Medicinal Products in the European Union, 
Volume 4, Annex 13, Investigational Medicinal Products. Brussels, February 2010.
39.
International Conference of Harmonisation. ICH Harmonised Tripartite Guideline E9. 
Statistical Principles for Clinical Trials, Step 4 Version. 5 Feb 1998.
40.
Koch GG. Comments on 'Current issues in non-inferiority trials' by Thomas R. Fleming, 
Statistics in Medicine, DOI: 10.1002/sim.2855. Stat Med. 2008;27(3):333-42.
41.
Schwartz NS, Clutter WE, Shah SD, Cryer PE. Glycemic thresholds for activation of 
glucose counterregulatory systems are higher than the threshold for symptoms. J Clin Invest. 
1987;79(3):777-81.
42.
International Committee of Medical Journal Editors. Recommendations for the Conduct, 
Reporting, Editing and Publication of Scholarly Work in Medical Journals; current version 
available at www.icmje.org.
CONFIDENTIAL


Trial ID: NN1218-4113
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Protocol - Appendix A
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
1 of 9
Appendix A: Titration Guideline
Trial ID: NN1218-4113
Efficacy and Safety of Fast-acting Insulin Aspart Compared to 
NovoRapid® both in Combination with Insulin Degludec with or 
without Metformin in Adults with Type 2 Diabetes (onset® 9)
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties
CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.


Trial ID: NN1218-4113
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Protocol - Appendix A
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
2 of 9
Table of Contents
Page
Table of Contents..............................................................................................................................................2
List of in-text tables..........................................................................................................................................2
1
Introduction...............................................................................................................................................3
2
Treatment regimens..................................................................................................................................4
2.1
Injection area..................................................................................................................................4
2.2
Time of injection............................................................................................................................4
3
Initiation and titration ..............................................................................................................................5
3.1
Initiation of insulin degludec (Visit 2)...........................................................................................5
3.2
Titration insulin degludec during run-in........................................................................................5
3.3
Treatment with bolus insulin during run-in ...................................................................................6
3.4
Initiation of faster aspart or NovoRapid® at Visit 14.....................................................................6
3.5
Titration of faster aspart or NovoRapid® from randomisation (Visit 14).......................................6
3.6
Deviations from the algorithm.......................................................................................................7
4
Data collection ...........................................................................................................................................8
5
Review procedure......................................................................................................................................8
6
References..................................................................................................................................................9
List of in-text tables
Page
Table 1
Increase of insulin degludec Dose .................................................................................................5
Table 2
Reduction of insulin degludec Dose ..............................................................................................6
Table 3
Faster aspart or NovoRapid® dose adjustment algorithm...............................................................7
CONFIDENTIAL


Trial ID: NN1218-4113
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Protocol - Appendix A
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
3 of 9
1
Introduction
The goal of insulin therapy is to achieve near normoglycaemia, i.e. to reach a pre-defined HbA1c
level with a low rate of hypoglycaemic episodes and as little weight gain as possible. Several trials 
have shown that this is difficult to achieve, unless plasma glucose (PG) values are intensively 
monitored and the insulin dose(s) frequently adjusted 1-6.
To ensure treatment uniformity between the sites, as well as to ensure that subjects receive an 
optimal treatment, titration algorithms have been developed specifying recommended dose 
adjustments at different PG levels.
It is recognised that treatments differ between different regions and countries. Likewise, specific 
titration guidelines may not be applicable in certain clinical situations. It is important that other 
information, such as symptoms of hypo/hyperglycaemia, previous response to dose adjustments, 
other glucose measurements and other indicators of the subject’s level of glycaemic control, is 
taken into consideration when decisions on dosing are made. The investigator should always use his 
clinical judgement to avoid safety hazards. The investigator is responsible for the treatment of the 
subjects and can therefore overrule the guideline.
To optimise and maintain glycaemic control, the Investigator should, throughout the trial be at least 
in weekly contact with the subjects to assist the subjects in adjusting insulin doses and to ensure the 
subject’s welfare.
CONFIDENTIAL


Trial ID: NN1218-4113
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Protocol - Appendix A
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
4 of 9
2
Treatment regimens
All subjects will be treated with insulin degludec and NovoRapid® /fast-acting insulin aspart (faster 
aspart) in a basal-bolus regimen.
At Visit 2 eligible subjects will be transferred from their previous basal insulin dose to insulin 
degludec once daily according to Section 3.1.
During the following 12 weeks the Investigator will focus on adjusting the basal insulin dose 
according to Section 3.2.
In addition, the subjects will continue their pre-trial bolus insulin analogue with or without 
metformin at Visit 2. No adjustments of bolus insulin should be performed by the Investigator 
unless for safety reasons during the run-in period.
At randomisation (after 12 weeks) eligible subjects will be randomised 1:1 into two parallel 
treatment groups:
1. mealtime faster aspart + insulin degludec
2. mealtime NovoRapid® + insulin degludec
During the following 16 weeks treatment period the Investigator will focus on adjusting the bolus
insulin dose according to Section 3.5.
2.1
Injection area
Insulin degludec should be injected subcutaneously into the thigh, or upper arm (deltoid area). 
Faster aspart or NovoRapid® should be injected subcutaneously into the abdominal wall.
Rotation of injection sites within a given region is recommended.
2.2
Time of injection
Insulin degludec should be administered once daily at any time of the day, preferably at the same 
time every day.
Faster aspart or NovoRapid® should be given 0-2 minutes prior to main meals. 
Main meals are defined as breakfast, lunch and main evening meal. Extra bolus dosing is allowed at 
the Investigator’s recommendation.
CONFIDENTIAL


Trial ID: NN1218-4113
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Protocol - Appendix A
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
5 of 9
3
Initiation and titration
3.1
Initiation of insulin degludec (Visit 2) 
Subjects’ previous basal insulin should be switched to insulin degludec once daily on unit-to-unit
basis at Visit 2 by the Investigator’s discretion. However, when switching from Toujeo® or twice 
daily basal insulin, 20% dose reduction in basal dose should be considered. 
3.2
Titration insulin degludec during run-in
Insulin degludec dose will be adjusted weekly by the Investigator in the run-in period in connection 
with the scheduled visit/phone contacts.
The dose of insulin degludec should be titrated based on the mean of three pre-breakfast SMPG
values measured on the three days prior to the contact in accordance with Table 1.
Insulin degludec should not be used to correct the postprandial glucose excursions.
If one or more SMPGs values are missing, the adjustment should be performed on the remaining 
SMPG value(s).
If one of the SMPG values is below target (< 4.0 mmol/L or 71 mg/dL) then the insulin degludec 
dose should be reduced in accordance with Table 2.
Table 1
Increase of insulin degludec Dose 
Mean Pre-breakfast SMPG Values 
Increase of insulin degludec dose 
mmol/L
mg/dL
U
4.0 – 5.0
71 – 90
No adjustment
5.1 – 7.0
91  – 126 
+ 2
7.1 – 8.0 
127 – 144
+ 4
8.1 – 9.0
145 – 162
+ 6
> 9.0
> 162
+ 8
CONFIDENTIAL


Trial ID: NN1218-4113
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Protocol - Appendix A
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
6 of 9
Table 2
Reduction of insulin degludec Dose
Lowest Pre-breakfast SMPG Value
Reduction of insulin degludec dose 
mmol/L
mg/dL
U
3.1 – 3.9
56 – 70
- 2
<3.1
< 56
- 4
3.3
Treatment with bolus insulin during run-in
Subjects should continue their pre-trial bolus insulin analogue with or without metformin at Visit 2, 
and no adjustments of bolus insulin should be performed by the Investigator unless for safety 
reasons during the run-in period.
3.4
Initiation of faster aspart or NovoRapid® at Visit 14
Subjects should be switched to faster aspart or NovoRapid® (blinded) unit-to-unit from previous 
mealtime bolus doses at Visit 14 by the Investigator’s discretion.
3.5
Titration of faster aspart or NovoRapid® from randomisation (Visit 14) 
Titration of bolus insulin (faster aspart or NovoRapid®) should be performed from randomisation 
(Visit 14) and onwards while no adjustments of basal insulin dose(s) should be performed by the
Investigator unless for safety reasons during the treatment period.
Subjects will be instructed to perform 4-point profiles at pre-breakfast, pre-lunch, pre- main evening 
meal and bedtime every day during the conduct of the trial for titration purposes.
Faster aspart or NovoRapid® should be titrated twice weekly to reach the glycaemic target of pre-
prandial and bedtime plasma glucose between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target 
fashion. 
1)
At the scheduled visit/phone contact, adjustment of faster aspart or NovoRapid® doses should 
be performed by investigator and based on pre-prandial and/or bedtime SMPG values which 
are measured during last 3-4 days before each scheduled visit/phone contact.
2)
In between the scheduled visit/phone contacts the subject should be instructed by the 
Investigator to use the same titration algorithm to self-titrate faster aspart or NovoRapid®
doses based on SMPG values measured on the remaining 4 – 3 days between scheduled 
visits/phone contacts.
The adjustments should be according to Table 3
!
Breakfast faster aspart or NovoRapid® will be titrated according to pre-lunch SMPG values 
measured on previous days
CONFIDENTIAL


Trial ID: NN1218-4113
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Protocol - Appendix A
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
7 of 9
!
Lunch faster aspart or NovoRapid® will be titrated according to pre-dinner SMPG values 
measured on previous days 
!
Main evening meal faster aspart or NovoRapid® will be titrated according to bedtime SMPG
values measured on previous days
Table 3
Faster aspart or NovoRapid® dose adjustment algorithm
Pre-prandial or bedtime SMPG Values
Dose adjustment
Rules for dose adjustment
mmol/L
mg/dL
U
< 4.0
< 71
- 1
≥ 1 SMPG below target
4.0 – 6.0
71 -108
0
0-1 SMPG above target
No SMPGs below target
> 6.0
> 108
+ 1
≥ 2 SMPGs above target
No SMPGs below target
Additional bolus dosing is allowed at the investigator’s recommendation. The dose will be entered 
in the eDiary ‘extra bolus insulin’.
3.6
Deviations from the algorithm
It is recommended that the algorithm is followed. However, it is also important that the decision to 
adjust the insulin degludec, faster aspart or NovoRapid® doses are based on all relevant information 
as described in Section 3. A reason for deviating from the algorithm should be entered into the 
eDiary web portal by the Investigator as applicable.
CONFIDENTIAL


Trial ID: NN1218-4113
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Protocol - Appendix A
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
8 of 9
4
Data collection
The titration data and hypoglycaemic episodes should be entered into the eDiary within 24 hours 
(for details referring to Protocol).
If titration data on a subject is missing then the Investigator will be asked for the reason.
5
Review procedure
Surveillance of titration data will be performed centrally by Novo Nordisk in an unbiased manner.
The data will be reviewed and significant changes from the titration algorithm will be followed up.
It is important that data regarding dose titration is entered into the eDiary. If delays occur, action 
cannot be taken in due time before the subject’s next site visit/phone contact. The aim is to reduce 
the time periods in which a subject may receive suboptimal treatment.
The titration data should be reviewed by Novo Nordisk within 24 hours (on weekdays). The 
reviewer may contact the investigator to get clarification regarding the reason for deviation or to 
request entry of missing data.
When the investigator receives an inquiry, a response should be received at Novo Nordisk within 24 
hours (on weekdays). 
During the trial HbA1c will be monitored by Novo Nordisk for additional surveillance of the 
glycaemic control. Novo Nordisk may be in contact with sites (visit or phone contact) to discuss 
progress in glycaemic control and titration of individual subjects based on SMPGs and HbA1c. This 
will be done in an unbiased and whenever possible in a blinded manner.
CONFIDENTIAL


Trial ID: NN1218-4113
CONFIDENTIAL
Date:
28 March 2017
1RYR1RUGLVN
Protocol - Appendix A
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
9 of 9
6
References 
1. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 
52-week, treat-to-target trial comparing insulin detemir with insulin glargine when 
administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 
diabetes. Diabetologia 2008; 51(3):408-416.
2. Hermansen K, Davies M, Derezinski T, Martinez RG, Clauson P, Home P. A 26-week, 
randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as 
add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. 
Diabetes Care 2006; 29(6):1269-1274.
3. Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B. 
Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral 
antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 2006; 28(10):1569-1581.
4. Riddle et al. The Treat-to-Target Trial. Randomized addition of glargine or human NPH 
insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26(11): 3080-3086.
5. Garber AJ, King AB, Del Prato S, Sreenan S, Balci MK, Muñoz-Torres M, Rosenstock J, 
Endahl LA, Francisco AM, Hollander P: Insulin degludec, an ultra-long acting basal insulin, 
versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 
diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target 
non-inferiority trial. Lancet. 2012 Apr 21;379(9825):1498-507.
6. Heller S, Buse J, Fisher M, Garg S, Marre M, Merker L, Renard E, Russell-Jones D, 
Philotheou A, Francisco AM, Pei H, Bode B: Insulin degludec, an ultra-long acting basal 
insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 
1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target 
non-inferiority trial. Lancet 2012 Apr 21;379(9825):1489-97.
CONFIDENTIAL


Trial ID: NN1218-4113
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Protocol - Appendix A
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
1 of 9
Appendix A: Titration Guideline
Trial ID: NN1218-4113
Efficacy and Safety of Fast-acting Insulin Aspart Compared to 
NovoRapid® both in Combination with Insulin Degludec with or 
without Metformin in Adults with Type 2 Diabetes (onset® 9)
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties
CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.


Trial ID: NN1218-4113
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Protocol - Appendix A
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
2 of 9
Table of Contents
Page
Table of Contents........................................................................................................................................2
List of in-text tables ....................................................................................................................................2
1
Introduction .........................................................................................................................................3
2
Treatment regimens.............................................................................................................................4
2.1
Injection area ............................................................................................................................4
2.2
Time of injection.......................................................................................................................4
3
Initiation and titration.........................................................................................................................5
3.1
Initiation of insulin degludec (Visit 2) .......................................................................................5
3.2
Titration insulin degludec during run-in.....................................................................................5
3.3
Treatment with bolus insulin during run-in................................................................................6
3.4
Initiation of faster aspart or NovoRapid® at Visit 14 ..................................................................6
3.5
Titration of faster aspart or NovoRapid® from randomisation (Visit 14) .....................................6
3.6
Deviations from the algorithm...................................................................................................7
4
Data collection......................................................................................................................................8
5
Review procedure ................................................................................................................................8
6
References ............................................................................................................................................9
List of in-text tables
Page
Table 1
Increase of insulin degludec Dose..............................................................................................5
Table 2
Reduction of insulin degludec Dose...........................................................................................6
Table 3
Faster aspart or NovoRapid® dose adjustment algorithm ............................................................7
CONFIDENTIAL


Trial ID: NN1218-4113
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Protocol - Appendix A
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
3 of 9
1
Introduction
The goal of insulin therapy is to achieve near normoglycaemia, i.e. to reach a pre-defined HbA1c
level with a low rate of hypoglycaemic episodes and as little weight gain as possible. Several trials 
have shown that this is difficult to achieve, unless plasma glucose (PG) values are intensively 
monitored and the insulin dose(s) frequently adjusted 1-6.
To ensure treatment uniformity between the sites, as well as to ensure that subjects receive an 
optimal treatment, titration algorithms have been developed specifying recommended dose 
adjustments at different PG levels.
It is recognised that treatments differ between different regions and countries. Likewise, specific 
titration guidelines may not be applicable in certain clinical situations. It is important that other 
information, such as symptoms of hypo/hyperglycaemia, previous response to dose adjustments, 
other glucose measurements and other indicators of the subject’s level of glycaemic control, is 
taken into consideration when decisions on dosing are made. The investigator should always use his 
clinical judgement to avoid safety hazards. The investigator is responsible for the treatment of the 
subjects and can therefore overrule the guideline.
To optimise and maintain glycaemic control, the Investigator should, throughout the trial be at least 
in weekly contact with the subjects to assist the subjects in adjusting insulin doses and to ensure the 
subject’s welfare.
CONFIDENTIAL


Trial ID: NN1218-4113
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Protocol - Appendix A
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
4 of 9
2
Treatment regimens
All subjects will be treated with insulin degludec and NovoRapid® /fast-acting insulin aspart (faster 
aspart) in a basal-bolus regimen.
At Visit 2 eligible subjects will be transferred from their previous basal insulin dose to insulin 
degludec once daily according to Section 3.1.
During the following 12 weeks the Investigator will focus on adjusting the basal insulin dose 
according to Section 3.2.
In addition, the subjects will continue their pre-trial bolus insulin analogue with or without 
metformin at Visit 2. No adjustments of bolus insulin should be performed by the Investigator 
unless for safety reasons during the run-in period.
At randomisation (after 12 weeks) eligible subjects will be randomised 1:1 into two parallel 
treatment groups:
1. mealtime faster aspart + insulin degludec
2. mealtime NovoRapid® + insulin degludec
During the following 16 weeks treatment period the Investigator will focus on adjusting the bolus
insulin dose according to Section 3.5.
2.1
Injection area
Insulin degludec should be injected subcutaneously into the thigh, or upper arm (deltoid area). 
Faster aspart or NovoRapid® should be injected subcutaneously into the abdominal wall.
Rotation of injection sites within a given region is recommended.
2.2
Time of injection
Insulin degludec should be administered once daily at any time of the day, preferably at the same 
time every day.
Faster aspart or NovoRapid® should be given 0-2 minutes prior to main meals. 
Main meals are defined as breakfast, lunch and main evening meal. Extra bolus dosing is allowed at 
the Investigator’s recommendation.
CONFIDENTIAL


Trial ID: NN1218-4113
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Protocol - Appendix A
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
5 of 9
3
Initiation and titration
3.1
Initiation of insulin degludec (Visit 2) 
Subjects’ previous basal insulin should be switched to insulin degludec once daily on unit-to-unit
basis at Visit 2 by the Investigator’s discretion. However, when switching from Toujeo® or twice 
daily basal insulin, 20% dose reduction in basal dose should be considered. 
3.2
Titration insulin degludec during run-in
Insulin degludec dose will be adjusted weekly by the Investigator in the run-in period in connection 
with the scheduled visit/phone contacts.
The dose of insulin degludec should be titrated based on the mean of three pre-breakfast SMPG
values measured on the last two days prior to and on the day of contact in accordance with Table 1.
Insulin degludec should not be used to correct the postprandial glucose excursions.
If one or more SMPGs values are missing, the adjustment should be performed on the remaining 
SMPG value(s).
If one of the SMPG values is below target (< 4.0 mmol/L or 71 mg/dL) then the insulin degludec 
dose should be reduced in accordance with Table 2.
Table 1
Increase of insulin degludec Dose 
Mean Pre-breakfast SMPG Values 
Increase of insulin degludec dose 
mmol/L
mg/dL
U
4.0 – 5.0
71 – 90
No adjustment
5.1 – 7.0
91  – 126 
+ 2
7.1 – 8.0 
127 – 144
+ 4
8.1 – 9.0
145 – 162
+ 6
> 9.0
> 162
+ 8
CONFIDENTIAL


Trial ID: NN1218-4113
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Protocol - Appendix A
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
6 of 9
Table 2
Reduction of insulin degludec Dose
Lowest Pre-breakfast SMPG Value
Reduction of insulin degludec dose 
mmol/L
mg/dL
U
3.1 – 3.9
56 – 70
- 2
<3.1
< 56
- 4
3.3
Treatment with bolus insulin during run-in
Subjects should continue their pre-trial bolus insulin analogue with or without metformin at Visit 2, 
and no adjustments of bolus insulin should be performed by the Investigator unless for safety 
reasons during the run-in period.
3.4
Initiation of faster aspart or NovoRapid® at Visit 14
Subjects should be switched to faster aspart or NovoRapid® (blinded) unit-to-unit from previous 
mealtime bolus doses at Visit 14 by the Investigator’s discretion.
3.5
Titration of faster aspart or NovoRapid® from randomisation (Visit 14) 
Titration of bolus insulin (faster aspart or NovoRapid®) should be performed from randomisation 
(Visit 14) and onwards while no adjustments of basal insulin dose(s) should be performed by the
Investigator unless for safety reasons during the treatment period.
Subjects will be instructed to perform 4-point profiles at pre-breakfast, pre-lunch, pre- main evening 
meal and bedtime every day during the conduct of the trial for titration purposes.
Faster aspart or NovoRapid® should be titrated twice weekly to reach the glycaemic target of pre-
prandial and bedtime plasma glucose between 4.0-6.0 mmol/L (71 - 108 mg/dL) in a treat-to-target 
fashion. 
1)
At the scheduled visit/phone contact, adjustment of faster aspart or NovoRapid® doses should 
be performed by investigator and based on pre-prandial and/or bedtime SMPG values which 
are measured during last 3-4 days before each scheduled visit/phone contact.
2)
In between the scheduled visit/phone contacts the subject should be instructed by the 
Investigator to use the same titration algorithm to self-titrate faster aspart or NovoRapid®
doses based on SMPG values measured on the remaining 3-4 days between scheduled 
visits/phone contacts.
The adjustments should be according to Table 3
!
Breakfast faster aspart or NovoRapid® will be titrated according to pre-lunch SMPG values 
measured on the previous three days
CONFIDENTIAL


Trial ID: NN1218-4113
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Protocol - Appendix A
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
7 of 9
!
Lunch faster aspart or NovoRapid® will be titrated according to pre-dinner SMPG values 
measured on the previous three days 
!
Main evening meal faster aspart or NovoRapid® will be titrated according to bedtime SMPG
values measured on the previous three days
Table 3
Faster aspart or NovoRapid® dose adjustment algorithm
Pre-prandial or bedtime SMPG Values
Dose adjustment
Rules for dose adjustment
mmol/L
mg/dL
U
< 4.0
< 71
- 1
≥ 1 SMPG below target
4.0 – 6.0
71 -108
0
0-1 SMPG above target
No SMPGs below target
> 6.0
> 108
+ 1
≥ 2 SMPGs above target
No SMPGs below target
Additional bolus dosing is allowed at the investigator’s recommendation. The dose will be entered 
in the eCRF ‘extra bolus insulin’.
3.6
Deviations from the algorithm
It is recommended that the algorithm is followed. However, it is also important that the decision to 
adjust the insulin degludec, faster aspart or NovoRapid® doses are based on all relevant information 
as described in Section 3. A reason for deviating from the algorithm should be entered into the 
eCRF .
CONFIDENTIAL


Trial ID: NN1218-4113
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Protocol - Appendix A
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
8 of 9
4
Data collection
The following data should be entered into the eCRF within 24 hours (on weekdays) after a site 
visit/phone contact:
!
Per protocol pre-prandial and bedtime SMPG values measured since the last visit/phone contact 
as described in sections 3.2 and 3.5
!
Basal and bolus insulin doses taken.
!
New insulin doses prescribed after titration
!
Reasons for deviation from the titration algorithms, if applicable
5
Review procedure
Surveillance of titration data will be performed centrally by Novo Nordisk in an unbiased manner. It 
is important that data regarding dose titration is entered into the eCRF within 24 hours (on 
weekdays). If delays occur, action cannot be taken in due time before the subject’s next site 
visit/phone contact. The aim is to reduce the time periods in which a subject may receive 
suboptimal treatment.
The data listed in section 4 will be reviewed by Novo Nordisk within 24 hours (on weekdays).
The reviewer may contact the investigator to get clarification regarding the reason for deviation or 
to request entry of missing data.
When the investigator receives an inquiry, a response should be received at Novo Nordisk within 24 
hours (on weekdays). 
During the trial HbA1c will be monitored by Novo Nordisk for additional surveillance of the 
glycaemic control. Novo Nordisk may be in contact with sites (visit or phone contact) to discuss 
progress in glycaemic control and titration of individual subjects based on SMPGs and HbA1c. This 
will be done in an unbiased and whenever possible in a blinded manner.
CONFIDENTIAL


Trial ID: NN1218-4113
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Protocol - Appendix A
Version:
4.0
UTN: U1111-1180-0636
Status:
Final
EudraCT no.: 2016-000878-38
Page:
9 of 9
6
References 
1.
Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 
52-week, treat-to-target trial comparing insulin detemir with insulin glargine when 
administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 
diabetes. Diabetologia. 2008;51(3):408-16.
2.
Hermansen K, Davies M, Derezinski T, Ravn GM, Clauson P, Home P, et al. A 26-week, 
randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as 
add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. 
Diabetes Care. 2006;29(6):1269-74.
3.
Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B. 
Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral 
antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther. 2006;28(10):1569-81.
4.
Riddle MC, Rosenstock J, Gerich J, Insulin Glargine Study Investigators. The treat-to-target 
trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 
diabetic patients. Diabetes Care. 2003;26(11):3080-6.
5.
Garber AJ, King AB, Del Prato S, Sreenan S, Balci MK, Munoz-Torres M, et al. Insulin 
degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment 
with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, 
randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379(9825):1498-
507.
6.
Heller S, Buse J, Fisher M, Garg S, Marre M, Merker L, et al. Insulin degludec, an ultra-
longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime 
insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-
label, treat-to-target non-inferiority trial. Lancet. 2012;379(9825):1489-97.
CONFIDENTIAL


Global and country key Novo Nordisk staff
Attachments I and II (if applicable) to the protocol are located in the Trial Master File.
Content: Global key staff and Country key staff
&21),'(17,$/
'DWH
1RYR1RUGLVN
9HUVLRQ
6WDWXV
)DVWDFWLQJLQVXOLQDVSDUW
7ULDO,'11
&OLQLFDO7ULDO5HSRUW
$SSHQGL[
-XQH

)LQDO
CONFIDENTIAL


Protocol Amendment
CONFIDENTIAL
Date:
09 June 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
1.0
UTN:U1111-1180-0636
Status:
Final
EudraCT No.:2016-000878-38
Page:
1 of 3
Protocol Amendment
no 1
to Protocol, final version 2.0
dated 28 March 2017
Trial ID: NN1218-4113
Efficacy and Safety of Fast-acting Insulin Aspart Compared to NovoRapid® both in 
Combination with Insulin Degludec with or without Metformin in Adults with Type 2 
Diabetes (onset® 9)
Trial phase: 3b
Applicable to all countries
Amendment originator:
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.


Protocol Amendment
CONFIDENTIAL
Date:
09 June 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
1.0
UTN:U1111-1180-0636
Status:
Final
EudraCT No.:2016-000878-38
Page:
2 of 3
Table of Contents   
Page
Table of Contents........................................................................................................................................2
1
Introduction including rationale for the protocol amendment...........................................................3
2
Changes ................................................................................................................................................3
CONFIDENTIAL


Protocol Amendment
CONFIDENTIAL
Date:
09 June 2017
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
1.0
UTN:U1111-1180-0636
Status:
Final
EudraCT No.:2016-000878-38
Page:
3 of 3
1
Introduction including rationale for the protocol amendment
This global protocol amendment is made to accommodate requests from the European regulatory
authorities (Voluntary Harmonised Procedure) received during the approval process.
In this protocol amendment:
!
Any new text is written in italics.
!
Any text deleted from the protocol is written using strike through.
2
Changes
6.6 Criteria for premature discontinuation of trial products
Efforts must be made so that subjects attend and complete all scheduled visit procedures. Subjects 
should stay in the trial irrespective of lack of adherence to randomised treatment, lack of adherence 
to visit schedule or missing assessments. Only subjects who decline any further contact with the site 
in relation to the trial will be considered as withdrawn from the trial (see Section 6.7).
The subject may be prematurely discontinued from trial products at the discretion of the investigator 
due to a safety concern.
The subject must be prematurely discontinued from trial products if the following applies after 
randomisation:
1. Included in the trial in violation of the inclusion and/or exclusion criteria and/or randomised in 
violation of the randomisation criterion.
2. Pregnancy 
3. Intention of becoming pregnant
4. Simultaneous participation in another clinical trial of an approved or non-approved 
investigational medicinal product
5. Lack of efficacy defined as fulfilment of all 4 below criteria:
∀
No reduction in HbA1c measured by central laboratory from screening (Visit 1) to visit 18, 
22 or 26 AND
∀
A daily average of 4-point SMPG readings (before breakfast, before lunch, before dinner 
and at bed time) on 3 consecutive days higher than 240 mg/dL (13.3 mmol/L) within the last
two weeks period AND
∀
A confirmatory FPG exceeding 240 mg/dL (13.3 mmol/L) or a confirmatory random PG
exceeding 300 mg/dL (16.7 mmol/L) measured by central laboratory AND
∀
No treatable intercurrent cause (e.g. non-compliance) for the hyperglycaemia at the 
investigator’s judgment
6. Unacceptable adverse event (including toxicity) that cannot be solved by any medical 
intervention or considered as non-acceptable risk at the investigator's judgment.
CONFIDENTIAL


Protocol Amendment no 2
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
1.0
     
Status:
Final
     
Page:
1 of 4
Protocol Amendment
no 2
to Protocol, version 3.0
dated 09 June 2017
Trial ID: NN1218-4113
Efficacy and Safety of Fast-acting Insulin Aspart Compared to NovoRapid® both in 
Combination with Insulin Degludec with or without Metformin in Adults with Type 2 
Diabetes (onset® 9)
Trial phase: 3b
Applicable to all countries
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.


Protocol Amendment no 2
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
1.0
     
Status:
Final
     
Page:
2 of 4
Table of Contents   
1
Introduction including rationale for the protocol amendment...........................................................3
Discontinuation of the glycaemic data collection system ........................................................................3
2
Changes ................................................................................................................................................3
2.1
High-level summary of changes: ...............................................................................................3
2.2
Primary protocol sections affected.............................................................................................3
CONFIDENTIAL


Protocol Amendment no 2
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
1.0
     
Status:
Final
     
Page:
3 of 4
1
Introduction including rationale for the protocol amendment
Discontinuation of the glycaemic data collection system
Due to an unusual data reporting pattern of hypoglycaemia and glycaemic values in two ongoing 
randomised clinical trials (NN1250-4252 and NN1218-4113), Novo Nordisk has decided to 
discontinue the glycaemic data collection system (i.e. the combined use of a BG-meter and eDiary) 
in trials using this system to protect the safety of the trial participants. This affects the 
NN1250-4252, NN1218-4113 and NN1250-4300 trials.
This protocol amendment has been created in alignment with the above decision to replace the 
electronic glycaemic data collection system with a paper diary solution and a new trial BG meter.
2
Changes
The discontinuation of the glycaemic data collection system necessitates update of many sections. 
Therefore, track-changes version of the protocol, titration guideline and SI-IC serves as
documentation of the changes.
2.1
High-level summary of changes:
-
Replacement of eDiary requirements with paper diary requirements (in alignment with the 
protocol template) including change of trial BG-meter. Throughout the protocol “eDiary”
has been replaced with “diary”
-
Clarification to titration guideline section 3.2. Information was provided to investigators in 
a memo dated 30-Nov-2017 to make it clear that insulin degludec titration is based on 
SMPGs two days prior to and on day of contact instead of three days prior to contact
-
In agreement with SI-IC SOP author it was decided to include the new statements regarding 
Personal Data Protection in the amended SI-IC according to updated SI-IC template version 
10.0
-
Minor clarifying updates to protocol text
2.2
Primary protocol sections affected
-
2 Flowchart
-
8.1.2 Run-in
-
8.1.9 Premature discontinuation of trial products
-
8.1.11 Review of results
-
8.3.2 Discontinuation of MyGlucoHealth BG-meter and eDiary (new section)
-
8.3.3 Self-measured plasma glucose
-
8.3.4 Insulin dose
-
8.4.2 Hypoglycaemic episodes
CONFIDENTIAL


Protocol Amendment no 2
CONFIDENTIAL
Date:
23 February 2018
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
1.0
     
Status:
Final
     
Page:
4 of 4
-
8.6.3 Diary
-
9.5 Auxiliary supplies
-
12.4.1 Reporting of technical complaints
-
12.4.2 Collection, storage and shipment of technical complaint samples
-
13.1 Corrections to case report forms
-
14 Monitoring procedures
-
16 Computerised systems
CONFIDENTIAL

SAP_001.pdf: 
Cover Page for Statistical analysis plan 
Sponsor name: 
Novo Nordisk A/S 
NCT number 
NCT03268005 
Sponsor trial ID: 
NN1218-4113 
Official title of study: 
Efficacy and Safety of Fast-acting Insulin Aspart Compared to 
NovoRapid® both in Combination with Insulin Degludec with 
or without Metformin in Adults with Type 2 Diabetes  
(onset® 9) 
Document date: 
20 June 2019 


/LQN
/LVWRIFRQWHQWV
6WDWLVWLFDODQDO\VLVSODQ
&21),'(17,$/
'DWH
1RYR1RUGLVN
9HUVLRQ
6WDWXV
)DVWDFWLQJLQVXOLQDVSDUW
7ULDO,'11
&OLQLFDO7ULDO5HSRUW
$SSHQGL[
-XQH

)LQDO
'RFXPHQWDWLRQRIVWDWLVWLFDOPHWKRGV
CONFIDENTIAL
Redacted VWDWLVWLFDODQDO\VLVSODQ 
Includes redaction of personal identifiable information only. 
. 


Statistical Analysis Plan
CONFIDENTIAL
Date:
12 February 2019
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT No.: 2016-000878-38
Page:
1 of 29
Statistical Analysis Plan
Trial ID: NN1218-4113
Efficacy and Safety of Fast-acting Insulin Aspart Compared to 
NovoRapid® both in Combination with Insulin Degludec with or 
without Metformin in Adults with Type 2 Diabetes (onset® 9)
Author:
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
12 February 2019
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT No.: 2016-000878-38
Page:
2 of 29
Table of contents   
Page
Table of contents.........................................................................................................................................2
List of abbreviations ...................................................................................................................................3
1
Introduction .........................................................................................................................................4
1.1
Trial information.......................................................................................................................4
1.2
Scope of the statistical analysis plan..........................................................................................5
2
Statistical considerations .....................................................................................................................6
2.1
Sample size calculation .............................................................................................................8
2.2
Definition of analysis sets........................................................................................................10
2.3
Primary endpoint.....................................................................................................................11
2.4
Secondary endpoints ...............................................................................................................15
2.4.1
Confirmatory secondary endpoints.........................................................................15
2.4.2
Supportive secondary endpoints .............................................................................17
2.4.2.1
Efficacy endpoints............................................................................17
2.4.2.2
Safety endpoints...............................................................................21
2.5
Supplementary analyses ..........................................................................................................26
3
Changes to the statistical analyses planned in the protocol..............................................................26
4
References ..........................................................................................................................................29
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
12 February 2019
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT No.: 2016-000878-38
Page:
3 of 29
List of abbreviations
ADA
American Diabetes Association
AE
adverse event
ALT
alanine aminotransferase
AST
aspartate aminotransferase
BG
blood glucose
CI
confidence interval
ECG
electrocardiogram
FAS
full analysis set
FPG
fasting plasma glucose
HbA1c
glycosylated haemoglobin
HDL
high density lipoprotein
ICH
international council on harmonisation
LDL
low density lipoprotein
MAR
missing at random
MedDRA
Medical Dictionary for Regulatory Activities
PG
plasma glucose
PP
per protocol
PPG
postprandial glucose
SAE
serious adverse event
SAP
statistical analysis plan
SD
standard deviation
SMPG
self-measured plasma glucose
T2DM
type 2 diabetes mellitus
TEAE
treatment emergent adverse event
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
12 February 2019
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT No.: 2016-000878-38
Page:
4 of 29
1
Introduction
1.1
Trial information
This is a phase 3b, 16-week, multicentre, multinational, 1:1 randomised, double-blind, active 
controlled, treat-to-target, parallel group trial with a 12-week run-in period comparing the effect and 
safety of faster aspart to NovoRapid® both in combination with insulin degludec with or without 
metformin in subjects with T2DM treated with a basal-bolus regimen.
The total duration of the trial is approximately 34 weeks divided into the following periods (see
Figure 1–1):
!
An approximately 2-week screening period
!
A 12-week run-in period primarily for optimisation of the basal insulin and subject training
!
A 16-week treatment period 
!
A 30-day follow-up period: FU1; 7 days after end of treatment and FU2; 30 days after end 
of treatment
Figure 1–1
Trial design
The trial includes a screening period followed by weekly visits/phone contacts during the trial. At 
Visit 2, all eligible subjects will be enrolled in a 12-week run-in period. After the run-in period, 
subjects eligible for randomisation (HbA1c ≤ 9.0% measured at Visit 13) will be randomised (1:1) to 
receive double blinded treatment with either faster aspart or NovoRapid® both in combination with 
once daily insulin degludec with or without metformin.
   -14    -12 weeks       
0
                 
                                16 weeks +7d+30d   
Screening
Randomisation
Faster aspart + insulin degludec ± metformin
NovoRapid
® + insulin degludec ± metformin 
End of 
treatment
Basal titration
Bolus titration
Bolus insulin analogue + insulin 
degludec ± metformin
FU1   FU2
12-week run-in period
16-week treatment period
HbA1c ≤9.0 % 
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
12 February 2019
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT No.: 2016-000878-38
Page:
5 of 29
Subjects will have a standardised meal test at baseline (Visit 14 before randomisation) and at end of 
treatment (Visit 30). The meal test is described in more detail in section 8.3.1 in the protocol.
After the 16-week treatment period, each subject will have a 30-day safety follow-up period.
The primary objective is to confirm the effect in terms of glycaemic control of treatment with faster 
aspart compared to NovoRapid® both in combination with insulin degludec with or without 
metformin in adults with T2DM treated with a basal-bolus regimen, using a non-inferiority 
approach.
The secondary objectives are to confirm superiority of faster aspart compared to NovoRapid® both 
in combination with insulin degludec with or without metformin in adults with T2D M treated with a 
basal-bolus regimen in terms of:
!
Postprandial glucose regulation
!
Overall glycaemic control
!
Postprandial glucose excursions
To compare the safety of faster aspart to NovoRapid® both in combination with insulin degludec 
with or without metformin in adults with T2DM treated with a basal-bolus regimen.
Subjects prematurely discontinued from trial product should continue with the per protocol planned 
visits at 4 (Visit 18), 8 (Visit 22), 12 (Visit 26), 16 (Visit 30) weeks after randomisatio n depending 
on when the subject discontinues trial products.
For further details on handling of subjects that prematurely discontinue from trial product and the 
trial in general, please see the trial protocol.
1.2
Scope of the statistical analysis plan
This statistical analysis plan (SAP) is based on the protocol Efficacy and Safety of Fast-acting 
Insulin Aspart Compared to NovoRapid® both in Combination with Insulin Degludec with or 
without Metformin in Adults with Type 2 Diabetes (onset® 9), version 4.0 (dated 23 February 2018).
The statistical analyses and derivations of endpoints presented in this SAP are almost identical to 
those described in the protocol. It contains minor clarifications for derivations, calculation of 
endpoints and analyses as well as some additions.
The changes to the statistical considerations proposed in this SAP and the reasons for the changes 
are described in section 3 and will be reported in the clinical trial report (CTR).
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
12 February 2019
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT No.: 2016-000878-38
Page:
6 of 29
2
Statistical considerations
General considerations
In general, for endpoints evaluated as a change from baseline and/or where a baseline adjustment is 
made, baseline is defined as information collected at randomisation (Visit 14). In case a 
measurement is not available at randomisation, the most recent measurement prior to randomisation 
will be used as baseline.
Two observation periods are defined, “in-trial” and “on-treatment”, and it will be specified which 
period each analysis will use.
!
In-trial: The observation period from date of randomisation and until last trial -related 
subject-site contact. The in-trial observation period includes data collected after treatment 
discontinuation.
!
On-treatment: The observation period from date of first dose of randomised 
NovoRapid®/faster aspart and to 7 days after the first occurrence of:
o
The day of last dose of randomised NovoRapid ®/faster aspart
o
The day before initiation of ancillary treatment
All efficacy endpoints will be summarised and analysed using the full analysis set (FAS), unless 
otherwise stated. Safety endpoints will be summarised using the safety analysis set and analysed 
using the FAS, unless otherwise stated. The FAS and safety analysis set are defined in section 2.2.
Presentation of results from a statistical analysis will include the estimated mean treatment effects 
(LSMeans) for change from baseline, if applicable. Estimated mean treatment differences (or ratios) 
will be presented together with two-sided 95% confidence interval (CI) for all endpoints analysed 
statistically.
Data collected before randomisation (Visit 14) will only be summarised descriptively.
Testing strategy and estimands
The primary objective of the trial is to confirm the effect of treatment with faster aspart compared to 
NovoRapid®, both in combination with insulin degludec with or without metformin in adults with 
T2DM in terms of glycaemic control, using a non-inferiority approach. 
More specifically the upper limit of the 95% confidence interval for the difference between faster 
aspart and NovoRapid® should be compared to a non-inferiority margin of 0.4%. If it is below or
equal to 0.4% non-inferiority will be considered established and effect demonstrated. 
The trial also aims to confirm superiority of treatment with faster aspart for a number of secondary 
confirmatory endpoints. The family-wise type I error rate will be controlled in the strong sense 
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
12 February 2019
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT No.: 2016-000878-38
Page:
7 of 29
using a hierarchical (fixed sequence) testing procedure under the framework of the primary 
estimand. This is based on a priority ordering of the null-hypotheses, and testing them in this order 
using the two-sided 95% confidence interval approach until an insignificant result appears. The 
effect is that rejection of a null hypothesis only will be considered for analyses where all previous 
null-hypotheses have been rejected in favour of faster aspart.
The steps in the hierarchical testing procedure are as follows:
Step 1 (Primary analysis): HbA1c non-inferiority of faster aspart versus NovoRapid®
Step 2: 1-hour PPG increment (meal test) superiority of faster aspart versus NovoRapid®
Step 3: HbA1c superiority of faster aspart versus NovoRapid ®
Step 4: 1,5-anhydroglucitol superiority of faster aspart versus NovoRapid ®
Primary estimand
The primary estimand is defined as the treatment difference between subjects randomised to faster 
aspart and NovoRapid® both in combination with insulin degludec with or without metformin, in 
adults with T2DM not optimally controlled with a basal-bolus regimen assessed by change from 
baseline in HbA1c 16 weeks after randomisation for all randomised subjects regardless of treatment 
discontinuation or use of ancillary treatment.
The primary estimand assesses the expected benefit a future population with T2DM can achieve if 
prescribed to faster aspart as compared to NovoRapid®. By not putting any restrictions on the 
treatment adherence, this estimand aims at a difference as close as possible to the one that can be 
expected in real-world clinical practice, provided that the treatment adherence and use of ancillary 
treatment reflects clinical practice. Thereby the primary estimand provides a treatment difference 
for clinicians concerning the glycaemic effect of faster aspart compared to NovoRapid® in the day 
to day life in subjects with T2DM in an adult population.
Secondary estimand
A secondary estimand is defined as the treatment difference in change from baseline in HbA1c 16 
weeks after randomisation between treatment with faster aspart and treatment with NovoRapid®
both in combination with insulin degludec with or without metformin in adult subjects with T2DM 
not optimally controlled with a basal-bolus regimen if all subjects had adhered to randomised 
treatment and did not receive ancillary treatment.  
The condition ‘adhered to randomised treatment and did not receive ancillary treatment’ should be 
interpreted as the exclusion of information collected after initiation of antidiabetic treatment that 
can mask or exaggerate the effect of the initially randomised treatment. Only data collected prior to 
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
12 February 2019
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT No.: 2016-000878-38
Page:
8 of 29
discontinuation of trial product or initiation of ancillary treatment is used to draw inference. This 
avoids confounding effects of ancillary treatment.
The two estimands will be repeated for the confirmatory endpoints
!
Change from baseline in 1-hour PPG increment (meal test) 16 weeks after randomisation
!
Change from baseline in 1,5-anhydroglucitol 16 weeks after randomisation
Visit reallocation
Subjects that prematurely discontinue from treatment or withdraw from trial will attend end of 
treatment visit called visit 30A. Data collected at this visit will be reallocated to the next scheduled 
visit where the given assessment is planned. As a general rule, all observed values from randomised 
subjects will be used in all statistical analyses, but in case two different values are associated to the 
same visit in time, the use of a given value will depend on the estimand of interest. For the primary 
estimand the reallocated on-treatment value will not be used and for the secondary estimand the 
reallocated on-treatment value will be used.
2.1
Sample size calculation
The sample size is determined to ensure a sufficient power for step 1 and step 2 in the hierarchical 
testing procedure for the primary estimand presented in section 2. The power for step 3 and 4 in the 
hierarchical testing procedure will also be presented. The sample size is determined using a non-
inferiority limit of 0.4% in step 1, which was chosen as described in section 5.2.1 in the protocol. 
The statistical evaluation will be done as described in sections 2.3 and 2.4.
In previous confirmatory trials where faster aspart has been investigated, the completion rates have 
been high. Therefore it will be expected that treatment discontinuation might be as low as 10% 
where trial discontinuation constitutes half of these and with similar withdrawal reasons in the 
treatment arms.
Power for the non-inferiority step (Step 1) is based on a t-statistic under the assumption of a one-
sided test of size 2.5% for the FAS. A mean treatment difference of -0.1% for the comparison 
between faster aspart and NovoRapid® in favour of faster aspart is expected. As trials in this 
population where data from treatment withdrawn subjects is retrieved is limited, a conservative 
estimate of the standard deviation (SD) in change from baseline in HbA1c of 0.8% was chosen. The 
power for superiority in step 3 will be calculated using the same assumptions as for step 1 but 
without the non-inferiority margin. 
For determination of power in step 2 in the hierarchical testing, where change from baseline in 1-
hour PPG increment 16 weeks after randomisation is compared between faster aspart and 
NovoRapid® a t-statistic with a two-sided test of size 5% is used, where the treatment difference is 
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
12 February 2019
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT No.: 2016-000878-38
Page:
9 of 29
expected to be at least 0.6 mmol/L [11 mg/dL]. The SD=3.5 mmol/L [63 mg/dL] in change from 
baseline in 1-hour PPG increments 16 weeks after randomisation based on laboratory analysed PG 
in a standardised meal test will be considered reasonable based on trials NN1218-3852 and 
NN1218-3853.
The power in step 4, where superiority of faster aspart over NovoRapid® in change from baseline in 
1,5-anhydroglucitol 16 weeks after randomisation is tested a t-statistic with a two-sided test of size 
5% is used. The mean treatment difference is expected to be at least 0.2 μg/mL and an SD of 
3.5μg/mL will be used based on trials NN1218-3852 and NN1218-3853.
The power calculations are done using proc power in SAS 9.4. Please refer to Table 2–1 for 
assumptions for the sample size calculation.
Table 2–1
Specifications assumed for sample size calculation
Statistical 
test
Significance 
level
Analysis 
population
Non-inferiority 
margin
SD
Mean 
difference
Randomisation 
scheme
Step 1 2-group t-test
One-sided 2.5 % FAS
0.4 % (absolute)
0.8 %
-0.1 %
1:1
Step 2 2-group t-test
Two-sided 5.0% FAS
NA
3.5 mmol/L
0.6 mmol/L
1:1
Step 3 2-group t-test
Two-sided 5.0% FAS
NA
0.8 %
-0.1 %
1:1
Step 4 2-group t-test
Two-sided 5.0% FAS
NA
3.5 μg/mL
0.2 μg/mL
1:1
In Table 2–2 the sensitivity of the sample size to the power shown for three different sizes of FAS. 
Three different choices of the mean difference are used to calculate the power in step 2.
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
12 February 2019
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT No.: 2016-000878-38
Page:
10 of 29
Table 2–2
Sensitivity of sample size to power
N 
total
N 
per 
arm
Step 
1
Step 2
Step 
3
Step 4
FAS FAS Mean 
diff
(%)
SD
(%)
Power 
(%)
Mean 
diff
(mmol/L)
SD
(mmol/L)
Power 
(%)
Mean 
diff
(%)
SD
(%)
Power 
(%)
Mean 
diff
(μg/mL)
SD
(μg/mL)
Power 
(%)
-0.1
0.8
>99.9
0.5
3.5
58.1
-0.1
0.8
47.4
0.2
3.5
13.9
920
460
-0.1
0.8
>99.9
0.6
3.5
73.8
-0.1
0.8
47.4
0.2
3.5
13.9
-0.1
0.8
>99.9
0.7
3.5
85.8
-0.1
0.8
47.4
0.2
3.5
13.9
-0.1
0.8
>99.9
0.5
3.5
64.7
-0.1
0.8
53.4
0.2
3.5
15.5
1072
536
-0.1
0.8
>99.9
0.6
3.5
80.1
-0.1
0.8
53.4
0.2
3.5
15.5
-0.1
0.8
>99.9
0.7
3.5
90.5
-0.1
0.8
53.4
0.2
3.5
15.5
-0.1
0.8
>99.9
0.5
3.5
70.4
-0.1
0.8
58.9
0.2
3.5
17.0
1224
612
-0.1
0.8
>99.9
0.6
3.5
85.0
-0.1
0.8
58.9
0.2
3.5
17.0
-0.1
0.8
>99.9
0.7
3.5
93.8
-0.1
0.8
58.9
0.2
3.5
17.0
In conclusion, 1072 subjects in the FAS (536 subjects per group) will ensure a marginal power of 
>99.9% to show non-inferiority in step 1, given that the actual treatment difference is -0.1%, and a 
marginal power of 80.1% to show superiority in step 2, given that the actual treatment difference is 
0.6 mmol/L.
Assuming a screening failure rate of 30% and run-in failure rate of 15%, 1803 subjects should be 
screened for inclusion in the trial.
2.2
Definition of analysis sets
The following analysis sets are defined in accordance with the ICH-E9 guidance1.
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
12 February 2019
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT No.: 2016-000878-38
Page:
11 of 29
!
Full Analysis Set (FAS) includes all randomised subjects. In exceptional cases, randomised 
subjects may be excluded from the FAS. In such cases, the reason for exclusion will be 
justified and documented. Subjects in the FAS will contribute to the evaluation “as 
randomised”
!
Per Protocol (PP) Analysis Set includes all subjects in the FAS, excluding subjects who:
o
Have violated any inclusion criteria
o
Have fulfilled any exclusion criteria
Subjects in the PP analysis set will contribute to the evaluation “as treated” 
!
Safety Analysis Set includes all subjects receiving at least one dose of randomised 
treatment. Subjects in the safety analysis set will contribute to the evaluation “as treated”. 
Randomised subjects who are lost to follow-up, and where no exposure information of the trial 
product or its comparator is available after randomisation, will be handled as unexposed.
Before data are released for statistical review, a blinded review of all data will take place to identify
serious non-adherence to the protocol that may potentially affect the results. Furthermore, extreme 
values and outliers will be identified by the statistician during programming and data review, 
according to ICH-E91. This will be performed using a fake randomisation.
The subjects or observations to be excluded, and the reasons for their exclusion must be 
documented and signed by those responsible before database lock. The subjects and observations 
excluded from analysis sets, and the reason for this, will be described in the clinical trial report.
2.3
Primary endpoint
The primary endpoint is the change from baseline in HbA1c 16 weeks after randomisation.
Primary analysis
1) The primary estimand will be addressed by the below primary analysis based on all subjects 
included in the FAS and using the in-trial observation period. Note that if subjects withdraw 
consent to contribute additional information or are completely lost to follow-up, missing
data will occur. The primary analysis will be implemented as a statistical model using 
multiple imputations where the subjects without HbA1c measurements at scheduled visits 
will have their change from baseline HbA1c value(s) imputed from the available information 
from the treatment group the subject has been randomised to. Note that this resembles in 
essence a mixed model of repeated measurements analysis. Subjects without post-
randomisation measurements contribute to the analysis, as the missing values will be 
imputed. The analysis will be implemented as follows:
!
In the first step, intermittent missing values are imputed using a Markov Chain 
Monte Carlo method, in order to obtain a monotone missing data pattern. This 
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
12 February 2019
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT No.: 2016-000878-38
Page:
12 of 29
imputation is done for each group separately and 100 copies of the dataset will be 
generated.
!
In the second step, for each of the 100 copies of the dataset, an analysis of variance 
model with region and metformin use at baseline (Yes/No) as factors and baseline 
HbA1c as covariate is fitted to the change in HbA1c from baseline to week 4 for each 
treatment group separately. The estimated parameters, and their variances, from 
these models are used to impute missing values at week 4 for subjects in each 
treatment group, based on region, metformin use at baseline (Yes/No) and baseline 
HbA1c.
!
In the third step, for each of the 100 copies of the dataset, missing values at week 8 
are imputed in the same way as for week 4. The imputations are based on an analysis 
of variance model with region and metformin use at baseline (Yes/No) as factors and 
baseline HbA1c and change from baseline in HbA1c at week 4 as covariates.
!
This stepwise procedure is then repeated sequentially for week 12 and 16
!
For each of the complete data sets, the change from baseline to week 16 is analysed 
using an analysis of variance model with treatment, region and metformin use at 
baseline (Yes/No) as factors, and baseline HbA1c as a covariate. 
!
The estimates and standard deviations for the 100 data sets are pooled to one 
estimate and associated standard deviation using Rubin’s formula:
m =
1
100
 m


SD =  1
100 
 SD



+ 1 + 1
100
1
100 −1 
(m −m)


where mi and SDi are the estimated means and standard deviations for the 100 copies 
of the dataset, and mMI and SDMI are the pooled estimates.
!
From mMI  and  SDMI, the 95% confidence interval for the treatment differences is 
calculated.
Non-inferiority of faster aspart will be considered confirmed if the upper boundary of the two-sided 
95% confidence interval is below or equal to 0.4% or equivalent if the p-value for the one-sided test 
of
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
12 February 2019
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT No.: 2016-000878-38
Page:
13 of 29
H0: D > 0.4%     against HA: D ≤0.4%,
is less than or equal to 2.5%, where D is the mean treatment difference (faster aspart minus 
NovoRapid®).
Note that as the anticipated number of subjects discontinuing treatment, but not trial is low, multiple 
imputations based on such subjects is not expected to be suitable.
Provided that the hierarchical testing allows, the evaluation of superiority will be based on the same 
statistical model, as the primary analysis 1). The associated sensitivity analysis that follows will 
investigate the robustness of non-inferiority (analyses 3a and 3d) and superiority (analyses 3b and 
3c) as well.
Sensitivity analyses for the primary analysis addressing the primary estimand
All sensitivity analyses for the primary analysis addressing the primary estimand will use the in-trial 
observation period.
2) First the primary analysis in 1) will be repeated, but excluding all factors except from 
treatment from the multiple imputation and analysis of variance models while still including 
baseline HbA1c as a covariate. This analysis will explore the influence of the different 
factors.
3) The primary analysis approach chosen for this trial relies on the assumption that missing 
data is missing at random (MAR). This assumption implies that the HbA1c for subjects 
leaving the trial, after their withdrawal, develops in a similar way as the HbA1c for similar 
subjects that remain in the trial (not necessarily on treatment) and had similar development 
of HbA1c before withdrawal. The MAR assumption may be questionable for subjects 
withdrawing at own will. Therefore the statistical model using multiple imputation will be 
repeated with the following alterations:
a) Imputations will be done from the treatment arm that the subject was randomised to 
and a value of 0.4% (non-inferiority margin) is added to the change from baseline in 
HbA1c at week 16 for subjects randomised to faster aspart with an imputed value at 
week 162. This will serve as a sensitivity analysis for the non-inferiority analysis.
b) Imputations will be done from the comparator arm (NovoRapid®). This will serve as 
a supplementary sensitivity analysis for the superiority analysis. The imputation will 
be done conditional on observed information for subjects on faster aspart without a 
measurement at week 16 such that the treatment effect diminishes gradually (copy 
reference/conditional imputation). It does not rely on the MAR assumption, but 
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
12 February 2019
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT No.: 2016-000878-38
Page:
14 of 29
assumes that subjects on faster aspart without a measurement at week 16 switch to 
NovoRapid®. The analysis will use data from the in-trial observation period.
c) Imputation will be done from the comparator arm (NovoRapid ®). This will serve as a 
supplementary sensitivity analysis for the superiority analysis. The imputation will 
be done with no regard to observed information for subjects on faster aspart without 
a measurement at week 16 such that the treatment effect diminishes immediately 
(jump to reference/unconditional imputation). It does not rely on the MAR 
assumption, but assumes that subjects on faster aspart without a measurement at 
week 16 switch to NovoRapid®. The analysis will use data from the in-trial 
observation period.
d) A tipping point analysis based on a statistical model using multiple imputations 
similar to 1), using the in-trial observation period, will be made. In this analysis, 
observations for subjects without a measurement are imputed based on the treatment 
arm they were randomised to and subjects on faster aspart without a measurement 
are given a penalty. This is done to investigate the robustness of the conclusion in the 
primary analysis with respect to the MAR assumption and mimics a scenario where 
the HbA1c of the subjects without a measurement in the faster aspart group evolve
less favourably than predicted. As a first step imputations will be done without 
penalty assuming MAR in the treatment group. Second, the imputed values for week 
16 in the faster aspart group will be added a penalty. This is done repeatedly, 
gradually increasing the penalty until the conclusion from the non-inferiority 
analysis no longer holds. This will serve as a sensitivity analysis for the non-
inferiority analysis and the specific value of the penalty that changes the conclusion 
will be used to evaluate the robustness of the conclusion of the non-inferiority 
analysis.
Analyses addressing the secondary estimand
All analyses addressing the secondary estimand will use the on-treatment observation period.
4) The secondary estimand will be analysed using the same statistical model using multiple 
imputations as the primary analysis in 1) except using the on-treatment observation period. 
5) A tipping point analysis based on a statistical model using multiple imputations, similar to 
sensitivity analysis 3)-d except using the on-treatment observation period.
6) A tipping point analysis based on a statistical model using multiple imputation, similar to 5) 
but with the modification that subjects without a measurement that discontinued treatment
due to non-eligibility (Subjects discontinuing randomised treatment prematurely due to 
criteria 1, 2, 3, and 4, which are defined in section 6.6 in the protocol) in the faster aspart
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
12 February 2019
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT No.: 2016-000878-38
Page:
15 of 29
group will not have a penalty added to the imputed values. This analysis is motivated by the 
fact that data from subjects prematurely discontinuing randomised treatment due to non-
eligibility can reasonably be assumed to be missing completely at random.
7) The same statistical model using multiple imputations as the analysis in 4 ), but using the PP 
analysis set and analysed using the on-treatment observation period. This analysis will 
investigate the situation that subjects might have deviated from the inclusion and exclusion 
criteria and will serve as sensitivity analysis for the non-inferiority analysis.
2.4
Secondary endpoints
2.4.1
Confirmatory secondary endpoints
If the effect of treatment with faster aspart can be confirmed in the primary analysis, the trial also 
aims to confirm effect of treatment with faster aspart for a number of secondary confirmatory 
endpoints using a hierarchical (fixed sequence) testing procedure as described in section 2 (General 
consideration). This is based on a priority ordering of the null-hypotheses, and testing them in this 
order using the two-sided 95% confidence interval approach until an insignificant result appears. 
The effect is that rejection of the null hypothesis will only be confirmed for endpoints where all 
previous null-hypotheses have been rejected in favour of faster aspart.
The confirmatory secondary endpoints are:
!
Change from baseline in 1-hour PPG increment 16 weeks after randomisation (meal test)
!
Change from baseline in 1,5-anhydroglucitol 16 weeks after randomisation
The steps in the hierarchical testing procedure are as follows:
Step 1 (Primary analysis): HbA1c non-inferiority of faster aspart versus NovoRapid®
Step 2: 1-hour PPG increment (meal test) superiority of faster aspart versus NovoRapid®
Step 3: HbA1c superiority of faster aspart versus NovoRapid®
Step 4: 1,5-anhydroglucitol superiority of faster aspart versus NovoRapid®
The primary estimand for the primary endpoint will be repeated for the confirmatory secondary 
endpoints, change from baseline in 1-hour PPG increment (meal test) and change from baseline in 
1,5-anhydroglucitol 16 weeks after randomisation. The analyses related to these estimands are 
defined below and will be used for the decisions to continue or not, throughout the hierarchical 
testing procedure. These analyses will be based on the FAS and use the in-trial observation period.
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
12 February 2019
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT No.: 2016-000878-38
Page:
16 of 29
As sensitivity analysis the secondary analysis 4) will also be repeated for the confirmatory 
secondary endpoints. The analyses will be based on the FAS and using the on-treatment observation 
period.
Change from baseline in 1-hour PPG increment 16 weeks after randomisation (meal test) 
(step 2)
As the second step of the hierarchical testing procedure change from baseline in 1-hour PPG 
increment (meal test) 16 weeks after randomisation will be tested for superiority of faster aspart 
compared to Novo Rapid®.
The 1-hour PPG increment will be analysed based on the laboratory measured values in the meal 
test, and is derived as the 1-hour PPG measurement minus the pre-prandial PG measurement.
The 1-hour PPG increment endpoint will be analysed using the FAS and the in-trial observation 
period based on a multiple imputation technique where the change from baseline in 1-hour PPG 
increment at week 16 for subjects with missing value are imputed based on data from subjects in the 
NovoRapid® arm with non-missing values at week 16. Multiple copies (100 copies) of the full 
dataset will be generated by imputing missing values based on estimated parameters as follows:
!
An analysis of variance model with region and metformin use at baseline (Yes/No) as 
factors and baseline 1-hour PPG increment as covariate is fitted to the change from baseline 
in 1-hour PPG increment at week 16 for the NovoRapid® group only. The estimated 
parameters, and their variances, from this model are used to impute missing values using 
stochastic simulation at week 16 for subjects in both treatment groups in order to generate 
100 complete datasets.
!
For each of the complete data sets, the change from baseline to week 16 is analysed using 
an analysis of variance model with treatment, region and metformin use at baseline 
(Yes/No) as factors, and baseline 1-hour PPG increment as covariate.
!
The estimates and standard deviations for the 100 data sets are pooled to one estimate and 
associated standard deviation using Rubin’s formula. From this, the pooled estimate and 
95% confidence interval for the treatment difference are calculated.
The superiority will be assessed by comparing the upper limit of the 95% CI to 0. If the upper 95% 
CI is below 0 then superiority will be confirmed.
Change from baseline in HbA1c 16 weeks after randomisation (step 3)
Step 3 in the hierarchical testing procedure is to confirm superiority of change from baseline HbA1c
16 weeks after randomisation of the effect of treatment with faster aspart compared to NovoRapid®. 
Superiority will be addressed based on the same 95% CI that was used for addressing the primary 
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
12 February 2019
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT No.: 2016-000878-38
Page:
17 of 29
analysis. Superiority will be confirmed if the upper boundary of the two-sided 95% confidence 
interval of the mean treatment difference (faster aspart minus NovoRapid®) is below 0.
Change from baseline in 1,5-anhydroglucitol 16 weeks after randomisation (step 4)
Step 4 in the hierarchical testing procedure is to confirm superiority of change from baseline in 1,5-
anhydroglucitol 16 weeks after randomisation of the effect of treatment with faster aspart compared 
to NovoRapid®. The endpoint will be analysed based on all planned post baseline measurements 
until or at 16 weeks after randomisation using a model similar to the primary analysis 1), but with 
baseline 1,5-anhydroglucitol as covariate. Superiority will be confirmed if the upper boundary of 
the two-sided 95% confidence interval of the mean treatment difference (faster aspart minus 
NovoRapid®) is below 0.
2.4.2
Supportive secondary endpoints
2.4.2.1
Efficacy endpoints
All endpoints except insulin dose in this section will be assessed using the FAS and the in-trial 
observation period and repeated using the on-treatment observation period. Insulin dose will be 
presented using the safety analysis set and will therefore only use the on-treatment observation 
period.
Change from baseline in FPG 16 weeks after randomisation
Change from baseline in FPG 16 weeks after randomisation will be analysed based on all planned 
post baseline measurements until or at 16 weeks after randomisation using a model similar to 1) 
except with baseline FPG as covariate.
If a subject achieves HbA1c target 16 weeks after randomisation
HbA1c < 7.0%
A dichotomous (responder/non-responder) endpoint will be defined based on whether a subject has 
met the HbA1c target (HbA1c <7.0%) 16 weeks after randomisation.
This responder endpoint will be analysed based on a logistic regression model using treatment,
region and metformin use at baseline (Yes/No) as factors, and baseline HbA1c as covariate. In 
analysis of the in-trial observation period subjects without an HbA1c measurement at week 16 will 
be treated as non-responders. In the analysis using the on-treatment observation period subjects who 
discontinue randomised treatment, initiate ancillary treatment, withdraw from trial, and/or have no 
HbA1c measurement at week 16 are included as non-responders.
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
12 February 2019
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT No.: 2016-000878-38
Page:
18 of 29
HbA1c < 7.0 % without severe hypoglycaemia
A dichotomous (responder/non-responder) endpoint will be defined based on whether a subject has 
met the HbA1c target (HbA1c <7.0%) 16 weeks after randomisation without treatment emergent 
severe hypoglycaemic episodes.
This responder endpoint will be analysed based on a logistic regression model using treatment,
region and metformin use at baseline (Yes/No) as factors and baseline HbA1c as covariate. In the 
analysis of the in-trial observation period subjects without an HbA1c measurement at week 16 will 
be treated as non-responders. In the analysis using the on-treatment observation period subjects who 
discontinue randomised treatment, initiate ancillary treatment, withdraw form trial, and/or have no 
HbA1c measurement at week 16 will be included as non-responders.
Change from baseline in 30- minutes, 1- hour, 2- hour, 3- hour and 4- hour PPG and 30-
minutes, 2- hour, 3- hour and 4- hour PPG increment 16 weeks after randomisation (meal 
test)
Laboratory measured PG from the meal test will be analysed for 30 minutes, 1-hour, 2-hours, 3-
hours and 4-hours PPG separately. The corresponding PPG increments will be derived separately 
using each PPG measurement minus the pre-prandial PG measurement.
Change from baseline in PPG and PPG increment 16 weeks after randomisation will be analysed 
separately using a model similar to the model used in hierarchical testing procedure step 2 for 1-
hour PPG increment 16 weeks after randomisation (meal test) except with the corresponding 
baseline value as covariate.
Change from baseline in endpoints derived from the 7-9-7-point SMPG profile 16 weeks after 
randomisation
In general, analyses will be based on the entire 7-9-7-point SMPG profile except for the analyses of 
nocturnal endpoints where information in the 9-point SMPG profile will be utilised.
PPG and PPG increments based on the 7-9-7-point SMPG profiles will be derived separately for PG 
measurements made 1 hour after the meal. In the following section this distinction will be 
considered implicit and without further explanation.
Pre-prandial PG and PPG will be recorded by the subjects as part of the 7-9-7-point SMPG profile 
prior to three defined visits. Individual mean mealtime PPG (post-breakfast, post-lunch, post-main 
evening meal) will be derived from the three profiles. Overall mean PPG will be derived from the 
individual derived mealtime PPG values.
PPG increment for each meal (breakfast, lunch, main evening meal) will be derived from the 7-9-7-
point SMPG profile as the difference between PPG values and pre-prandial PG values in each 
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
12 February 2019
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT No.: 2016-000878-38
Page:
19 of 29
separate profile. The mean of the derived increments will then be calculated separately for each 
meal. Mean 1 hour PPG increments over all meals will be derived as the mean of all corresponding 
mean meal increments.
!
Change from baseline in mean of the 7-9-7-point SMPG profile
The mean of the 7-9-7-point SMPG profile is defined as the area under the curve profile 
divided by the measurement time, and is calculated using the linear trapezoidal technique.
Change from baseline in the mean of the 7-9-7-point SMPG profile 16 weeks after 
randomisation will be analysed based on all planned post baseline measurements until or at 
16 weeks after randomisation using a model similar to 1) except with the corresponding 
baseline value as covariate.
!
Change from baseline in PPG and PPG increment (mean, breakfast, lunch and main evening 
meal)
Change from baseline in PPG and PPG increment endpoints 16 weeks after randomisation 
for mean over all three meals and the individual meals will be analysed separately based on 
all planned post baseline measurements until or at 16 weeks after randomisation using a 
model similar to 1) except with the corresponding baseline value as covariate.
!
Fluctuation in 7-9-7-point SMPG profile
The fluctuation in the 7-9-7-point SMPG profile is defined as:
1
 |() −
| 
!

where T, PG(t) and 
 denotes the length of the profile, the PG value at time t and the mean 
of the profile, respectively. It will be calculated using the linear trapezoidal technique.
Fluctuation in the 7-9-7-point SMPG profile will be logarithmically transformed and 
analysed based on all planned post baseline measurements until or at 16 weeks after 
randomisation using a model similar to 1) except with the corresponding log-transformed 
baseline value as covariate. Estimated treatment means and the estimated treatment 
differences with corresponding 95% CI will be back-transformed to the original scale, 
resulting in estimated geometric means, a treatment ratio and a 95% CI for the treatment 
ratio.
!
Change from baseline in nocturnal SMPG measurements
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
12 February 2019
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT No.: 2016-000878-38
Page:
20 of 29
Change from baseline in nocturnal SMPG measurements will be assessed by considering the 
difference between PG values available at bedtime, at 4 AM and the before breakfast value 
the following day: (4 AM PG value minus at bedtime PG value), (before breakfast PG value 
minus at bedtime PG value) and (before breakfast PG value minus 4 AM PG value). 
Change from baseline in nocturnal SMPG measurements 16 weeks after randomisation will 
be analysed based on all planned post baseline measurements until or at 16 weeks after 
randomisation using a model similar to 1) except with the corresponding baseline values as 
covariate.
If a subject achieves PPG target (based on overall mean of daily PPG measurements in 7-9-7-
point SMPG profile) 16 weeks after randomisation:
Overall PPG (1 hour) ∀7.8 mmol/L [140 mg/dL]
A dichotomous (responder / non-responder) endpoint will be defined based on whether a subject has 
reached an overall mean 1 hour PPG ∀7.8 mmol/L [140 mg/dL] 16 weeks after randomisation, 
where PPG is derived from the 7-9-7-point SMPG profile.
This responder endpoint will be analysed based on a logistic regression model using treatment, 
region and metformin use at baseline (Yes/No) as factors, and baseline overall 1-hour mean PPG as 
covariate. In analysis of the in-trial observation period subjects without an overall mean 1 hour PPG 
at week 16 will be treated as non-responder. In the on-treatment observation period analysis
subjects who discontinue randomised treatment, initiate ancillary treatment, withdraw from trial, or 
have no 1-hour mean PPG measurement at week 16 will be included as non-responders.
Overall PPG (1-hour ) ∀7.8 mmol/L [140 mg/dL] without severe hypoglycaemia
A dichotomous (responder / non-responder) endpoint will be defined based on whether a subject has 
reached an overall 1-hour PPG ∀7.8 mmol/L [140 mg/dL] 16 weeks after randomisation without 
any treatment emergent severe hypoglycaemic episodes.
This responder endpoint will be analysed based on a logistic regression model using treatment, 
region and metformin use at baseline (Yes/No) as factors, and baseline mean 1-hour PPG as 
covariate. In analysis of the in-trial observation period subjects without an overall mean 1 hour PPG 
at week 16 will be treated as non-responders. In the on-treatment observation period analysis
subjects who discontinue randomised treatment, initiate ancillary treatment, withdraw from trial, or 
have no 1-hour mean PPG measurement at week 16 will be included as non-responders.
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
12 February 2019
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT No.: 2016-000878-38
Page:
21 of 29
Insulin dose (Units/day and Units/kg/day; total basal, total bolus, total daily insulin dose and 
individual meal insulin dose) 16 weeks after randomisation
The insulin doses will be summarised descriptively by treatment week according to regimen, both 
by meal type and as total daily dose in units and units/kg (total daily and separately for each 
mealtime dose). Insulin doses will be summarised using the on-treatment observation period and 
using the safety analysis set.
Lipids-lipoproteins profile 16 weeks after randomisation
Lipid endpoints (total cholesterol, HDL cholesterol, LDL cholesterol) will be logarithmically 
transformed and analysed separately based on all planned post baseline measurements until or at 16 
weeks after randomisation using a model similar to 1) except with the corresponding log-
transformed baseline measurement as covariate. Estimated treatment means and the estimated 
treatment difference with corresponding 95% CI will be back-transformed to the original scale, 
resulting in estimated geometric means, a treatment ratio and a 95% CI for the treatment ratio.
2.4.2.2
Safety endpoints
In terms of AEs, as a minimum, SAEs will be tabulated separately using the in-trial observation 
period.
All events in the in-trial observation period will be listed with information about whether it 
appeared in the on-treatment observation period or not.
Number of treatment emergent adverse events
Adverse events (AEs) will be coded using the Medical Dictionary for Regulatory Activities 
(MedDRA). AEs will be presented based on system organ class and preferred terms.
A Treatment Emergent Adverse Event (TEAE) is defined as an event that has an onset date on or 
after the first day of exposure to randomised treatment, and no later than seven days after the last 
day of exposure to randomised treatment.
TEAEs are summarised descriptively, whereas AEs not defined as treatment emergent are presented 
in listings, including AEs reported in the 30-day follow-up period. The summaries of TEAEs are
made displaying the number of subjects with at least one event, the percentage of subjects with at 
least one event, the number of events and the event rate per 100 patient years of exposure. These 
summaries are done by seriousness, severity, relation to insulin treatment, relation to technical 
complaint, premature treatment discontinuation due to AEs, and outcome.
Furthermore, summary tables based on system organ class and preferred terms are made for:
!
All TEAEs
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
12 February 2019
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT No.: 2016-000878-38
Page:
22 of 29
!
Serious TEAEs
!
Possibly or probably related TEAEs
!
Severe TEAEs
!
TEAEs with preferred term that are experienced by at least 5% of the subjects in any 
treatment arm or by at least 5% of all subjects
For AEs where additional information is recorded, this will be listed.
AEs occurring during the run-in period are considered non-treatment emergent and will be 
summarised separately.
Number of treatment emergent injection site reactions
Treatment emergent injection site reactions occurring during the trial will be summarised and listed.
Classification of Hypoglycaemia
Treatment emergent: hypoglycaemic episodes will be defined as treatment emergent if the onset of 
the episode occurs on or after the first day of exposure to randomised treatment, and no later than 
one day after the last day of exposure to randomised treatment.
Nocturnal hypoglycaemic episodes: episodes occurring between 00:01 and 05.59 both inclusive.
Hypoglycaemic episodes are classified according to the Novo Nordisk classification of 
hypoglycaemia (see Figure 2–1) and the ADA classification of hypoglycaemia (see Figure 2–2).
Novo Nordisk classification of hypoglycaemia
In normal physiology, symptoms of hypoglycaemia occur below a PG level of 3.1 mmol/L (56 
mg/dL).3 Therefore, Novo Nordisk has included hypoglycaemia with PG levels below this cut-off 
point in the definition of BG confirmed hypoglycaemia.
Novo Nordisk uses the following classification (see Figure 2–1) in addition to the ADA 
classification:
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
12 February 2019
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT No.: 2016-000878-38
Page:
23 of 29
!
Severe hypoglycaemia according to the ADA classification.4
!
Severe or BG confirmed hypoglycaemia: An episode that is severe according to the ADA 
classification4 or BG confirmed by a PG value <3.1 mmol/L (56 mg/dL) with or without
symptoms consistent with hypoglycaemia.
Hypoglycaemic
episode
PG ≤ 3.9 mmol/L 
(70 mg/dL) 
or 
Alleviation of 
symptoms 
or
Seizure, coma or 
fatal 
SMPG
measurement
PG < 3.1 mmol/L
(56 mg/dL)
with symptoms
PG < 3.1 mmol/L
(56 mg/dL)
without
symptoms
Symptomatic BG 
confirmed 
hypoglycaemia
Asymptomatic BG 
confirmed 
hypoglycaemia
Yes
No
Severe or 
BG confirmed 
symptomatic 
hypoglycaemia
BG confirmed 
hypoglycaemia
Severe or BG 
confirmed 
hypoglycaemia
Note: Glucose measurements are performed with capillary blood calibrated to plasma equivalent glucose values
BG: blood glucose  PG: plasma glucose  SMPG: Self-measured plasma glucose  
Subject 
able to 
treat him/
herself
Severe 
hypoglycaemia
(ADA 2013)
Figure 2–1
Novo Nordisk classification of hypoglycaemia 
ADA classification4 of hypoglycaemia 
!
Severe hypoglycaemia: An episode requiring assistance of another person to actively
administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose 
concentrations may not be available during an event, but neurological recovery following 
the return of PG to normal is considered sufficient evidence that the event was induced by a 
low PG concentration.
!
Asymptomatic hypoglycaemia: An episode not accompanied by typical symptoms of 
hypoglycaemia, but with a measured PG concentration ≤3.9 mmol/L (70 mg/dL).
!
Documented symptomatic hypoglycaemia: An episode during which typical symptoms of 
hypoglycaemia are accompanied by a measured PG concentration ≤3.9 mmol/L (70 
mg/dL).
!
Pseudo-hypoglycaemia: An episode during which the person with diabetes reports any of 
the typical symptoms of hypoglycaemia with a measured PG concentration > 3.9 mmol/L 
(70 mg/dL) but approaching that level.
!
Probable symptomatic hypoglycaemia: An episode during which symptoms of 
hypoglycaemia are not accompanied by a PG determination but that was presumably caused 
by a PG concentration ≤3.9 mmol/L (70 mg/dL).
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
12 February 2019
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT No.: 2016-000878-38
Page:
24 of 29
Hypoglycaemic 
episode 
PG ≤ 3.9 mmol/L 
(70 mg/dL) 
or 
Alleviation of 
symptoms 
or
Seizure, coma or 
fatal 
SMPG
measurement
Asymptomatic 
hypoglycaemia
Documented 
symptomatic 
hypoglycaemia
Pseudo-
hypoglycaemia
Probable 
symptomatic 
hypoglycaemia
No
Yes
No measurement 
with symptoms
PG > 3.9 mmol/L 
(70 mg/dL)
with symptoms
PG ≤3.9 mmol/L 
(70 mg/dL)
with symptoms
PG ≤3.9 mmol/L 
(70 mg/dL)
without symptoms
No
Yes
Note: Glucose measurements are performed with capillary blood calibrated to plasma equivalent gl ucose values
PG: plasma glucose  SMPG: Self-measured plasma glucose  
Subject 
able to 
treat him/
herself
Severe 
hypoglycaemia
(ADA 2013)
Figure 2–2
ADA classification of hypoglycaemia
Treatment emergent hypoglycaemic episodes are presented in terms of the number of subjects with 
at least one event (N), the percentage of subjects with at least one event (%), the number of events 
(E) and the event rate per 100 years of exposure (R). Separate summaries are made by severity 
considering all episodes, nocturnal and daytime episodes using Novo Nordisk and ADA classified 
episodes. All episodes will also be summarised by category, including summaries in relation to time 
since start of meal, as occurring within the following time intervals:
!
During first 1, 2, and 4 hours after start of meal
!
Between 1 (exclusive) to 2 hours (inclusive) after start of meal
!
Between 2 (exclusive) to 3 hours (inclusive) after start of meal
!
Between 3 (exclusive) to 4 hours (inclusive) after start of meal
!
Between 2 (exclusive) to 4 hours (inclusive) after start of meal
The number of treatment emergent severe or BG confirmed hypoglycaemic episodes (all, daytime, 
nocturnal, 1 hour, 2 hours, 4 hours, 1 (exclusive) to 2 hours (inclusive), 2 (exclusive) to 3 hours 
(inclusive), 3 (exclusive) to 4 hours (inclusive), and 2 (exclusive) to 4 hours (inclusive) after start of 
the meal) will be analysed based on the FAS using a negative binomial regression model with a log -
link function and the logarithm of the time period in which a hypoglycaemic episode is consid ered 
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
12 February 2019
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT No.: 2016-000878-38
Page:
25 of 29
treatment emergent as offset. The model will include treatment, region and metformin use at 
baseline (Yes/No) as factors. To the extent where data allow, separate analysis will be performed 
for severe hypoglycaemic episodes (all).
Change from baseline in clinical evaluations 16 weeks after randomisation:
Physical examination
The physical examination parameters (head, ears, eyes, nose, throat, neck, respiratory system, 
cardiovascular system, gastrointestinal system incl. mouth, musculoskeletal system, central and 
peripheral nervous system, skin), and their change from baseline, will be summarised descriptively
using the on-treatment period. All findings will be listed.
Vital signs
Vital signs include diastolic blood pressure, systolic blood pressure and pulse. The measurements 
will be summarised descriptively using the on-treatment period and both actual values as mean 
change and change from baseline.
Electrocardiogram
ECG findings will be summarised descriptively using the on-treatment period and including 
summaries of the change from baseline. Change from baseline will be summarised as 
normal/abnormal not clinically significant/abnormal clinically significant categorisation in shift 
tables.
Fundoscopy/fundus photography
Fundoscopy/fundus photography findings will be summarised descriptively using the on-treatment 
period and including summaries of the change from baseline. Change from baseline will be 
summarised as normal/abnormal not clinically significant/abnormal clinically significant 
categorisation in shift tables.
Change from baseline in clinical laboratory assessments 16 weeks after randomisation
Change from baseline 16 weeks after randomisation in central laboratory assessments: 
!
Haematology (erythrocytes, haematocrit, haemoglobin, leucocytes, thrombocytes)
!
Biochemistry (ALT, AST, albumin, alkaline phosphatase, creatinine, potassium, sodium, 
total bilirubin, total protein)
Individual laboratory values will be compared to their relevant reference range (when existing) and 
flagged as being below or above the range. The measurements and their change from baseline will 
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
12 February 2019
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT No.: 2016-000878-38
Page:
26 of 29
be summarised descriptively using the on-treatment period. Change from baseline will be 
summarised both the actual values and the low/normal/high categorisation in shift tables.
Change from baseline in body weight and body mass index 16 weeks after randomisation 
The measurements will be summarised descriptively using the on-treatment period and the actual 
values as mean change.
Change from baseline in body weight will be analysed based on all planned post baseline 
measurements until or at 16 weeks after randomisation using a statistical model similar to 1) except 
with the corresponding baseline measurement as covariate. The analysis will be based on the safety 
analysis set and the on-treatment observation period.
2.5
Supplementary analyses
Discontinuation of the glycaemic data collection system
Following the observation of unusual glycaemic data patterns, the original glycaemic data 
collection system (combined use of MyGlucoHealth Wireless BG-meter and an electronic diary was 
discontinued during the trial, and subjects were switched to a new BG-meter and paper diary.
A dichotomous variable will be defined according to whether a subject had experienced more or 
less than 6 weeks between the date of switch of glycaemic data collection system and date of 
randomisation. A supplementary analysis will be performed by repeating the primary analysis in 1), 
but including the aforementioned dichotomous variable as a factor, in addition to the already 
included factor variables. The analysis will be under the framework of the primary estimand, i.e.
based on the full analysis set and the in-trial observation period.
Different meal tests between countries
Subjects in Russia, Serbia and Argentina received a different meal test (volume) compared to 
subjects in all other countries. A dichotomous variable will be defined according to whether or not a 
subject comes from one of the aforementioned three countries and so received the non-standard 
meal test. Supplementary analyses will be carried out by repeating the analyses for change from 
baseline in 30-minutes, 1-hour, 2-hours, 3-hours and 4-hours PPG increment (meal test) 16 weeks 
after randomisation, but including the aforementioned dichotomous variable as a factor in addition 
to the already included factor variables. The analyses will be under the framework of the primary 
estimand, i.e. based on the full analysis set and the in-trial observation period.
3
Changes to the statistical analyses planned in the protocol
Minor editorial corrections have been made throughout the document.
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
12 February 2019
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT No.: 2016-000878-38
Page:
27 of 29
General considerations
It has been clarified how data collected at visit 30A are handled.
Statistical analysis
It has been clarified that the family-wise type 1 error rate will be controlled under the framework of 
the primary estimand.
In the primary analysis 1) for change from baseline in HbA1c, it has been clarified that any missing 
change from baseline HbA1c value will be imputed.
In the sensitivity analysis 2) for change from baseline in HbA1c, it has been clarified that baseline 
HbA1c is included as a covariate in both the multiple imputation model and analysis of variance 
model.
The descriptions of analyses for change from baseline in HbA1c and PPG and PPG increment have 
been revised to clarify that all subjects without a measurement at week 16 (not only subjects 
withdrawing from trial in general) should have their values imputed. The new description is aligned 
with the primary analysis.
For the sensitivity analyses for the primary analysis addressing the primary estimand, it has been 
clarified for each analysis whether it serves as a sensitivity analysis for the non-inferiority analysis 
or the superiority analysis.
In order to emphasize the difference between sensitivity analyses 3b) and 3c), the wording has been 
rearranged.
Tipping point analysis 5) has been repeated for the in-trial observation period in the additional 
sensitivity analysis 3d).
For change from baseline in 1-hour PPG increment (meal test) it has been clarified how the 
endpoint is derived. The derivation is aligned with the derivation for the other endpoints based on 
the meal test. It has been clarified that imputation is to be performed based on subjects in the 
NovoRapid® arm with non-missing values at week 16 instead of completers in the NovoRapid®
arm.
In the statistical analyses for subjects reaching HbA1c or PPG (SMPG) targets, it has been clarified 
that subjects without an HbA1c or 1-hour mean PPG measurement at week 16 will be included as 
non-responders in analyses of both the in-trial and on-treatment observation periods. To reflect that 
the definition of the on-treatment observation period takes into account ancillary treatment, it has 
been clarified that subjects who initiate ancillary treatment are also included as non-responders in 
analyses of the on-treatment observation period.
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
12 February 2019
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT No.: 2016-000878-38
Page:
28 of 29
“Change from baseline” has been removed for fluctuation in the 7-9-7-point SMPG profile and 
lipids-lipoprotein profile because data are logarithmically transformed and change from baseline 
potentially include negative values.
Adverse events
Since data on AEs leading to withdrawal is not collected, this information can not be summarised.
Summary table for possibly “and” probably related TEAEs has been changed to possibly “or”
probably related TEAEs in accordance with previous trials.
Hypoglycaemic episodes
The endpoints treatment emergent hypoglycaemic episodes occurring between 1 (exclusive) to 2 
hours (inclusive), 2 (exclusive) to 3 hours (inclusive), 3 (exclusive) to 4 hours (inclusive) after start 
of meal have been added to further investigate the safety of faster aspart.
It has been clarified that a separate statistical analysis of number of treatment emergent severe 
hypoglycaemic episodes will only be performed  on the overall number of episodes, not subdivided 
into daytime and nocturnal or according to timing after start of meal.
Change from baseline in clinical laboratory assessments 16 weeks after randomisation
Total protein has been added to biochemistry in accordance with section 8.5.2 in the protocol.
Change from baseline in body weight and body mass index 16 weeks after randomisation
In order to align with previous trials, the analysis of change from baseline in body weight will be 
based on the safety analysis set and the on-treatment observation period.
Supplementary analyses
To account for the potential additional variability introduced by the switch of glycaemic data 
collection system, a supplementary analysis for the primary endpoint (HbA1c) has been specified.
To account for the potential additional variability introduced by using different meal test in different 
countries, supplementary analyses addressing the endpoints of PPG increments (meal test) have 
been specified.
CONFIDENTIAL


Statistical Analysis Plan
CONFIDENTIAL
Date:
12 February 2019
1RYR1RUGLVN
Trial ID: NN1218-4113
Version:
2.0
UTN: U1111-1180-0636
Status:
Final
EudraCT No.: 2016-000878-38
Page:
29 of 29
4
References
1.
International Conference on Harmonisation. ICH Harmonised Tripartite Guideline E9. 
Statistical Principles for Clinical Trials. 5 Feb 1998.
2.
Koch GG. Comments on 'Current issues in non-inferiority trials' by Thomas R. Fleming, 
Statistics in Medicine, DOI: 10.1002/sim.2855. Stat Med. 2008;27(3):333-42.
3.
Schwartz NS, Clutter WE, Shah SD, Cryer PE. Glycemic thresholds for activation of 
glucose counterregulatory systems are higher than the threshold for symptoms. J Clin Invest. 
1987;79(3):777-81.
4.
Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al. Hypoglycemia 
and diabetes: a report of a workgroup of the American Diabetes Association and the 
Endocrine Society. Diabetes Care. 2013;36(5):1384-95.
CONFIDENTIAL